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Abstract 
Protein kinases are central mediators of signal transduction pathways and 
transcriptional regulation. Lymphoid malignancies are characterised by aberrant 
activation of key signal transduction pathways and specific gene expression 
programmes. Consequently, targeting kinases involved in these signal transduction 
pathways is a promising therapeutic strategy. Because gene expression is regulated at 
the level of chromatin, the aim of this study was to assess the effects of chromatin-
modifying kinases on histone phosphorylation and transcriptional regulation in B cell 
lymphoma and the consequences of kinase inhibition for tumour cell viability and the 
chromatin structure of target genes. 
The kinase PIM1, whose mRNA is highly expressed in the aggressive activated B cell-
like diffuse large B cell lymphoma (ABC-DLBCL), but not germinal centre B cell-like 
DLBCL (GCB-DLBCL), has been shown to associate with the transcription factor MYC 
and to regulate the expression of MYC target genes by phosphorylating histone 
H3S10. Therefore, effects of PIM1 on viability and gene expression were evaluated in 
ABC-DLBCL and in the MYC-dependent Burkitt lymphoma (BL). However, pan-PIM 
kinase inhibition or knockdown of PIM1 did not effectively reduce viability of ABC-
DLBCL or Burkitt lymphoma cell lines. Further, the expression of the MYC- and PIM1-
bound GNL3 gene was largely unaffected by alterations in PIM kinase levels or activity. 
In conclusion, PIM kinases do not seem to be bona fide therapeutical targets in DLBCL 
and BL. 
The second part of this project aimed to understand the effects of Ibrutinib on 
chromatin structure in chronic lymphocytic leukaemia (CLL) cells. Ibrutinib inhibits 
Bruton’s tyrosine kinase, and thus B cell receptor (BCR) signalling, and is currently 
being tested in clinical trials for the treatment of CLL. In vitro, Ibrutinib inhibited BCR-
induced gene expression and histone H3T6 and T11 phosphorylation. A possible 
kinase targeting H3T6 and H3T11 downstream of the BCR might be zipper-interacting 
protein kinase (ZIPK), a ZIPK inhibitor blocked H3T6p and H3T11p and gene 
expression. Short-term Ibrutinib treatment appeared to inhibit histone turnover but did 
not reduce H3K4me3, H3K9ac, H2A.Z or POL II recruitment at target genes, indicating 
that it inhibits only some aspects of transcription. In contrast, long-term Ibrutinib 
treatment decreased H3K4me3 and H3K9ac in promoter regions, possibly by an 
indirect, gene silencing-dependent mechanism. In summary, the results suggest that 
Ibrutinib blocks progression of CLL by inhibiting only some branches of BCR signalling 
and interestingly, many transcription-associated changes to the chromatin remain 
unaltered, while transcription is effectively inhibited. 
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1 Introduction 
1.1 Overview 
B cell malignancies can arise from different stages of normal B cell development 
through B cells acquiring mutations that result in the reduction of apoptosis and 
enhance proliferation. Often, B cell intrinsic properties, e.g. the expression of the DNA 
mutating machinery used for immunoglobulin hypermutation (Lenz et al., 2007; 
Pasqualucci et al., 2001) or the chronic activation of B cell receptor signalling (Burger & 
Chiorazzi, 2013; Davis et al., 2010), facilitate malignant transformation. Further, other 
cells of the immune system or the lymphoid organs play a role in driving proliferation of 
the malignant cells (Bhattacharya et al., 2011; Burger et al., 2000; Ito et al., 2012; 
Lagneaux et al., 1998; Os et al., 2013; Patten et al., 2008). 
Malignant cells often show aberrant gene expression profiles and, consistently, 
important drivers of malignant transformation are key transcription factors, like MYC in 
Burkitt lymphoma, NFκB in activated B cell-like diffuse large B cell lymphoma (ABC-
DLBCL) and BCL6 in germinal centre B cell-like DLBCL (GCB-DLBCL), and/or the 
activation of key signal transduction pathways, like the B cell receptor pathway, through 
aberrant signalling in DLBCL, through chronic signalling in CLL or through tonic 
signalling in Burkitt lymphoma (Alizadeh et al., 2000; Hatzi & Melnick, 2014; Z. Li et al., 
2003; Niemann & Wiestner, 2013). Because kinases are currently the preferred 
therapeutic targets, targeting kinases involved in these transformation-driving pathways 
can provide a good means of treating B cell malignancies. However, treating patients 
with drugs targeting only a single enzyme often leads to rapid induction of resistance 
(le Coutre et al., 2000; Woyach et al., 2014). Thus, identifying novel targetable kinases 
is important to improve the treatment of B cell malignancies. Interesting targets in 
DLBCL and Burkitt lymphoma might be the kinases PIM1 and PIM2. mRNAs for both 
kinases are highly expressed in the more aggressive ABC-DLBCL as compared to 
GCB-DLBCL (Alizadeh et al., 2000; Care et al., 2013; Wright et al., 2003). Further, 
PIM1 has been associated with transcriptional regulation at MYC target genes (Zippo 
et al., 2007) and might therefore contribute to the transcriptional deregulation and thus 
tumour formation or progression in ABC-DLBCL and the MYC-dependent Burkitt 
lymphoma. Of note, PIM kinase knockout mice only show a very mild phenotype: they 
are viable and fertile, although they have a reduced body size and their peripheral T 
cells show a reduced proliferative response towards T cell receptor and IL-2 stimulation 
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(Mikkers et al., 2004). This indicates that therapeutic inhibition of PIM kinases might 
have a desirable side-effect profile. 
On the other hand, it is important to understand how drugs work, which are already 
used for treating B cell malignancies, for example the Bruton’s tyrosine kinase inhibitor 
Ibrutinib, which is currently evaluated in clinical trials for the treatment of CLL. It leads 
to remission and thus knowledge about its mechanism of action will help us to better 
understand the disease, which ultimately provides a means of developing novel drugs 
targeting the essential survival pathways. These drugs can be used in conjunction with 
the original drug to prevent resistances or in patients, who have already become 
resistant to Ibrutinib. 
This study mainly focussed on effects of kinases and kinase inhibitors on the 
chromatin, because the ultimate driving force for B cell malignancies is aberrant gene 
expression and the chromatin is the platform, at which gene expression is regulated 
(Taylor et al., 2013). Through histone tail modifications or the use of histone variants, 
transcription can be activated or repressed (Berger, 2007; Li, Carey, et al., 2007). 
Understanding which changes to the chromatin structure are mediated by certain signal 
transduction pathways and kinases and which of these are important for tumour 
maintenance, will eventually allow for the identification of drugable targets. Moreover, 
histone modifications are indicative of the activation status of a gene and thus the 
phenotype of a cell. They can therefore also be used as a diagnostic tool and to predict 
drug sensitivity and drug response (Taylor et al., 2013). 
 
1.2 B cells and B cell receptor signalling 
1.2.1 B and T lymphocytes in lymphoid tissues 
B and T lymphocytes are cells of the adaptive immune system. B cells develop in the 
bone marrow, T cells in the thymus (Janeway et al., 2001). T cell responses are cell-
mediated, which means that direct contact between the T cell and target cell is usually 
required. Cytotoxic T cells kill infected or abnormal cells, while T helper cells stimulate 
other cells of the immune system and help them to carry out their specific function. In 
contrast, B lymphocytes mediate the humoral immune response by producing 
immunoglobulins in response to an antigenic challenge, which serve to either neutralise 
or opsonise the antigen (Alberts, 2008).  
Mature B and T cells circulate in the blood or home to the secondary lymphoid tissues 
(lymph node, spleen, mucosa-associated lymphoid tissues (MALT)) (Janeway et al., 
2001). These have a specific architecture: B and T cells migrate to different areas 
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which are associated with specific stromal cells and other leukocytes (Koning & 
Mebius, 2012; Mebius & Kraal, 2005). In the lymph nodes, B cells form follicles, which 
are surrounded by more diffusely distributed T cells (Figure 1.1) (Janeway et al., 2001; 
Koning & Mebius, 2012). The spleen consists of the red pulp, where the blood is 
cleared of old cells and foreign particles, and the white pulp, which is formed by 
lymphoid cells (Mebius & Kraal, 2005). The central arteries are surrounded by the 
periarterial lymphoid sheath (PALS), which mainly consists of T cells. B cells form 
follicles adjacent to the PALS (Koning & Mebius, 2012). The perifollicular zone also 
contains some scattered B and T cells (Steiniger et al., 1997). Specialised marginal 
zone B cells can be found in the marginal zone between the follicles and the 
perifollicular zone. In contrast to rodents, human marginal zone-like B cells can also be 
found in the circulation and beneath the subcapsular sinus in lymph nodes (Figure 1.1) 
(Weill et al., 2009). 
 
 
Figure 1.1 Schematic composition of the spleen and lymph nodes (adapted from 
Koning and Mebius, 2012 and Mebius and Kraal 2005).  
One section of the spleen depicting one central arteriole with the PALS is shown, 
while a section of the whole lymphnode is depicted. 
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1.2.2 The B cell receptor 
Immunoglobulins and the signalling molecules CD79a and b form the B cell receptor 
(BCR) on the surface of the cell, allowing for specific responses to antigens (Figure 
1.2) (Jung et al., 2006). 
 
 
Figure 1.2 The B cell receptor.  
The core B cell receptor consisting of the immunoglobulin and the accessory 
CD79a and b chains. 
 
The immunoglobulins consist of two heavy (IgH) and two light chains (Igλ or Igκ), each 
of which has a variable, antigen-recognising and a constant dimerization and effector 
region. The large diversity of immunoglobulins, which allows for the recognition of 
almost unlimited numbers of antigens, is generated by genomic rearrangement of the 
IGH and IGK or IGL loci (Jung et al., 2006; Watson & Breden, 2012). In the germ line, 
the genomic loci for the light chains consist of multiple V (variable) and J (joining) 
segments and the constant region(s), while the heavy chain locus has additional D 
(diversity) segments in between the V and J regions (Figure 1.3) (Cook & Tomlinson, 
1995; Early et al., 1980). 
 
 
Figure 1.3 The immunoglobulin loci.  
Schematic representation of the IGH, IGK and IGL genomic loci with variable (V), 
diversity (D), joining (J) and constant (C) regions. The IGH gene has different C 
segments encoding for different immunoglobulin isotypes (μ, δ, γ, ε, α). 
CD79a/b 
heavy chain 
light chain 
Immunoglobulin 
variable region 
constant region 
- 5 - 
Through homologous recombination events during B cell development, different V(D)J 
segments are joined, leading to the expression of distinct BCRs (Figure 1.4). The 
lymphocyte-specific enzymes recombination-activating gene 1 (RAG1) and RAG2, as 
well as the general DNA-double strand break repair pathway play an essential role in 
this process (Gellert, 2002; Mombaerts et al., 1992; Shinkai et al., 1992). In humans, 
44 functional VH, grouped into 7 different families, 27 functional DH and 6 functional JH 
segments have been identified (Cook & Tomlinson, 1995; van Dongen et al., 2003). 
For IGK and IGL 43 and 38 functional V and 5 and 4 functional J regions are known 
(van Dongen et al., 2003). In addition to this combinatorial diversity, further 
diversification is achieved during the recombination process through insertions or 
deletions in the joining regions, which increases the heterogeneity of the BCR (Gellert, 
2002; Tonegawa, 1983). And last, activated B cells undergo somatic hypermutation of 
the V region, which leads to almost unlimited diversity of the receptor (Pascual et al., 
1994). Importantly, malignant B cells often use stereotyped B cell receptors with a 
restricted repertoire of V, D and J regions and distinct mutation patterns, implicating the 
stimulation by common antigens in disease pathogenesis (Darzentas & Stamatopoulos, 
2013; Sutton et al., 2013).  
 
T cell receptors are generated by a similar mechanism but do not undergo somatic 
hypermutation (Gellert, 2002). Further, while B cell receptors can recognise both 
soluble and surface-bound antigens and even non-protein substrates, T cells can 
recognise only peptides that are bound to major histocompatibility complex (MHC) 
molecules on the surfaces of other cells (Janeway et al., 2001). 
 
 
Figure 1.4 VDJ recombination.  
VDJ recombination generates a functional IGH chain by altering the genomic 
composition of the IGH locus. 
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1.2.3 B cell development and maturation 
Because the development of B cell malignancies is intricately linked to B cell 
development and activation, these will be reviewed in the following sections. With the 
support of bone marrow stromal cells, B cells develop from haematopoietic stem cells 
into pro- and then pre-B cells (Janeway et al., 2001). During this development, B cells 
rearrange their B cell receptor genes. The heavy chain rearrangement occurs in 
pro-B cells and when a functional µ heavy chain is generated, which means that 
in-frame recombination occurred, the cell becomes a pre-B cell (Boekel et al., 1998; 
Pieper et al., 2013). As there are two IGH alleles, the cell has two chances to generate 
such a functional µ heavy chain or it undergoes apoptosis. The newly generated heavy 
chain and the surrogate light chain then form the pre-B cell receptor, which triggers cell 
division and reorganisation of the IGK light chain genes (Pieper et al., 2013). In 
contrast to the heavy chain locus, each allele can undergo several attempts of 
recombination to generate a functional gene, before recombination of the other allele 
occurs (Langerak & Dongen, 2012). If IGK gene rearrangement is unsuccessful, IGL 
rearrangement is initiated, so that most cells proceed to the next developmental stage 
(Burg et al., 2001). Immature B cells express a functional IgM receptor, consisting of 
IgH and Igκ or Igλ chains (Figure 1.5) (Pieper et al., 2013).  
Immature B cells first home to the spleen, where they develop into marginal zone or 
follicular B cells (Figure 1.5) (Pieper et al., 2013). Marginal zone B cells express 
hypermutated IgM and form the first line of defence against blood-borne pathogens 
(Weill et al., 2009; Weller et al., 2004). In a T cell-independent response, they develop 
into IgM-secreting plasma cells (Oliver et al., 1999; Spencer et al., 1998; Timens et al., 
1989). But most of the B cells in the periphery are follicular B cells that can be found in 
the follicles in spleen and lymph nodes and are involved in the germinal centre reaction 
(Srivastava et al., 2005). In humans, both marginal zone and follicular B cells circulate 
between the lymphoid tissues and the blood until they encounter their antigen and 
become activated (Steiniger et al., 2005; Weller et al., 2004). B cell malignancies can 
develop from pre-B cells (B cell acute lymphocytic leukaemia), from marginal zone or 
follicular B cells and their activated progeny (Rickert, 2013). 
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Figure 1.5 B cell development.  
A haematopoietic stem cell gives rise to a pro-B cell, which activates IGH 
recombination. Upon successful recombination, the pre-B cell receptor is 
expressed and the cell undergoes light chain rearrangement. The immature B cell 
leaves the bone marrow and homes to the spleen, where it develops into either a 
marginal zone or a follicular B cell. If the cell recognises an autoantigen, it can 
undergo receptor editing, become anergic or undergo apoptosis. 
 
 
1.2.4 The humoral immune response 
When the mature B cell encounters its cognate antigen, the BCR is cross-linked and 
signal transduction is triggered. However, to become fully activated, a follicular B cell 
normally requires T cell help. T cells can only provide this, if they have previously been 
primed by an encounter with their antigen on dendritic cells (Mempel et al., 2004; Stoll 
et al., 2002). B cells internalise the Ig-bound antigen, process and present it via their 
MHC class II receptors (Abbas et al., 1985; Zotos & Tarlinton, 2012). They migrate into 
the T cell zone to make contact with primed T cells (Reif et al., 2002) and if a T cell 
recognises the antigen, it stimulates the B cell via cell surface receptors like CD40 
ligand (CD40L) and CD28, as well as cytokines like interleukin-4 (IL-4) and IL-21 
(Figure 1.6) (Damle et al., 1991; Ettinger et al., 2005; Lane et al., 1992; Lederman et 
al., 1992; Zotos & Tarlinton, 2012).  
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Figure 1.6 B cell activation.  
Primed T cells activate antigen-specific B cells through interactions of cell surface 
receptors and cytokines. 
 
 
 
Figure 1.7 The humoral immune response.  
A B cells become activated by T cells. B Some activated B cells develop into 
antigen-secreting plasma cells. C Activated B cells migrate to the B cell follicle, 
proliferate and form a germinal centre. SHM and CSR occur. D B cells with low-
affinity B cell receptors undergo apoptosis. E B cells with high-affinity B cell 
receptors get more T cell help, proliferate and generate plasma (F) or memory 
cells (G). 
 
`` 
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In a first wave of activation, some of the B cells then proliferate in an extrafollicular 
response and develop into antigen-secreting plasma cells (Figure 1.7 A, B) 
(MacLennan et al., 2003). The second phase of the response is characterised by the 
formation of a germinal centre. The activated B cells migrate to the B cell zone and 
proliferate extensively (Figure 1.7 C). Simultaneously, somatic hypermutation (SHM) of 
the variable Ig regions and class switch recombination (CSR) occur (Figure 1.7 C, 
Figure 1.8) (Schmidlin et al., 2009). In both mice and humans, the enzyme activation-
induced cytidine deaminase (AID) is required for these processes (Muramatsu et al., 
2000; Revy et al., 2000). SHM leads to the stochastical generation of cells expressing 
immunoglobulins with higher affinity for the antigen (affinity maturation), which are 
selected for further proliferation and the generation of memory and plasma cells. The 
selection occurs through competition for T cell help. B cells compete with other B cells 
and soluble immunoglobulin for a limiting amount of antigen and cells with higher 
affinity BCRs take up, process and present more antigen and therefore interact with 
antigen-specific T cells more often (Figure 1.7 D, E) (Allen et al., 2007; Shulman et al., 
2014; Y. Zhang et al., 2013). 
CSR results in the genomic recombination of the IGH constant region, deleting Cμ and 
Cδ and replacing it by Cγ, Cε or Cα (Figure 1.8) (Kracker & Durandy, 2011). In this 
process, transcription of the specific switch region upstream of the C segment plays an 
important role (Fujieda et al., 1995; Gauchat et al., 1990; Stavnezer-Nordgren & Sirlin, 
1986). The activation of promoters upstream of the switch regions is regulated by 
cytokines and their combination dictates which immunoglobulin class the B cell 
switches to (Avery et al., 2008; Gascan et al., 1991; Punnonen et al., 1993). Class 
switching changes the properties of the immunoglobulin. Firstly, signalling properties of 
IgG and IgE differ from that of IgM (Sato et al., 2007; Wakabayashi et al., 2002). 
Secondly, effector functions are different. IgA is, for example efficiently exported 
through mucosal epithelia and it triggers anti-inflammatory responses (Cerutti, 2008). 
Serum-IgE has a very short half-life of about two days but can be bound to high-affinity 
FcεRI on mast cells and basophils, which function in the defence of parasites and are 
mediators of atopic diseases (Moon et al., 2009; Stone et al., 2010). IgG can bind to 
inhibitory FcγRII, regulating B cell function, or to activating FcγRI and III to trigger 
macrophage endocytosis, NK cell and neutrophil activation (Anderson et al., 1990; 
Ravetch & Bolland, 2001; Titus et al., 1987). 
The outcome of the germinal centre reaction is the generation of memory and plasma 
cells, which express high affinity, class-switched immunoglobulins (Figure 1.7 F, G) 
(Shlomchik & Weisel, 2012). Plasma cells secrete high amounts of these 
immunoglobulins to mediate the humoral immune response. After elimination of the 
antigen, apoptosis of the B cells leads to germinal centre contraction (Janeway et al., 
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2001). However, long-lived plasma cells can survive in the bone marrow and 
continuously secrete immunoglobulins (Chu & Berek, 2013) and memory B cells can 
survive for decades without repeated antigenic stimulation (Yu et al., 2008). Upon 
repeated encounter with the antigen, a secondary immune response is mediated by 
these cells. They are rapidly activated and generate plasma cells, which secrete high-
affinity immunoglobulin (Good & Tangye, 2007; Liu et al., 1995). 
 
Figure 1.8 Somatic hypermutation and class switch recombination.  
Somatic hypermutation and class switch recombination are both mediated by 
AID. SHM occurs in the VDJ region of the IGH or the VJ region of the IGL chain. 
CSR leads to the excision of circular DNA and religation of the switch regions (S), 
joining the variable with a different constant region.  
 
B cell malignancies can arise from different stages of the germinal centre reaction, from 
memory or plasma cells (Alizadeh et al., 2000; Chiorazzi & Ferrarini, 2011; García-
Muñoz et al., 2012). Thus, some malignancies have activated AID and are 
characterised by on-going somatic hypermutation, which also targets genes other than 
the immunoglobulin loci and can therefore generate oncogenic mutations to facilitate 
tumour progression (Pasqualucci et al., 2004; Pérez-Durán et al., 2007; Ramiro et al., 
2004). Further, malignant cells can present with class-switched immunoglobulins or 
retain IgM and IgD expression (Lanasa & Weinberg, 2011; Ruminy et al., 2011). Like 
their normal counterparts, malignant B cells are often dependent on T cell help via 
CD40L stimulation for their survival (Ito et al., 2012; Os et al., 2013). 
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1.2.5 Self-tolerance 
In the whole process of B cell development, maturation and activation, self-reactive 
immunoglobulins can arise. It has been shown that about 75% of the immature B cells 
in the bone marrow of human subjects react with auto-antigens (Wardemann et al., 
2003). Therefore, a strict control system, eliminating those B cells, must be in place. In 
the bone marrow, autoreactive cells undergo receptor editing (rearrangement of the 
light chain) and if this fails to ablate autoreactivity, they are removed by apoptosis or 
become anergic (Goodnow et al., 1988; Melamed & Nemazee, 1997; Nemazee & 
Bürki, 1989). Both apoptosis and anergy can also be induced in auto-reactive cells in 
the peripheral lymphoid organs and even in the germinal centre (Chan et al., 2012; 
Goodnow et al., 1989; Russell et al., 1991). These mechanisms of immune tolerance 
can often be circumvented by malignant B cells, e.g. via mutations of FAS (Müschen et 
al., 2002) or deregulation of BCL2 proteins (Del Gaizo Moore et al., 2007), allowing for 
their uncontrolled proliferation and survival. 
Anergic cells are unresponsive to antigenic stimulation, have a low IgM but high IgD 
surface expression and a reduced life span (Fulcher & Basten, 1994; Yarkoni et al., 
2010). About 2.5% of the peripheral B cells in humans show an anergic phenotype and 
cannnot be stimulated by cross-linking of either IgM or IgD (Duty et al., 2009). 
However, if these cells are kept in vitro in culture medium over night, they recover their 
ability to be activated (Duty et al., 2009). This is consistent with findings in mice, 
showing that removal of the antigen reverses anergy (Gauld et al., 2005). In agreement 
with these findings, continuous occupancy of and signalling via the BCR promote 
inhibitory downstream effects (Brauweiler et al., 2007; Healy et al., 1997; Merrell et al., 
2006; O’Neill et al., 2011). Further, anergic cells can be activated when T cell help is 
given (Fulcher et al., 1996). Due to the mechanism of antigen presentation to naïve T 
cells in the thymus, these are usually self-tolerant, so that activation of autoreactive B 
cells is prohibited (Yarkoni et al., 2010). In conclusion, anergy is generally induced in B 
cells that are stimulated via the BCR without getting a second signal from T cells. 
Anergy plays an important role in chronic lymphocytic leukaemia, as these cells are 
often autoreactive (see section 1.3.1.2). They do, however, avoid apoptosis, which 
usually follows the induction of anergy, and display an increased life span (Del Gaizo 
Moore et al., 2007; Souers et al., 2013). 
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1.2.6 B cell receptor signalling 
B cell receptor signalling plays a major role in the survival and proliferation of many 
mature B cell malignancies and blocking B cell receptor signalling pathways, for 
example by inhibiting BTK with Ibrutinib, is a promising therapeutic strategy for the 
treatment of several B cell neoplasms (Niemann & Wiestner, 2013). In different 
malignancies, different arms of the BCR pathway play predominant roles and different 
mechanisms for deregulated signalling can be observed (see Section 1.3). While CLL 
cells display chronically active BCR signalling, often without mutations in the BCR 
pathway (Burger & Chiorazzi, 2013), DLBCL cells acquire a plethora of mutations that 
activate BCR signalling (Davis et al., 2010) and Burkitt lymphoma cells are dependent 
on tonic BCR signalling (Schmitz et al., 2012), which is also constitutively active in 
normal B cells. Therefore, the current understanding of normal B cell receptor 
signalling is reviewed in the next section. 
 
1.2.6.1 Activation of upstream BCR signalling pathways 
Antigen binding to the BCR results in intracellular signalling events, triggered by 
crosslinking of the membrane-bound immunoglobulins (Rudich et al., 1988). Depending 
on the strength and nature of the transmitted signal and the presence or absence of co-
stimulatory signals, B cells can be activated, become anergic or even apoptotic 
(Matsuuchi & Gold, 2001). In resting cells, BCRs associate with both positive (e.g. 
CD19, CD45) and negative regulatory co-receptors (e.g. CD5, CD22, CD72) (Monroe, 
2006). 
Signalling is mediated by the clustering of antigen-bound receptors and their relocation 
to lipid rafts (P.C. Cheng et al., 1999; Sohn et al., 2006). This is believed to exclude 
negative co-receptors from BCR complexes to allow stable activation of BCR signalling 
(Monroe, 2006). Upon activation, LYN or other Src-family kinases (SFKs) 
phosphorylate the CD79a and CD79b immunoreceptor tyrosine-based activation motifs 
(ITAMs) (Clark et al., 1992; Schmitz et al., 1996; Sohn et al., 2006). To be activated 
and recruited to the receptor, LYN has to be dephosphorylated at a C terminal tyrosine 
by the phosphatase of the co-receptor CD45 (Pao & Cambier, 1997). CD79 
phosphorylation leads to the recruitment of the spleen tyrosine kinase (SYK) via its 
tandem SH2 domains, which changes its conformation and allows for 
autophosphorylation and activation (Rowley et al., 1995). In a positive feedback loop, 
SYK then amplifies ITAM phosphorylation (Rolli et al., 2002) (Figure 1.9). It was even 
proposed that LYN is only capable of phosphorylating one of the ITAM tyrosine 
residues, resulting in low-affinity SYK recruitment, which then phosphorylates the 
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second tyrosine residue to stimulate its own full activation (Rolli et al., 2002). Monroe 
hypothesised that this can only happen after full activation of the BCR when the 
receptors are clustered in lipid rafts, as SYK would only then be recruited sufficiently 
(Monroe, 2006).  
Non-ITAM tyrosine phosphorylation of CD79a Y204 leads to the recruitment of B cell 
linker protein (BLNK) via its SH2 domain (Engels et al., 2001; Kabak et al., 2002). This 
allows SYK to phosphorylate this adapter protein, which facilitates recruitment of 
downstream effectors, like growth factor receptor-bound protein 2 (GRB2) with son of 
sevenless (SOS), the VAV gauanine nucleotide exchange factors, Bruton’s tyrosine 
kinase (BTK) and phospholipase C γ (PLCγ) via their SH2 domains (Fu et al., 1998; 
Ishiai et al., 1999) (Figure 1.9). Interestingly, GRB2 associates with BLNK in resting 
cells via its SH3 domain and interaction is increased upon BLNK phosphorylation 
through additional SH2 domain binding. However, only activation of the BCR leads to 
localisation of BLNK/GRB2-SOS to the membrane, bringing them into close proximity 
to their target rat sarcoma (RAS) (Fu et al., 1998).  
Binding of BTK to BLNK is required for Y551 phosphorylation by SYK, which leads to 
its activation (Baba et al., 2001). BTK can then phosphorylate and activate PLCγ, 
which is necessary for most downstream signalling events (Rodriguez et al., 2001). 
BTK and PLCγ also have pleckstrin homology (PH) domains, which interact with 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) generated by phosphatidylinositol-3 
kinase (PI3K). This integrates PI3K signalling into the pathway and serves to enhance 
and prolong membrane localisation and activation of BTK and PLCγ (Kurosaki et al., 
2000) (Figure 1.9). 
 
Figure 1.9 Activation of the upstream BCR signalling cascade.  
Phosphorylation of CD79 leads to recruitment of SYK and BLNK, which is 
phosphorylated by SYK to allow for BTK, PLCγ and GRB2 recruitment. SYK 
reinforces CD79 phosphorylation and phosphorylates and activates BTK, which 
then activates PLCγ. 
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1.2.6.2 Calcium signalling 
PLCγ catalyses the hydrolysis of phosphatidylinotisol-4,5-bisphosphate to the second 
messengers inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to 
receptors on the ER and stimulates Ca2+ release (Kurosaki et al., 2000). Elevated 
intracellular Ca2+ activates CaMKII (Valentine et al., 1995) and the phosphatase 
Calcineurin, which targets NFAT. NFAT dephoshorylation results in its nuclear 
translocation and activation of target gene transcription (Choi et al., 1994; 
Venkataraman et al., 1994) (Figure 1.10). 
Further, both Ca2+ and DAG activate different PKC isoforms. PKCs can be divided into 
classical (α, β, γ), novel (δ, ε, η, θ) and atypical (ζ, λ, τ), depending on their structure 
and regulation. Classical PKCs are regulated by both Ca2+ and DAG, novel PKCs are 
regulated by DAG only and atypical PKCs are regulated by neither of the two (Guo et 
al., 2004). In B cells, different PKC isoforms have been shown to be activated 
downstream of the BCR: PKCβ, PKCδ, PKCε and PKCζ (Barbazuk & Gold, 1999; 
Leitges et al., 1996; Martin et al., 2002; Pracht et al., 2007; Ting et al., 2002). PKCη 
seems to play a role in pre-BCR signalling (Oda et al., 2008) and the PKC-related 
proteins PKCµ and PKCν can also be activated upon BCR stimulation (Matthews et al., 
2003; Sidorenko et al., 1996). 
 
 
Figure 1.10 Activation of Ca2+-dependent pathways.  
PLCγ stimulates Ca2+-dependent signalling pathways through the production of 
IP3. Ca2+ activates Calcineurin and thus NFAT, which stimulates transcription. 
Ca2+ and DAG activate classical PKCs and trigger downstream BCR signalling. 
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PKCδ has been shown to play both positive and negative roles in BCR signalling. It is 
required for activation of cAMP response element-binding protein (CREB), which in 
turn is important for B cell proliferation and survival (Blois et al., 2004; Zhang et al., 
2002). On the other hand, PKCδ knockout mice show enhanced production of 
autoreactive B cells and PKCδ loss-of-function causes B cell autoimmunity in humans 
(Belot et al., 2013; Kuehn et al., 2013; Mecklenbräuker et al., 2002; Miyamoto et al., 
2002; Salzer et al., 2013). These effects are due to a function of PKCδ in both negative 
selection of immature B cells and negative regulation of BCR signalling in mature B 
cells. Consistently, PKCδ knockout mice show enhanced phosphorylation of CD79a 
and SYK upon BCR cross-linking (Limnander et al., 2014). 
 
1.2.6.3 Activation of NFκB 
At least in mice, PKCβ has essential and non-redundant functions during BCR 
signalling. PKCβ knockout mice show a phenotype which is comparable to BTK-
deficiency: a reduction in mature B cells, a reduced response to T cell-independent 
antigens and no proliferative response to BCR stimulation (Leitges et al., 1996). In both 
primary B cells from mouse and human B cell lines, PKCβ has been shown to activate 
the inhibitor of nuclear factor κB (NFκB) kinase (IKK), and thus NFκB, through 
activation of the adapter protein caspase recruitment domain (CARD)-containing and 
membrane-associated guanylate kinase (MAGUK) protein (CARMA1). PKCβ 
phosphorylates the CARMA1 linker domain, relieving its autoinhibition and facilitating 
the interaction with the BCL10 CARD domain (Sommer et al., 2005). BCL10 forms a 
complex with mucosa-associated lymphoid tissue lymphoma translocation gene 1 
(MALT1) and the E2 complex UBC13-MMS2 (Zhou et al., 2004) (Figure 1.11). The 
active complex contains BCL10-MALT1 oligomers (Sun et al., 2004). In T cells, both 
the E3 ligases mind bomb 2 (MIB2) and tumour necrosis factor (TNF) receptor-
associated factor 6 (TRAF6) have been described to associate with the complex to 
mediate autoubiquitination and ubiquitination of target proteins (Stempin et al., 2011; 
Sun et al., 2004). PKCδ has been shown to inhibit CARMA1 function in a kinase-
independent fashion by blocking its association with MALT1 and TRAF6 (Liu et al., 
2012). 
Ubiquitination of MALT1 and BCL10 have been shown to mediate interaction with the 
NFκB essential modulator (NEMO), the IKK inhibitory subunit (Oeckinghaus et al., 
2007; Wu & Ashwell, 2008) (Figure 1.11). Then, NEMO is ubiquitinated by K63-linked 
ubiquitin chains, which does not lead to its degradation but is essential for sustained 
NFκB activation (Zhou et al., 2004). Further, autoubiquitination of the E3 ligase 
generates a binding site for the TGF-beta activated kinase 1 (TAK1) binding proteins 2 
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and 3 (TAB2/3) which form a complex with TAK1 (Kanayama et al., 2004). TAK1 is 
activated by autophosphorylation and can then phosphorylate and activate IKKβ 
(Stempin et al., 2011; Sun et al., 2004) (Figure 1.11). 
Active IKKβ contributes to CARMA1 activation in a feedforward loop by 
phosphorylating the linker domain (Shinohara et al., 2007). Further, IKK now 
phosphorylates IκBα, targeting it for ubiquitination and degradation (Chen et al., 1996; 
Traenckner et al., 1995). NFκB can then translocate into the nucleus and activate 
target gene transcription (Figure 1.11), including genes encoding caspase inhibitors, 
like the cellular inhibitors of apoptosis (IAPs) and FLICE-like inhibitory protein (FLIP), 
the antiapoptotic proteins BCL2 and BCL-XL, proteins that drive proliferation, like cyclin 
D1/D2 and MYC, as well as cytokines like TNF, IL1, IL2, IL6, and the immunmodulators 
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) (Stoffel, 2005; 
Tracey et al., 2005). 
 
 
Figure 1.11 Activation of the NFκB pathway.  
Activation of the NFκB transcription factor is mediated via PKC-dependent 
activation of CARMA1, which associates with BCL10, MALT1 and ubiquitin 
ligases to facilitate recruitment and activation of the IKK complex. The active IKK 
phosphorylates IκBα and leads to its degradation, allowing for nuclear 
translocation of NFκB. 
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1.2.6.4 Activation of the RAS/RAF/MEK/ERK pathway 
Activation of the PLCγ-PKC pathway is also important for the activation of the 
RAS/RAF/MEK/ERK pathway. This pathway generally regulates cell adhesion and 
migration, cell cycle progression, cell survival and proliferation but also differentiation 
(Roskoski Jr., 2012). In B cells, ERK stimulates pre-B cell expansion, but is also 
required for their cell cycle exit and IGK rearrangement (Mandal et al., 2009; Yasuda et 
al., 2008). Further, ERK activity is required for the transition of immature to mature B 
cells and for the BCR-induced proliferation of mature B cells (Richards et al., 2001; 
Rowland et al., 2010; Teodorovic et al., 2014). 
The activity of the guanosine triphosphatase (GTPase) RAS is regulated by binding of 
GTP (active) and GDP (inactive). Guanine nucleotide exchange factors (GEFs), like 
SOS and RAS guanine nucleotide releasing proteins (RASGRPs) stimulate exchange 
of GDP for GTP, whereas GTPase-activating proteins (GAPs) stimulate the RAS 
intrinsic GTPase. RAS-GTP activates the RAF/MEK/ERK pathway (Campbell et al., 
1998). Surprisingly, GRB2-SOS recruitment to BLNK is not sufficient for RAS 
activation, whereas a different pathway using RASGRP3 is essential (Coughlin et al., 
2005; Oh-hora et al., 2003; Roose et al., 2007). RASGRP3 is recruited to the plasma 
membrane by the PLCγ substrate DAG via its C1 domain (Oh-hora et al., 2003). It is 
then activated by T133 phosphorylation, possibly directly mediated by PKC (Zheng et 
al., 2005). In a positive feed forward loop, RAS-GTP allosterically activates SOS, which 
can then contribute to RAS activation and both RASGRPs and SOS are required for full 
and sustained activation of the RAF/MEK/ERK pathway (Roose et al., 2007) (Figure 
1.12). 
RAS-GTP recruits RAF kinases to the membrane, where they can be activated through 
phosphorylation and dephosphorylation events (Wellbrock et al., 2004). Both RAF1 and 
BRAF are expressed in B cells and both kinases are required for full activation of 
immediate early gene expression, while only BRAF is essential for sustained activation 
of ERK (Brummer et al., 2002). RAF phosphorylates two serine residues in MEK1 and 
MEK2 and activates them. MEKs can then phosphorylate ERK1/2 on threonine and 
tyrosine residues (Wellbrock et al., 2004) (Figure 1.12). 
Activated ERKs phosphorylate nuclear and cytosolic substrates. In the cytosol ERKs 
mainly phosphorylate other kinases, like ribosomal S6 kinases (RSK1-4), mitogen and 
stress-activated protein kinases (MSK1/2) and MAP kinase-interacting kinases 
(MNK1/2) (Roskoski Jr., 2012). RSKs and MSKs phosphorylate and activate or 
stabilise the transcription factors CREB and FOS, respectively. (Chen et al., 1993; 
Deak et al., 1998; Pierrat et al., 1998). Further, RSKs have been shown to 
phosphorylate and inactivate glycogen synthase kinase 3β (GSK3β) (Figure 1.12), 
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thereby inhibiting its repressive phosphorylation of a plethora of substrates, like NFAT, 
JUN, cyclin D1 and the translation initiation factor eIF2B (Diehl et al., 1998; Neal & 
Clipstone, 2001; Nikolakaki et al., 1993; Sutherland et al., 1993; Welsh & Proud, 1993). 
They also promote cap-dependent translation via phosphorylation of the ribosomal 
protein S6 and the translation initiation factor eIF4B, which is a cofactor for the eIF4A 
RNA helicase (Lawson et al., 1989; Roux et al., 2007; Shahbazian et al., 2006). 
Moreover, RSKs can inhibit apoptosis by phosphorylating and inhibiting BCL2-
associated agonist of cell death (BAD) at S112 and death-associated protein kinase 
(DAPK1) (Anjum et al., 2005; Bonni et al., 1999; Shimamura et al., 2000). Additionally, 
RSK2 and MSK1/2 are capable of phosphorylating histone H3 at serine 10 and 
serine 28 to regulate transcription (He et al., 2003; Sassone-Corsi et al., 1999; Soloaga 
et al., 2003). 
 
 
Figure 1.12 Stimulation of the RAS/RAF/MEK/ERK pathway.  
Activation of the RAS/RAF/MEK/ERK pathway is predominantly mediated via 
RASGRP3, while SOS is subsequently activated by RAS-GTP. RAS activates 
RAF, which phosphorylates MEK1/2, which in turn activates ERK1/2. ERK targets 
RSKs and MSKs and activates transcription factors. RSKs and MSK stimulate 
cap-dependent translation and gene expression. 
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ERK1/2 can also directly phosphorylate anti-apoptotic proteins, like BCL2-interacting 
mediator of cell death (BIMEL) (Ley et al., 2004; Luciano et al., 2003; Marani et al., 
2004). Further, transcription factors of the ETS family, ELK1, ELK3 and ELK4 as well 
as ETS1 and ETS2 can be phosphorylated and activated by ERK1/2, which leads to 
the expression of immediate early genes, like FOS, MYC and EGR1 (Ducret et al., 
2000; Gille et al., 1992; Janknecht et al., 1995; Marais et al., 1993; Paumelle et al., 
2002; Seidel & Graves, 2002; Yang et al., 1996; Yang et al., 1998). In addition, the 
activator protein 1 (AP1) transcription factors FOS and JUN can be phosphorylated by 
ERK1/2 and RSKs, which leads to their stabilisation or activation, respectively (Morton 
et al., 2003; Okazaki & Sagata, 1995) (Figure 1.12). MYC is also phosphorylated and 
stabilised through RAS-dependent phosphorylation, which is most likely directly 
mediated by ERKs (Murphy et al., 2004; Sears et al., 2000). 
 
1.2.6.5 Activation of the PI3K/AKT pathway 
Class IA PI3Ks (α, β and δ) consist of a catalytical p110 and one of five regulatory p85-
family subunits, which are SH2 domain-containing adapter proteins (Limon & Fruman, 
2010; Okkenhaug et al., 2007). The p85 proteins normally block p110 activity via 
inhibitory interactions of their SH2 domains with the p110 subunit, which are relieved 
when the SH2 domains bind phospho-tyrosine, leading to PI3K activation (Burke et al., 
2011; X. Zhang et al., 2011). 
PI3Kδ is highly expressed in B cells and plays the dominant role in BCR signalling 
(Bilancio et al., 2006; Clayton et al., 2002; Jou et al., 2002; Okkenhaug et al., 2002). 
p85 can directly bind to two phosphorylated YXXM motifs in the CD19 intracellular 
domain (Tuveson et al., 1993) and this binding is essential for normal B cell activation 
(Y. Wang et al., 2002). The phosphorylation of CD19 Y513 is directly mediated by LYN 
(Fujimoto et al., 2000; van Noesel et al., 1993; Roifman & Ke, 1993), but apart from 
Y513, Y482 phosphorylation by an as yet unknown kinase is essential for PI3K 
recruitment and activation (Ishiura et al., 2010) (Figure 1.13). 
As mice lacking p85α have a much more severe phenotype than CD19 knockout mice, 
additional pathways must be in place that activate PI3K (Engel et al., 1995; Fruman et 
al., 1999). Indeed, PI3K can also bind to the B cell adaptor for PI3K (BCAP) (Okada et 
al., 2000), which is recruited to CD79a by the adaptor NCK. NCK binds the non-ITAM 
Y204p, which is phosphorylated in a LYN-dependent manner (Castello et al., 2013). 
BCAP carries proline-rich regions and is recruited by the NCK SH3 domains (Castello 
et al., 2013). BCAP phosphorylation by SYK and BTK generates binding sites for the 
p85 subunit of PI3K (Okada et al., 2000) (Figure 1.13). Knockout of both BCAP and 
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CD19 leads to an almost complete inhibition of PI3K activation upon CD79b cross-
linking, suggesting that these two pathways are sufficient for PI3K activation (Aiba et 
al., 2008). 
However, PI3K can also be activated via the GEF VAV. VAV1/2/3 are recruited to both 
CD19 and BLNK via their SH2 domains (Fu et al., 1998; O’Rourke et al., 1998), are 
activated through tyrosine phosphorylation by SYK or LYN (Deckert et al., 1996; 
Fujimoto et al., 2000) and function as RHO and RAC GEFs (Crespo et al., 1997; 
Movilla & Bustelo, 1999; Schuebel et al., 1998). RHO and RAC GTPases regulate 
cytoskeletal reorganisation and VAV has been shown to be essential for BCR 
internalisation (Malhotra et al., 2009). Further, RAC1-GTP directly binds to and 
stimulates PI3K (Inabe et al., 2002; Murga et al., 2002; Reynolds et al., 2002) (Figure 
1.13). 
 
Figure 1.13 Activation of PI3K.  
Activation of PI3K is mediated by different mechanisms. CD19 directly recruits 
and activates PI3K. Additionally, the NCK-BCAP complex, which associates with 
CD79, can be phosphorylated by BTK and mediate PI3K recruitment and 
activation. Additionally, RAC-GTP, induced by VAV, can interact with and activate 
PI3K. 
 
After activation, PI3K phosphorylates PI-4,5-P2 to generate PI-3,4,5-P3, which serves 
as a docking molecule for pleckstrin homology (PH) domain-containing proteins, like 
BTK and PLCγ (Figure 1.13). This increases membrane recruitment and prolongs 
signalling via these pathways (Fruman & Limon, 2012). The best characterised PI3K 
signal transduction pathway leads to the activation of protein kinase B (PKB/AKT). AKT 
has a PH domain and binding to PIP3 results in a conformational change, which is 
necessary for AKT activation by the downstream kinase PDK1 (Milburn et al., 2003). 
PDK1 is also recruited to PIP3 and this recruitment is necessary for its activity towards 
AKT (Alessi et al., 1997; McManus et al., 2004; Stokoe et al., 1997). PDK1 
phosphorylates AKT at a threonine in the activation loop (Alessi et al., 1997; Stokoe et 
al., 1997). A second residue in the C-terminal hydrophobic domain is phosphorylated 
mainly by mammalian target of rapamycin complex 2 (mTORC2), which is also directly 
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regulated by PIP3 (Gan et al., 2011; Sarbassov et al., 2005) (Figure 1.14). Although this 
phosphorylation does not activate AKT, it increases PDK1-dependent phosphorylation. 
Therefore, phosphorylation of the hydrophobic domain likely precedes activation of 
AKT by PDK1 under physiological conditions (Scheid et al., 2002). 
AKT suppresses apoptosis by targeting BAD-S136 (Datta et al., 1997) and forkhead 
box O (FOXO) transcription factors. AKT-mediated phosphorylation of FOXOs in the 
nuclear localisation sequence (NLS) leads to their nuclear export (Figure 1.14). FOXO 
transcription factors stimulate the expression of genes encoding for pro-apoptotic 
proteins, like BIM and FAS ligand (FASL), and negative cell cycle regulators, like 
p21CIP1, p27KIP1 and cyclin G2, but also genes that protect cells from environmental 
stress, like the DNA repair factor growth arrest and DNA damage 45 (GADD45), 
superoxide dismutase (MnSOD) and catalase (Greer & Brunet, 2005). Conversely, 
FOXO1 is also required for the expression of genes that are essential for B cell 
function, like RAG1, RAG2 and AID (Dengler et al., 2008). Consistently, AKT activation 
leads to suppression of CSR (Omori et al., 2006). 
 
 
Figure 1.14 The PI3K/AKT pathway.  
The production of PIP3 leads to the activation of PDK1, mTORC2 and 
subsequently AKT. AKT inhibits apoptosis and stimulates cell proliferation 
through inhibition of GSK3β and FOXO transcription factors and the activation of 
mTORC1 by inhibiting the TSC complex and phosphorylating PRAS40. mTORC1 
enhances cap-dependent translation and anabolic processes. 
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AKT also stimulates cell survival and proliferation by phosphorylating and inhibiting 
GSK3β (van Weeren et al., 1998) and by activating mTORC1. AKT can phosphorylate 
and inactivate the GAP tuberous sclerosis complex (TSC1/2), thus increasing GTP-
bound RAS homolog enriched in brain (RHEB-GTP) in the cell (Dan et al., 2002; Inoki 
et al., 2002; Inoki et al., 2003; Manning et al., 2002; Potter et al., 2002; Tee et al., 
2003). RHEB-GTP stimulates mTORC1 activity by a yet unknown mechanism (Wang & 
Proud, 2011). AKT also directly phosphorylates the inhibitory proline-rich AKT 
substrate of 40 kDa (PRAS40) subunit of mTORC1, leading to its dissociation and 
binding to 14-3-3 proteins (Kovacina et al., 2003; Sancak et al., 2007; Vander Haar et 
al., 2007) (Figure 1.14). This step is crucial for the activation of mTORC1 (Vander Haar 
et al., 2007).  
Among others, mTORC1 regulates mRNA translation and protein synthesis through the 
phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) 
and ribosomal S6 kinases (S6K1/2), thereby leading to cell growth and cell cycle 
progression (Hay & Sonenberg, 2004; Laplante & Sabatini, 2012). Further, mTORC1 
inhibits autophagy and stimulates lipid and glucose metabolism (Düvel et al., 2010; Kim 
et al., 2011). Particular functions for mTORC1 in B cells have not been studied in 
detail, but knockout of mTOR in murine B cells leads to reduced formation of germinal 
centres and impaired CSR because of a decrease in AID due to increased AKT activity 
(S. Zhang et al., 2013). Conversely, deletion of TSC1, which leads to a hyperactive 
mTORC1, also impairs germinal centre formation and response to T cell-dependent 
antigens (Benhamron & Tirosh, 2011). 
 
1.2.6.6 Negative regulators of BCR signalling 
Negative coreceptors for the BCR are FcγRIIB, Fc receptor-like (FCRL2-5), CD22, 
sialic acid-binding Ig-like lectin 10 (SIGLEC10), platelet/endothelial cell adhesion 
molecule 1 (PECAM1), leukocyte immunoglobulin-like receptor, subfamily B 
(LILRB1/2), leukocyte-associated Ig-like receptor 1 (LAIR1), programmed cell death 1 
(PD1) and CD72 (Tsubata, 2012; Verbrugge et al., 2006). The negative coreceptors 
CD22 and SIGLEC10 recognise sialic acid residues, which are abundant on 
mammalian but not bacterial cells, possibly dampening B cell responses particularly 
towards self-antigens (Lanoue et al., 2002; Tsubata, 2012). FcγRIIB binds the Fc 
portion of IgG, thus negatively regulating B cell responses when circulating IgG levels 
are already high (Heyman, 2003). CD72 binds CD100, which is expressed on T cells, 
activated B cells and activated antigen-presenting cells. Ligand binding to CD72 
inhibits its activity, therefore enhancing antigen response by B cells (Kumanogoh et al., 
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2000). Generally, most of these inhibitory co-receptors recruit phosphatases, the main 
negative regulators of BCR signalling.  
Immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in negative coreceptors, like 
CD22, FcγRIIB and PECAM1 have been shown to be targeted by LYN (Nishizumi et 
al., 1998; Tourdot et al., 2013). Their phosphorylation leads to the recruitment of SH2 
domain-containing phosphotyrosine phosphatases (SHP1, SHP2) or SH2 domain-
containing inositol polyphosphate-5-phosphatase (SHIP) (Doody et al., 1995; Okazaki 
et al., 2001; Ono et al., 1996; Tridandapani et al., 1997) (Figure 1.15). SHIP can also 
bind to monophosphorylated CD79 in anergic B cells, where it is constitutively active 
and required for their phenotype (O’Neill et al., 2011). Further, SHIP is recruited by the 
adapter docking protein 3 (DOK3), which is constitutively localised to the plasma 
membrane via its PH domain and is phosphorylated by LYN upon BCR stimulation 
(Lemay et al., 2000). SHIP targets PIP3, thereby inactivating the PI3K pathway and 
limiting activation of BTK and PLCγ (Damen et al., 1996; Nitschke, 2005). Possible 
SHP1/2 targets include CD79, SYK, BTK and BLNK (Adachi et al., 2001; Huang et al., 
2003; Jang et al., 2014; Maeda et al., 1999; Mizuno et al., 2000; Okazaki et al., 2001) 
(Figure 1.15). SHP1 has also been shown to target VAV1 (Stebbins et al., 2003) and 
actin, leading to actin depolymerisation (Baba et al., 2003). 
FcγRIIB can also activate phosphatase and tensin homolog (PTEN), an inositol 
polyphosphate-3-phosphatase that targets PI-3,4-P2 and PIP3, thereby regulating the 
PI3K-AKT pathway (Brown et al., 2004) (Figure 1.15). Generally, inactive PTEN is 
intramolecularly folded, which inhibits its membrane localisation and activity. Releasing 
this autoinhibition by different mechanisms activates the enzyme. This can be 
facilitated by enhanced membrane recruitment after phosphorylation and SUMOylation 
or by protein-protein interactions (J. Huang et al., 2012; Shi et al., 2012; Song et al., 
2012). On the other hand, phosphorylation, acetylation and oxidation can inhibit PTEN 
and ubiquitination targets it for degradation (Shi et al., 2012; Song et al., 2012). 
Adapter proteins can mediate phosphatase-independent inhibitory effects. DOK1 binds 
RASGAP and inhibits the ERK pathway (Tamir et al., 2000; Yamanashi et al., 2000) 
(Figure 1.15). It was first proposed that SHIP is required to recruit DOK1 to the plasma 
membrane (Tamir et al., 2000), but a subsequent study found that SHIP is not required 
for DOK1 recruitment (Phee et al., 2001). Consistently, in T cells and fibroblasts, the 
PH domains of DOK1 and DOK2 bind PI-5-P, PI-3,4-P2, PI-4,5-P2 and PI-3,4,5-P3 and 
this is necessary for their membrane recruitment and function as repressors of 
signalling (Guittard et al., 2009; Zhao et al., 2001). DOK3 does not bind RASGAP, but 
associates with GRB2, which is required to attenuate SYK activation and Ca2+ flux 
(Lösing et al., 2013; Stork et al., 2007) (Figure 1.15). 
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Further, kinases function as negative regulators of BCR signalling. Some of the 
negative coreceptors recruit the C-terminal SRC kinase (CSK), which negatively 
regulates SFKs (Okada, 2012; Sayós et al., 2004; Verbrugge et al., 2006) and PKCβ is 
involved in a negative feedback loop by phosphorylating an inhibitory serine residue of 
BTK (Figure 1.15). Consistently, PKCβ inhibition results in an increased Ca2+ signal 
upon BCR cross-linking (Kang et al., 2001). 
 
 
Figure 1.15 Inhibitory BCR signalling.  
Negative regulation of B cell receptor signalling is mediated by inhibitory co-
receptors and membrane-associated adapter proteins (DOKs). LYN-mediated 
phosphorylation of negative co-receptors leads to the recruitment of SHIP, which 
targets PIP3, and SHP, which inhibits BTK, BLNK, CD79 and SYK. FcγRII 
activation stimulates PTEN, which inhibits the AKT pathway. DOK3 recruits 
GRB2, which attenuates SYK-signalling, DOK1 inhibits activation of RAS. CSK 
phosphorylates and inhibits LYN, while PKCβ negatively regulates BTK. 
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1.3 B cell malignancies 
As mentioned earlier, malignant B cells can arise from different stages of the 
differentiation and maturation process. The World Health Organisation (WHO) 
classifies B cell malignancies into precursor and mature B cell neoplasms. Among 
others, mature B cell neoplasms include non-Hodgkin lymphomas (NHLs), like chronic 
lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone 
lymphomas, follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma 
(DLBCL) and Burkitt lymphoma (BL), Hodgkin lymphoma and plasma cell malignancies 
(myeloma, plasmacytoma) (Jaffe, 2009; Shankland et al., 2012). Of note, CLL and SLL 
are essentially the same disease at different stages. CLL shows peripheral blood 
involvement, while SLL is mainly restricted to tissue sites. Therefore, the WHO 
classifies CLL as an NHL (Harris et al., 1999). 
In this study, the NHLs CLL, DLBCL and BL were of special interest. NHL is the fifth 
most common cancer in the UK and about 90% of the cases derive from B cells, the 
remaining 10% are T or NK cell malignancies (Shankland et al., 2012). While most 
NHLs are indolent diseases, DLBCL and BL are classified as aggressive lymphomas.  
 
1.3.1 Chronic lymphocytic leukaemia (CLL) 
CLL is the most common leukaemia in the Western world. Patients are diagnosed at a 
median age of over 70 years and about two thirds of patients are male (Catovsky et al., 
1989; Shankland et al., 2012; Zhang & Kipps, 2014). Patients present with a clonal 
expansion of CD5+ B cells in the blood and lymphoid tissues. CLL is a heterogeneous 
disease and can be divided into two subgroups, depending on whether the BCR is 
mutated (M-CLL) or unmutated (UM-CLL). The BCR is classified as unmutated when 
the VH region is at least 98% identical to germ line. UM-CLL has a poor prognosis, 
whereas M-CLL patients have a much longer overall survival (Hamblin et al., 1999). 
 
1.3.1.1 B cell receptor signalling in disease pathogenesis 
Generally, CLL cells use stereotyped BCRs. VH1, several VH3 and some VH4 alleles, 
usually combined with a restricted set of D and J segments, are significantly 
overrepresented in CLL cells compared to normal CD5+ B cells (Fais et al., 1998; 
Messmer et al., 2004; Murray et al., 2008; Tobin et al., 2004; Widhopf II et al., 2004). 
The heavy chain complementarity-determining region 3 (HCDR3), which is formed by 
part of the V, all of the D and part of the J regions, is commonly longer in BCRs of UM-
CLL patients and long HCDR3s have been associated with polyreactivity (Aguilera et 
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al., 2001; Murray et al., 2008). Also, HCDR3 regions of receptors using the same VH 
segment in different patients are stereotyped independent of their length and mutation 
status of the receptor (Hervé et al., 2005; Tobin et al., 2003; Tobin et al., 2004). All 
these observations suggest that stimulation by common antigens plays an essential 
role in CLL pathogenesis. 
Consistently, BCRs of most UM-CLL and some M-CLL cells are polyreactive towards 
autoantigens and various microbial molecules (Bröker et al., 1988; Hervé et al., 2005; 
Myhrinder et al., 2008; Sthoeger et al., 1989). Other monoreactive M-CLL BCRs 
display high affinity towards fungal antigens, which stimulate their proliferation 
(Hoogeboom et al., 2013). Also, CLL BCRs have recently been described to recognise 
regions in adjacent Ig molecules, leading to constitutive BCR cross-linking and auto-
activation. This feature is independent of the mutation status but mediated by the 
HCDR3 region (Binder et al., 2013; Minden et al., 2012). Consistently, CLL cells do 
show features of constant antigen engagement in vivo and generally express low levels 
of surface IgM (Krysov et al., 2010).  
In agreement with an important role for BCR signalling in disease pathogenesis, 
stronger responses to BCR cross-linking in vitro are linked with poor clinical outcome 
(Cesano et al., 2013; Roy et al., 2012) and several components of the BCR signalling 
pathway are deregulated in CLL cells. Both LYN and SYK are overexpressed and 
constitutively active (Buchner et al., 2009; Contri et al., 2005) and in contrast to non-
malignant cells, UM-CLL cells often overexpress the SYK family kinase Zeta-chain-
associated protein kinase 70 (ZAP70), which associates with CD79b and enhances 
signalling in response to IgM crosslinking independent of its kinase activity (L. Chen et 
al., 2002; Chen et al., 2008). BTK activation after BCR cross-linking is enhanced in 
CLL cells compared to normal B cells (Cheng et al., 2014). CLL cells also have higher 
levels of nuclear NFκB compared to normal B cells (Furman et al., 2000) and some 
patients display constitutive phosphorylation of ERK1/2 (Muzio et al., 2008). Further, 
the PI3K/AKT pathway is constitutively active (Ringshausen et al., 2002; Zhuang et al., 
2010). 
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1.3.1.2 Anergy in CLL 
In vivo, UM-CLL cells show a more pronounced BCR gene expression signature than 
M-CLL cells and in vitro most UM-CLL cells respond better to IgM cross-linking and 
show a stronger proliferative response than M-CLL cells (Guarini et al., 2008; 
Herishanu et al., 2011; Lanham et al., 2003). However, most cells respond to IgD and 
CD79 cross-linking and can recover responsiveness to IgM cross-linking after 
incubation in vitro, indicating that the underlying mechanism of unresponsiveness is 
anergy (Lanham et al., 2003; Mockridge et al., 2007). This is consistent with the 
constant antigen exposure and the resulting low surface IgM expression of CLL cells 
(Gauld et al., 2005; Krysov et al., 2010). Moreover, unresponsive CLL cells have been 
shown to have constitutively active ERK1/2 and NFAT but not AKT, features that 
resemble murine anergic B cells (Muzio et al., 2008).  
Anergy is more often seen in M-CLL and therefore correlates with a good prognosis 
(Mockridge et al., 2007). However, anergy participates in CLL development as it 
increases the survival of CLL cells in vitro (Apollonio et al., 2013). This finding was 
surprising, as anergic cells normally have a short life span, which is linked to BIM-
mediated apoptosis (Enders et al., 2003; Oliver et al., 2006). Indeed, CLL cells express 
high levels of BIM, but its function is counteracted by simultaneous overexpression of 
BCL2 and targeting BCL2 in CLL leads to rapid induction of apoptosis (Del Gaizo 
Moore et al., 2007; Souers et al., 2013). Further, like CLL cells, anergic B cells fail to 
differentiate into plasma cells and it was recently shown that anergy is also linked to 
the maturation defect of CLL B cells (Duckworth et al., 2014). The data indicate that the 
chronic nature of CLL is intricately linked to the induction of anergy in conjunction with 
a defect in apoptosis. 
 
1.3.1.3 Cell of origin 
The cell of origin of CLL is still a matter of on-going debate. It was believed that CLL 
cells might derive from naturally occurring CD5+ B cells, which normally represent a 
minor population of B cells and might be a counterpart of murine CD5+ B1 cells. They 
are seen as the source of natural antibodies, which are constitutively secreted, 
polyreactive and usually unmutated immunoglobulins (Dono et al., 2004). However, the 
question whether a B1 cell compartment exists in humans has still not been resolved. 
Consistently, CD5 can be upregulated on conventional activated B cells and is 
associated with anergy and receptor editing (Gagro et al., 2000; García-Muñoz et al., 
2012; Hillion et al., 2005; Hippen et al., 2000; Morikawa et al., 1993; Zupo et al., 1994). 
CD5 functions as a co-receptor for the BCR and directly associates with it (Lankester et 
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al., 1994). It has been shown to be phosphorylated by LYN, to recruit SHP1 (Tibaldi et 
al., 2011) and to attenuate BCR-induced PLCγ activation, Ca2+ signalling and ERK 
phosphorylation (Gary-Gouy et al., 2000; Gary-Gouy, Harriague, Dalloul, et al., 2002). 
Conversely, CD5 seems to play a positive role in the activation of signal transducer and 
activator of transcription 3 (STAT3) and NFAT2 and the production of IL-10, which 
promotes cell survival (Garaud et al., 2011; Gary-Gouy, Harriague, Bismuth, et al., 
2002). 
Due to the finding that CD5 is a dynamically expressed surface molecule and does not 
distinguish one specific B cell subset, other hypotheses on the cell of origin were 
proposed. CLL cells might derive from marginal zone B cells, as these can have both 
mutated and unmutated BCRs, which are often polyreactive, and, like CLL cells, they 
display a memory phenotype (Chiorazzi & Ferrarini, 2011) (Figure 1.16 A). 
Alternatively, M-CLL cells might be derived from germinal centre cells that have 
generated an autoreactive BCR during SHM and have then become anergic, while UM-
CLL cells are autoreactive, anergic pre-germinal centre cells (García-Muñoz et al., 
2012) (Figure 1.16 B). 
 
Figure 1.16 Possible cells of origin for CLL clones.  
A CLL cells could be derived from marginal zone memory B cells, which are often 
polyreactive and can have mutated BCRs. B Alternatively, UM-CLL cells could be 
derived from pre-germinal centre B cells, which have become anergic due to 
autoreactivity, while M-CLL cells could be develop from germinal centre cells that 
have become autoreactive and anergic. 
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1.3.1.4 The microenvironment in disease pathogenesis 
Similar to normal B cells, CLL cells depend on stimulation from other cell types like 
stromal cells, nurse-like cells (NLCs) and T cells for proliferation and survival 
(Bhattacharya et al., 2011; Burger et al., 2000; Lagneaux et al., 1998; Os et al., 2013; 
Patten et al., 2008). In absence of these stimuli in cell culture, CLL cells undergo 
spontaneous apoptosis (Burger et al., 2000; Lagneaux et al., 1998). In vivo, 
proliferation occurs at specific tissue sites, so called pseudofollicles in the lymph nodes 
(Donhuijsen et al., 1983; Herishanu et al., 2011). Homing to lymphoid tissues first 
requires transendothelial migration (TEM) and CLL cells express CCR7, the receptor 
for CCL21 and CCL19, which is required for TEM (Till et al., 2002). Further, CLL cells 
in the blood express high levels of CXCR4 and CXCR5 which allow them to home to 
specific areas in the lymphoid tissues, where stromal cells and NLCs produce the 
ligands CXCL12 and CXCL13 (Burger et al., 1999; Bürkle et al., 2007; Dürig et al., 
2001; Möhle et al., 1999). These molecules do not only serve as chemoattractants but 
provide potent pro-survival signals as well (Burger et al., 2000; O’Hayre et al., 2010; 
Ticchioni et al., 2007). Binding of the chemokines leads to receptor endocytosis and 
BCR stimulation downmodulates the receptors, so that tissue CLL cells have low levels 
of CXCR4/5, which facilitates their recirculation to the blood (Burger et al., 1999; 
Burger et al., 2000; Bürkle et al., 2007; Calissano et al., 2011; Vlad et al., 2009). 
Consistently, recently stimulated, proliferating Ki67+ CLL cells display lower CXCR4/5 
surface expression (Bennett et al., 2007). Cells in the blood, where stimulatory signals 
are low or absent, then upregulate CXCR4/5 again, which allows for their remigration 
into lymphoid tissues (Calissano et al., 2011; Herishanu et al., 2011). These same cells 
also show higher levels of surface IgM, consistent with the in vitro findings that 
absence of stimulation leads to upregulation of the receptor. They are most responsive 
to BCR stimulation in vitro and most likely represent the subset of cells that can 
proliferate upon stimulation in the lymph node (Coelho et al., 2013) (Figure 1.17). 
In total, 0.1% to 13.8% of cells in the peripheral blood are Ki67+ (Damle et al., 2007) 
and, depending on the patient, between 0.1% and over 1% of the CLL cells are newly 
generated each day. As most of the patients show very little change in white blood cell 
counts, the proliferation must be counterbalanced by apoptosis (Messmer et al., 2005). 
Consistently, apoptotic cells make up 0.5% to over 10% of the CLL cells in the 
peripheral blood (Cheng et al., 2014). Therefore, CLL is a very dynamic disease and a 
shift in the balance between proliferation and apoptosis leads to either progression or 
regression. 
 
 
- 30 - 
 
 
 
 
Figure 1.17 CLL cells depend on the microenvironment for proliferation.  
In pseudofollicles the cells receive proliferation and survival signals from stromal, 
nurse-like (NLC) and T cells. Downregulation of the BCR and chemokine 
receptors leads to their egress into the circulation, where the lack of stimulation 
leads to reexpression of the receptors. Cells then either enter the tissue again or 
undergo apoptosis. 
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1.3.2 Diffuse large B cell lymphoma 
DLBCL accounts for about one third of the NHL cases and is a heterogeneous disease 
(Shankland et al., 2012). One of the hallmarks of DLBCL is the frequent genomic 
aberration, which facilitates abnormal cell proliferation and survival and arises through 
spontaneous mutations, genomic translocation, copy number variations or aberrant 
somatic hypermutation (ASHM) (Bea et al., 2005; Pasqualucci et al., 2001). Most, if not 
all, DLBCL cases express AID and show ASHM, which recurrently targets a number of 
genes. ASHM requires active transcription and usually targets regions up to 2 kb 
downstream of the TSS (Pasqualucci et al., 2001). Apart from ASHM, AID is likely to 
play a role in chromosomal translocations because these are usually observed 
between genes that are targeted by ASHM and the switch regions of the IgH locus and 
their frequency correlates with AID expression levels (Lenz et al., 2007). 
Depending on the gene expression profile, DLBCLs have been grouped into germinal-
centre B cell-like (GCB), activated B cell-like (ABC) and type 3 DLBCL (Alizadeh et al., 
2000; Rosenwald et al., 2002; Wright et al., 2003). GCB-DLBCL cells derive from 
activated germinal centre (GC) B cells and about 85% of the cases express BCL6 
(Iqbal et al., 2007). ABC-DLBCL cells are post-GC B cells that entered plasmablastic 
differentiation and show an NFκB gene expression signature (Pasqualucci & Dalla-
Favera, 2014; Rosenwald et al., 2002; Wright et al., 2003) (Figure 1.18). Consistently, 
ABC-DLBCL cell lines are dependent on chronically active BCR and NFκB signalling 
and knockdown of BTK, CD79, IgM or Igκ inhibits survival of these cells (Davis et al., 
2010). Additionally, a number of mutations that activate the NFκB pathway have been 
identified in ABC-DLBCL (Boone et al., 2004; Compagno et al., 2009; Davis et al., 
2010; Georg Lenz et al., 2008; Ngo et al., 2011; Shembade et al., 2010). 
The classification is also predictive of disease outcome and under current standard 
treatment, which is a combination immunochemotherapy of rituximab, 
cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (Habermann, 
2012), GCB-DLBCL and ABC-DLBCL patients have 5-year survival rates of about 80% 
and 50 - 60%, respectively (Y. Huang et al., 2012; G Lenz et al., 2008; Perry et al., 
2014). Interestingly, the mRNAs encoding for the kinases PIM1 and PIM2 are among 
the genes that are highly expressed in ABC-DLBCL but not GCB-DLBCL (Care et al., 
2013; Wright et al., 2003). Both genes are NFκB targets, which explains their 
preferential expression in ABC-DLBCL (Asano et al., 2011; Zhu et al., 2002). Because 
PIM kinases have been shown to cooperate with MYC during lymphomagenesis (Allen 
et al., 1997; van der Lugt et al., 1995; van Lohuizen et al., 1991; Verbeek et al., 1991), 
they might contribute to the aggressive phenotype of ABC-DLBCL. It has already been 
shown in other cell types that the cooperation between PIM1 and MYC is at least in 
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part mediated through a direct activation of MYC-dependent transcription by PIM1 (for 
more details on PIM kinases see section 1.6) (J. Kim et al., 2010; Zippo et al., 2007). 
Therefore PIM kinases might play a role in aberrant transcriptional regulation in ABC-
DLBCL. In agreement with this hypothesis, MYC is expressed in about 70% of ABC-
DLBCL cases (S. Hu et al., 2013). Interestingly, both MYC and PIM1 are also 
frequently targeted by ASHM (Khodabakhshi et al., 2012). 
 
 
 
Figure 1.18 Current hypothesis for the origin of ABC- and GCB-DLBCL.  
GCB-DLBCL cells are derived from activated germinal centre cells, while ABC-
DLBCL cells show features of cells that entered plasmablastic differentiation. 
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1.3.3 Burkitt lymphoma 
Burkitt lymphoma is a GC-derived malignancy and can be classified into endemic 
(eBL), sporadic (sBL) and immunodeficiency-associated disease (Frick et al., 2012). 
eBL is seen in some regions of Africa and is associated with malaria and Epstein-Barr 
virus (EBV) infection (Shankland et al., 2012). sBL occurs in all parts of the world and 
immunodeficiency-associated BL is usually linked to HIV infection (Frick et al., 2012).  
Burkitt lymphoma cells depend on MYC activity for proliferation and survival (Gomez-
Curet et al., 2006; Spender & Inman, 2012) and the hallmark of BL is the 
overexpression of MYC through a translocation of the MYC gene into close proximity of 
one of the Ig enhancers (IgH, Igκ or Igλ) (Dalla-Favera et al., 1982). As GC B cells, BL 
cells express AID and MYC is typically fused to the IgH switch region (Pasqualucci et 
al., 2004; Ramiro et al., 2004). MYC is normally repressed by BCL6 in GCs, but the 
BCL6 binding sites are removed through the translocation, so that expression is no 
longer inhibited (Dominguez-Sola et al., 2012; Schmitz et al., 2014). Consistently, the 
untranslocated MYC allele is usually silent (ar-Rushdi et al., 1983). 
In normal cells, overexpression of MYC leads to induction of the proapoptotic protein 
BIM and activation of the p53 apoptotic pathway via induction of ARF (Sakamuro et al., 
1995; Zindy et al., 1998). In about 70% of sBL cases, MYC is mutated by ASHM 
(Bemark & Neuberger, 2000; Schmitz et al., 2012) and most mutations occur in the N-
terminal MYC box I (MBI). Two common mutations have been shown to selectively 
inhibit transcriptional activation of the BIM gene, without affecting proliferation 
compared to wild type MYC (Hemann et al., 2005). Further, the BIM promoter is 
hypermethylated and silenced in about 50% of patients (Richter-Larrea et al., 2010). In 
addition, p53 mutations occur in about 35% of BLs but rarely together with the MYC 
mutations that show reduced activation of BIM (Schmitz et al., 2012) (Figure 1.19).  
 
1.3.3.1 Tonic BCR signalling in BL 
Two thirds of BL cell lines show a reduced amount of viable cells when CD79a or SYK 
are knocked down, suggesting that BCR signalling is important for BL cell survival. 
Unlike ABC-DLBCL cells, they do not depend on NFκB but rather on PI3K/AKT activity, 
indicating that BL, like normal B cells, depend on tonic BCR signalling (Schmitz et al., 
2012). In mice, PI3K has been shown to strongly cooperate with MYC in 
lymphomagenesis and to result in a Burkitt-like tumour (Sander et al., 2012).  
The PI3K-AKT pathway can further be activated through PTEN inactivating mutations 
or PTEN downregulation through the MYC-dependent overexpression of miR17-92 
(Schmitz et al., 2012). Additionally, mutations in the PI3K regulatory subunit gene 
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PI3KR1 were detected (Love et al., 2012). Cooperation of MYC and AKT seems to 
require AKT-mediated FOXO phosphorylation, because FOXO normally inhibits 
expression of several MYC-dependent genes (Bouchard et al., 2004). Further, FOXO 
directly activates ARF transcription, thereby inhibiting MYC-dependent 
lymphomagenesis (Bouchard et al., 2007). Additionally, mTORC1-mediated activation 
of eIF4E and the BCL2 protein MCL1 supress MYC-dependent apoptosis (S. Li et al., 
2003; Mills et al., 2008) (Figure 1.19).  
 
 
Figure 1.19 Oncogenic pathways and mutations in Burkitt lymphoma.  
Frequent mutations are depicted as stars. The hallmark of BL is the 
overexpression of MYC, which cooperates with the PI3K pathway to drive tumour 
cell survival. The PI3K pathway is activated through MYC via miR19, through 
activation of tonic BCR signalling or through mutations in PTEN or the p85 
subunit of PI3K. Moreover, apoptosis is frequently counteracted by mutations in 
MYC, which inhibit BIM expression or by p53 mutations 
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1.4 Kinase inhibitors as therapeutics and tools to study protein 
function 
Targeting proteins with small molecule inhibitors is a developing field in cancer therapy. 
Some tumours are absolutely dependent on the activity of specific pathways, e.g. 
Burkitt lymphomas are dependent on MYC and PI3K, ABC-DLBCL and CLL are 
dependent on BCR signalling, so that inhibiting one of those pathways results in 
inhibition of tumour cell viability. Other tumours are even dependent on one specific 
oncogene, a mechanism called oncogene addiction (Weinstein & Joe, 2006). Most 
inhibitors have so far been developed against kinases, because these are intricately 
involved in different signal transduction pathways and inhibition of key kinases elicits a 
significant response (J. Zhang et al., 2009). Further, developing inhibitors for 
transcription factors is often unsuccessful. For example, although considerable efforts 
have been made, there is no specific MYC inhibitor available to date (McKeown & 
Bradner, 2014). Moreover, kinase inhibitors show a favourable side-effect profile 
because the negative effects of kinase inhibition on tumour cells can usually be 
circumvented in normal cells, as these are not relying on one specific pathway for their 
viability and normal function (J. Zhang et al., 2009). 
However, one problem that arises during the treatment of cancers with kinase 
inhibitors, is the development of resistances through mutations, for example of BTK in 
Ibrutinib-treated CLL (Woyach et al., 2014), amplifications of the target, e.g. 
amplification of the BCR-ABL1 gene in Imatinib-treated CML (le Coutre et al., 2000) or 
upregulation of alternative pro-survival pathways (Engelman et al., 2007). Most kinase 
inhibitors were designed to specifically target certain kinases, but they are rarely 
specific in vivo, and often this unspecificity is even required for their biological activity. 
The BCR-ABL inhibitor Imatinib, for example, does also target the tyrosine kinase KIT 
and inhibition of both kinases is necessary to induce apoptosis in CML cells (Belloc et 
al., 2009). Therefore, it is important to understand how kinase inhibitors work in a 
cellular context, which exact pathways they target and which other oncogenes 
cooperate with the targeted protein, so that alternative drugs for treatment of resistant 
patients or drugs for combination therapy can be developed. 
Another application kinase inhibitors can be used for, is the study of kinase functions in 
vitro. Because kinase inhibitors are often not highly specific for the targeted drug 
(Knight & Shokat, 2005), it is important to make use of different, structurally distinct 
kinase inhibitors (Martin & Arthur, 2012). Only effects elicited by all these different 
inhibitors are then likely to be due to inhibition of the kinase of interest. 
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1.4.1 Example: Treatment of CLL with inhibitors of the BCR pathway 
Because CLL cells are dependent on BCR signalling for their survival and proliferation, 
inhibitors of several components of the BCR pathway are now being extensively tested 
in clinical trials. We were aiming to better understand the mechanism of action of 
Ibrutinib, which will be reviewed in the following section. 
 
1.4.1.1 Ibrutinib 
Ibrutinib is an inhibitor of BTK with an IC50 of 0.5 nM. It covalently binds to C481 in the 
BTK active site and blocks its catalytic activity (Honigberg et al., 2010). It also potently 
inhibits several other kinases (Table 1.1), of which the SFKs B lymphoid kinase (BLK), 
FGR, LCK, FYN and LYN, as well as the kinases CSK, JAK3 and fms-related tyrosine 
kinase 3 (FLT3) might have roles in CLL (Abts et al., 1991; Aoki et al., 1994; Mankaï et 
al., 2008). Ibrutinib inhibits cell proliferation and survival, as well as signalling via 
CXCR4 and migration towards CXCL12/13 in vitro (Chang et al., 2013; Honigberg et 
al., 2010; Ponader et al., 2012). This possibly explains why CLL cells in patients 
redistribute from the lymphoid tissues into the peripheral blood, so that Ibrutinib-treated 
patients present with lymphocytosis in the first weeks to months of treatment (Byrd et 
al., 2013; de Rooij et al., 2012). 
 
Name IC50 (nM) Name IC50 (nM) 
BTK 0.5 JAK3 16.1 
BLK 0.5 FRK 29.2 
BMX 0.8 LCK 33.2 
CSK 2.3 RET 36.5 
FGR 2.3 FLT3 73 
BRK 3.3 TEC 78 
HCK 3.7 ABL 86 
EGFR 5.6 FYN 96 
YES 6.5 RIPK2 152 
ERBB2 9.4 SRC 171 
ITK 10.7 LYN 200 
Table 1.1 Kinases targeted by Ibrutinib.  
IC50 values for kinases inhibited by Ibrutinib as determined in vitro using a 33P 
filtration binding assay with 33P-ATP. Adapted from Honigberg et al., 2010. 
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Generally, Ibrutinib is well tolerated in patients and leads to a durable remission, even 
in relapsed or refractory patients (Byrd et al., 2013). It is, however, still unclear how 
Ibrutinib leads to remission. One study suggested that apoptosis of CLL cells in both 
blood and lymphoid tissues is induced by Ibrutinib (Wodarz et al., 2014), whereas a 
second study shows that Ibrutinib treatment does not increase apoptosis above the 
normal level in untreated patients (Cheng et al., 2014). In the first study, death rates of 
0.5% per day were estimated on the basis of an earlier study by Messmer et al., while 
apoptosis was directly measured before and after treatment in the second study 
(Cheng et al., 2014; Messmer et al., 2005; Wodarz et al., 2014). Further, the latter 
study showed that Ibrutinib induces apoptosis in vitro only at concentrations that cannot 
be achieved in vivo (Advani et al., 2013; Cheng et al., 2014). Thus, inhibition of 
proliferation in conjunction with unchanged death rates seems to account for the 
reduction in disease burden. 
Some patients have already been described to be resistant to Ibrutinib and relapsed 
under treatment. Out of six patients analysed by Woyach et al., four had a C481S 
mutation in BTK, making the inhibition of BTK by Ibrutinib reversible. One patient had 
an R665W mutation in PLCγ and the sixth patient presented with the BTK C481S and 
three PLCγ mutations (L845F, R665W and S707Y). All three PLCγ mutations led to a 
gain of function and neither Ca2+ flux nor ERK or AKT activation after IgM cross-linking 
were inhibited by Ibrutinib in vitro (Woyach et al., 2014). Therefore, it is of interest to 
understand the exact mechanism of action of Ibrutinib to develop new therapeutics for 
patients with Ibrutinib-resistant CLL. Further, this suggests that Ibrutinib should be used 
as a combination therapy with other drugs and understanding how Ibrutinib works, will 
help clinicians choose useful combination schemes. 
 
1.4.1.1.1  Other inhibitors of the BCR pathway 
Apart from Ibrutinib, other BCR pathway inhibitors are available and are studied in 
clinical trials for use in CLL. These are Fostamatinib, a SYK inhibitor and Idelalisib, a 
PI3Kδ inhibitor. Like Ibrutinib, Fostamatinib and Idelalisib inhibit BCR and chemokine 
signalling and cause an initial lymphocytosis (Buchner et al., 2010; Hoellenriegel et al., 
2011; Robak & Robak, 2013). Both drugs are also well tolerated by patients and lead to 
remission (Friedberg et al., 2010; Khan et al., 2014; Wiestner, 2012). 
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1.5 The transcription factor MYC 
As described earlier, overexpression of MYC is the hallmark of Burkitt lymphoma. 
Further, it is expressed in most cases of ABC-DLBCL, where it might cooperate with 
the kinases PIM1 and PIM2 to promote tumour cell survival or proliferation. Consistent 
with a role in tumourigenesis, MYC was initially discovered as the cellular homolog of 
the transforming gene of the avian myelocytomatosis virus (Sheiness & Bishop, 1979) 
and was then found to be an integration site for avian leukosis virus, which leads to its 
increased expression from the viral enhancer/promoter (Hayward et al., 1981; Payne et 
al., 1982).  
Increased expression of MYC, or of the related MYCN or MYCL, is found in many kinds 
of tumours and can be mediate by genomic amplification, translocation, retroviral 
insertion or retroviral transduction (Alitalo et al., 1983; Conacci-Sorrell et al., 2014; Kohl 
et al., 1983; Nau et al., 1985; Schwab et al., 1983). Further, increased expression of 
MYC can result from the activation of upstream signal transduction pathways and the 
stabilisation of the MYC protein (Gregory & Hann, 2000; Salghetti et al., 1999; Sears et 
al., 2000). MYC overexpression is associated with poor clinical outcome (McKeown & 
Bradner, 2014) and MYC inhibition in mice by expressing a dominant negative MYC 
derivative, is effective against RAS-driven glioma and KRAS-driven lung cancer, 
indicating that targeting MYC is a valid therapeutic approach (Annibali et al., 2014; 
Soucek et al., 2013). However, because no specific MYC inhibitor could be developed 
to date (McKeown & Bradner, 2014), it is important to better understand the MYC 
signalling network and to identify drugable targets that influence MYC-dependent 
transcription. Consistently, is has already been shown that targeting histone 
deacetylase 3 (HDAC3) and enhancer of zeste homolog 2 (EZH2), which are 
components of a transcriptional repressive MYC complex, inhibits lymphoma growth in 
vitro and in vivo (X. Zhang et al., 2012). Other such targets could be the PIM kinases, 
whose known functions will be reviewed in chapter 1.6.  
 
1.5.1 Structure of the MYC transcription factor 
The MYC family transcription factors have an N-terminal transactivation domain, which 
includes the two conserved MYC boxes MBI and MBII, a middle domain with MBIII, 
MBIV and a proline glutamate serine threonine (PEST) domain, and a C-terminal DNA-
binding and dimerization basic helix-loop-helix leucine zipper (bHLHZ) domain 
(Conacci-Sorrell et al., 2014) (Figure 1.20). MYC binds DNA as a heterodimer with the 
transcription factor MYC-associated factor X (MAX) and dimerization occurs via the 
HLHZ domain (Blackwood & Eisenman, 1991; Blackwood et al., 1992; Nair & Burley, 
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2003). MYC/MAX heterodimers bind Enhancer box (E box) elements with the 
consensus sequence 5’-CACGTG-3’ and stimulate transcription (Amati et al., 1993; 
Blackwood et al., 1992; Kretzner et al., 1992). In contrast to MYC, MAX does not have 
a transactivation domain (Figure 1.20), which explains why MAX homodimers do not 
activate transcription (Amati et al., 1993; Kato et al., 1992; Kretzner et al., 1992). MAX 
can also form heterodimers with MNT or MXD1-4 and mediate transcriptional 
repression through the recruitment of SIN3A or SIN3B, which associate with histone 
deacetylases (HDACs) (Ayer et al., 1995; Hooker & Hurlin, 2006; Hurlin et al., 1995; 
Hurlin et al., 1997; Kadamb et al., 2013; Schreiber-Agus et al., 1995). 
 
 
Figure 1.20 Structure of MYC, MAX and MNT.  
MB = MYC box, PEST = proline, glutamate, serine, threonine-rich sequence, 
bHLHZ = basic helix-loop-helix leucine zipper. MAX can form heterodimers with 
MYC or MNTs to activate or repress transcription, respectively. Adapted from 
Conacci-Sorrell et al., 2014. 
 
1.5.2 Regulation of MYC 
MYC can be transcribed from different promoters, the main ones being P1 and P2, 
which initiate approximately 25% and 75% of transcripts, respectively (Levens, 2010; 
Watt et al., 1983). The functions of these different transcripts remain, however, still 
elusive. Transcription of the MYC gene is tightly regulated by most extracellular 
signals, including WNT, NOTCH, growth factors, TGFβ, interferons and interleukins 
(Levens, 2010). However, our understanding of the molecular processes behind MYC 
regulation are just beginning to be elucidated. Binding sites for a plethora of 
transcription factors have been identified in the MYC promoter and extensive cross-talk 
between these factors can be observed (Calo et al., 2003; C.-R. Chen et al., 2002; 
Duyao et al., 1990; Ghosh et al., 1999; Hiebert et al., 1989; Ho et al., 2005; Iavarone et 
al., 2003; Kabbout et al., 2014; Kessler et al., 1992; Mognol et al., 2012; Roussel et al., 
1994; Thalmeier et al., 1989; Toualbi et al., 2006; Yagi et al., 2002; Yochum et al., 
2010) (Figure 1.21). 
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Apart from transcriptional regulation, the MYC gene product is regulated at the 
posttranscriptional, translational and posttranslational level. The mRNA contains 3’ AU-
rich elements (AREs) and is bound by the decay-promoting factor tristetraprolin (TTP) 
(Marderosian et al., 2006). The mRNA stability is also reduced by several microRNAs, 
like let-7a, miR-145 and miR-34 (Cannell et al., 2010; Christoffersen et al., 2009; 
Sachdeva et al., 2009; Sampson et al., 2007). The MYC mRNA can be translated 
starting either from a canonical AUG or an upstream CUG codon and translation of 
both forms is dependent on eIF4E (Carter et al., 1999; Hann et al., 1988). Further, 
binding of AU-rich element binding factor 1 (AUF1) to the ARE stimulates MYC 
translation, while binding of the protein translational repression by RNA binding (TIAR) 
has the opposite effect (Liao et al., 2007) (Figure 1.21). 
 
 
Figure 1.21 Regulation of MYC expression.  
MYC transcription is regulated by a number of extracellular signals through a 
plethora of transcription factors. The mRNA stability is regulated by miRNAs and 
TTP, translation is influenced by ARE binding proteins and is cap-dependent. 
MYC protein stability is regulated by kinases and ubiquitin ligases. ETS = E-
twenty-six oncogene homolog, E2F = Adenovirus E2 gene promoter region 
binding factor, SMAD = Mothers against decapentaplegic homolog, MBP1 = 
MYC-binding protein 1 
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MYC is a very unstable protein and has a half-life of about 25 minutes (Hann & 
Eisenman, 1984). The MBI is essential for the regulation of MYC stability, which is 
increased by phosphorylation of S62 but decreased by T58 phosphorylation (Sears et 
al., 2000). S62 can be phosphorylated by ERK, whereas T58 is targeted by GSK3β 
(Sears et al., 2000). Phosphorylation of T58 does, however, only occur when S62 is 
already phosphorylated (Lee et al., 2008; Lutterbach & Hann, 1994; Sears et al., 2000). 
Dually phosphorylated MYC is bound by the E3 ligase F box and WD repeat domain 
containing 7 (FBW7) to be ubiquitinated and degraded (Welcker et al., 2004; Yada et 
al., 2004). Interestingly, T58 is often mutated in BL, which increases MYC protein 
stability (Bahram et al., 2000). Another protein that can regulate MYC stability is S 
phase kinase-associated protein 2 (SKP2) (Figure 1.21). SKP2 interacts with the MBII 
domain, ubiquitinates MYC and leads to its degradation. Intriguingly, it also enhances 
transcriptional activation by MYC (S.Y. Kim et al., 2003; von der Lehr et al., 2003). 
Binding of p14ARF to MYC inhibits SKP2-mediated ubiquitination and leads to 
expression of non-canonical target genes. Loss of ubiquitination is, for example, 
sufficient to stimulate expression of proapoptotic genes, like BIM (Q. Zhang et al., 
2013). 
 
1.5.3 MYC target genes and functions 
MYC generally promotes cell growth and cell cycle progression, but when 
overexpressed, it also sensitises cells to apoptosis. Therefore, cancers overexpressing 
MYC always show second hit mutations that counteract its proapoptotic functions 
(Meyer et al., 2006). 
MYC most strongly upregulates genes implicated in ribosome biogenesis, translation, 
RNA processing, metabolism and biosynthesis, cell cycle control and transcriptional 
regulation (Bretones et al., 2014; Fernandez et al., 2003; Ji et al., 2011; Jones et al., 
1996; Zeller et al., 2006). MYC also directly stimulates transcription of genes for rRNAs 
and tRNAs by POL I and POL III and increases processing of the 45S rRNA (Gomez-
Roman et al., 2003; Goodfellow et al., 2006; Kenneth et al., 2007; Poortinga et al., 
2004; Schlosser et al., 2003). Consistently, MYC-repressed genes include negative cell 
cycle regulators like p21CIP and p15INK4B (Wang et al., 2011; Zeller et al., 2006). MYC 
has also been shown to have transcription independent effects on cell proliferation by 
directly regulating DNA replication through replication origin licensing (Dominguez-Sola 
et al., 2007) (Figure 1.22).  
MYC stimulates apoptosis through the induction of BIM (Campone et al., 2011; 
Hemann et al., 2005) and BAX (Mitchell et al., 2000) and repression of BCL2 and 
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BCL2L1 (encoding BCL-XL) (Eischen et al., 2001; Maclean et al., 2003). MYC-mediated 
induction of the miR17-92 cluster does, however, play an important role in repressing 
BIM, as well as other tumour suppressors like PTEN or SIN3B (Li et al., 2014; 
O’Donnell et al., 2005; Xiao et al., 2008). MYC also indirectly induces p14ARF and thus 
activates the p53 pathway and BIM expression (Q. Zhang et al., 2013; Zindy et al., 
1998). Further, MYC triggers an autoregulatory feedback loop by stimulating 
expression of MAX, MNT, MXD1 and MXD3 and by downregulating its own expression 
(Penn et al., 1990; Zeller et al., 2006) (Figure 1.22).  
Although some specific MYC target genes have been described, the range of MYC 
functions seems to be a lot wider. Under physiological conditions, MYC is bound to 
approximately 10% of all known promoters, mainly with canonical 5’-CACGTG-3’ E 
boxes, but when overexpressed it also binds to lower affinity 5’-CANNTG-3’ E boxes in 
enhancers and to non-E box elements (Fernandez et al., 2003; Z. Li et al., 2003; Nie et 
al., 2012; Sabò et al., 2014; Walz et al., 2014). MYC preferentially binds to E boxes 
associated with CpG islands and to sites, which already show higher levels of histone 
acetylation, indicating that MYC is not a pioneer factor (Fernandez et al., 2003; Zeller 
et al., 2006). MYC binding can further enhance acetylation, but this does not 
necessarily increase mRNA expression (Fernandez et al., 2003). Consistently, only 
about 20% of MYC-associated genes are directly regulated by MYC when assessed by 
microarray (Nie et al., 2012; Zeller et al., 2006).  
However, recent work suggests that MYC regulates all bound genes, but that 
conventional normalisation methods mask this effect, simply because the normalisation 
genes are upregulated as well. Accordingly, MYC leads to an increase in the total 
cellular RNA content. This is, at least in part, a transcriptional effect as MYC binding to 
promoters and proximity of the MYC binding site to the TSS correlate with the level of 
gene expression. Also, normal transcription factors bind with high affinity to target sites 
but a second population can be detected as background binding. MYC, however, 
shows a range of affinities for genomic sites with the background being inseparable 
from specific binding. And last, MYC/MAX globally stimulate pause release by 
increasing P-TEFb recruitment to all active genes (Lin et al., 2012; Nie et al., 2012; 
Rahl et al., 2010). 
In contrast, other studies suggest that MYC does specifically up- or downregulate 
cancer-associated genes and that amplification of total RNA expression can occur as a 
secondary mechanism through transcriptional regulation by those target gene products 
or through mRNA stabilisation. The discrepancies between these studies seem to arise 
from differences in the starting levels of MYC protein and the cell types analysed. Low 
MYC expression prior to induction will thus lead to both amplification of all genes and 
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specific regulation of a subset of target genes, whereas high basal MYC levels 
counteract amplification of transcription and lead to a specific regulation of some genes 
(Sabò et al., 2014; Walz et al., 2014). 
 
Figure 1.22 MYC target genes.  
MYC targets include a number of genes that induce proliferation by enhancing 
translation, metabolism or cell cycle progression. MYC also directly stimulates 
DNA replication. However, high MYC levels sensitise cells to apoptosis by both 
p53-dependent and -independent pathways. CDK = Cyclin-dependent kinase, 
hTERT = human telomerase reverse transcriptase 
 
1.5.4 Mechanisms of transcriptional activation by MYC 
Transcriptional coactivators are mostly recruited by the MBII domain. One of these is 
the transformation/transcription domain-associated protein (TRRAP), which is part of 
several human acetyltransferase complexes (Frank et al., 2003; McMahon et al., 1998) 
(Figure 1.23). TRRAP recruits the 2 MDa SPT3-TAF9-GCN5 acetyltransferase 
(STAGA) and the 60 kDa Trans-Activator of Transcription (Tat)-interacting protein 
(TIP60) acetyltransferase complex for transactivation (Liu et al., 2003; McMahon et al., 
2000). TRRAP is also part of the p300/CBP-associated factor (PCAF) and the GCN5-
containing TATA-binding protein (TBP)-free TAFII-containing complex (TFTC), 
therefore also likely recruiting those complexes to MYC (Brand et al., 1999; Vassilev et 
al., 1998). GCN5 also directly interacts with MBI and the linker between MBI and MBII 
and this interaction is required for STAGA recruitment (Zhang et al., 2014). Further, 
MYC can directly recruit the p300 and CBP acetyltransferases to its N- or C-terminus, 
respectively (Faiola et al., 2005; Vervoorts et al., 2003). GCN5, TIP60, CBP and p300 
have been shown to acetylate MYC. While one study showed that CBP enhances MYC 
stability by acetylation, another study suggests that acetylation by p300 and CBP 
destabilises MYC. However, their binding to MYC counteracts this effect, resulting in an 
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overall stabilisation of MYC (Faiola et al., 2005; Vervoorts et al., 2003). Acetylation by 
GCN5 and TIP60 leads to stabilisation of MYC (Patel et al., 2004). STAGA is required 
for transactivation by mediating histone H3 acetylation, as well as POL II and Mediator 
recruitment (Liu et al., 2008; Martinez et al., 2001). The TIP60 complex mediates 
acetylation of H4 and H2A (Ikura et al., 2000) and p300 and CBP are capable of 
acetylating all four core histones (Ogryzko et al., 1996). 
MYC has also been shown to interact with the INI1 subunit of the SWI/SNF complex 
via its bHLHZ domain and functional SWI/SNF is required to activate a reporter 
construct (S.-W.G. Cheng et al., 1999). In addition, MYC recruits the positive 
transcription elongation factor b (P-TEFb), consisting of Cyclin T and CDK9, via direct 
binding of Cyclin T to the MBI (Eberhardy & Farnham, 2002; Kanazawa et al., 2003). 
Further, the kinase PIM1 binds to the MBII domain, it phosphorylates histone H3S10 
and stimulates the recruitment of P-TEFb to nucleosomes (Zippo et al., 2007; Zippo et 
al., 2009). The transactivation domain also binds the core transcription factors TFIIH 
and TBP (McEwan et al., 1996). Furthermore, MYC directly stimulates POL I and POL 
III transcription. To facilitate POL III-dependent transcription, MYC binds TFIIIB and 
recruits TRRAP and GCN5 (Gomez-Roman et al., 2003; Kenneth et al., 2007) (Figure 
1.23). Similarly, at POL I-dependent rDNA genes, MYC recruits components of the 
POL I and enhances acetylation at these sites (Grandori et al., 2005). 
 
Figure 1.23 Mechanisms by which MYC can activate transcription.  
MYC interacts with acetyltransferases (CBP, p300, TIP60, STAGA and possibly 
also PCAF and TFTC), which acetylate histones or other proteins and STAGA 
interacts with and recruits the Mediator. Further, MYC tethers general 
transcription factors, like TFIIH, TBP, TFIIIB and P-TEFb to the chromatin and it 
has also been shown to interact with the SWI/SNF complex. 
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1.5.5 Repression of transcription by MYC 
A common mechanism of transcriptional repression by MYC/MAX heterodimers is their 
binding to other activating transcription factors, which results in the formation of a 
repressive complex. The transcription factor MYC-interacting Zinc-finger protein 1 
(MIZ1), for example, activates the expression of genes encoding antiproliferative 
proteins, like p21CIP and p15INK4B, but also of BCL2 (Herold et al., 2002; Kosan et al., 
2010; Seoane et al., 2001; Staller et al., 2001). MIZ1 recruits p300 and nucleophosmin 
(NPM1) as coactivators and binding of MYC/MAX to MIZ1 replaces these cofactors 
(Staller et al., 2001; Wanzel et al., 2008). Association of MYC/MAX with MIZ1 leads to 
the recruitment of HDACs and DNMT3A (Brenner et al., 2005; Varlakhanova et al., 
2011) (Figure 1.24). In embryonic stem cells, MYC binds to 30% of MIZ1-associated 
genes and co-occupied genes are predominantly differentiation-associated genes. 
Consistently, knockdown of MYC leads to differentiation of embryonic stem (ES) cells, 
indicating that MYC-mediated repression of MIZ1 target genes is a general 
phenomenon (Varlakhanova et al., 2011). Similarly, MYC has been shown to bind to 
the Specificity protein 1 (SP1)-SMAD complex and to inhibit its transactivation function 
(Feng et al., 2002). 
Apart from coactivators, the transactivation domain can also be bound by inhibitory 
factors, like myc modulator 1 (MM1), which binds Transcription intermediary factor 1 
beta (TIF1β) to recruit the SIN3-HDAC complex (Mori et al., 1998; Satou et al., 2001). 
Additionally, MM1 promotes degradation of MYC, by directly interacting with the 
proteasome (Kimura et al., 2007). The MBIII plays an important role in MYC-mediated 
repression of pro-apoptotic genes by recruiting HDAC3 (Kurland & Tansey, 2008). 
 
Figure 1.24 Transcriptional repression by MYC.  
A MIZ1 is a transcriptional activator that induces gene expression through 
interactions with NPM1 and p300. B MYC replaces transcriptional co-activators 
from MIZ1 and recruits DNMT3A and HDACs to repress transcription. This 
process is E box-independent. 
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1.6 The PIM protein kinase family 
Studying PIM kinases in the context of lymphoma is of great interest, because they 
were first described as oncogenes in both T and B cells. Moreover, both PIM1 and 
PIM2 mRNAs are part of an ABC-DLBCL gene expression profile that distinguishes this 
type of DLBCL from GDB-DLBCL (Alizadeh et al., 2000; Care et al., 2013; Wright et al., 
2003). Further, they have been shown to cooperate with MYC, which itself is an 
important oncogene in lymphomagenesis (Breuer et al., 1989; Cuypers et al., 1984; 
van Lohuizen et al., 1989; van Lohuizen et al., 1991; Verbeek et al., 1991). In contrast 
to MYC, PIM kinases can be targeted therapeutically by small molecule inhibitors, a 
large number of which has been developed in recent years. Some of these inhibitors 
have already been tested at the pre-clinical stage (Burger et al., 2013; Garcia et al., 
2014; Keeton et al., 2014). Therefore, it will be helpful to determine whether PIM 
kinases are valid therapeutic targets in DLBCL and the MYC-dependent BL. 
 
1.6.1 PIM kinases cooperate with MYC in lymphomagenesis 
The related kinases proviral integration site for Moloney murine leukaemia virus 1 
(PIM1), PIM2 and PIM3 form the PIM kinase family of constitutively active 
serine/threonine kinases (Qian et al., 2005). All three PIM kinases are conserved in 
mammals, C. elegans expresses one PIM kinase homolog, PRK-2, and over 300 PIM 
kinases have been found in the zebrafish genome by computational analysis, whereas 
no Drosophila homolog is known to date (Rakshambikai et al., 2013; Zheng et al., 
2011). Pim1 and Pim2 were initially identified as targets for the integration of Moloney 
murine leukaemia virus (MMLV) in murine T cell lymphoma, indicating that they 
function as oncogenes (Breuer et al., 1989; Cuypers et al., 1984) (Figure 1.25 A). The 
oncogenicity of PIM1 was confirmed in mice that express Pim1 under control of the 
IGH enhancer (Eµ), which leads to specific expression in B and T cells. Pim1 was found 
to be a weak oncogene, as only 5 – 10% of these mice have developed T cell 
lymphomas at 7 months of age (van Lohuizen et al., 1989) (Figure 1.25 B). However, if 
these mice are injected with MMLV after birth, lymphomas develop faster and much 
more frequently and, interestingly, insertion of the virus occurs either upstream of Myc 
or Mycn in all cases, suggesting a strong cooperation between Myc and Pim1 during 
lymphomagenesis (van Lohuizen et al., 1989) (Figure 1.25 C).  
In contrast to Eµ-Pim1 transgenic mice, Eµ-Myc transgenic mice develop B cell 
lymphoma (Adams et al., 1985). If Eµ-Myc mice are injected with MMLV, 35% of 
insertions can be found upstream of the Pim1 locus in B cell tumours (Figure 1.25 D) 
and Eµ-Myc/Eµ-Pim1 double transgenic mice develop pre-B cell leukaemia prenatally, 
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again indicating cooperation between the two oncogenes (van Lohuizen et al., 1991; 
Verbeek et al., 1991) (Figure 1.25 E). Similarly, Eµ-Mycn/Eµ-Pim1 and Eµ-Mycl/ Eµ-Pim1 
double transgenic mice develop early onset B or T cell malignancies, respectively, 
although the phenotype is less severe than in Eµ-Myc/Eµ-Pim1 double transgenic mice 
(Möröy et al., 1991). 
 
Figure 1.25 PIM kinases as oncogenes in murine lymphomas.  
Early studies in mice suggest a cooperation between PIM kinases and MYC in 
oncogenesis. A MMLV-induced T cell lymphomas show insertion of the virus 
upstream of Pim1 or Pim1 and Myc. B PIM1 or PIM2 overexpression leads to 
lymphomagenesis with low penetrance, injection of the virus results in 
accelerated lymphomagenesis through insertion upstream of Myc or Mycn (C). D 
Injection of MMLV into MYC overexpressing mice results in tumours carrying 
insertions upstream of Pim1. E Overexpression of PIM1 or PIM2 and MYC 
induces early onset leukaemia. F MMLV infection of MYC overexpressing, Pim1 
knockout mice results in proviral insertion upstream of Pim2, indicating that PIM2 
can compensate for PIM1. 
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Eµ-Myc/Pim1-/- mice infected with MMLV show proviral insertion upstream of Pim2 in 
80% of tumours, compared to only 15% in Pim1 WT animals (van der Lugt et al., 1995) 
(Figure 1.25 F). Additionally, proviral insertion at the Pim3 locus occurs in 25% of Eµ-
Myc/Pim1-/-/Pim2-/- mice, suggesting that PIM kinases can compensate for each other 
during lymphomagenesis (Mikkers et al., 2002). Consistently, the phenotypes of Eµ-
Pim2 mice resemble those of Eµ-Pim1 mice. Eµ-Pim2 mice develop T cell lymphoma 
with relatively long latency (Figure 1.25 B) and Eµ-Myc/Eµ-Pim2 mice are born with pre-
B cell leukaemia (Allen et al., 1997) (Figure 1.25 E). 
 
1.6.2 Regulation of PIM expression 
PIM kinases are widely expressed in haematopoietic, neuronal and epithelial cells of 
different origins, in embryonic stem cells, as well as in smooth and cardiac muscle cells 
and in the testis (Amson et al., 1989; Katakami et al., 2004; Konietzko et al., 1999; 
Muraski et al., 2007; Sorrentino et al., 1988; Stewart & Rice, 1995; Wingett et al., 1992; 
Zippo et al., 2004). As constitutively active enzymes, PIM kinases are mainly regulated 
at the expression level. Expression of PIM kinases can be induced by a variety of 
growth factors and cytokines through the activation of STAT1, STAT3, STAT4 and 
STAT5 (Lilly et al., 1992; Matikainen et al., 1999; Morcinek et al., 2002; Nosaka et al., 
1999; Shirogane et al., 1999). Further, the NFκB pathway stimulates the expression of 
PIM kinases (Asano et al., 2011; Zhu et al., 2002). PIM3 has been shown to be a direct 
MYC and ETS1 target gene (Forshell et al., 2011; Y.-Y. Li et al., 2009) (Figure 1.26).  
All three PIM genes give rise to a single transcript, but translation initiation from non-
canonical CUG codons results in expression of two PIM1 (34 kDa and 44 kDa) and 
three PIM2 isoforms (34 kDa, 38 kDa and 40 kDa) (Nawijn et al., 2011; Xie et al., 2006; 
Yan et al., 2003). The PIM1 mRNA is destabilised by AREs in its 3’UTR (Domen et al., 
1987) and binding of TTP to one of these elements enhances mRNA degradation (H.K. 
Kim et al., 2012; Mahat et al., 2012). Additionally, miR-1 and miR-33a have been 
shown to regulate PIM1 mRNA levels (Nasser et al., 2008; Thomas et al., 2012). 
Translation of PIM mRNAs is cap-dependent and stimulated by eIF4E (Hoover et al., 
1997; Schatz et al., 2011) (Figure 1.26). eIF4E also enhances nuclear export of the 
PIM1 mRNA, by binding to a specific stem loop structure in the 5’ UTR, called eIF4E 
sensitivity element (Culjkovic et al., 2006). 
The PIM1 protein has a half-life of less than 5 minutes. Its activity and protein levels 
are negatively regulated by the prolyl isomerase PIN1 and the protein phosphatase 2A 
(PP2A) (Losman et al., 2003; Ma et al., 2007). Consistently, PIM1 autophosphorylates 
and has predicted phosphorylation sites for a large variety of kinases, but it is currently 
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unknown, whether PP2A targets the autophosphorylation residues or sites 
phosphorylated by another, unknown kinase (Bachmann et al., 2004; Brault et al., 
2010). Binding of heat shock protein 90 (HSP90) stabilises PIM1, while binding of 
HSP70 increases its ubiquitination and proteasomal degradation (Shay et al., 2005). 
Hypoxia has been shown to prevent ubiquitination and degradation of PIM1 and to 
induce its translocation from the cytoplasm to the nucleus (Jian Chen et al., 2009) 
(Figure 1.26). 
Although both PIM1 isoforms have comparable kinase activities in vitro (Saris et al., 
1991), their subcellular localisations, and therefore their functions, are different. The 
44 kDa PIM1L has a proline-rich domain capable of interacting with SH3 domains of 
membrane-associated proteins. It has been shown to bind to the Tec family kinase 
BMX and activate it (Xie et al., 2006). No functional differences have been described 
for the different PIM2 isoforms, but their half-lives range from 10 minutes for the 38 kDa 
isoform to more than 60 minutes for the 34 kDa isoform (Yan et al., 2003). 
 
Figure 1.26 Regulation of PIM kinase expression.  
The expression of PIM1 and PIM2 is regulated by cytokines and growth factors 
via STATs and NFκB. PIM3 expression is regulated by MYC and ETS1. PIM1 
mRNA stability is reduced by TTP and translation of all mRNAs is cap-dependent. 
PIM1 protein stability is influenced by phosphorylation and heat shock proteins. 
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1.6.3 Mechanisms of PIM function 
Several molecular mechanisms for the oncogenic potential of PIM kinases and for the 
cooperation between PIM kinases and MYC have been described. PIM1 and PIM2 can 
directly stabilise MYC through phosphorylating S329, which inhibits T58p and 
increases S62p (Y. Zhang et al., 2008). PIM1 has been shown to be recruited to the 
chromatin by binding to the MYC MBII and to induce gene expression through 
phosphorylation of histone H3S10 (Zippo et al., 2007). H3S10p leads to recruitment of 
14-3-3 proteins, which serve as adaptors for the acetyl transferase MOF. MOF 
acetylates H4K16, which is recognised by the bromodomain containing protein 4 
(BRD4), an adapter for P-TEFb. Thus, PIM1 stimulates transcriptional elongation 
(Zippo et al., 2009) (Figure 1.27, see section 1.7.2.1 for a description of the POL II 
transcription cycle). PIM1 is required for the expression of 20% of the MYC-induced 
genes after serum shock in HEK293 cells (Zippo et al., 2007). Consistently, PIM1 
overexpression in prostate cancer cell lines enhances expression of MYC target genes 
(J. Kim et al., 2010) and PIM1 knockdown is sufficient to decrease proliferation, 
survival and tumourigenicity of MYC-overexpressing prostate cancer cells (Wang et al., 
2012). PIM1 was also described to be nuclear in Burkitt lymphoma, which would allow 
for cooperation of PIM1 and MYC at the chromatin level (Ionov et al., 2003). 
 
Figure 1.27 Mechanism of transcriptional activation by PIM1.  
The DNA-binding transcription factor MYC recruits PIM1 to the chromatin, where 
it phosphorylates histone H3S10. This leads to the recruitment of 14-3-3 proteins, 
the acetyltransferase MOF and acetylation of H4K16. Recruitment of BRD4 and 
P-TEFb then triggers transcriptional elongation. 
 
Cooperation between PIM2 and MYC requires the ability of PIM2 to stimulate the NFκB 
pathway via activation of the kinase COT. Blocking NFκB in MYC and PIM2 
overexpressing cells induces apoptosis in vitro and inhibits growth in a tumour graft 
model (Hammerman et al., 2004). Interestingly, proviral insertion in Eµ-Myc/Pim1-/-/ 
Pim2-/- mice occurred upstream of the Tpl2 gene, which encodes COT, in 
approximately 20% of the tumours (Mikkers et al., 2002). PIM1 can also activate the 
NFκB pathway via TAK1 (K. Kim et al., 2010) and stabilisation of RelA/p65 through 
direct phosphorylation (Nihira et al., 2010) (Figure 1.28). 
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Further, PIM kinases have been shown to have several other MYC-independent pro-
proliferative and anti-apoptotic effects. PIM1, PIM2 and PIM3 phosphorylate BAD at 
S112 and other sites, which leads to binding of 14-3-3 proteins and inhibits its 
interaction with anti-apoptotic BCL-XL (Aho et al., 2004; Macdonald et al., 2006). PIM1 
has also been shown to phosphorylate and inhibit the apoptosis signalling kinase 1 
(ASK1), which results in reduced JNK and p38 MAPK phosphorylation and protects 
cells from H2O2-induced apoptosis (Gu et al., 2009) (Figure 1.28). 
To stimulate cell cycle progression, PIM1 phosphorylates and inhibits MAP/microtubule 
affinity-regulating kinase 3 (MARK3). MARK3 phosphorylates CDC25C-S216, which 
leads to its cytoplasmic sequestration by 14-3-3 proteins, so that it cannot 
dephosphorylate and activate CDK1. Thus, inhibition of MARK3 by PIM1 leads to G2/M 
progression (Bachmann et al., 2004). Further, PIM1 has been shown to directly 
phosphorylate and activate CDC25C (Bachmann et al., 2006) and CDC25A. The latter 
stimulates apoptosis in Rat1 fibroblasts but is predicted to also promote G1/S and 
G2/M progression (Mochizuki et al., 1999). The CDK inhibitors p21CIP1 and p27KIP1 are 
also PIM1 or PIM1/2/3 targets, respectively, and phosphorylation by PIM kinases leads 
to their cytoplasmic localisation, which allows for G1/S transition (Morishita et al., 2008; 
Z. Wang et al., 2002; Zhang et al., 2007). PIM1 also stimulates p27KIP1 degradation by 
phosphorylating and stabilising SKP2 (Cen et al., 2010) (Figure 1.28). 
PIM kinases share several substrates with AKT and PIM2 has been shown to 
compensate for mTORC1 inhibition during haematopoiesis and in acute myeloid 
leukaemia (AML) (Hammerman et al., 2005; Tamburini et al., 2009). Consistently, 
treating AML cells with both a pan-PIM and an AKT inhibitor synergistically reduces cell 
growth and survival (Meja et al., 2014). PIM1 does, for example, phosphorylate 
FOXO1a, FOXO3a (Morishita et al., 2008), as well as PRAS40-T246, which leads to 
activation of mTORC1 (F. Zhang et al., 2009). PIM2 has been shown to stimulate 
phosphorylation of 4EBP1 and eIF4E (Hammerman et al., 2005; Tamburini et al., 
2009). Like AKT, PIM1/2/3 can also phosphorylate and stabilise MDM2 (Hogan et al., 
2008; Ionov et al., 2003) (Figure 1.28). Interestingly, stabilisation of MDM2 can also be 
mediated by kinase-dead PIM1 (Wood et al., 2009). Conversely, some PIM1 
overexpressing cells show increased p53 (Hogan et al., 2008; Zemskova et al., 2010), 
which might be mediated by an enhanced interaction of phosphorylated MDM2 with 
p14ARF, which inhibits degradation of p53 (Hogan et al., 2008). Therefore, PIM kinases 
could induce senescence or apoptosis in p14ARF and p53 expressing cells but have 
growth promoting effects in cells having no or low expression of these proteins 
(Zemskova et al., 2010). In this context, it is worth noting that MDM2 has functions 
distinct from p53 activation. It can, for example serve as a co-factor for NFκB and also 
stabilise PIM1 (Hogan et al., 2008; Thomasova et al., 2012). 
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At the chromatin, PIM1 can target proteins other than histone H3, like the splicing 
factor PIM-associated protein 1 (PAP1) (Maita et al., 2000; Maita et al., 2004) and the 
heterochromatin protein 1γ (HP1γ) (Koike et al., 2000). One study suggests that PIM1-
dependent phosphorylation of HP1γ-S93 enhances its association with H3K9me3 and 
promotes heterochromatin formation (Jin et al., 2014). Other than MYC, PIM1 has been 
shown to phosphorylate and activate NFAT1 (Rainio et al., 2002), RUNX transcription 
factors (Aho et al., 2006), the androgen receptor (AR) (Ha et al., 2013; Linn et al., 
2012) and the vitamin D receptor (VDR) (Maier et al., 2012) (Figure 1.28). 
Further, migration of cells via CXCR4 is regulated by PIM1. The kinase phosphorylates 
the intracellular domain to facilitate proper receptor recycling and PIM1 is essential for 
CXCR4 surface expression. Consistently, PIM1 levels in leukaemic blasts from AML 
patients correlate with membrane CXCR4 (Grundler et al., 2009) and expression of all 
three PIM kinases correlates with CXCR4 phosphorylation in DLBCL (Brault et al., 
2012). PIM kinases can also contribute to drug resistance of tumour cells. PIM1L has 
been shown to phosphorylate the ATP-binding cassette transporter G2 (ABCG2), 
promote multimerisation and substance export (Xie et al., 2008). 
 
Figure 1.28 PIM kinase targets.  
PIM kinases are bona fide oncogenes. They promote cell cycle progression and 
inhibit apoptosis via a number of different mechanisms. They enhance cap-
dependent translation and influence transcription by targeting a lot of different 
transcription factors. 
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1.6.4 PIM kinases in human cancers 
1.6.4.1 PIM kinases in haematological malignancies 
Early studies showed that PIM1 is overexpressed in 30% of lymphoid and myeloid 
human leukaemias. However, no correlation with MYC overexpression was found 
(Amson et al., 1989). PIM2 is overexpressed in AML (Mizuki et al., 2003). Both PIM1 
and PIM2 mRNAs are overexpressed in the NHLs CLL, DLBCL and mantle cell 
lymphoma (MCL), whereas PIM2 is also overexpressed in follicular lymphoma, MALT 
lymphomas, nodal marginal zone lymphomas and multiple myeloma (Cohen et al., 
2004; Gómez-Abad et al., 2011). No overexpression of PIM3 is seen in NHL (Gómez-
Abad et al., 2011). PIM2 expression in CLL correlates with ZAP70 expression and poor 
prognosis (Hüttmann et al., 2006) and PIM2/3 are required for CLL cell survival, 
whereas PIM1 mediates CXCR4-dependent cell migration (Decker et al., 2014). Both 
PIM1 and PIM2 have been shown to be upregulated upon EBV infection and to 
stimulate the transactivation potential of Epstein–Barr virus nuclear antigen 2 (EBNA2) 
(Rainio et al., 2005).  
 
1.6.4.1.1 PIM kinases in DLBCL 
PIM1 and PIM2 mRNAs are highly expressed in ABC-DLBCL compared to GCB-
DLBCL (Care et al., 2013; Wright et al., 2003). However, PIM protein-positive tumours 
do not differ significantly between non-GCB- and GCB-DLBCL. In one study, only 27% 
of ABC-DLBCL samples expressed PIM2 protein, compared to 18% for GCB-DLBCL 
(Gómez-Abad et al., 2011). In a second study, around 80% of both non-GCB and GCB 
cases were positive for PIM1, 70% of non-GCB and 55% of GCB cases were positive 
for PIM2 and about 55% of each were positive for PIM3 (Brault et al., 2012). It should 
however be noted that these studies did not differentiate between high and low PIM 
kinase expression. A difference between ABC- and GCB-DLBCL was observed when 
nuclear PIM1 was studied. 10 out of 12 cases with predominant nuclear PIM1 staining 
were of the non-GCB type and nuclear PIM1 was highly correlated with disease stage 
(Brault et al., 2012). However, no correlation between PIM and MYC expression was 
found. In contrast, PIM1 and PIM2 expression did correlate with activation of STATs 
and expression of ABCB1 (Brault et al., 2012). Nevertheless, expression of PIM1 
and/or PIM2 is indicative of disease-free, disease-specific and overall survival in non-
GCB-, but not GCB-DLBCL (Brault et al., 2012; Gómez-Abad et al., 2011).  
As mentioned before, PIM1 is also a target of ASHM in DLBCL, but surprisingly, 3 out 
of 5 mutants analysed showed reduced kinase activity and only one mutation resulted 
in an increase in kinase activity, suggesting that PIM1 may have kinase-independent 
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functions (Brault et al., 2010; Deutsch et al., 2007; Kumar et al., 2005). Consistently, 
inhibition of PIM kinases was moderately effective or not effective in inhibiting 
proliferation or inducing apoptosis in DLBCL cell lines (Brault et al., 2012; Gómez-Abad 
et al., 2011). Therefore, Brault et al. proposed that PIM kinases are more progression 
markers than bona fide therapeutical targets in DLBCL. PIM kinase inhibitors seem to 
be most effective in multiple myeloma, AML, MCL and CLL (Cervantes-Gomez et al., 
2013; Lisa S. Chen et al., 2009; Chen et al., 2011; Decker et al., 2014; Garcia et al., 
2014; Hiasa et al., 2014; Keeton et al., 2014; Q. Yang et al., 2012). As the present 
study was started in 2011, we were, however, unaware of the limited impact of PIM 
kinase inhibition on DLBCL cell survival at this time. 
 
1.6.4.2 PIM kinases in solid tumours 
Apart from haematopoietic malignancies, PIM1 is highly expressed in prostatic 
intraepithelial neoplasia and prostate cancer (Cibull et al., 2006; Dhanasekaran et al., 
2001). MYC and PIM1 cooperate in prostate tumourigenesis and inhibition of PIM 
kinases in MYC-expressing cancers decreases proliferation, survival and 
tumourigenicity (J. Wang et al., 2010; Wang et al., 2012). PIM1 is further found highly 
expressed in mammary carcinoma cell lines (Gapter et al., 2006; Malinen et al., 2013), 
in squamous cell carcinoma (Peltola et al., 2009), pancreatic ductal adenocarcinoma 
(Reiser-Erkan et al., 2008), non-small cell lung cancer (Jin et al., 2012) and bladder 
cancer (Guo et al., 2010). Unexpectedly, PIM1 expression is associated with a good 
prognosis in both prostate and pancreatic carcinomas (Dhanasekaran et al., 2001; 
Reiser-Erkan et al., 2008).  
PIM2 is associated with disease progression and invasion in prostate cancer (Dai et al., 
2005) and both PIM2 and PIM3 are highly expressed in hepatocellular carcinoma (Fujii 
et al., 2005; Gong et al., 2009). PIM3 is further implicated in pancreatic cancer (Li et 
al., 2006) and progression of gastric adenocarcinoma (Zheng et al., 2008). 
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1.7 Chromatin and the regulation of transcription 
A hallmark of cancer in general is the deregulation of gene expression (Hanahan & 
Weinberg, 2000; Lee & Young, 2013; Sadikovic et al., 2008). In recent years it has 
been increasingly recognised that gene expression is mainly regulated at the level of 
the chromatin, through structural organisation of genes, DNA methylation, 
posttranslational modifications (PTMs) of histones and transcription factors and co-
factors (Berger, 2007; Li, Carey, et al., 2007). Especially DNA methylation has been 
extensively studied and was found to be deregulated in haematological malignancies 
(Galm et al., 2006; Yu, 2006). Further, inhibitors against some epigenetic modifiers, like 
HDACs or EZH2 have already been shown to be effective against several 
haematological malignancies (Bhadury et al., 2014; Duan et al., 2005; Ferreira et al., 
2014; Garapaty-Rao et al., 2013; McCabe et al., 2012; X. Zhang et al., 2012). BET 
(bromodomain and extra terminal domain) inhibitors, which target adapter proteins that 
recognise histone acetylation marks, are very potent drugs against MYC-dependent 
lymphomas (Delmore et al., 2011). However, kinases are preferred targets for cancer 
therapy and they are significantly involved in the regulation of transcription downstream 
of signalling pathways and possibly also in the regulation of constitutively transcribed 
genes. Therefore, it might be important to identify chromatin-associated kinases as 
therapeutic targets, because they are likely contributing to the deregulated gene 
expression programme. PIM1 is, for example, required for the expression of 20% of 
MYC-regulated genes in serum-shocked HEK293 cells (Zippo et al., 2007). 
Kinases do not act in isolation, but trigger the establishment of other chromatin 
modifications, like histone acetylation or methylation (Kim et al., 2014; Liokatis et al., 
2012; Zippo et al., 2009), or structural rearrangement of the chromatin (Drobic et al., 
2010). Therefore, it is also of interest to study effects of kinases on chromatin 
organisation and other histone modifications. Further, it might be helpful to determine 
which effects established kinase inhibitors have at the chromatin level to understand 
their mechanism of action and thus mechanisms of resistance. Altogether, a better 
understanding of the still elusive relationship between signalling kinases and chromatin 
alterations might lead to the identification of novel therapeutic targets or useful 
combinations of drugs.  
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1.7.1 Chromatin structure 
Chromatin is the DNA with its associated proteins and RNAs. The role of chromatin is 
to package DNA to fit into the cell, to allow mitosis and meiosis, DNA repair and 
replication, and to control gene expression (Campos & Reinberg, 2009). The most 
abundant proteins in chromatin are the histones. These are small, positively charged, 
globular proteins with an extended N-terminal tail, which form octameres of two copies 
of H2A, H2B, H3 and H4 each (core histones). Approximately 146 bp of DNA are 
wrapped around these octameres to form nucleosomes (Luger et al., 1997; Alberts, 
2008). Two nucleosomes are connected by so-called linker DNA, resulting in a “beads-
on-a-string” structure (Luger et al., 2012). Further compaction of the chromatin is 
achieved through the linker histone H1, interactions between the nucleosomes and 
through non-histone proteins (Alberts, 2008; Hediger & Gasser, 2006; Luger et al., 
2012) (Figure 1.29).  
 
Figure 1.29 Schematic overview of open and closed chromatin structures. 
Chromatin compaction is mediated by histone H1 and other structural proteins. 
 
Generally, densely packed, inactive regions are collectively called heterochromatin, 
while open chromatin regions are referred to as euchromatin. In recent years, it has, 
however, been established that there are different forms of both eu- and 
heterochromatin, which are characterised by different densities of chromatin 
packaging, differential use of histone variants, distinct posttranslational modifications of 
histones and binding of specific non-histone proteins and non-coding RNAs (Ernst & 
Kellis, 2010; Ernst et al., 2011; Julienne et al., 2013; Ram et al., 2011). In Drosophila, 
five different types of chromatin have been identified, two of which are classic 
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heterochromatin, characterised by the presence of either heterochromatin protein 1 
(HP1) or Polycomb proteins, two are different euchromatic chromatin states and the 
bulk of chromatin is silent, non-HP1- or -Polycomb-associated chromatin, which is 
devoid of associated proteins and histone posttranslational modifications (black or 
“null” chromatin) (Filion et al., 2010). Similarly, in human cells, four principal chromatin 
states have been detected: euchromatin, Polycomb-silenced chromatin, HP1-
associated heterochromatin and silent “null” chromatin (Ciabrelli & Cavalli, 2014; 
Julienne et al., 2013) (Table 1.2). If further subdivided, chromatin adopts specific and 
distinct structures at promoters, actively transcribed regions, regulatory elements, 
silenced and repetitive regions, like telomeres, centromeres and pericentromeric 
regions (Ernst & Kellis, 2010; Ernst et al., 2011; Julienne et al., 2013; Ram et al., 2011) 
(Figure 1.30).  
 
Chromatin 
state 
Euchromatin Polycomb-
silenced 
Hetero-
chromatin 
Null 
chromatin 
H3K4me3 ++ - - - 
H3K36me3 ++ - - - 
H3K27ac ++ - - - 
H3K79me2 ++ - - - 
H3K9me1 ++ + - - 
H2A.Z ++ + - - 
H4K20me1 + + - - 
H3K27me3 +/- ++ - +/- 
H3K9me3 +/- +/- ++ - 
POL II ++ +/- - - 
SIN3A ++ - - - 
CTCF + + - +/- 
HP1γ ++ +/- - - 
Table 1.2 Chromatin marks associated with the four principal chromatin states. 
Adapted from Julienne et al. 2013. ++ strong enrichment of mark, + enrichment of 
mark, +/- mark enriched at some loci, - mark not present. Coloured cells show 
chromatin modifications and proteins characteristic of the different chromatin 
states. 
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Figure 1.30 Chromatin marks and proteins associated with specific euchromatic 
regions. 
Different combinations of chromatin modifications mark specific regions in 
euchromatin. These are also associated with different levels of transcription and 
DNase hypersensitive sites (DHS). These correlations were described by Ernst et 
al. 2011 and Ernst and Kellis 2010. 
 
Further, chromatin is topologically organised in the nucleus of the cell. Inactive 
chromatin regions are associated with the nuclear lamina, while actively transcribed 
domains are localised to the centre of the nucleus (Foster & Bridger, 2005; Guelen et 
al., 2008). Moreover, specific microdomains have recently been identified, so called 
topologically associating domains (TADs). These are linear, about 1 Mb long stretches 
of chromatin, which fold into three-dimensional structures and are separated from each 
other by house-keeping genes or insulators (Ciabrelli & Cavalli, 2014; Dixon et al., 
2012). The lengths of these TADs are conserved among cell types, while the intrinsic 
organisation can be variable, even in cells of the same type (Dixon et al., 2012; 
Nagano et al., 2013). Each TAD adopts one of the four principal chromatin states and 
genes within a TAD are usually co-regulated (Ciabrelli & Cavalli, 2014). Although intra-
TAD interactions are preferred, long-range interactions between different TADs can 
also be observed (Nagano et al., 2013). Interactions occur between promoters and 
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enhancers as well as between co-regulated promoters to enhance or repress 
transcription (Li et al., 2012). 
 
1.7.2 Transcription through chromatin 
Chromatin is generally a repressive environment for transcription. Nucleosomes pose a 
barrier towards the POL II and inhibit binding of transcription factors to DNA (Petesch & 
Lis, 2012). Consistently, densely packed chromatin inhibits processive transcription, 
while open chromatin, regions with low nucleosome occupancy and high nucleosome 
turnover are accessible for the transcription machinery. Therefore, transcriptional 
regulation occurs largely at the level of nucleosomes and there is extensive cross-talk 
between POL II, transcription factors, histone variants, histone posttranslational 
modifications and chromatin remodelling complexes. For example, histone variants and 
histone PTMs can recruit transcription factors and chromatin remodelling complexes 
and together they can lead to the recruitment of the POL II. Posttranslational 
modifications of the POL II C-terminal domain (CTD) are required for transcription, by 
recruiting RNA processing enzymes (Cho et al., 1997; Ghosh et al., 2011), but also by 
binding enzymes that modify or remodel histones (Kizer et al., 2005; Kwon et al., 
2010). Therefore, modifications of the POL II CTD during transcription, histone variants 
and histone PTMs are reviewed in the following sections. 
 
1.7.2.1 The POL II transcription cycle 
The largest subunit of the POL II carries an extended C-terminal domain (CTD), which 
consists of 52 heptad repeats with the consensus sequence Y-S-P-T-S-P-S (Egloff & 
Murphy, 2008). Serine, threonine and tyrosine residues in the CTD are subjected to 
extensive phosphorylation, which generates a CTD code (Buratowski, 2003; 
Heidemann et al., 2013; Komarnitsky et al., 2000). 
The POL II is recruited to the chromatin in its hypophosphorylated form via interactions 
with general transcription factors and the Mediator. At the promoter, both S5 and S7 
are phosphorylated by the TFIIH subunit CDK7 in a Mediator-dependent fashion 
(Boeing et al., 2010). These phosphorylation events release the POL II from the 
Mediator (Søgaard & Svejstrup, 2007) and S5p generates a binding platform for the 
capping enzyme guanylyltransferase (Cho et al., 1997; Ghosh et al., 2011) (Figure 
1.31). While the POL II progresses along the gene, S5 is dephosphorylated (Tietjen et 
al., 2010). Several different phosphatases have been described in mammals (Hsu et 
al., 2014; Lehman & Dahmus, 2000; Lin et al., 2002; Thompson et al., 2006; 
- 60 - 
Washington et al., 2002; Yeo et al., 2003). S7p also peaks in the 5’ region of the gene, 
but stays higher during transcription than S5p (Tietjen et al., 2010). 
At protein-coding genes, phosphorylation of S2 occurs during elongation and peaks 
towards the 3’ end (Tietjen et al., 2010). In the promoter region, P-TEFb mediates S2 
phosphorylation, while CDK12 and CDK13 phosphorylate the elongating POL II 
(Bartkowiak et al., 2010). P-TEFb stimulates transcription elongation mainly through 
the phosphorylation of the Suppressor of Ty 5 (SPT5) subunit of DRB sensitivity-
inducing factor (DSIF), an SPT4-SPT5 heterodimer (Kim & Sharp, 2001), and of the 
negative elongation factor (NELF) (Fujinaga et al., 2004). The NELF-DSIF complex 
induces pausing of the POL II 20 to 60 nt downstream of the TSS, probably via binding 
to nascent RNA (Kwak & Lis, 2013). P-TEFb-mediated phosphorylation of SPT5 and 
NELF leads to dissociation of NELF from the POL II and turns DSIF into a 
transcriptional activator to allow for processive elongation. DSIF and the PAF1 complex 
(PAF1C) bind cooperatively to the POL II and both are required for gene expression 
(Yexi Chen et al., 2009). S2p is essential for the recruitment of splicing and 
polyadenylation factors (Ahn et al., 2004; Davidson et al., 2014; Gu et al., 2013) 
(Figure 1.31). At the same time, efficient cleavage and polyadenylation are required for 
high levels of S2p (Davidson et al., 2014). 
 
Figure 1.31 The POL II transcription cycle.  
Hypophosphorylated POL II is recruited to the chromatin by the Mediator (M). 
Phosphorylation of the CTD S5 and S7 initiate transcription and bind the capping 
enzymes (CE). The NELF/DSIF complex induces pausing downstream of the 
TSS, which is relieved by P-TEFb. CTD S2 phosphorylation is required for the 
recruitment of polyadenylation factors (PFs). Phosphatases dephosphorylate the 
CTD and POL II is recycled. 
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1.7.2.2 The histone code hypothesis 
Especially histone tail modifications and histone variants are predictive of different 
chromatin states. Enhancers are, for example, characterised by histone H3K4 
monomethylation (H3K4me1) and when they are active, also by H3K27 acetylation. 
Core promoters are generally marked by H3K4me3 and histone acetylation, while 
heterochromatin is distinguished by the presence of H3K9me3 or H3K27me3 
(Bernstein et al., 2005; B.E. Bernstein et al., 2006; Creyghton et al., 2010; Ernst & 
Kellis, 2010; Ernst et al., 2011; Heintzman et al., 2007; Heintzman et al., 2009; 
Mikkelsen et al., 2007; Rivera & Ren, 2013). Consistently, it had been proposed that 
combinations of histone post-translational modifications function as a histone code, in 
which marks are established sequentially or simultaneously and which is instructive for 
the fate of certain chromatin regions (Strahl & Allis, 2000). The marks are established 
by “writer” proteins and serve as docking platforms for chromatin “readers”, which often 
recognise distinct combinations of histone modifications. Thus, the same histone PTMs 
can, depending on the context, instruct different outcomes, like the activation or 
repression of transcription by recruiting RNA polymerases, transcription factors and co-
factors or transcriptional repressors. H3K9me2/3 are, for example, associated with 
heterochromatin formation and recruitment of the HP1 protein (Bannister et al., 2001; 
Jacobs et al., 2001; Lachner et al., 2001). Phosphorylation of the adjacent H3S10 
prevents HP1 binding to H3K9me2/3 (Fischle et al., 2005; Hirota et al., 2005; 
Papamokos et al., 2012), but can activate transcription (Winter et al., 2008).  
 
1.7.2.3 Regulation of transcription by histone variants 
As part of the histone code, histone variants, which usually differ from canonical 
histones by a few amino acids or extended N- or C-terminal tails, regulate transcription. 
In mammalian cells, the histones H1, H2A, H2B and H3 exist in several isoforms, which 
are associated with specific chromatin states and mediate different effector functions 
(Talbert & Henikoff, 2010).  
 
1.7.2.3.1 The Histone H3.3 variant 
H3.1 and H3.2 are the canonical histone H3 variants (referred to as H3), which are 
mainly deposited into the chromatin during DNA replication. H3.3, which differs from 
the canonical histone variants by 5 amino acids, can be introduced into the chromatin 
at any time of the cell cycle, because different histone chaperones are responsible for 
its deposition (Drané et al., 2010; Galvani et al., 2008; Goldberg et al., 2010; Konev et 
al., 2007; Tagami et al., 2004). H3.3 can be found in actively transcribed regions of the 
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genome and at transcription factor binding sites, but also at telomeres and 
pericentromeric regions (Ahmad & Henikoff, 2002; Goldberg et al., 2010; Santenard et 
al., 2010; Schwartz & Ahmad, 2005; Sutcliffe et al., 2009; Tagami et al., 2004; Tamura 
et al., 2009). Consistent with their presence in actively transcribed and regulatory 
regions, H3.3-containing nucleosomes are less stable than nucleosomes formed with 
canonical H3 and repress the formation of higher order chromatin structures 
(Braunschweig et al., 2009; Chen et al., 2013; Jin & Felsenfeld, 2007). 
 
1.7.2.3.2 Histone H2A.Z 
H2A can be replaced by its variant H2A.Z in promoter and pericentromeric regions 
(Rangasamy et al., 2003). It is integrated into the chromatin by a SWI/SNF family 
chromatin-remodelling enzyme, the SWR1 complex in yeast and p400 or SRCAP in 
humans (Gévry et al., 2007; Kobor et al., 2004; Ruhl et al., 2006). It was proposed that 
H2A.Z is randomly deposited throughout the genome, but that active transcription leads 
to the eviction of H2A.Z-containg nucleosomes and their replacement by H2A-
containing nucleosomes. That explains, why H2A.Z is enriched in non-transcribed 
regions, like heterochromatin, but depleted from gene bodies (Hardy et al., 2009). 
Knockout of H2A.Z is lethal in Drosophila and mice (van Daal & Elgin, 1992; Faast et 
al., 2001), but not in yeast. However, H2A.Z is required for the transcription of inducible 
genes in S. cerevisiae and the C-terminal portion of H2A.Z had been shown to directly 
interact with the POL II. H2A.Z is globally present at active and inactive promoters in 
yeast and facilitates stable nucleosome positioning (Guillemette et al., 2005; Raisner et 
al., 2005). However, upon induction of gene expression H2A.Z is removed from 
promoters (Adam et al., 2001; Larochelle & Gaudreau, 2003). 
In Drosophila, H2A.Z-containing nucleosomes have been shown to pose a lower 
barrier to transcription than normal H2A-containing nucleosomes, probably because 
the H2A.Z-H2B dimer can be evicted more easily, leaving a H3-H4 tetramer that 
facilitates the passage of the POL II (Weber et al., 2014). Genome wide studies in 
human cells showed that H2A.Z is generally associated with distal regulatory elements, 
independent of their activation status. In contrast to yeast, it is however only associated 
with active or poised, but not silent, promoters. Nevertheless, like in yeast, H2A.Z-
containing nucleosomes are found flanking the nucleosome-free region (NFR) (Barski 
et al., 2007; Hardy et al., 2009) and H2A.Z leads to stable positioning of nucleosomes 
around the NFR (Gévry et al., 2009). Specific recruitment of the variant histone is 
observed at silent promoters in humans prior to activation (Gévry et al., 2009; Hardy et 
al., 2009), possibly facilitated by transcription factors. Consistently, the oestrogen 
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receptor (ER) has been shown to directly associate with p400 (Gévry et al., 2007; 
Gévry et al., 2009). As H2A.Z deposition facilitates stable nucleosome positioning, 
transcription factor binding sites or the TATA box could be exposed, which allows for 
transcription initiation (Gévry et al., 2009) (Figure 1.32). H2A.Z is generally required for 
POL II recruitment, as is evident from global loss of POL II from the chromatin upon 
H2A.Z knockdown (Hardy et al., 2009). After recruitment of the POL II, H2A.Z is lost 
from the promoters to allow for elongation (Gévry et al., 2007; Hardy et al., 2009; John 
et al., 2008). Consistent with a role in POL II recruitment to promoters, the proximity of 
H2A.Z to the TSS correlates with POL II occupancy and with the level of gene 
expression in mouse brain and liver (Bargaje et al., 2012).  
 
 
Figure 1.32 Deposition of H2A.Z at promoters.  
H2A.Z is absent from silent promoters and is deposited during activation by the 
p400 chromatin remodelling complex. H2A.Z facilitates the stable generation of a 
nucleosome-free region (NFR) and is required for POL II recruitment. Upon 
induction of gene expression, H2A.Z is evicted. 
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1.7.2.4 Histone posttranslational modifications 
Although histone variants are part of the histone code, it is mainly fomed by diverse 
PTMs of histones, especially histone tails. These modifications add another layer of 
complexity to the histone code. Lysines can be mono-, di- or trimethylated, acetylated, 
ubiquitinated or SUMOylated, arginines can be mono-, symmetrically or asymmetrically 
dimethylated, citrullinated or ADP-ribosylated. Glutamine residues can also be 
methylated. Phosphorylation of serine, threonine and tyrosine residues and N-
acetylglucosaminylation of serine and threonine residues can take place. Further, 
proline isomerisation has been observed (Sakabe et al., 2010). 
 
1.7.2.4.1 Histone acetylation 
Acetylation of lysine residues reduces the positive charge of histones, disrupts histone-
DNA interactions and is generally associated with transcriptional activation (Bannister 
& Kouzarides, 2011). Nuclear histone acetyltransferases (HATs) can be divided into at 
least three families, the GCN5-related N-acetyltransferase (GNAT), the MOZ, Ybf2, 
Sas2 and Tip60 (MYST) and the CBP/p300 families (Yang & Seto, 2007). HATs form 
large, up to several MDa, multiprotein complexes that allow them to be active in vivo 
(Allard et al., 1999; Grant et al., 1997; John et al., 2000). Acetyl moieties are removed 
by histone deacetylases (HDACs), which are usually part of HDAC complexes, 
including the SIN3A complex (Bannister & Kouzarides, 2011). 
Acetylated histone residues that are widely associated with transcriptional activation 
are H3K9, H3K14, H3K27, H3K56, H4K5, H4K8, H4K12 and H4K16 (Smolle & 
Workman, 2013). Apart from fulfilling a passive function through destabilising histone-
DNA interactions, acetylation marks can also directly be recognised by the 
bromodomains and tandem plant homeodomain (PHD) fingers of histone modification 
reader proteins (Dhalluin et al., 1999; Lange et al., 2008; Qiu et al., 2012; Yap & Zhou, 
2010; Zeng et al., 2010).  
One protein recruited to acetylated lysine residues is the TAFII250 subunit of the TFIID, 
which recognises di- or tetraacetylated H4 via its double bromodomain (Jacobson et 
al., 2000). Other bromodomain-containing proteins are the acetyltransferases CBP, 
p300, GCN5 and PCAF, the chromatin remodelling enzymes SWI/SNF related, matrix 
associated, actin-dependent regulator 2 (SMARCA2) and SMARCA4, Mixed lineage 
leukaemia (MLL1) and some transcription factors (Dhalluin et al., 1999; Filippakopoulos 
et al., 2012; Hudson et al., 2000; Ragvin et al., 2004; Shen et al., 2007; Zeng et al., 
2008) (Figure 1.33). Important acetyl lysine binding proteins are the bromodomain and 
extra terminal domain (BET) proteins (BRDs), a family consisting of BRD2, BRD3, 
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BRD4 and BRDT (Filippakopoulos et al., 2012; Shi & Vakoc, 2014). These proteins 
have two bromodomains and recognise dually acetylated substrates (Dey et al., 2003). 
They serve as adaptor proteins to recruit transcriptional regulators. BRD4 has been 
shown to recruit P-TEFb (Jang et al., 2005; Yang et al., 2005), the Mediator 
(Houzelstein et al., 2002; Jiang et al., 1998; Yang et al., 2005), the H3K36 mono- and 
dimethyltransferase NSD3 and the arginine demethylase Jumonji domain-containing 
protein (JMJD6) to facilitate transcription inititation and elongation (Rahman et al., 
2011). BRD4 has also been described as an atypical protein kinase that can 
phosphorylate the POL II CTD S2 directly (Devaiah et al., 2012). Consistently, BRD4 
has been shown to occupy promoters and enhancers genome-wide together with 
Mediator and POL II S2p (Lovén et al., 2013; W. Zhang et al., 2012). Recently, BET 
inhibitors have been developed and have been shown to be effective in inhibiting 
growth of Burkitt lymphoma, multiple myeloma and AML cell lines. One mechanism of 
action is the inhibition of transcription of MYC and BCL2 (Dawson et al., 2011; Delmore 
et al., 2011; Mertz et al., 2011).  
 
Figure 1.33 Regulation and functions of histone acetylation.  
Writers of histone acetylation marks are acetyltransferases of the MYST family 
(MOF, TIP60, Monocytic leukaemia zinc finger protein (MOZ), MOZ-related factor 
(MORF) and Histone acetyltransferase bound to ORC (HBO1)), the GNAT family 
(GCN5, PCAF) and the p300/CBP family. These acetyltransferases are 
themselves readers of the acetylation marks and other reader proteins include 
the MLL1 methyltransferase, the SWI/SNF family proteins SMARCA2/4, BRD4 
and transcription factors (TFs). Further, acetylation of histones generally 
counteracts chromatin compaction by changing the charge of the nucleosome. 
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1.7.2.4.2 Histone methylation 
Methylation of lysines competes with acetylation of the same residues. Methylation 
does not change the charge of the histones and does thus not disrupt histone-DNA 
interactions (Bannister & Kouzarides, 2011). Therefore, the main purpose of 
methylation marks is to recruit specific proteins to stimulate or suppress transcription. 
Methylation occurs on several lysines, but the best-characterised are H3 lysines 4, 9, 
27, 36, 79 and histone H4K20 (Tan et al., 2011; Wozniak & Strahl, 2014). These lysine 
methylation marks show a specific distribution along transcribed genes, at enhancers 
and at repressed chromatin regions. 
 
1.7.2.4.2.1 H3K4 methylation 
H3K4me2/3 are high in active core promoter regions (Bernstein et al., 2005; Koch et 
al., 2007), H3K4me1/2 can be found further downstream of the TSS (Koch et al., 2007) 
and H3K4me1 marks active or poised enhancers (Heintzman et al., 2007). In humans, 
six H3K4 methyltransferases, which are only functional in multiprotein complexes 
homologous to the yeast Set1/COMPASS (Complex proteins associated with Set1) 
complex, have been identified: SET domain-containing 1A (SET1A), SET1B and 
MML1-4 (Shilatifard, 2012). SET1A/B are responsible for the bulk of H3K4me3 in the 
cells (Wu et al., 2008), MLL1 and MLL2 are required for H3K4me3 only at a subset of 
genes (P. Wang et al., 2009) and MLL3/4 have recently been described as the major 
enhancer-associated monomethyltransferases (Herz et al., 2012; D. Hu et al., 2013). 
Di- and trimethylation of H3K4, but not H3K4me1, through the SET1 complex are 
stimulated by monoubiquitination of H2BK120, which is carried out by the RAD6/BRE1 
E2/E3 complex. H2Bub is found in the promoters and gene bodies of transcribed genes 
and, interestingly, on-going transcription is required for efficient H2B ubiquitination (Kim 
et al., 2009). Further, the PAF1C is required for proper H2B ubiquitination and H3K4 
methylation. It binds to the POL II and serves as a docking platform for both the 
RAD6/BRE1 and, at least in yeast, the SET1 complex (Kim et al., 2009; Krogan et al., 
2003; Ng et al., 2003; Zhu et al., 2005). In mice and humans, MLL1 has been shown to 
interact with the PAF1C (Milne et al., 2010; Muntean et al., 2010). 
Chromatin readers recognise methylation marks through PHD fingers, chromodomains, 
Tudor, Bromo-adjacent homology domain (BAH), PWWP or CW domains (Wozniak & 
Strahl, 2014). H3K4me3 recruits several transcription activating proteins, like the TAF3 
subunit of the TFIID via its PHD finger (Vermeulen et al., 2007). The efficiency of TFIID 
recruitment, and thus of the preinitiation complex, can therefore be fine-tuned through 
binding of TBP to the TATA box, through histone H4 acetylation and through H3K4me3 
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(Wozniak & Strahl, 2014). Other proteins recruited by H3K4me3 are the chromatin 
remodelling enzyme chromodomain helicase DNA-binding protein 1 (CHD1) (Lin et al., 
2011), the STAGA and HBO1 HAT complexes (Hung et al., 2009; Saksouk et al., 2009; 
Vermeulen et al., 2010) and the Jumonji domain-containing protein 2A (JMJD2A) 
demethylase, which demethylates H3K9me3 and H3K36me3 (Huang et al., 2006; Kim 
et al., 2006). Further, in a positive feed-forward loop, SET1A/B and MLL1 complexes 
are recruited by H3K4me3 (Eberl et al., 2013; Milne et al., 2010; Z. Wang et al., 2010). 
H3K4me1 at enhancers is specifically read by the TIP60 HAT (Jeong et al., 2011). 
Other proteins, including the DNA methyltransferases DNMT3A and DNMT3B 
specifically bind to H3 that is unmethylated on K4 and their binding is inhibited by 
H3K4me2/3 (Ooi et al., 2007; Yingying Zhang et al., 2010). Under certain conditions, 
H3K4me3 can also lead to recruitment of transcriptional repressors. The SIN3A-
HDAC1 complex is recruited to H3K4me3 after genotoxic stress (Shi et al., 2006) 
(Figure 1.34). 
 
Figure 1.34 Regulation and functions of H3K4 methylation.  
In humans, MLL3 and MLL4 mainly mediate H3K4me1 at enhancers, while 
SET1A/B, MLL1 and MLL2 mediate H3K4me3. H3K4me3 is enhanced by H2Bub. 
Proteins that interact with H3K4me3 are TFIID, acetyltransferases (STAGA, 
HBO1), the chromatin remodeller CHD1 and the demethylase JMJD2A. 
Generally, H3K4me3 mediates transcriptional activation, but under some 
conditions the SIN3A-HDAC complex can also be recruited to this mark. 
H3K4me1 interacts with TIP60. 
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1.7.2.4.2.2 H3K36 methylation 
H3K36me1/2 are enriched in the 5’ regions of actively transcribed genes, whereas 
H3K36me2/3 are higher towards the 3’ end (Bannister et al., 2005; Lucio-Eterovic et 
al., 2010). Among others, nuclear receptor-binding SET domain proteins (NSD1/2/3) 
are H3K36 mono- and dimethyltransferases, whereas SET domain-containing 2 
(SETD2) is a trimethyltransferase (Edmunds et al., 2008; Y. Li et al., 2009; Qiao et al., 
2011; Wagner & Carpenter, 2012). 
At least in yeast, the SETD2 homolog Set2 has been shown to interact with the POL II 
CTD that is phosphorylated on both S2 and S5 and this interaction is important for 
H3K36 methylation. The interaction domain is conserved in human SETD2, making it 
plausible that SETD2 also interacts with the POL II (Kizer et al., 2005). Further, 
recruitment of SETD2 to genes is increased by splicing and consistently, H3K36me3 is 
highest along intron-containing genes and increases over spliced exons (de Almeida et 
al., 2011). Conversely, H3K36me3 has also been associated with alternative splicing 
by recruiting proteins that suppress splice site usage (Luco et al., 2011). 
In both yeast and humans, H3K36 methylation promotes the establishment of 
repressive chromatin to inhibit aberrant transcription initiation (Carvalho et al., 2013). 
H3K36me3 leads to the recruitment of the Rpd3S HDAC complex in yeast, maintaining 
the gene body in a hypoacetylated state to repress cryptic initiation from intragenic 
promoters (Carrozza et al., 2005; Joshi & Struhl, 2005; Keogh et al., 2005; Li, Gogol, et 
al., 2007). The homologous PF1-MRG15-SIN3B-HDAC1 complex in humans is 
targeted to both H3K4me3- and H3K36me3-containing nucleosomes and can thus be 
found directly downstream of the TSS but not throughout the transcribed region. 
Consistently, it regulates the level of transcription but not aberrant transcription 
initiation (Jelinic et al., 2011). In humans, deacetylation of the coding region is most 
likely mediated by HDAC6, which directly interacts with the POL II CTD (Z. Wang et al., 
2009). 
During transcription elongation, nucleosomes are disassembled and removal of the 
H2A-H2B dimer is sufficient to allow for the passage of the POL II (Belotserkovskaya et 
al., 2003). H3K36me3 mediates the recruitment of the histone chaperone facilitates 
transcription (FACT) complex, which is crucial for both the removal and the 
reestablishment of H2A-H2B dimers in the wake of POL II transcription (Carvalho et al., 
2013). Consistently, H3K36me3 inhibits the interaction of histone chaperones with H3 
in yeast, conserving the H3-H4 tetramer but allowing for exchange of the H2B-H2A 
dimers (Venkatesh et al., 2012). Therefore, H3K36me3 both facilitates transcription 
elongation and inhibits cryptic transcription initiation (Carvalho et al., 2013). Further, 
H3K36me3 recruits DNMT3A via its PWWP domain (Dhayalan et al., 2010). 
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Conversely, H3K36me3 can also recruit transcriptional activators, like the 
acetyltransferase MOZ (Vezzoli et al., 2010) (Figure 1.35). 
 
 
 
Figure 1.35 Deposition and effector functions of H3K36me3.  
Trimethylation of H3K36 is mediated by SETD2. At the 5’ end of genes, where 
H3K4me3 is also present, a HDAC1-containing complex is recruited, to mediate 
transcriptional repression. H3K36me3 alone is sufficient to recruit the 
transcriptional activator MOZ, the histone chaperone FACT, which both activates 
elongation and represses cryptic transcription initiation, and the transcriptional 
repressor DNMT3A. H3K36me3 also mediates alternative splicing and, 
reciprocally, its establishment is regulated by splicing. 
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1.7.2.4.2.3 H3K9 methylation and HP1 proteins 
Methylation marks that are traditionally associated with silent chromatin are H3K9me3, 
H3K27me3 and H4K20me3. Methyltransferases for H3K9 are histone H3K9 
methyltransferase 3 (G9A) (Tachibana et al., 2001), G9A-like protein (GLP) (Ogawa et 
al., 2002), SET domain-containing B1 (SETDB1) (Schultz et al., 2002), PR domain 
containing 2 (PRDM2) (K.-C. Kim et al., 2003), suppressor of variegation 3-9 
homolog 1 (SUV39H1) (Rea et al., 2000) and SUV93H2 (O’Carroll et al., 2000). 
Demethylases belong to the Jumonji domain-containing histone demethylase 
(JHDM2/KDM3) (Yamane et al., 2006), JMJD2/KDM4 (Cloos et al., 2006; Fodor et al., 
2006; Klose et al., 2006; Whetstine et al., 2006) and KDM8 families (Horton et al., 
2010; Krishnan et al., 2011; Loenarz et al., 2010).  
The best-studied H3K9me3 interacting proteins are the heterochromatin proteins 
HP1α, HP1β and HP1γ. They recognise H3K9me3 with their chromodomain (Bannister 
et al., 2001; Jacobs et al., 2001; Lachner et al., 2001) and dimerise via their 
chromoshadow domain (Brasher et al., 2000; Cowieson et al., 2000). Further, the 
dimeric chromoshadow domain interacts with other proteins, like SUV39H1 and 
SUV420H2, which methylates H4K20 (Souza et al., 2009; Yamamoto & Sonoda, 2003) 
(Figure 1.36). While HP1α and HP1β are mainly associated with constitutive 
heterochromatin (Minc et al., 1999), HP1γ can be found in both eu- and 
heterochromatin (Minc et al., 2000).  
The exact mechanisms for heterochromatin formation are not yet clear. HP1 proteins 
associate with the chromatin in a dynamic fashion and this dynamic interaction is 
required for chromatin condensation (Cheutin et al., 2003; Festenstein et al., 2003). 
SUV39H1, in contrast, seems to stably bind heterochromatic regions. Therefore, it was 
proposed that SUV39H1 recruits HP1 to heterochromatin via direct protein-protein 
interactions and H3K9 methylation (Krouwels et al., 2005). This hypothesis is 
supported by experiments in mouse ES cells expressing a SUV39H1 mutant deficient 
for HP1 interaction. In these cells, SUV39H1 was recruited to pericentromeric regions 
but HP1 and SUV420H recruitment were impaired (Muramatsu et al., 2013). HP1 and 
SUV93H1 also interact with DNMT1 and DNMT3A (Fuks et al., 2003) and the methyl 
CpG-binding protein 2 (MeCP2) interacts with and recruits HP1, reinforcing 
heterochromatin formation (Agarwal et al., 2007). Further, non-coding RNAs (ncRNAs) 
are implicated in the establishment of heterochromatin (Bouzinba-Segard et al., 2006; 
Deng et al., 2009; Pal-Bhadra et al., 2004) (Figure 1.36). 
H3K9me2/3 and HP1γ-S83p are also associated with the body of actively transcribed, 
euchromatic genes and HP1γ directly interacts with the POL II CTD, when it is 
phosphorylated at S2 or S5 (Lomberk et al., 2006; Vakoc et al., 2005). Drosophila 
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HP1c interacts with the FACT complex and recruits it to the elongating POL II (Kwon et 
al., 2010). Further, HP1γ promotes inclusion of alternative exons by slowing down the 
POL II, which allows for binding of the spliceosome to weak splice sites, and by binding 
to the nascent mRNA (Saint-André et al., 2011). In addition, HP1 proteins are also 
associated with gene repression. Transcription factors can recruit SUV39H1 or G9A 
and HP1 to mediate chromatin compaction (Xiaoping Chen et al., 2009; Lee et al., 
2010; Lomberk et al., 2012; Nielsen et al., 2001; Yahi et al., 2008). However, at least in 
Drosophila, some genes which are transcribed in a heterochromatin environment, 
require HP1 proteins for their expression (Lu et al., 2000). 
 
 
Figure 1.36 Heterochromatin formation.  
Mechanisms implicated in heterochromatin formation are the recruitment of HP1 
proteins by H3K9me3, SUV39H1, MeCP2 and ncRNAs. Conversely, HP1 also 
recruits DNMT3A and SUV20H to reinforce heterochromatin formation. 
Interaction of HP1 with the chromatin is very dynamic. 
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1.7.2.4.2.4 H3K27 methylation and Polycomb complexes 
Mono-, di- and trimethylation of H3K27 is mediated by enhancer of zeste homolog 1 
(EZH1) and EZH2, which are part of the Polycomb repressive complex 2 (PRC2) 
(Ferrari et al., 2014; Shen et al., 2008). H3K27me3 is associated with transcriptional 
silencing. It serves as a docking site for the PRC1 (E. Bernstein et al., 2006; Cao et al., 
2002; Fischle et al., 2003; Kaustov et al., 2011; Min et al., 2003), which contains the 
ubiquitin E3 ligase RING1 and mediates H2AK119 ubiquitination (Cao et al., 2005; 
Wang et al., 2004). PRC1 mediates chromatin compaction and gene repression, which 
is dependent on H2Aub at some genes but not others (Endoh et al., 2012; Francis et 
al., 2004). In a positive feedforward loop, H2Aub leads to further PRC2 recruitment 
(Kalb et al., 2014). 
It is only incompletely understood, how PRC2 is initially recruited to the DNA, but 
binding to unmethylated CpG islands, recruitment by transcription factors and the 
involvement of ncRNAs have been described (Arnold et al., 2013; Dietrich et al., 2012; 
Herranz et al., 2008; Kanhere et al., 2010; Ku et al., 2008; Lynch et al., 2012; 
Mendenhall et al., 2010; Rinn et al., 2007; Tanay et al., 2007; Zhao et al., 2008). In a 
feedforward loop, PRC2 also binds to H3K27me3 (Margueron et al., 2009). Intriguingly, 
recent studies suggest that PRCs do not initiate gene silencing but are recruited to 
already silenced loci, probably to reinforce and maintain silencing (Hosogane et al., 
2013; Riising et al., 2014; Yuan et al., 2012). Many PRC targets are poised genes, 
which are marked by both H3K4me3 and H3K27me3 (Pan et al., 2007; Zhao et al., 
2007). They are occupied by S5 phosphorylated POL II and can be rapidly activated 
(Brookes et al., 2012). 
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1.7.2.4.3 Histone phosphorylation 
Especially H3S10 and H3S28 phosphorylation are associated with rapid transcriptional 
activation upon stimulation with growth factors, cytokines or after stress (Mahadevan et 
al., 1991; Sawicka et al., 2014; Yamamoto et al., 2003). Histone phosphorylation is 
involved in the regulation of gene expression by extracellular signals. Many signalling 
kinases can translocate into the nucleus and phosphorylate chromatin-associated 
proteins, like histones, transcription factors, the POL II or structural proteins to regulate 
gene expression (Baek, 2011; Koike et al., 2000; Tee et al., 2014). Phosphorylation of 
H3S10 by Aurora A and B, of H3T11 by Zipper-associated protein kinase (ZIPK) and 
phosphorylation of H3S28 were initially linked to mitosis and meiosis (Crosio et al., 
2002; Goto et al., 1999; Gurley et al., 1978; Paulson & Taylor, 1982; Preuss et al., 
2003; Wang et al., 2006; Wei et al., 1998). Later, these marks have also been 
associated with rapid transcriptional activation and H3S10 is phosphorylated in 
apoptotic cells (Park & Kim, 2012). 
 
1.7.2.4.3.1 Phosphorylation of H3S10 and H3S28 
Kinases known to target H3S10 are PIM1 (Zippo et al., 2007), IKKα (Anest et al., 2003; 
Yamamoto et al., 2003), CDK8 (Meyer et al., 2008), MSK1/2 (Soloaga et al., 2003; 
Strelkov & Davie, 2002; Thomson et al., 1999), JNK (Tiwari et al., 2012), PKA 
(DeManno et al., 1999) and COT (Choi et al., 2008). MSK1/2 also phosphorylate 
H3S28 (Soloaga et al., 2003; Zhong et al., 2001) (Figure 1.37). The kinases are usually 
recruited by transcription factors. MSK1/2 can be recruited by ELK1 (Hsu et al., 2013; 
H.-M. Zhang et al., 2008), the progesterone receptor (Vicent et al., 2006) and NFκB 
(Vermeulen et al., 2003). PIM1 is recruited by MYC (Zippo et al., 2007), IKKα binds to 
NFκB (Anest et al., 2003), JNK is recruited by NF-YA (Tiwari et al., 2012) or the ER 
(Sun et al., 2012) and CDK8 is part of a specific Mediator (Wang et al., 2001).  
Phosphorylation of either S10 or S28 lead to gene activation. Consistently, tethering 
MSK1 to target genes is sufficient for the activation of transcription (Lau & Cheung, 
2011) and H3S28p can also stimulate POL III-mediated transcription (Q. Zhang et al., 
2011). Although MSK1/2 can phosphorylate both H3S10 and H3S28, these 
modifications do not occur together on the same nucleosome or even the same 
promoter region in vivo (Drobic et al., 2010; Dunn & Davie, 2005; Dyson et al., 2005). 
Interestingly, different stimuli can lead to the recruitment of distinct kinases to the same 
promoters to mediate transcriptional activation. For example, MSK1/2 lead to H3S10 
phosphorylation in response to growth factors, but they are dispensable for 
phosphorylation of H3 at the same promoters in response to TNF stimulation (Duncan 
et al., 2006). 
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Nucleosomes which contain phosphorylated H3 are hyperacetylated (Barratt et al., 
1994) and both acetylation and phosphorylation of the same histone tail are required 
for efficient gene activation (Clayton et al., 2000; Hauser et al., 2002; Soloaga et al., 
2003). Consistently, yeast Gcn5 has been shown to preferentially acetylate histone H3 
that is phosphorylated on S10 (Cheung et al., 2000; Lo et al., 2000), while MSK1, on 
the other hand, does not prefer acetylated substrates (Liokatis et al., 2012). Further, 
IKKα-mediated H3S10 phosphorylation is required for subsequent H3K14 acetylation 
by CBP (Yamamoto et al., 2003) and CDK8-Mediator can be found in a complex with 
TRRAP/GCN5L to mediate phosphoacetylation of H3 and activate transcription (Meyer 
et al., 2008). Further, phosphorylation of H3 by MSK1 stimulates H4K12 but not H4K16 
acetylation (Lau & Cheung, 2012), whereas PIM1-mediated H3S10 phosphorylation 
stimulates H4K16 but not H4K12 acetylation (Zippo et al., 2009). H3 phosphorylation 
by MSK1/2 can also lead to the inhibition of deacetylation, for example by displacing 
the SIN3A-HDAC2 complex from the HDAC1 promoter (Sawicka et al., 2014).  
H3S10p and H3S28p can be recognised by several members of the 14-3-3 adapter 
protein family, which bind substrates as homo- or heterodimers (Keum et al., 2012; 
Macdonald et al., 2005; Walter et al., 2008). While H3S28p is strongly bound, binding 
to H3S10p is weak and requires concomitant acetylation of K9 or K14, with S10pK14ac 
being the best substrate (Macdonald et al., 2005; Walter et al., 2008; Winter et al., 
2008). 14-3-3 proteins are essential for phosphorylation-dependent induction of gene 
expression and knockdown of 14-3-3 is sufficient to inhibit expression of the HDAC1 
gene, without affecting phosphoacetylation (Winter et al., 2008). 14-3-3ε has been 
shown to bind the CDK9 subunit of P-TEFb to facilitate POL II S2 phosphorylation and 
pause release (Keum et al., 2012). Similarly, 14-3-3ζ can recruit the MOF acetyl 
transferase to PIM1-phopshorylated enhancer regions, which leads to the recruitment 
of P-TEFb (Zippo et al., 2009). 14-3-3 proteins and MSK1 also form a multiprotein 
complex with the SWI/SNF chromatin remodeller, recruiting it to immediate early genes 
(Drobic et al., 2010). The 14-3-3ε/ζ heterodimer can recruit the H3K4 methyltransferase 
SET and MYND domain-containing 3 (SMYD3) and the p52 subunit of TFIIH to activate 
transcription (Li et al., 2011) (Figure 1.37).  
Interestingly, H3S10pK14ac and H3K9me2S10pK14ac are equally good substrate for 
14-3-3 proteins, suggesting that phosphoacetylation of the H3 tail can override 
inhibitory K9 methylation to activate gene expression (Winter et al., 2008). Moreover, 
H3S10p mediates dissociation of repressive HP1 proteins from H3K9me2/3 (Fischle et 
al., 2005; Hirota et al., 2005; Papamokos et al., 2012). While most studies suggest that 
S10p is sufficient for the dissociation, one study claims that both S10p and K14ac have 
to be present (Mateescu et al., 2004). Further, H3K9me3S10p is present at Polycomb-
regulated genes in conjunction with H3K27me3. The K9me3S10p double modification 
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reduces binding of PRCs and paused POL II to the promoters and mediates stable 
gene repression in differentiated cells (Sabbattini et al., 2014). Furthermore, H3S28p 
can trigger the release of PRC from promoters, facilitate H3K27 acetylation and gene 
activation (Gehani et al., 2010; Lau & Cheung, 2011). 
Phosphatases for H3S10p include MAP kinase phosphatase 1 (MKP1), which 
preferentially binds H3 when it is phosphoacetylated (Gadewal et al., 2013; Kinney et 
al., 2009), protein phosphatase 1 (PP1) (Qian et al., 2011) and PP2A (Simboeck et al., 
2010). PP1 can also target H3S28p (Qian et al., 2011) (Figure 1.37). 
 
 
 
Figure 1.37 Kinases that mediate H3S10 phosphorylation and target proteins.  
Several kinases, like MSK1/2, PIM1, IKKα, JNK, CDK8, PKA and COT 
phosphorylate H3S10. Simultaneous acetylation of H3K14 leads to the 
recruitment of 14-3-3 proteins, which serve as adaptors for TFIIH, the H3K4 
methyltransferase SMYD3, the nucleosome remodelling complex SWI/SNF and 
P-TEFb, either directly or via MOF, acetylation of H4 and the BRD4 adapter 
protein. These effectors stimulate transcriptional initiation or elongation. Further, 
H3S10p leads to displacement of HP1 and the double H3K9me3S10p mark 
displaces PRC2 from repressed promoters, leading to stable gene silencing. 
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1.7.2.4.3.2 Other histone phosphorylation marks 
Effects of histone phosphorylation marks other than H3S10p on transcription have 
hardly been studied and are only poorly understood. Intriguingly, apart from H3S10, 
both RSK2 and MSK1 have been shown to phosphorylate histone H2AS1, which 
inhibits transcription (Postnikov et al., 2006; Zhang et al., 2004). 
Further, the H3.3-specific S31 can be phosphorylated. One kinase which mediates 
H3.3S31 phosphorylation is IKKα. IKKα can bind to the POL II CTD S2p and S5p and 
travel with the POL II along the gene to mediate intragenic H3.3S31 phosphorylation. 
HP1γ facilitates IKKα loading from the CTD onto the chromatin and inhibits H3S10 
phosphorylation by IKKα, which explains the preferential S31 phosphorylation within 
the gene body (Thorne et al., 2012). However, the function of H3.3S31p is not yet 
clear. 
Upon androgen receptor (AR) activation, protein kinase C-related kinase 1 (PRK1) is 
recruited and phosphorylates H3T11. This stimulates JMJD2 to demethylate H3K9me3 
and promotes POL II S5 phosphorylation (Metzger et al., 2008). Further, H3T11p is 
bound by the WDR5 subunit of the MLL1 complex, which leads to an increase in 
H3K4me3 (Kim et al., 2014). Subsequently, PKCα and PKCβ can phosphorylate H3T6, 
which blocks demethylation of H3K4me1/2 but not H3K9me1/2 by LSD1 at androgen 
receptor target genes (Metzger et al., 2010) (Figure 1.38). Pyruvate kinase M2 (PKM2) 
has been shown to phosphorylate H3T11 upon EGF receptor activation and lead to 
activation of MYC and CCND1 expression (W. Yang et al., 2012) 
 
Figure 1.38 Histone H3T6 and T11 phosphorylation at AR-target genes.  
Histone H3T6 or H3T11 phosphorylation by PKCs or PRK1, respectively, lead to 
transcriptional activation at androgen receptor target genes. H3T11p stimulates 
JMJD2 to demethylate K9 and recruits MLL1 to trimethylate K4. H3T6p inhibits 
LSD1-mediated K4 demethylation but stimulates its activity towards K9me1/2. 
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2 Aims and Objectives 
 
The overall aim of this work was to analyse the effects of signalling kinases and their 
inhibition on chromatin structure and transcription in B cell lymphoma and leukaemia. 
Kinase inhibitors are now widely studied for the therapeutic use in haematopoietic 
malignancies and kinases affect key pathways, which are important for malignant 
transformation. Deregulation of these pathways results in aberrant gene expression 
programmes, which ultimately drive malignant transformation. Because gene 
expression is regulated at the chromatin level, identifying kinases, which mediate their 
oncogenic effects via the regulation of chromatin structure by phosphorylating histone 
and non-histone proteins, is of particular interest. Further, the chromatin structure is 
indicative of the activation status of a gene and thus the phenotype of a tumour. 
Therefore, global chromatin analysis could be an important tool to assess tumour stage 
and response to treatment.  
 
In the first part of this study, functions of PIM kinases in DLBCL and BL were assessed. 
High PIM1 and PIM2 mRNA expression are a distinguishing factor of the more 
agressive ABC-DLBCL vs. GCB-DLBCL (Care et al., 2013; Wright et al., 2003). 
Consistent with a function in transcriptional regulation, PIM1 can be nuclear in DLBCL 
and BL and this is associated with progressive disease (Brault et al., 2012; Ionov et al., 
2003). Further, PIM1 has been shown to associate with MYC, to phosphorylate histone 
H3S10 and to promote transcriptional elongation (Zippo et al., 2007; Zippo et al., 
2009). Therefore, our aim was to assess the potential therapeutic value of PIM kinases 
in B cell lymphoma. In particular, we wanted to clarify, whether PIM kinases are 
important for the viability of DLBCL and BL cell lines, whether they mediate MYC-
dependent gene expression in these cells and whether their effect on viability is 
correlated with their effect on transcriptional regulation. 
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In the second part of this study, the effects of Ibrutinib on the chromatin structure in 
CLL cells were analysed. Although Ibrutinib is already used in clinical trials for the 
treatment of haematological malignancies, little is known about its mechanism of 
action. It is hypothesised that it inhibits BCR signalling by blocking BTK (Honigberg et 
al., 2010). Because some patients already developed Ibrutinib resistances (Woyach et 
al., 2014), understanding which key pathways and chromatin-mediated effects are 
altered downstream of the BCR in Ibrutinib-treated cells is of vital importance to identify 
useful combination therapies and possibly novel drugable targets. Therefore, our aim 
was to identify BCR signalling-dependent chromatin changes, which are altered by 
Ibrutinib treatment. Histone phosphorylation, methylation and acetylation, as well as the 
use of histone variants, were analysed. Further, we wanted to globally assess the 
effects of Ibrutinib on histone modifications in vitro to facilitate the development of a 
tool for the analysis of drug response in vivo in patients. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals, solutions, consumables 
Product Manufacturer 
0.2 ml PCR tubes Fisher Scientific, Loughborough, UK 
1.5 ml and 0.5 ml tubes Eppendorf, Hamburg, Germany 
10 x Trypsin-EDTA Life Technologies, Carlsbad, US 
100 x Penicillin/Streptomycin (pen/strep) Life Technologies, Carlsbad, US 
100 x proteinase inhibitor cocktail (PIC, 
P8340) 
Sigma Aldrich, Dorset, UK 
100 x TE Sigma Aldrich, Dorset, UK 
15 ml and 50 ml tubes Corning Incorporated, Corning, NY, US 
16% Formaldehyde Fisher Scientific, Loughborough, UK 
2 x ReddyMix PCR Master Mix Fisher Scientific, Loughborough, UK 
5 mg/ml glycogen Life Technologies, Carlsbad, US 
50 x TAE Severn Biotech, Kidderminster, UK 
Agencourt AMPure XP Beckman Coulter, High Wycombe, UK 
Amaxa® Cell Line Nucleofector® Kit V Lonza Group Ltd, Basel, Switzerland 
Amersham HyperfilmTM ECL GE Healthcare, Little Chalfont, UK 
Axygen 96 well PCR Microplate clear, 
PCR-96-C 
Corning Incorporated, Corning, NY, US 
AZD1208 Active Biochemicals, Maplewood, NJ, 
US 
Bradford reagent Bio-Rad, Hertfordshire, UK 
Buffers P1, P2, P3 QIAGEN, Manchester, UK 
Cell culture consumable Corning Incorporated, Corning, NY, US 
Cryotubes Sarstedt, Leicester, UK 
D1000 Screen Tapes, sample buffer and 
ladder for 2200 TapeStation 
Agilent Technologies, Stockport, UK 
DAPK inhibitor Merck Millipore, Nottingham, UK 
dATP, dCTP, dGTP, dTTP Promega, Southampton, UK 
DNA Clean &ConcentratorTM-5 Kit Zymo Research, Freiburg, Germany 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Sigma Aldrich, Dorset, UK 
Dynabeads® Protein G Life Technologies, Carlsbad, US 
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EDTA tubes Greiner Bio-One, Stonehouse, UK 
Electroporation cuvettes Cell Projects, Maidstone, UK 
Ethidium bromide solution, 10 mg/ml Bio-Rad, Hertfordshire, UK 
FACS tubes BD Biosciences, Oxford, UK 
Foetal calf serum (FCS) GE Healthcare, Little Chalfont, UK 
Freezing container Agilent Technologies, Stockport, UK 
Gel Loading Dye, Blue (6 x) New England Biolabs, Hitchin, UK 
Gö6983 Merck Millipore, Nottingham, UK 
GoTaq® qPCR Master Mix Promega, Southampton, UK 
HyCloneTM water Fisher Scientific, Loughborough, UK 
Ibrutinib Pharmacyclics, Sunnyvale, CA, US 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
Sigma Aldrich, Dorset, UK 
LymphoprepTM Axis-Shield, Dundee, UK 
MicroPlex Library PreparationTM kit Diagenode, Seraing (Ougrée), Belgium 
MMLV Reverse Transcriptase and buffer Life Technologies, Carlsbad, US 
PageRulerTM Prestained Protein Ladder Fisher Scientific, Loughborough, UK 
Phosphate buffered saline (PBS) Sigma Aldrich, Dorset, UK 
Phusion® high-fidelity polymerase and 
buffers 
New England Biolabs, Hitchin, UK 
PIM1/2 inhibitor VI Merck Millipore, Nottingham, UK 
PKCβ inhibitor Merck Millipore, Nottingham, UK 
Platinum® Pfx DNA polymerase and 
buffer 
Life Technologies, Carlsbad, US 
Polyvinylidene fluoride (PVDF) 
membrane, Amersham Hybond-P 
GE Healthcare, Little Chalfont, UK 
Proteinase K Roche, Burgess Hill, UK 
Puromycin Sigma Aldrich, Dorset, UK 
QIAGEN Plasmid Maxi Prep QIAGEN, Manchester, UK 
QIAquick Gel Extraction Kit QIAGEN, Manchester, UK 
QIAquick PCR Purification Kit QIAGEN, Manchester, UK 
Quant-iT™ Broad-Range DNA Assay Kit Life Technologies, Carlsbad, US 
Quercetagetin Merck Millipore, Nottingham, UK 
Random Primers, 3 µg/µl Life Technologies, Carlsbad, US 
Restriction endonucleases, buffers and 
100x BSA 
New England Biolabs, Hitchin, UK 
RNase A (1 mg/ml) Life Technologies, Carlsbad, US 
RNaseOut Life Technologies, Carlsbad, US 
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RPMI-1640 Sigma Aldrich, Dorset, UK 
RQ1 RNAse-free DNAse and buffer Promega, Southampton, UK 
RSK inhibitor II Merck Millipore, Nottingham, UK 
SMI4a Enzo Life Sciences, Exeter, UK 
SuperSignal West Pico Enhanced 
Chemiluminescent Substrate/ 
SuperSignal West Femto Enhanced 
Chemiluminescent Substrate 
Fisher Scientific, Loughborough, UK 
T4 DNA ligase and buffer New England Biolabs, Hitchin, UK 
Taq DNA Polymerase and buffers Life Technologies, Carlsbad, US 
TRIzol® Life Technologies, Carlsbad, US 
Trypan Blue solution Sigma Aldrich, Dorset, UK 
U0126 Merck Millipore, Nottingham, UK 
 
3.1.2 Equipment 
Product Manufacturer 
2200 TapeStation Agilent Technologies, Stockport, UK 
ABI 7500 and ABI 7900HT Life Technologies, Carlsbad, US 
AmaxaTM NucleofectorTM Lonza Group Ltd, Basel, Switzerland 
BDTM LSRII Flow Cytometer BD Biosciences, Oxford, UK 
Bioruptor® Diagenode, Seraing (Ougrée), Belgium 
Centrifuge 5415D Eppendorf, Cambridge, UK 
Centrifuge 5810R Eppendorf, Cambridge, UK 
FLUOStar GALAXY BMG Labtech, Aylesbury, UK 
Gel DocTM XR Bio-Rad, Hertfordshire, UK 
Gene Pulser® II Bio-Rad, Hertfordshire, UK 
Heat block QBD2 Grant Instruments, Cambridge, UK 
HiSeq® 2000 System Illumina, Little Chesterford, UK 
Konica SRX-101A Konica Minolta Business Solutions (UK) 
Ltd, Basildon, UK 
Micromix5 Euro/DPC, Gwynedd, UK 
Mini-PROTEAN® System Bio-Rad, Hertfordshire, UK 
Mithras LB940 plate reader Berthold technologies, Bad Wildbad, 
Germany 
NanoDrop 1000 Fisher Scientific, Loughborough, UK 
PTC-200 PCR cycler M J Research Inc., Watertown, MA, US 
T3000 Thermocycler Biometr, Göttingen, Germany 
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Vortex mixer Bibby Scientific, Stone, UK 
 
3.1.3 Buffers 
All chemicals were purchased from Sigma Aldrich, unless otherwise stated.  
 
Name Ingredients 
10 x Annealing Buffer 300 mM HEPES-KOH, pH 7.4 
1 M Potassium Acetate (KAc) 
20 mM Magensium Acetate (MgAc2) 
10 x Running Buffer 0.25 M Tris-HCl, pH 8.6 
1.9 M Glycine 
1% Sodium dodecyl sulfate (SDS) 
10% acrylamide separating gel 6.7 ml 30% acrylamide-bisacrylamide 
(29:1) solution (Severn Biotech, 
Kidderminster, UK) 
8.3 ml dH2O 
5 ml 4 x Lower Buffer  
50 µl 25% ammonium persulfate (APS)  
20 µl Tetramethylethylendiamin (TEMED) 
12.5% acrylamide separating gel 8.3 ml 30% acrylamide-bisacrylamide 
(29:1) solution 
6.7 ml dH2O 
5 ml 4 x Lower Buffer  
50 µl 25% APS  
20 µl TEMED  
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2 x IP Buffer 50 mM Tris-HCl, pH 8 
4 mM Ethylenediaminetetraacetic acid 
(EDTA) 
300 mM NaCl (VWR International, 
Lutterworth, UK) 
2% Triton X-100 
0.4% SDS (Bio-Rad, Hertfordshire, UK) 
0.1 x proteinase inhibitor cocktail (PIC) 
2 μM Phenylmethylsulfonyl fluoride 
(PMSF) 
0.5 mM NaF 
2 mM NaVO3 
4 x Lower Buffer 1.5 M Tris-HCl, pH 8.8 
0.4% SDS 
4 x SDS Sample Buffer (SSB) 0.35 M Tris pH 6.8 
30% glycerol 
10% SDS 
0.6 M Dithiotreitol (DTT) 
0.012% bromophenol blue 
Acrylamide stacking gel 0.8 ml 30% acrylamide-bisacrylamide 
(29:1) solution 
3.6 ml dH2O 
1.5 ml Upper Buffer  
50 µl 25% APS  
20 µl TEMED 
Buffer A 10 mM HEPES pH 8 
10 mM EDTA 
0.5 mM Ethyleneglycol tetraacetic acid 
(EGTA) 
0.25% Triton X-100 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
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Buffer B 10 mM HEPES pH 8 
200 mM NaCl 
1 mM EDTA 
0.5 mM EGTA 
0.01% Triton X-100 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
Elution Buffer  1% SDS 
100 mM NaHCO3 
Glycerol Buffer 10 mM Tris-HCl, pH 7.4 
0.1 mM EDTA 
5 mM MgAc2 
10% glycerol 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
Hypotonic cell lysis buffer  
HCLB-300/ -500 
20 mM HEPES, pH 7.5 
0.5 mM KCl 
1.5 mM MgCl2 
0.5 mM DTT 
0.5% Triton X-100 
10% glycerol 
300 or 500 mM NaCl 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
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LiCl Buffer 10 mM Tris-HCl pH 8 
250 mM LiCl 
0.5% NP40 
0.5% Na deoxycholate 
1 mM EDTA 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
PBS-NP40 0.1% NP40 in PBS 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
Propidium iodide (PI) staining solution 100 μg/ml PI in PBS 
0.6% NP40 
1 mg/ml RNase A 
Proteinase K suspension 50 mg/ml Proteinase K in 
50% glycerol 
50% 1 x TE 
RF1 75 mM KCl 
50 mM KAc 
50 mM MnCl2 
10 mM CaCl2 
15% glycerol 
pH 5.8 
RF2 10 mM 3-(N-morpholino)propansulfonic 
acid (MOPS) 
10 mM KCl 
75 mM CaCl2 
15% glycerol 
pH 6.8 
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RIPA 10 mM Tris-HCl 
1 mM EDTA 
0.5 mM EGTA 
140 mM NaCl 
0.1% SDS 
1% Triton X-100 
0.1% Na deoxycholate 
1 x PIC 
2 μM PMSF 
1 mM DTT 
0.5 mM NaF 
2 mM NaVO3 
TBST 50 mM Tris-HCl pH 7.6 
150 mM NaCl 
0.1% Tween-20 
Transfer Buffer 25 mM Tris-HCl, pH 8.3 
192 mM Glycine 
20% Methanol 
Upper Buffer 0.5 M Tris-HCl, pH 6.8 
0.4% SDS 
Washing Buffer 1 20 mM Tris-HCl pH 8 
2 mM EDTA 
1% Triton X-100, 
0.1% SDS 
150 mM NaCl 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
Washing Buffer 2 20 mM Tris-HCl pH 8 
2 mM EDTA 
1% Triton X-100 
0.1% SDS 
500 mM NaCl 
0.1 x PIC 
2 μM PMSF 
0.5 mM NaF 
2 mM NaVO3 
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3.1.4 Antibodies 
Antibody Company Application 
F(ab')2 fragment goat anti-
human IgM (109-006-129) 
Jackson 
ImmunoResearch, West 
Grove, PA, US 
BCR stimulation 
F(ab')2 fragment goat anti-
human IgM and IgG (109-
006-127) 
Jackson 
ImmunoResearch, West 
Grove, PA, US 
BCR stimulation 
mouse anti-flag M2 
(F1804) 
Sigma Aldrich, Dorset, UK ChIP 
mouse anti-Histone 
H2BK120ub (05-1312) 
Merck Millipore, 
Nottingham, UK 
ChIP 
mouse anti-POL II CTD 
(ab817) 
Abcam, Cambridge, UK ChIP 
mouse anti-β-actin 
(A1978) 
Sigma Aldrich, Dorset, UK Western blot, 1:100,000 in 
TBST with 5% milk 
rabbit anti-BAD (9239) Cell Signaling Technology, 
Leiden, The Netherlands 
Western blot, 1:1,000 in 
TBST with 5% milk 
rabbit anti-BADS112p 
(5284) 
Cell Signaling Technology, 
Leiden, The Netherlands 
Western blot, 1:1,000 in 
TBST with 5% BSA 
rabbit anti-H2A.Z (ab4174) Abcam, Cambridge, UK ChIP 
rabbit anti-H3K9ac 
(39917) 
Active Motif, La Hulpe, 
Belgium 
ChIP 
rabbit anti-Histone H3 
(ab1791) 
Abcam, Cambridge, UK Western blot, 1:100,000 in 
TBST with 5% milk 
ChIP, IP 
rabbit anti-Histone 
H3.3S31p (ab92628) 
Abcam, Cambridge, UK Western blot, 1:3,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-Histone 
H3K27me3 (07-449) 
Merck Millipore, 
Nottingham, UK 
ChIP 
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rabbit anti-Histone 
H3K4me3 (04-745) 
Merck Millipore, 
Nottingham, UK 
ChIP 
rabbit anti-Histone 
H3K9acS10p (ab12181) 
Abcam, Cambridge, UK Western blot, 1:3,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-Histone 
H3S10p (060570) 
Merck Millipore, 
Nottingham, UK 
ChIP 
rabbit anti-Histone 
H3T11p (ab5168) 
Abcam, Cambridge, UK Western blot, 1:10,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-Histone H3T3p 
(04-746) 
Merck Millipore, 
Nottingham, UK 
Western blot, 1:3,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-Histone H3T6p 
(ab14102) 
Abcam, Cambridge, UK Western blot, 1:1,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-HPRT (FL-218) Santa Cruz Biotechnology, 
Dallas, TX, US 
Western blot, 1:3,000 in 
TBST with 5% BSA 
rabbit anti-MYC (sc-764) Santa Cruz Biotechnology, 
Dallas, TX, US 
Western blot, 1:3,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-PIM1 (2907) Cell Signaling Technology, 
Leiden, The Netherlands 
Western blot, 1:500 in 
TBST with 5% milk 
rabbit anti-PIM1 (A300-
313A) 
Bethyl Laboratories, 
Montgomery, TX, US 
ChIP, IP 
rabbit anti-POL II CTD 
S2p (ab5095) 
Abcam, Cambridge, UK Western blot, 1:10,000 in 
TBST with 5% BSA 
ChIP 
rabbit anti-POL II CTD 
S5p (ab5131) 
Abcam, Cambridge, UK ChIP 
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rabbit anti-ZIPK (AHP490) AbD Serotec, Kidlington, 
UK 
Western blot, 1:10,000 in 
TBST with 5% milk 
ChIP, IP 
rat anti-PIM2 (61159) Active Motif, La Hulpe, 
Belgium 
Western blot, 1:3,000 in 
TBST with 5% BSA 
 
goat anti-rabbit IgG HRP 
(111-035-003) 
Jackson 
ImmunoResearch, West 
Grove, PA, US 
WB, 1:10,000 
goat anti-rat IgG HRP (18-
4818-82) 
eBioscience, Hatfield, UK WB, 1:10,000 
mouse anti-rabbit IgG, 
light chain-specific, HRP 
(211-032-171) 
Jackson 
ImmunoResearch, West 
Grove, PA, US 
WB, 1:10,000 
normal rabbit IgG (sc-
2027) 
Santa Cruz Biotechnology, 
Dallas, TX, US 
IP 
rabbit anti-mouse IgG 
HRP (315-035-003) 
Jackson 
ImmunoResearch, West 
Grove, PA, US 
WB, 1:10,000 
 
3.1.5 Primers and oligonucleotides 
Primers were designed using primer BLAST (Ye et al., 2012). Some changes to the 
standard setting were made: primers were designed with an optimal length of 22 nt, the 
maximal PCR product length was set to 150bp, the maximal melting temperature 
difference was 1°C and, when possible, the maximal GC content in the most 3’ 5 nt 
was 2. Primers were synthesised by Sigma Aldrich. 
Name Sequence 5’ ! 3’ 
3xflag-EGFP-
EcoRI F 
ATATGAATTCATGGATTACAAGGATGACGACGATAA 
GGATTACAAGGATGACGACGATAAGGATTACAA 
GGATGACGACGATAAGGTGAGCAAGGGCGAGGAGCT 
3xflag-EGFP-
NotI R 
ATATGCGGCCGCTTACTTGTACAGCTCGTCCA 
- 90 - 
3xflag-PIM1-
EcoRI F 
ATATGAATTCATGGATTACAAGGATGACGACGATAA 
GGATTACAAGGATGACGACGATAAGGATTACAA 
GGATGACGACGATAAGGTCTTGTCCAAAATCAACTC 
3xflag-PIM1-
NotI R 
ATATGCGGCCGCCTATTTGCTGGGCCCCGGCG 
ARID3A F ATGGCCCTGGTGGCCGATGA 
ARID3A R CGGCTTTCGGAGGCTTGGCT 
BCL2 F ATGTGTGTGGAGAGCGTCAA 
BCL2 R GCCGGTTCAGGTACTCAGTC 
BCL2A1 +0.1 F CTACGCACGAAAGTGACTAGGA 
BCL2A1 +0.1 R GATACATGGAGGCTGGTGGAAT 
BCL2A1 +10.4 
F 
TAATTTCTTGGGTCTGGCTGGA 
BCL2A1 +10.4 
R 
CACACCTGAAAGGGTCTACCG 
BCL2A1 F ACAATCACACACCTATGCTGGT 
BCL2A1 R TCATCCAGCCAGATTTAGGTTCA 
CCND2 -0.2 F AGCTTGCGTCACCGCTT 
CCND2 -0.2 R GTCCTCCCCTTAAAACTGGTCT 
CCND2 +31.6 F CCAGCAGTCCTCAGAATGGAAT 
CCND2 +31.6 R TGACTTGTACCGCCATAACACA 
CCND2 F GTCGATGATCGCAACTGGAAGT 
CCND2 R AATCCACGTCTGTGTTGGTGAT 
CCR6 F CTGTGGTGTGTGAGAAGGAAGT 
CCR6 R ACATAGTGAAGGACGACGCATT 
CCR7 F CCTCCCTCCATCGTTTTCTTCA 
CCR7 R AGGGGATGAGTGTGCTTTTAGG 
CD40 F TGAGTGACTGCACAGAGTTCAC 
CD40 R TAGGTTGGGGTCGCAGTATTTG 
CDC25B F CACCGAGAGCTGATTGGAGATT 
CDC25B R ACCATCGTTTCTGGTGAGATGT 
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CTCF site 1 F GGCCCAGGACTCCACGTTCAGA 
CTCF site 1 R GCCCTCTGGTGTTTGGCAGCAA 
CTCF site 3 F CACCCAGCAGAGGGCCCAGATA 
CTCF site 3 R CCCTTCGCCTTCTCTCCAGCCA 
CXCR4 F GCACATCATGGTTGGCCTTATC 
CXCR4 R GAGTGTGACAGCTTGGAGATGA 
CXCR5 F CACCCTACCACATCGTCATCTT 
CXCR5 R TTCAGCTTGCAGGTATTGTCCA 
DUSP2 -0.3 F CTAAAGGGGGACCTGCATCTG 
DUSP2 -0.3 R GACTAAGGGAAGGGAAGGTGTT 
DUSP2 +2.4 F GGAAGTGATGGGTGTGTCATGT 
DUSP2 +2.4 R AAATAATTTTCCAGCGCCAGCA 
DUSP2 +3.1 F CATTTGGAGTGTCATCCAGCCA 
DUSP2 +3.1 R ACAGACCACGGACAGATCCTTA 
DUSP2 +4.2 F AGGAGTGAGGTTGATCTGATGT 
DUSP2 +4.2 R CCAGCCGTTATGAGTGTCCAT 
DUSP2 F TACTTCCTGCGAGGAGGCTT 
DUSP2 R GGCTGGTTTTGTCCCCTGTT 
DUSP4 +0.2 F GACCGGCAAAAATACACGGGA 
DUSP4 +0.2 R GGAGGAGAGTGTGTTTACGAGA 
DUSP4 +17.7 F TCAACCACTTCTGGCTTGGTTA 
DUSP4 +17.7 R GTTCTTTCCTCCCCTTCCAAGT 
DUSP4 F ATCACGGCTCTGTTGAATGTCT 
DUSP4 R ATGTCGGCCTTGTGGTTATCTT 
EGR1 -0.1 F GCCATATTAGGGCTTCCTGCTT 
EGR1 -0.1 R GATCCGCCTCTATTTGAAGGGT 
EGR1 -0.85 F TACAGTGTCCCAAGAACCAAGT 
EGR1 -0.85 R CGATCTATGGCACGGTGTCTTT 
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EGR1 -6.1 F CCTGGGGTAGGAGCAGAACT 
EGR1 -6.1 R TGTCACACTTTCCGACTGACTT 
EGR1 +2.2 F CTGCGACATCTGTGGAAGAAAG 
EGR1 +2.2 R GCCGCAAGTGGATCTTGGTAT 
EGR1 +3.8 F GCTGCGATTGGGTATGTGTTTC 
EGR1 +3.8 R AGAAAACCTCACAGCCCTCAAT 
EGR1 F ACAAAAGTGTTGTGGCCTCTTC 
EGR1 R GTGGCCGGGGATGGATAAGA 
FOSL1 -37 F CGGGGATCAAAGATGAAGAA 
FOSL1 -37 R TGGGGAGCAGATAGCTGAGT 
FOSL1 +1.15 F GCCCTCGATCCCTTTGCCGAATG 
FOSL1 +1.15 R AGGAAATGGGCACCTGCAGCCT 
FOSL1 F CGAAGGCCTTGTGAACAGAT 
FOSL1 R GAAGTCGGTCAGTTCCTTCCT 
GAPDH F ACAGTCAGCCGCATCTTCTT 
GAPDH R ACGACCAAATCCGTTGACTC 
GNL3 -0.5 F AGGCCCTGAGCAACGGAGGAA 
GNL3 -0.5 R GCGCACTACGGGTCGGAAACTC 
GNL3 -3.5 F CCTGCCCAACTGCCCCCTAGTC 
GNL3 -3.5 R GGGGGAGGGTGTTTTCCAGACCT 
GNL3 -6.5 F TCCTGCTTGGGCCTGGTGTTGA 
GNL3 -6.5 R GCTACCTCCCCTTCCAGCAGTGT 
GNL3 +0.1 F CCAGCGGAGGCAGGTTGATGTG 
GNL3 +0.1 R TGGCTGCAGCAACTTCCAGACG 
GNL3 +0.4 F TTAACCGCGCGGGCTCATTCTG 
GNL3 +0.4 R CAGCTCTCACCTGGGCCAGTCT 
GNL3 +3.5 F GCCTCCGATGTTGTCCTAGAGGTGTT 
GNL3 +3.5 R TCCCCACTGCCTAGCACTGTCTC 
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GNL3 +5 F TGGGCTCTGGAGCCTGATTGCT 
GNL3 +5 R AGCATTCTTCTTTGCCTTCACACGCT 
GNL3 +9 F CCAAGGTGGCGGACATTCCACA 
GNL3 +9 R AGCAGAACCCTGGCTGGTAGCAT 
GNL3 F GGCAGGTTGATGTGTTTGTG 
GNL3 R TATGGCAGGTCATGCGTTTA 
ID2 -1.4 F GGAAGGCCCTCCGCAAACTTCT 
ID2 -1.4 R TGACAGCTATGCGCCCCATGAC 
ID2 -1.7 F AGGCTCGAACTGTGGGAGGACT 
ID2 -1.7 R CTGCCTGCGACTCTGTCCCTGA 
ID2 F ATCCCCCAGAACAAGAAGGT 
ID2 R GGTGATGCAGGCTGACAATA 
LYN F CAGCAAGGGAAGGTGCTAAG 
LYN R TTCCAAAGGACCACACATCA 
MYC +0.1 F TGCCTCTCGCTGGAATTACTAC 
MYC +0.1 R GAGGGATCGCGCTGAGTATAAA 
MYC +5.5 F CAGGAAGCATCTTAGAACCTCCA 
MYC +5.5 R GAGGGTGGTCTTAAGAAAGGCA 
MYC F (B cell 
lines) 
GTAGTGGAAAACCAGCAGCC 
MYC F (CLL) GGAGGGATCGCGCTGAGTATAA 
MYC R (B cell 
lines) 
CTCGTCGCAGTAGAAATACGG 
MYC R (CLL) TGCCTCTCGCTGGAATTACTACA 
NCL F GCTTGGCTTCTTCTGGACTCAT 
NCL R CCATTTTCTTGGGGTCACCTTG 
NPM1 -7 F GAGAGTGGCACACTTCATCTCCAT 
NPM1 -7 R GAGGTCTGAAAGGGTAGGTCATCA 
NPM1 +1 F GCCTGCTTGTTGGAGCGGGTAGA 
NPM1 +1 R GCCGAAGCACGCGAGGTAAGTC 
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NPM1 +2 F TCATTCTGCTTTGCCCTCTGGTAGC 
NPM1 +2 R TTTGTCGGCCTTTAGTTCACAACCTGT 
NPM1 +24 F CAGTTCTGTGCCGTTTTCCTTGGGA 
NPM1 +24 R TACACGCCCAAAGCAGCAAGCA 
NPM1 +4 F GGGGCTGGTGCAAAGGATGAGT 
NPM1 +4 R GCAGCAGAAGCCCCCATGTTCA 
PIM1 F CAGGCAGAGGGTCTCTTCAG 
PIM1 R TCCATGGATGGTTCTGGATT 
PIM2 F GCCTGGCCCCCAAACCTTCTTC 
PIM2 R GGGGTACATCCTCGGCTGGTGT 
PPP6C F TGGAAATGCTAATGCCTGGAGA 
PPP6C R TTCCTGATTCCGTTCGATGGTT 
PRDX1 F AGTGATTGGTGCTTCTGTGGAT 
PRDX1 R CCCCATAATCCTGAGCAATGGT 
SEPX1 -0.3 F CGCGGAAAGGCTGCATGACCTC 
SEPX1 -0.3 R CGCGAATCCGTAGGGTCGTGTC 
SEPX1 F TGTCGTTCTGCAGCTTCTTC 
SEPX1 R ATAGCCACACTTGGCACACA 
shMYC F CGGTCCTGAGACAGATCAGCAACAACTC 
GAGTTGTTGCTGATCTGTCTCAGGTTTTTG 
shMYC R AATTCAAAAACCTGAGACAGATCAGCAACAACTC 
GAGTTGTTGCTGATCTGTCTCAGGACCGGTAC 
shPIM1 1196 TGCTGTTGACAGTGAGCGAGCAGAGGGTCTCTTCAGAAT 
GTAGTGAAGCCACAGATGTACATTCTGAAGAGACCCTCTG 
CCTGCCTACTGCCTCGGA 
shPIM1 1600 TGCTGTTGACAGTGAGCGATCTCTTCTTCTCATAGGTGTC 
TAGTGAAGCCACAGATGTAGACACCTATGAGAAGAAGAG 
AGTGCCTACTGCCTCGGA 
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shPIM1 2138 TGCTGTTGACAGTGAGCGCACAGTTGGCATGGTAGTATA 
CTAGTGAAGCCACAGATGTAGTATACTACCATGCCAACT 
GTATGCCTACTGCCTCGGA 
shPIM1_1 F CCGGACATCCTTATCGACCTCAATCCTC 
GAGGATTGAGGTCGATAAGGATGTTTTTTG 
shPIM1_1 R AATTCAAAAAACATCCTTATCGACCTCAATCCTC 
GAGGATTGAGGTCGATAAGGATGT 
shPIM1_2 F CCGGCATCCGCGTCTCCGACAACTTCTC 
GAGAAGTTGTCGGAGACGCGGATGTTTTTTG 
shPIM1_2 R AATTCAAAAAACATCCGCGTCTCCGACAACTTCTC 
GAGAAGTTGTCGGAGACGCGGATG 
shPIM2 1600 TGCTGTTGACAGTGAGCGCCCACACAAACTTAGTTCATAT 
TAGTGAAGCCACAGATGTAATATGAACTAAGTTTGTGTGG 
TTGCCTACTGCCTCGGA 
shPIM2 664 TGCTGTTGACAGTGAGCGAGCCCAGGATCTCTTTGACTA 
TTAGTGAAGCCACAGATGTAATAGTCAAAGAGATCCTGG 
GCGTGCCTACTGCCTCGGA 
shPIM2 881 TGCTGTTGACAGTGAGCGCACACTGACTTTGATGGGACA 
ATAGTGAAGCCACAGATGTATTGTCCCATCAAAGTCAGTG 
TATGCCTACTGCCTCGGA 
shPIM2_1 F CCGGGATGAACCCTACACTGACTTTCTC 
GAGAAAGTCAGTGTAGGGTTCATCTTTTTG 
shPIM2_1 R AATTCAAAAAGATGAACCCTACACTGACTTTCTC 
GAGAAAGTCAGTGTAGGGTTCATC 
shPIM2_2 F CCGGCCAGGATCTCTTTGACTATATCTC 
GAGATATAGTCAAAGAGATCCTGGTTTTTG 
shPIM2_2 R AATTCAAAAACCAGGATCTCTTTGACTATATCTC 
GAGATATAGTCAAAGAGATCCTGG 
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SM2C F GATGGCTGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG 
SM2C R GTCTAGAGGAATTCCGAGGCAGTAGGCA 
SNORD19 F TGGGTGAGGTACGAGGAAACAGT 
SNORD19 R GGCTTTGCTGAGATCAGAGTTGGAT 
SNORD19B F GGTTGAAATATGATGAGTGTACAAA 
SNORD19B R CTGGCTGAAATCAGAGTTGGA 
SNORD69 F GTGAAGCAAATGATGATAAACTGGA 
SNORD69 R AGCTCAGGGTTGGATTGAACAG 
TBP F TGCTCACCCACCAACAATTTAG 
TBP R TCTGGGTTTGATCATTCTGTAGATTAA 
TLR10 F GCTAACAACACACCCTTGGAAC 
TLR10 R GCAAGCACCTGAAGACAGAATC 
 
3.1.6 Plasmids 
3.1.6.1 pCMV6-XL4-PIM1 
The pCMV6-XL4-PIM1 construct was purchased from OriGene (Cambridge 
Bioscience, Cambridge, UK). The GenBank accession number for the pCMV6-XL4 
parental plasmid is AF067196. For an overview of the plasmid structure, see Figure 
3.1. The full-length PIM1 cDNA was cloned between the two NotI restriction sites. 
 
 
Figure 3.1 Map of pCMV6-XL4 (from OriGene).  
MCS = multi cloning site, ColE1 = Colicin E1, Ampr = ampicillin resistance 
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3.1.6.2 pCMV-SPORT6 
The pCMV-SPORT6 vector (Life Technologies, Figure 3.2) was a kind gift from Justin 
Gillespie. It was used for cloning 3 x flag-tagged-PIM1 and -PIM1-KD between the NotI 
and EcoRI sites. 
 
Figure 3.2 Map of pCMV-SPORT6 (from GenBank). 
CMV 1E = CMV promoter 
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3.1.6.3 pMSCV-miR30 
pMSCV-miR30 (Figure 3.3) was a kind gift from Peter Laslo and was used for cloning 
of PIM1 and PIM2 shRNAs for transient transfection. The shRNAs were cloned 
between the XhoI and EcoRI sites. 
 
 
Figure 3.3 Map of the pMSCV-miR30 vector.  
Ψ = viral packaging signal, PGK = murine phosphoglycerate kinase promoter, 
PAC = Puromycin N-acetyltransferase, LTR = long terminal repeat 
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3.1.6.4 pLKO_IPTG_3xLacO 
The pLKO_IPTG_3xLacO-shLuc vector was purchased from Sigma Aldrich. The 
parental vector map is shown in Figure 3.4. The luciferase shRNA (shLuc) was inserted 
between the AgeI and EcoRI sites, destroying the AgeI site. Therefore, shMYC was 
cloned between the KpnI and EcoRI sites, reconstituting the AgeI site, to allow for 
cloning of shPIM1_1, shPIM1_2, shPIM2_1 and shPIM2_2 between the AgeI and 
EcoRI sites. 
 
Figure 3.4 Map of pLKO_IPTG_3xLacO (adapted from Sigma Aldrich).  
RRE = Rev response element, hU6 = human U6 promoter, LacO = Lac operator, 
cPPT = central polypurine tract, GSG-F2A = Glycine-Serine-Glycine fused to 2A 
peptide from foot-and-mouth disease virus (FMDV), LacI = Lac inhibitor, WPRE = 
Woodchuck hepatitis virus posttranscriptional regulatory element, HIV sin 3’ LTR 
= HIV self-inactivating 3’ LTR, RSV = respiratory syncytial virus promoter 
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3.2 Methods 
3.2.1 Patient samples 
Samples from CLL patients were anonymised clinical blood waste samples. Ethical 
approval was granted by the NHS Research Ethics Committee (reference numbers 
04/Q1205/178, 04/Q1205/125 and 14/WS/0098). No samples were taken specifically 
for this study and informed consent was not required. Samples were taken in EDTA 
tubes. 
 
3.2.1.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Due to logistic requirements, samples were stored in the EDTA tubes at 4°C over night, 
obtained the next day and processed immediately. Blood was diluted 1:2 in phosphate-
buffered saline (PBS) and carefully layered over a sucrose density gradient 
(LymphoprepTM). After centrifugation at 200 x g for 20 min (acceleration reduced to 
60%, brake off), the different blood cell types had separated (see Figure 3.5). PBMCs 
were then recovered with a Pasteur pipette, transferred into a new tube and washed 
twice with PBS. Although I was studying CLL B cells, no specific B cell enrichment step 
was performed, as PBMCs from CLL patients are mainly B cells (in a study with 11 
patients conducted by Bonyhadi et al. 85.5% ± 8.1% of PBMCs were B cells (Bonyhadi 
et al., 2005)). Cells were counted and plated into T25 flasks at appropriate densities or 
were frozen. 
 
 
Figure 3.5 Cell separation after use of LymphoprepTM. 
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3.2.2 Cell culture  
3.2.2.1 Maintenance of cell lines 
All cells were cultured at 37°C and 5% CO2. HEK293 cells were cultured in DMEM with 
10% FCS and pen/strep. OCI-Ly3 and OCI-Ly10 cells (ATCC) were maintained in 
IMDM substituted with 20% FCS and pen/strep at densities of 0.5 – 1 x 106 cells/ml. 
OCI-Ly19, SUDHL6, Raji, Ramos (ATCC), murine L cells stably expressing CD40L 
(CD40L cells) and M210B4 cells were cultured in RPMI-1640 with 10% FCS and 
pen/strep. OCI-Ly19 and SUDHL6 cells were maintained at 0.5 – 1.0 x 106 cells/ml and 
Raji and Ramos cells were cultured at 0.1 – 1.0 x 106 cells/ml. All suspension cells 
were spun down at 100 x g for 10 min at room temperature once a week prior to 
splitting to remove cell debris. CD40L cells were first generated and described by 
Garrone et al. (Garrone et al., 1995) and were a kind gift from Sean Diehl. 
HEK293, CD40L and M210B4 cells were cultured to 80% density, then the medium 
was removed, the cells were washed with PBS and treated with 0.5 x Trypsin-EDTA for 
10 minutes at 37°C. The reaction was stopped with 10 ml fresh culture medium. The 
cells were washed off the flask and transferred into 50 ml tubes. They were then 
sedimented by centrifugation at 300 x g for 5 min, resuspended in fresh culture 
medium, split 1:5 for HEK293 and 1:10 for CD40L and M210B4 cells and seeded into 
new culture flasks. When used as feeders for CLL cells, CD40L and M210B4 cells 
were irradiated with a total dose of 50 Gy for 50 minutes. M210B4 cells were directly 
seeded into tissue culture flasks, while CD40L cells were frozen down and thawed as 
required. CLL cells were cultured with or without feeder cells in RPMI-1640 with 10% 
FCS and pen/strep at densities of 0.1 x 107 cells/ml with and 0.5 x 107 cells without 
feeder cells. 
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3.2.2.2 Cell counting 
Depending on the observed cell density, cells in culture medium were diluted 1:5 to 
1:50 in Trypan Blue solution. 20 µl of this suspension were applied to a 
haemocytometer and all four large squares were counted (Figure 3.6). To obtain the 
cell number per ml, the following formula was used: !"##	%&'(") '# * 	+,")+-"	!"##	%&'(") #+)-"	./&+)" ∗ 103⁄⁄ ∗ 56#&768%	9+!78) 
 
Figure 3.6 Schematic representation of the counting area of a haemocytometer. 
 
 
3.2.2.3 MTT assay 
The MTT assay measures mitochondrial integrity, which can be used as a measure of 
cell viability. MTT has a yellow colour, but is converted into a purple formazan product 
in viable/metabolically active cells. The accumulation of the product can be detected by 
measuring the absorbance of the sample at around 570 nm (Riss et al., 2004). 
For the assay, 90 µl of cell suspension were transferred into duplicate wells of 96 well 
plates. For the standard curve, cells were counted using a haemocytometer and 5 µl, 
10 µl, 20 µl, 50 µl, 60 µl and 90 µl of this suspension, made up to 90 µl with culture 
medium, were also measured in duplicate. As controls, 90 µl culture medium, and 
culture medium with DMSO or the inhibitors tested, were used. 10 µl MTT (50 mg/ml) 
were added to each well and mixed well on a plate shaker. The plate was then 
incubated at 37°C and 5% CO2, controlled every hour for MTT turnover and after 3 to 
6 h, when formation the formazan product became visible, the formation of the product 
was measured. The plate was centrifuged at 3,200 x g for 5 minutes to sediment 
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suspension cells and free formazan product. Then, 50 µl of the medium were removed 
from each well and the formazan product was solubilised by adding 100 µl DMSO. The 
plate was mixed well on a plate shaker and after a 5 minute incubation, the 
absorbances at 570 nm and 630 nm were measured, using the Mithras LB940 plate 
reader. The analysis was then done using Microsoft Excel. First, the absorbance at 
570 nm was corrected by the absorbance at 630 nm. :;<== * :>?@ − :BC@ 
Then, the average of the two duplicates was taken and subtracted by the corrected 
absorbance of medium with DMSO or the appropriate inhibitor. :DEFGH * :(.+'J#");<== − :(!8%7)8#);<== 
The Afinal values of the standards were then plotted against the cell numbers to 
generate a standard curve. Linear regression was used to fit a curve. From that, the 
cell numbers in the samples could be calculated. For long-term experiments, cells were 
split to maintain appropriate cell densities and calculated cell numbers were multiplied 
by the dilution factor of the cell suspension. 
 
3.2.2.4 Freezing of cells 
Exponentially growing cells were collected by centrifugation and resuspended in cold 
90% FCS and 10% DMSO at a density of 106 cells/ml for cell lines and 
10 x 107 cells/ml for CLL cells. 1 ml of the suspension was transferred into cryotubes 
and stored into a freezing container at -80°C for at least 24 h. The tubes were then 
transferred into the liquid nitrogen storage tank. 
 
3.2.2.5 Treatment of lymphoma cell lines with PIM inhibitors 
OCI-Ly3, OCI-Ly10, SUDHL6, OCI-Ly19, Raji and Ramos cells were treated with 
different PIM kinase inhibitors. The cells were seeded into appropriate tissue culture 
flasks or plates on the day of, or the day before the experiment and then treated with 
40 µM SMI4a, 40 µM Quercetagetin, 40 µM PIM1/2 inhibitor VI, 1 to 10 µM AZD1208 
or DMSO (control) for desired times. The medium was changed every second day and 
cells were either counted using a haemocytometer or cell vitality was measured using 
the MTT assay. Alternatively, RNA or protein were prepared. 
In vitro, using 0.1 μM ATP and BAD as a substrate, SMI4a has an IC50 of 24 nM for 
PIM1 and of 100 nM for PIM2 (Xia et al., 2009). The IC50 for proliferation of PC3 
prostate cancer cells was found to be 17 μM (Xia et al., 2009). Using BAD as a 
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substrate and 10 μM ATP, the IC50 of Quercetagetin was found to be 340 nM for PIM1 
and 3.45 μM for PIM2 and the IC50 for p-BAD in RWPE2 prostate cancer cells is 
5.55 μM (Holder et al., 2007). The IC50 for PIM1/2 inhibitor VI (SMI16a) was determined 
using 0.1 μM ATP and BAD as a substrate as being 150 nM for PIM1 and 20 nM for 
PIM2. Its IC50 for proliferation of PC3 prostate cancer cells was found to be 48 μM (Xia 
et al., 2009). 
AZD1208 is a potent PIM kinase inhibitor that shows an IC50 for p-BAD in a cellular 
assay in U2OS cells of 10 nM for PIM1, 151 nM for PIM2 and 102 nM for PIM3. Tested 
against 442 kinases at a concentration of 1 μM, PIM kinases were inhibited most 
strongly and only 13 other kinases were inhibited by 50% or more. However, affinity of 
AZD1208 was at least 43-fold higher for PIM kinases than for all those other kinases. 
Growth of AZD1208-sensitive AML cell lines was inhibited at AZD1208 concentrations 
lower than 1 μM (Keeton et al., 2014). 
 
3.2.2.6 Treatment of Raji cells with DRB 
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is an inhibitor of transcription 
elongation. It targets the CDK9 subunit of P-TEFb and leads to a rapid loss of 
elongating POL II and promoter-bound CTD-S2-phosphorylated POL II (Baumli et al., 
2010). 
Raji cells were cultured in complete medium and then treated with 100 µM DRB for 1 h 
or were left untreated. Chromatin was either harvested directly after DRB treatment or 
the cells were released from transcriptional inhibition. For that purpose, the cells were 
washed twice with PBS, taken up in fresh medium and cultured until chromatin was 
prepared.   
 
3.2.2.7 Serum starvation and release of Raji cells 
Raji cells were cultured in normal growth medium for two to three days and then serum 
starved. The cells were sedimented by centrifugation at 300 x g for 5 min, then washed 
three times in sterile PBS and resuspended in RPMI-1640 with 0.5% FCS and 
pen/strep. They were cultured for up to 4 h and then FCS was added to result in a final 
concentration of 10% FCS. To monitor RNA and protein expression, aliquots of cells 
were harvested at different times. 
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3.2.2.8 Stimulation of Raji cells via the BCR or with PMA 
Raji cells were seeded in tissue culture flasks in normal medium and the next day they 
were stimulated with 10 µg/ml anti-IgM/anti-IgG or 100 ng/ml PMA for 0 to 24 h. Protein 
or RNA were prepared at different time points. 
 
3.2.2.9 Serum shock of HEK293 cells 
HEK293 cells were cultured in 6-well plates in full medium to about 50% confluence. 
They were then either left untreated or treated over night with 40 µM SMI4a, 
Quercetagetin, PIM1/2 inhibitor VI or equivalent amounts of DMSO. The next day, 
serum shock was performed by adding 1 ml FCS, resulting in a total concentration of 
33% FCS. RNA was harvested at the desired time points. 
 
3.2.2.10 Stimulation of the B cell receptor on CLL cells 
CLL cells were kept in culture medium for 16 h to 48 h to facilitate reexpression of the 
B cell receptor. Then they were treated with either 1 µM Ibrutinib, 0.2 to 10 µM PKCβ 
inhibitor, 20 µM DAPK inhibitor, 10 µM U0126, 1 µM Gö6983, 10 µM RSK inhibitor II or 
equivalent amounts of DMSO for 2 h. Afterwards, cells were either harvested (0 h anti-
IgM) or treated with 10 µg/ml goat anti-human IgM for 10 min up to 24 h. Chromatin, 
RNA and protein were harvested for further analyses. 
PKCβ inhibitor (CAS 257879-35-9) is a potent ATP-competitive inhibitor for PKCβI (IC50 
= 21 nM) and PKCβII (IC50 = 5 nM). It inhibits PKCα with an IC50 of 331 nM, PKCε with 
an IC50 of 2.8 μM and PKCγ with an IC50 of > 1 μM (Tanaka et al., 2004). In two further 
screens, this inhibitor was, however, just as potent against RSK1-4 as it is against 
PKCβ and it also targeted PKCθ and PKCη (Anastassiadis et al., 2011; Gao et al., 
2013). 
Gö6983 (CAS 133053-19-7) is an ATP-competitive PKC inhibitor (PKCα and PKCβ IC50 
= 7nM, PKCγ IC50 = 6 nM, PKCδ IC50 = 10 nM, PKCζ IC50 = 60 nM) (Gschwendt et al., 
1996). In two other screens, it also potently inhibited PKCε, η and θ and it inhibited 
RSK1/2/3/4 with similar efficiencies to PKCs (Anastassiadis et al., 2011; Gao et al., 
2013). 
U0126 (CAS 109511-58-2) non-competitively inhibits MEK1/2 with IC50 values of 72 nM 
or 58 nM, respectively, in a kinase assay using 40 μM ATP. Using 10 to 20 μM ATP, 
the IC50 values for Abl, Cdk2, Cdk4, ERK, JNK, MEKK, MKK3, MKK4, MKK6 and PKC 
are more than 10 μM. U0126 almost completely inhibits ERK1/2 phosphorylation in 
COS7 cells at a concentration of 10 μM (Favata et al., 1998). 
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RSK inh II (CAS 501437-28-1) is an ATP-competitive inhibitor that targets RSK1/2/3/4 
with IC50 < 31 nM in kinase assays using 100 μM ATP. It does not target PKCβ, but has 
moderate activity towards PKCα, GSK3β, CDK2 and CK1 and strongly inhibits PLK1 
and Aurora B at approximate Km concentration of ATP. The IC50 for inhibition of RSK1/2 
in HEK293 cells is 1 μM (Sapkota et al., 2007). 
At 10 µM ATP, DAPK inhibitor shows IC50 values of 69 and 225 nM against DAPK1 and 
DAPK3, respectively. Of the other kinases tested at apparent Km concentration of ATP, 
it only significantly inhibited p70S6K (see Table 3.1) (Okamoto et al., 2009). 
 
no inhibition at 10 μM IC50 > 10 μM 1 μM < IC50 < 10 μM 
ABL Erk1 MARK1 PKCζ CK1δ FGFR1 p70S6K 
AKT1 FLT3 MAPKAPK2 PKD2 DYRK1α KDR  
AKT2 FYN MET PKGα ERK2 SGK1  
AMPK GSK3β MSK1 PRAK    
AurA HGK MST2 ROCK2    
BTK IGF1R p38α RSK1    
CAMK2 INSR PAK2 SRC    
CAMK4 IRAK4 PIM2 SYK    
CDK2 LCK PKA c-TAK1    
CHK1/2 LYN PKCβ2 c-Raf    
Table 3.1 Other kinases targeted by DAPK inhibitor (adapted from Okamoto et al., 
2009). 
 
3.2.2.11 Transient transfection of lymphoma cell lines 
Raji cells were transfected using the AmaxaTM NucleofectorTM as indicated by the 
manufacturer. Briefly, 107 Raji cells were suspended in 100 µl complete Nucleofector 
Solution V, 10 µg plasmid DNA were added and the cells were subjected to 
nucleofection, using programme M-013. Immediately after, cells were suspended in 
500 µl pre-warmed culture medium and transferred into appropriate cell culture flasks. 
SUDHL6 cells were transfected using the Gene Pulser® II. 5 x 106 cells were 
suspended in 500 µl RPMI-1640, mixed with 10 µg DNA and transferred into a pre-
chilled electroporation cuvette. Electroporation was performed at 200 V or 260 V and 
1000 µF. Cells were then taken up in pre-warmed medium and transferred into 
appropriate culture flasks. 
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3.2.2.12 Generation of stably transfected cell lines 
3.2.2.12.1 Testing the sensitivity of Raji cells towards puromycin 
2 x 105 Raji cells were seeded into 6 well plates and left untreated or were treated with 
1 µg/ml, 2.5 µg/ml, 5 µg/ml, 7.5 µg/ml or 10 µg/ml puromycin in triplicate, respectively. 
The medium with puromycin was renewed after two days and the effects on cell vitality 
were monitored over four days. 1 µg/ml puromycin was found to effectively induce cell 
death and this concentration was used in future experiments. 
 
3.2.2.12.2 Selection of stably pLKO_IPTG_3xLacO-shRNA transfected single cell 
clones 
Raji cells were transfected as for transient expression of the gene product and kept in 
T25 flasks. 24 h after transfection, cells were treated with 1 µg/ml puromycin. The 
medium was changed twice a week and after 10 days, a limiting dilution was 
performed. Cells were counted, diluted to cell concentrations of 20 cells/100 µl, 
10 cells/100 µl, 5 cells/100 µl and 1 cell/100 µl and plated into 96 well plates as shown 
in Figure 3.7. 
 
 
Figure 3.7 Plate layout for selection of stable, single cell clones by limiting 
dilution. 
 
Wells were checked for presence of single cells 24 h later and these wells were 
expanded. Evaporated medium was replaced with puromycin-containing medium twice 
a week. Expanded, single cell-derived colonies were transferred into 48-, then 24-, 12- 
and 6-well plates. An aliquot was then tested for efficient knockdown, while the rest of 
the cells were expanded further and frozen down. 
 
 
20 cells/ 100 μl  
10 cells/ 100 μl  
5 cells/ 100 μl  
1 cell/ 100 μl  
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3.2.2.12.3 Induction of shRNA expression 
Stably transfected Raji cells were seeded into appropriate tissue culture dishes and left 
untreated or were treated with 5 mM IPTG in normal culture medium. The medium with 
IPTG was renewed every second day and the cells were counted or RNA, protein or 
chromatin were harvested after two to ten days. 
 
3.2.2.13 Cell cycle synchronisation 
3.2.2.13.1 Thymidine/nocodazole block 
A thymidine/nocodazole block used to synchronise cells in M phase as described by 
Whitfield et al. (Whitfield et al., 2000). Thymidine blocks DNA replication by inhibiting 
the generation of dCDP (Van Potter, 1963; Reichard et al., 1960) and nocodazole 
inhibits microtubule polymerisation (Zieve et al., 1980). 
Raji cells were grown in normal growth medium to a density of about 0.8 x 106 cells/ml. 
They were then treated with 2 mM thymidine for 24 h, to block cell cycle progression in 
S phase. Subsequently, the cells were sedimented by centrifugation at 300 x g for 
5 min, washed twice with PBS and resuspended in normal growth medium to allow for 
progression through S and G2 phase. 3 h later, 100 ng/ml nocodazole were added for 
12 h to block cell cycle progression in M phase. Afterwards, the cells were washed 
twice with PBS and released into normal growth medium. Cell cycle progression was 
monitored using flow cytometry and RNA and chromatin were prepared at different time 
points. 
 
3.2.2.13.2 Analysis of cell cycle progression by flow cytometry 
To assess the cell cycle synchronisation, cellular DNA was stained with propidium 
iodide (PI). In G0/G1 phase, cells have half the DNA content of cells in M phase, 
therefore they are stained half as brightly. This difference can be measured by flow 
cytometry. 
Synchronised cells were sedimented by centrifugation at 200 x g, washed twice with 
PBS, resuspended in 100 μl PBS and then fixed with 5 ml 70% ethanol. The fixed cells 
were stored at 4°C for up to a few days. On the day of analysis, the ethanol was 
removed by sedimenting the cells at 500 x g for 10 min. Afterwards, the cells were 
washed twice in PBS and transferred into FACS tubes between the two washes. The 
cell pellet was taken up in 50 μl staining solution and incubated on ice in the dark for at 
least 45 min. The cells were then suspended in 400 μl PBS and analysed on a BD 
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LSRII flow cytometer. The intensity of the PI staining was measured using an excitation 
wavelength of 488 nm and detecting emission in the PE channel at 562–588 nm. 
Cells were first gated on forward and side scatter to exclude apoptotic cells (Figure 3.8 
A). Then cells were gated for positive PI staining by plotting forward scatter values 
against PI (Figure 3.8 B) and then only single cells (no duplets, triplets etc.) were 
included in the analysis by gating on the height and area of the PI signal (Figure 3.8 C).  
 
 
Figure 3.8 Gating strategy for cell cycle analysis using PI. 
 
These cells were then further analysed for the cell cycle stage using the ModFit 
software (Verity Software House). Briefly, the PE area histogram was plotted and the 
G1 peak centre was defined. The G2/M peak was set at about twice the value of the 
G1 peak and the widths of the peaks were adjusted to match the shape of the 
histogram. The software then calculated percentages of cells in the different cell cycle 
stages. 
 
 
 
 
 
 
 
 
A B C 
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3.2.3 Molecular cloning 
3.2.3.1 PCR amplification of DNA inserts 
PIM1 and PIM2 shRNAs for cloning into pMSCV-miR30 were amplified from 
oligonucleotides using the ReddyMix PCR Master Mix. Per reaction, 12 µl ReddyMix 
were combined with 11 µl HyCloneTM water, 1 µl 10 µM SCV2 for and rev and 1 µl 1 µM 
shRNA oligonucleotide. The PCR was done under the following conditions: 
95°C 5 min 1 x 
95°C 30 s 
30 x 54°C 30 s 
68°C 30 s 
68°C 10 min 1 x 
 
DNA coding for PIM1S and kinase dead PIM1S (PIM1-KD) was amplified from pCMV5-
flag-PIM1 and -PIM1-KD vectors, which were a kind gift from Andrew MacDonald 
(Macdonald et al., 2006). Kinase-dead PIM1 carries a mutation, which converts the 
aspartate in the DFG motif into an alanine (D186A). This region is part of the ATP-
binding pocket (Kumar et al., 2005). The primers used were partly complementary to 
PIM1, but the 5’ primer had a 3 x flag overhang and a NotI restriction site, whereas the 
3’ primer had an EcoRI restriction overhang (see section 3.1.5). The amplification was 
tested both with Pfx and Phusion DNA polymerases, but a product was obtained from 
the reaction with Phusion polymerase only. 
For the PCR with Pfx polymerase, 18 µl HyCloneTM water, 3.75 µl 10 x Pfx buffer, 
0.75 µl 25 mM dNTPs, 0.5 µl 50 mM MgSO4, 0.75 µl 10 µM primer mix PIM1S for and 
rev, 10 ng pCMV5-flag-PIM1 or -PIM1-KD and 0.4 µl Pfx polymerase were mixed. The 
PCR was done using the following conditions: 
 
94°C 5 min 1 x 
94°C 15 s 
5 x 50°C 30 s 
68°C 1 min 
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94°C 15 s 
30 x 60°C 30 s 
68°C 1 min 
4°C hold  
 
For the PCR with Phusion polymerase, the following was combined in a 0.5 ml tube: 
12.4 µl HyCloneTM water, 4 µl 5 x HF buffer, 0.2 µl 25 mM dNTPs, 10 µM primers 
PIM1S for and rev, 10 ng pCMV5-flag-PIM1 or -PIM1-KD and 0.2 µl Phusion. The PCR 
was run under the following conditions: 
98°C 30 s 1 x 
98°C 10 s 
5 x 50°C 30 s 
72°C 30 s 
98°C 10 s 
30 x 60°C 30 s 
72°C 30 s 
72°C 10 min 1 x 
4°C hold  
 
The PCR products were then analysed on a 1% agarose gel and purified using the 
QIAquick PCR Purification Kit, eluting with 20 µl elution buffer. 
 
3.2.3.2 Agarose gel electrophoresis 
1% agarose gels were prepared by boiling 1 g agarose in 100 ml 1 x TAE buffer until 
dissolved. The solution was then allowed to cool to about 60°C, then 10 µl 
Ethidiumbromide solution (10 mg/ml) were added and the gel was cast. After gelling of 
the agarose, the gel was transferred into a tank filled with 1 x TAE, DNA samples in gel 
loading dye and DNA ladder were loaded and the gel was run at 50 V until the desired 
separation was achieved. Then, the DNA was visualised using the Gel DocTM XR. 
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3.2.3.3 Annealing of shRNAs 
For cloning of shRNAs into pLKO_IPTG_3xLacO, validated MISSION® shRNAs 
(Sigma Aldrich) were customised and ordered as two complementary oligonucleotides. 
The annealed oligonucleotides carry a 5’ AgeI-complementary overhang, a 3’ EcoRI 
cohesive overhang and a 21 nt long target sequence, separated from the 
complementary siRNA sequence by a 6 nt linker (Figure 3.9). The customisation 
included the addition of a G or C in forward and reverse oligonucleotides, behind the 
poly-T tract or before the poly-A tract, respectively, to retain the EcoRI site after ligation 
of the shRNA into the vector. The MYC shRNA was designed specifically for cloning 
into the pLKO_IPTG_3xLacO-shLuc vector, in which the AgeI site had been destroyed. 
Therefore, the shMYC oligonucleotides were cloned between the KpnI and EcoRI sites. 
They were designed to reintroduce the original vector sequence and allow for cloning 
of the other shRNAs between the AgeI and EcoRI sites. 
 
 
Figure 3.9 shRNA oligonucleotides after annealing. 
 
 
For annealing of the purchased oligonucleotides, 9 µl 100 µM sense oligonucleotide, 
9 µl 100 µM antisense oligonucleotide and 2 µl 10 x annealing buffer were combined 
and incubated in a PCR machine under the following conditions: 
95°C, 78°C, 74°C, 70°C, 67°C, 63°C, 
60°C, 56°C, 53°C, 50°C, 48°C, 46°C, 
44°C, 42°C, 40°C, 39°C, 37°C, 36°C, 
35°C, 34°C, 33°C, 32°C, 31°C 
5 min each 
30°C, 28°C, 26°C, 24°C, 22°C, 20°C 10 min each 
 
The annealing reaction was then diluted 50 x with HyCloneTM water and ligated into the 
pLKO_IPTG_3xLacO vector. 
 
5’-CCGGACATCCTTATCGACCTCAATCCTCGAGGATTGAGGTCGATAAGGATGTTTTTTG-3’      
    3’-TGTAGGAATAGCTGGAGTTAGGAGCTCCTAACTCCAGCTATTCCTACAAAAAACTTAA-5’ 
target sequence 
AgeI  
overhang 
EcoRI 
overhang siRNA linker 
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3.2.3.4 Restriction digest of vectors and DNA inserts 
To insert oligonucleotides into the vector, both the vector and the PCR products have 
to be digested with restriction endonucleases. 6 µg of the vector or 10 µl PCR product, 
2 µl buffer, 2 µl 10 x BSA and 1 µl of each restriction enzyme were mixed with water to 
make up 20 µl. The reaction was incubated at 37°C for 1 to 4 h, depending on the 
enzymes used. 
pLKO_IPTG_3xLacO-shLuc was digested with KpnI and EcoRI in NEBuffer 1 and 
pLKO_IPTG_3xLacO-shMYC was digested with AgeI and EcoRI in NEBuffer 4. pCMV-
SPORT6 and 3 x flag-PIM1S and -PIM1S-KD were digested with EcoRI and NotI in 
NEBuffer 4. pMSCV-miR30 and the shRNAs for cloning into this vector were digested 
with EcoRI and XhoI in NEBuffer 2. Subsequently, the reaction was analysed on a 1% 
agarose gel. The digested vector was then cut out of the gel and purified using the 
QIAquick Gel Extraction Kit, eluting with 20 µl elution buffer. The digested PCR 
products were purified using the QIAquick PCR Purification Kit. Finally, DNA 
concentrations were measured using the NanoDropTM spectrometer. 
 
3.2.3.5 Ligation of vector and insert 
For the ligation of vectors with the respective insert, 50 ng of cut vector were mixed 
with the appropriate amount of insert, 1 µl 10 x T4 DNA ligase buffer, 1 µl T4 DNA 
ligase and HyCloneTM water to 10 µl. 
The amount of insert needed was calculated using the following formula: 
+'8&%7(6%.")7) * 	 .6L"(6%.")7) ∗ +'8&%7(,"!78)).6L"(,"!78)) ∗ 6%.")7 ,"!78)	)+768%⁄  
The reaction was incubated at room temperature for 16 h and then directly used for 
transformation of E.coli DH5α. 
 
3.2.3.6 Generation of chemically competent E. coli 
E. coli DH5α were grown at 37°C over night in 5 ml LB medium and then transferred 
into 100 ml LB medium to be grown to an OD600 of 0.4 to 0.5. The culture was then 
cooled to 4°C and the bacteria were sedimented by centrifugation at 3,200 x g and 4°C 
for 15 min. The pellet was resuspended in 30 ml RF1, incubated on ice for 2 min and 
spun down by centrifugation at 3,200 x g at 4°C for 15 min. Now, the pellet was taken 
up in 8 ml RF2, incubated on ice for 15 min and then the suspension was frozen in 
methanol/dry ice as 100 µl aliquots. Competent cells were stored at -80°C. 
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3.2.3.7 Transformation of chemically competent E.coli 
Competent E.coli DH5α were carefully thawed on ice and mixed with all of the ligation 
reaction or 100 pg of pure vector. They were then incubated on ice for 20 min, heat 
shocked at 42°C for 1 min and cooled on ice. Afterwards, all of the cells transformed 
with ligation reactions were plated on LB agar plates with 100 µg/ml ampicillin, whereas 
only 10 µl of the plasmid-transformed cells were plated. The plates were then 
incubated at 37°C over night. 
 
3.2.3.8 Colony PCR 
E.coli colonies from ligation reactions were transferred into 100 µl LB medium in 1.5 ml 
tubes and incubated shaking at 37°C for 4 h. Then, 1 µl of this mix was used for a 
control PCR to check presence of the insert in the vector. 
1 µl bacterial culture was mixed with 15.7 µl water, 2 µl 10 x PCR buffer without MgCl2, 
0.5 µl 50 mM MgCl2, 0.16 µl 25 mM dNTPs, 2 µl 50 µM primer mix and 0.3 µl Taq 
Polymerase. The PCR was run under the following conditions: 
94°C 5 min 1 x 
94°C 15 s 
30 x 60°C 30 s 
72°C 1 min/kb 
72°C 5 min 1 x 
4°C hold  
 
The products were then analysed on a 1% agarose gel and colonies showing only one 
PCR product of the right size were inoculated for miniprep. For shRNA cloning, no 
colony PCR was performed, the clones were directly subjected to minipreps and 
control digested. 
 
3.2.3.9 Miniprep 
Plasmids were isolated from bacteria using the alkaline lysis method. Briefly, cells are 
first resuspended in a Glucose-Tris-EDTA buffer containing RNase, are then lysed with 
0.2 M NaOH/1% SDS and the suspension is neutralised with a potassium acetate 
solution (Engebrecht & Brent, 2001), which leads to precipitation of genomic DNA, 
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proteins and high molecular weight RNAs (Bimboim & Doly, 1979). After removal of the 
precipitated molecules, the plasmid can be precipitated using Isopropanol. 
For the plasmid preparation, E.coli colonies were transferred into 5 ml LB with 
100 µg/ml ampicillin and cultured at 37°C shaking over night. The next day, 3 ml of the 
suspension were transferred into a new tube and sedimented by centrifugation at 
10,000 x g for 5 min. The pellet was thoroughly resuspended in 300 µl buffer P1, then 
300 µl P2 were added and the tube was inverted 6 to 8 times. After a 2 minute 
incubation at room temperature, 300 µl cold P3 were added. The suspension was 
incubated on ice for 5 min, then centrifuged for 10 min at 16,100 x g and 4°C. 800 µl of 
the supernatant were transferred to a new tube and 560 µl of isopropanol were added. 
The samples were mixed by inverting, the DNA was precipitated by centrifugation at 
16,100 x g for 30 min at 4°C and the pellet was washed with 1 ml 70% ethanol. After 
another centrifugation at 16,100 x g and 4°C for 10 min, the pellet was air dried and 
resuspended in 20 µl 1 x TE. 
The DNA concentration was measured and the plasmid was used for a control 
digestion. pCMV-SPORT6-PIM1S/-PIM1S-KD were digested with the same restriction 
endonucleases used for cloning, pMSCV-miR30-shRNA plasmids were digested with 
BglII and HindIII in NEBuffer 2, which results in excision of a 900 bp fragment. The 
pLKO_IPTG_3xLacO-shRNA plasmids were cut with EcoRI and NotI in NEBuffer 4 and 
AgeI and NotI in NEBuffer 4. NotI and EcoRI should cut a fragment of about 1200 bp 
out of the vector, while the AgeI site was destroyed during cloning, leading to a vector 
cut only by NotI in the second reaction. For pLKO_IPTG_3xLacO-shMYC, both 
reactions result in a fragment of about 1200 bp. The resulting fragments were analysed 
on a gel and if they matched the expected fragment sizes, the plasmid was sent for 
sequencing to Source Bioscience, Nottingham, UK. The sequenced insert was 
compared to the reference sequence using BLASTN (http://blast.ncbi.nlm.nih.gov/ 
Blast.cgi) and if the two sequences matched, the bacterial colony carrying the plasmid 
was used for maxiprep. 
 
3.2.3.10 Maxiprep 
To obtain DNA, which is clean enough for transfection into mammalian cell lines, the 
plasmid had to be purified further and large-scale preparations of the plasmid were 
carried out using the QIAGEN Plasmid Maxi Kit according to the manufacturer’s 
recommendations. 5 µl E.coli culture containing the plasmid (rest from miniprep) were 
transferred into 5 ml of LB with 100 µg/ml ampicillin and incubated for 8 h at 37°C 
shaking. This starting culture was then used to inoculate a 500 ml over night culture, 
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which was subjected to maxiprep. The resulting DNA pellet was resuspended in 50 to 
100 µl of 1 x TE. After measuring the DNA concentration using the NanoDropTM, the 
plasmid DNA was stored at -20°C. 
 
3.2.4 Protein analysis 
3.2.4.1 Preparation of protein lysates 
Suspension cells were collected by centrifugation at 300 x g for 5 min at room 
temperature, resuspended in 1 ml PBS, transferred into a 1.5 ml tube and pelleted by 
centrifugation at 16.100 x g for 10 s. The pellet was resuspended in an appropriate 
amount of RIPA buffer (20 – 50 μl). Samples were then stored at -80°C until used. 
 
3.2.4.2 Bradford protein assay 
For protein samples generated from cell lines, a Bradford protein assay was used to 
measure protein concentrations in the sample. Bradford reagent was diluted 1:5 in 
dH2O and 1-2 μl of protein lysate were mixed with 500 μl of diluted reagent. For the 
standard curve, a 1 μg/μl BSA solution was prepared and 0 μg, 2 μg, 4 μg, 6 μg, 8 μg 
or 10 μg were added to 500 μl of diluted Bradford reagent. The absorbance of the 
samples at 595 nm was then measured in 150 μl duplicates using the Mithras plate 
reader. The analysis was done using Microsoft Excel. The standard curve was 
generated by plotting the absorbance against the amount of BSA used. From that, the 
protein concentrations of the samples could be calculated. 
 
3.2.4.3 Nuclear-cytoplasmic fractionation 
Nuclear-cytoplasmic fractionation was done using the Rapid, Efficient and Practical 
(REAP) method as described by Suzuki et al. (Suzuki et al., 2010). Briefly, cells were 
sedimented by centrifugation at 300 x g for 5 min, the cell pellet was resuspended in 
1 ml cold PBS and transferred into a 1.5 ml tube. The cells were sedimented by 
centrifugation at 16,100 x g for 10 s at 4°C and washed two more times with cold PBS. 
Then, the cells were lysed in 100 μl cold PBS-NP40 by carefully pipetting five to six 
times. The nuclei were immediately sedimented by centrifugation at 16,100 x g for 10 s 
at 4°C and the supernatant was removed as the cytoplasmic fraction. The nuclei were 
washed twice in PBS-NP40 and sedimented each time by centrifugation at 16,100 x g 
for 10 s at 4°C. Finally, the nuclei were taken up in 100 μl PBS-NP40 and 33 μl 4 x 
SSB. Nuclear and cytoplasmic fractions were stored at -80°C. Prior to SDS-
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Polyacrylamide gel electrophoresis (SDS-PAGE), nuclear lysates were sonicated for 
5 min using the Bioruptor at high power, 30 s on, 30 s off. 
 
3.2.4.4 Immunoprecipitation 
The primary antibody used for immunoprecipitation was bound to Dynabeads 
Protein G. To this end, 20 μl Dynabead suspension were mixed with 200 μl PBS-NP40. 
The beads were separated from the supernatant using a magnet and washed once 
more with PBS-NP40, before they were resuspended in 200 μl PBS-NP40 and 4.8 μg 
of the appropriate antibody were added. The suspension was then incubated at 4°C 
rotating for 2 h. 
In the meantime, about 2 x 107 cells were sedimented by centrifugation, washed once 
with PBS and lysed in cold PBS-NP40. If histones were to be analysed, the cell 
suspension was then sonicated for 5 min using the Bioruptor at high power, 30 s on, 
30 s off, otherwise the lysate was immediately used for immunoprecipitation. 
The beads with the bound primary antibody were washed once with 200 μl PBS-NP40 
and then incubated with the lysate from 5 x 106 to 107 cells in 100 μl PBS-NP40 for 2 h 
at 4°C rotating. Afterwards, the supernatant was removed and the beads were washed 
once with PBS-NP40, once or twice with HCLB-300 and once or twice with HCLB-500. 
Then, the bound proteins were eluted with 30 μl PBS-NP40 and 10 μl 4 x SSB by 
heating the suspension at 65°C for 10 min and flicking the tube every 2 to 3 min. The 
eluate was then transferred to a new tube, stored at -80°C and analysed by SDS-
PAGE and western blotting. 
 
3.2.4.5 SDS-PAGE 
Polyacrylamide gels were cast using the Mini-PROTEAN® gel stand. For the cell lines, 
20 µg to 40 µg of protein or protein lysate from 2 x 105 CLL cells were combined with 
an appropriate amount of dH2O and 4 x SSB. The CLL samples were then subjected to 
a 5 minute sonication at high setting, 30 s on, 30 s off. Samples were denatured at 
95°C for at least five minutes. Subsequently, the samples and 5 µl protein ladder were 
loaded and the gels were run at 30 to 50 mA/gel in 1 x running buffer until the desired 
separation was achieved.  
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3.2.4.6 Western blotting 
After separating proteins on an SDS-polyacrylamide gel, western blotting was 
performed using a PVDF membrane, which was activated in methanol and then 
washed with transfer buffer. Four sheets of filter paper and the gel were equilibrated in 
transfer buffer for 5 min until the transfer sandwich was assembled as shown in Figure 
3.10. 
 
Figure 3.10 Assembly of the transfer sandwich. 
For western blotting, the acrylamide gel and the membrane were placed between 
filter papers so that the membrane faces the anode. 
 
The blotting was performed at 4°C in a tank filled with 1 x transfer buffer for 1.5 h at 
300 mA with constant stirring. After the blotting, the membrane was washed in TBST, 
blocked with 5% milk or 5% BSA in 1 x TBST for at least 30 min, washed again and 
incubated with the primary antibody against the protein of interest over night. 
Afterwards, the membrane was washed three times 10 min with 1 x TBST and then 
incubated with the appropriate secondary antibody diluted in 5% milk or 5% BSA in 
1 x TBST, respectively. After a 1 h incubation at room temperature, the membrane was 
washed three times ten minutes in 1 x TBST and treated with HRP substrate for 5 min. 
Then, the membrane was exposed to a chemiluminescence film (Amersham 
HyperfilmTM ECL), which was developed using the Konica SRX-101A developer. 
 
3.2.5 RNA analysis 
3.2.5.1 Preparation of total RNA 
Total RNA was prepared from 0.5 - 2 x 106 cells using TRIzol® according to the 
manufacturer’s recommendations. The RNA pellet was redissolved in 16.5 µl 
HyCloneTM water, 2 µl 10 x DNase buffer, 1 µl DNase and 0.5 µl RNaseOut and 
incubated at 37°C for 30 min to digest contaminating genomic DNA. Afterwards, 0.5 ml 
TRIzol® were added and the RNA was extracted again. The dry RNA pellet was taken 
up in 10 - 20 μl of HyCloneTM water and dissolved at 55°C for 10 min. After that, the 
RNA concentration was determined using the NanoDropTM spectrophotometer and the 
RNA was stored at -80°C. 
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3.2.5.2 Measuring RNA and DNA concentrations 
To determine the concentration of DNA or RNA in solution, the NanoDropTM 
spectrophotometer was used. DNA and RNA concentrations were determined by 
measuring the absorbance of the sample at 260 nm and normalising to the absorbance 
at 340 nm, using the following formulas: !MNO * (:PB@ − :C3@) ∗ 50%-'# !RNO * (:PB@ − :C3@) ∗ 40%-'# 
Further, the ratio between absorbance at 260 nm and 280 nm was calculated as a 
measure of purity: 
J&)67T → (:PB@ − :C3@)(:PV@ − :C3@) * 1.8	98)	J&)"	YZ:, 2.0	98)	J&)"	]Z: 
RNA samples with lower values were still used for cDNA synthesis, but results were 
analysed more carefully. Similarly, DNA with lower values was still used for cloning and 
transfection. 
 
3.2.5.3 cDNA synthesis 
For the cDNA synthesis, 0.5 - 1 µg of RNA were mixed with HyCloneTM water and 1 µl 
diluted random primers (1 µM) to a final volume of 14 µl and incubated at 70°C for 
5 min. Hereafter, the mixture was chilled on ice and 4 µl 5 x FS buffer, 1 µl MMLV 
reverse transcriptase, 0.5 µl RNaseOut and 0.5 µl 25 mM dNTPs were added. The 
cDNA synthesis was performed at 37°C for 1 h, followed by a denaturation at 95°C. 
The cDNA was diluted 1:5 in 1 x TE and stored at -20°C. 
 
3.2.5.4 qPCR 
For real-time qPCR, cDNA was diluted 1:10, genomic DNA (gDNA) from ChIP 
experiments 1:5 or 1:50 (input samples) in HyCloneTM water. For the standard curve, 
aliquots of all cDNA or ChIP input samples used in the experiment were mixed and 
diluted 1:5 for cDNA or 1:20 for ChIP inputs. A 1:5 dilution series was made, with the 
lowest concentrated sample being 1:625 or 1:2500 diluted, respectively. The PCR 
reaction was carried out in duplicate in clear 96- or 384-well plates. For each well 5 µl 
diluted DNA, 5 µl GoTaq® qPCR Master Mix and 0.02 µl primer mix (500 µM forward 
and reverse primer) were combined. If the PCR was run using the ABI 7900HT, 0.05 µl 
CXR dye were also added to each sample. A sample with HyCloneTM water instead of 
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DNA was used as a negative control. The qPCR was run in an ABI 7500 for 96 well 
plates or ABI 7900HT real-time cycler for 384 well plates under the following 
conditions: 
 
50°C 2 min 1 x 
95°C 10 min 1 x 
95°C 15 s 
40 x 
60°C 1 min 
 
The amplification was followed by a melting curve analysis from 60°C to 95°C to 
ensure the specificity of the amplification. Only samples, for which the melting curve 
had only one peak with high amplitude were included in the analysis (Figure 3.11). 
 
 
Figure 3.11 Example dissociation curves for a 1:5 dilution series of input DNA 
and a water control sample. 
 
Ct values were calculated individually for each primer pair to make sure that the 
threshold was set in the exponential phase of the reaction. The final analysis was 
carried out in Microsoft Excel, using the efficiency-corrected ΔΔCt method (Pfaffl, 
2001). The standard curve was generated by plotting the Ct values against the relative 
amounts of DNA in the individual samples. Linear regression was performed and the 
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efficiency (E) of the amplification was calculated using the slope (a) of the curve in the 
following formula: ^ * 10_`/G 
 
An efficiency of 2 means that the DNA was exactly doubled in every PCR cycle, E < 2 
means that it was less than doubled and E > 2 means that it was more than doubled. 
Then, the amount of DNA in the samples was calculated relative to a control sample 
using the following formula: 
)"#+76,"	+'8&%7	89	YZ: *	 ( b^G=cdb)_ebfghijf,kglmnj( b^G=cdb)_ebfghijf,opqfhpn 	( =^dDd=dF;d)_ebhjrjhjqoj,kglmnj( =^dDd=dF;d)_ebhjrjhjqoj,opqfhpn  
 
 
Figure 3.12 Example amplification curves for a 1:5 dilution series of input DNA 
and a water control sample.  
The Ct values were set in the exponential phase of the amplification. 
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3.2.6 Chromatin analysis 
To detect protein-DNA interactions, chromatin immunoprecipitation (CHIP) was used. 
Figure 3.13 shows a brief overview of the procedure.  
 
 
Figure 3.13 Chromatin immunoprecipitation (ChIP).  
After cross-linking the DNA and its associated proteins, cells are lysed and the 
chromatin is fragmented. Application of an antibody coupled to magnetic beads 
leads to precipitation of the protein of interest and its associated DNA. After 
elution of the complex from the beads, the cross-linking is reversed, the DNA is 
purified and subsequently analysed by real-time qPCR. Alternatively, a library can 
be generated and sequenced. 
 
 
3.2.6.1 Preparation of chromatin 
Cells in culture medium were treated with formaldehyde at a final concentration of 1.5% 
for 10 min at room temperature with gentle agitation. The cells were then scraped off 
the tissue culture flask, transferred into 50 ml tubes and sedimented by centrifugation 
at 800 x g for 5 min. Cell lines were washed three times with 10 ml PBS, whereas CLL 
cells were resuspended in 1 ml PBS and transferred into 1.5 ml tubes. They were 
washed twice by spinning for 10 s at 16,100 x g and resuspending in PBS. 
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Subsequently, the cells were resuspended in 10 ml or 1 ml buffer A, respectively, and 
incubated at 4°C for 10 min on a rotating wheel. Sedimentation of the nuclei was done 
by centrifugation at 800 x g for 5 min (cell lines) or 16.100 x g for 10 s (CLL cells). The 
supernatant was discarded and the nuclei were resuspended in 10 ml or 1 ml buffer B, 
respectively. After a 10 min incubation at 4°C on a rotating wheel, the nuclei were 
again sedimented and resuspended in 100 µl glycerol buffer/2 x 107 cells. The 
suspension was then either frozen at -80°C and thawed later for sonication (cell lines) 
or directly subjected to sonication (CLL cells). 
 
3.2.6.2 Chromatin sonication 
The nuclei in glycerol buffer were mixed with an equal amount of 2 x IP buffer and 
sonicated using the Bioruptor sonicator. For each cell line and for the primary CLL 
cells, sonication conditions were optimised by testing different sonication times and 
analysing samples on a 1% agarose gel. Samples for analysis were treated like input 
samples and run on a gel after the 4 h incubation with proteinase K (see section 
3.2.6.3). Sonication was satisfactory, when the bulk of the fragments was seen 
between 200 and 1000 bp. The chromatin of the lymphoma cell lines was sonicated for 
2 x 15 min on high power, with 30 s on, 30 s off. The CLL chromatin was sonicated for 
2 x 10 min on high power, with 30 s on, 30 s off. After the first cycle, the tubes were 
inverted a couple of times to guarantee optimal chromatin shearing. Subsequently, cell 
debris was removed by centrifugation at 5,900 x g for 5 min and the supernatant was 
transferred to a new tube. The chromatin was then either frozen at -80°C for up to a 
few days or directly used for ChIP. 
 
3.2.6.3 Chromatin immunoprecipitation (ChIP) 
For the chromatin precipitation, 10 µl of Dynabeads Protein G were washed twice with 
100 µl 1 x IP buffer, using a magnet. The beads were then resuspended in 100 µl 
1 x IP buffer and 2.4 µg of the desired antibody were added. Binding of the antibody to 
the Protein G was achieved during a two hour incubation at 4°C on a rotating wheel. 
Afterwards, the beads were washed once with 1 x IP buffer. The sheared chromatin 
was diluted in 1 x IP buffer, so that 100 µl of the suspension contained the chromatin of 
2 x 106 to 2 x 107 cells, depending on the antibody used. The beads were then 
resuspended with 100 µl of this chromatin suspension and incubated for 2 h at 4°C on 
a rotating wheel. 10 - 20 µl of chromatin suspension were kept as an input sample. 
In the next step, the beads were washed once with 100 µl each of washing buffer 1, 
washing buffer 2, LiCl buffer and twice with 100 µl 1 x TE. They were then 
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resuspended in 50 µl freshly prepared elution buffer and incubated at 65°C for 4 h. 
Simultaneously, the input samples were mixed with 1 µl 10 µg/µl RNase A and 
incubated at 37°C for 30 min. Next, 1 µl 50 µg/µl Proteinase K were added and the 
samples were incubated at 65°C for 4 h. Afterwards, the eluates and the inputs were 
transferred into a 96-well plate. Elution buffer was added to the input samples to make 
up 50 µl and all samples were subjected to DNA purification. 
 
3.2.6.4 DNA purification 
3.2.6.4.1 Purification using AMPure beads 
If ChIP samples were used for qPCR, 90 µl of AMPure bead suspension were added to 
50 µl of DNA sample. The samples were mixed by inversion, incubated at room 
temperature for 5 min and the beads were separated from the supernatant using a 
magnet. The supernatant was discarded and, on the magnet, the beads were washed 
twice with freshly prepared 70% ethanol without disturbing the pellet. The beads were 
then air-dried for 5 min and the DNA was eluted with 33 µl of 1 x TE. The DNA was 
now used for qPCR (see section 3.2.5.4). 
 
3.2.6.4.2 Purification using phenol-chloroform precipitation 
If ChIP samples were prepared for library generation and sequencing, the DNA was 
purified using phenol-chloroform precipitation. 50 µl of DNA were mixed with 150 µl 
freshly prepared 3:1 phenol-chloroform and vortexed for 10 s. The samples were 
centrifuged at 15,000 x g for 5 min at room temperature, the upper aqueous layer was 
transferred to a fresh tube and mixed with 150 µl chloroform. The mixture was again 
vortexed for 10 s, spun at 15,000 x g for 5 min at room temperature and the upper 
aqueous layer was transferred into a fresh tube. Then, 4 ml 5 mg/ml glycogen, followed 
by 250 µl ice cold 100% ethanol were added. After gentle mixing, the samples were 
incubated at -20°C for 30 min. After that, the DNA was pelleted by a 15 minute 
centrifugation at 15,000 x g and 4°C. The pellet was washed with 250 µl freshly 
prepared ice cold 70% ethanol, pelleted again by centrifugation at 15,000 x g and 4°C 
for 15 min and the supernatant was removed. After another 2 min centrifugation to 
remove all residual ethanol, the pellet was air dried and then incubated in 20 µl 0.1 x 
TE at 37°C for 45 min to resuspend the DNA. The samples were then stored at 4°C for 
up to a few days. 
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3.2.6.5 Analysis of ChIP-qPCR data 
qPCR data were normalised as described in section 3.2.5.4. In formula 1), the input 
samples served as controls, and an invariant genomic region was used as the 
reference.  
1)	)"#+76,"	+'8&%7	89	YZ: * 	 ( b^G=cdb)_ebfghijf,kglmnj( b^G=cdb)_ebfghijf,opqfhpn 	( =^dDd=dF;d)_ebhjrjhjqoj,kglmnj( =^dDd=dF;d)_ebhjrjhjqoj,opqfhpn  
 
3.2.6.6 Library preparation for ChIP-sequencing (ChIP-seq) 
Before library preparation, the quality of the ChIP was assessed by qPCR using an 
aliquot of the sample. 
 
3.2.6.6.1 DNA quantification  
For the DNA quantification, the Quant-iT DNA assay kit (LifeTechnologies) was used 
according to the manufacturer’s recommendations. The DNA staining solution was 
prepared by diluting the DNA dye 1:200 in the required amount of dilution buffer. Then, 
a black 96-well plate was set up as shown in Figure 3.14. 2 µl of each sample and each 
standard were diluted in 198 µl DNA staining solution. As the DNA concentrations in 
the samples were very low, the standards were diluted 1:10 in DNA staining solution to 
generate a standard curve in the range of the sample DNA concentrations. The 
samples were mixed by briefly shaking the plate on a plate shaker. Then, the 
fluorescence of the samples was measured with an excitation wave length of 485 nm 
and the emission was detected at 520 nm using a FLUOStar GALAXY fluorometer. 
 
 
Figure 3.14 Set up of DNA quantification assay 
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The analysis was done by the FLUOstar software. The standard curve was calculated 
using the 1:10 diluted standards by plotting the fluorescence units against the DNA 
concentrations and performing a linear regression. Using the equation calculated for 
the standard curve, the DNA concentrations in the samples could be determined. 
 
3.2.6.6.2  Library generation 
1 to 10 ng of DNA were used to prepare ChIP-seq libraries using the MicroPlex Library 
Preparation kit (Diagenode), following the manufacturer’s recommendations. 10 µl of 
(diluted) DNA sample were mixed with 2 µl Template Preparation Buffer and 1 µl 
Template Preparation Enzyme. After a brief centrifugation, the samples were incubated 
in a thermal cycler at 22°C for 25 min, then at 55°C for 20 min, followed by 22°C for up 
to 10 min. The liquid was collected at the bottom of the tube by centrifugation and 1 µl 
of each Library Synthesis Buffer and Library Synthesis Enzyme were added. The 
samples were mixed thoroughly, briefly centrifuged and incubated in a thermal cycler at 
22°C for 40 min and then kept at 4°C for up to 30 min. After another centrifugation 
step, the library was amplified. For this purpose, 8 µl nuclease-free water, 48.5 µl 
Library Amplification Buffer and 1.5 µl Library Amplification Enzyme were added. The 
samples were mixed by pipetting, before 2 µl of the indexing reagents were combined 
with the samples. 
As the Illumina sequencer uses a red laser to sequence A/C and a green laser to 
sequence G/T, it is important to combine indices for multiplexing so that every position 
gives a signal in both channels (Table 3.2). 
A  T  C  A C  G A  T  C  A C G 
C  G  A  T G T C  G  A  T  G T 
T  T  A  G  G  C T  T  A  G  G C 
T  G  A  C C A T  A  G  C  T  T 
A  C A G T G G  G C  T  A  C 
G  C  C  A A T C  T  T  G  T  A 
not okay ! position 3 only red! okay ! both colours in all 
positions 
Table 3.2 Examples of acceptable and not acceptable combinations of indices for 
Illumina sequencing. 
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The samples were then spun down and the DNA was amplified in a thermal cycler 
using the following programme: 
72°C 3 min 1 x 
85°C 2 min 1 x 
98°C 2 min 1 x 
98°C 20 s 
4 x 67°C 20 s 
72°C 40 s 
98°C 20 s 15 – 18 x, depending on 
the amount of starting 
material 72°C 50 s 
4°C hold  
 
The quality of the library was then analysed using the TapeStation. If no prominent 
band between 200 to 400 bp was detected, the sample was immediately subjected to 
further amplification cycles, using the following conditions: 
98°C 20 s 
2 – 3 x 
72°C 50 s 
4°C hold  
 
Subsequently, the library was again analysed on the TapeStation. If the prominent 
band at 200 to 400 bp was detected, the library was then size-selected using AMPure 
beads. 
 
3.2.6.6.3 Analysis of the library using the TapeStation 
The buffer, ladder and Screen Tape were equilibrated at room temperature for 30 min. 
Then, 3 µl of sample buffer were pipette-mixed with 1 µl of ladder or 1 µl of library DNA 
in an 8-well strip. The strip, a Screen Tape and loading tips were placed in the 
TapeStation and the run was started. The analysis was performed using the 
TapeStation analysis software.  
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3.2.6.6.4 Library size selection using AMPure beads 
The library samples were transferred into 1.5 ml tubes, made up to 100 µl with 0.1 x TE 
and mixed with 80 µl AMPure bead suspension. The mix was then vortexed, incubated 
at room temperature for 5 min and the beads were separated from the supernatant 
using a magnet. The beads have bound large, the supernatant contains shorter DNA 
fragments. The supernatant was transferred into a new 1.5 ml tube and combined with 
20 µl AMPure beads, which bind the shorter DNA fragments. The mix was again 
vortexed, incubated for 5 min and then the beads were sedimented using a magnet. 
The supernatant was discarded and, on the magnet, the beads were washed twice with 
freshly prepared 80% ethanol without disturbing the pellet. After air-drying the beads, 
the DNA was eluted with 20 µl 0.1 x TE. The size-selected library was once more 
analysed using the TapeStation. A successful purification leads to an enrichment of 
fragments between 200 and 400 bp and a loss of any larger DNA fragments. If 
necessary, the size selection was repeated. The concentration of the size-selected 
library was measured using the Quant-iT DNA analysis kit. 
 
3.2.6.6.5 Sequencing of the library 
Six of the amplified, size-selected libraries were combined, when possible at equal 
concentrations, to a final concentration of 2 ng/µl. If necessary, the pool was 
concentrated using the DNA Clean & Concentrator Kit according to the manufacturers 
recommendations. The DNA was eluted with 10 µl 0.1 x TE. The sequencing was 
performed by the Next Generation Sequencing Facility of the University of Leeds using 
the Illumina HiSeq 2000 sequencer in rapid mode according to the manufacturer’s 
instructions. 
 
3.2.6.7 Data analysis of ChIP-seq data 
The analysis of the sequencing raw data was done by Matthew Care. Briefly, the reads 
were trimmed to remove adapters and low confidence regions using a python script. 
Low confidence regions were defined as regions spanning four nucleotides with an 
average Phred quality score < 20, which is less than 99% accuracy. The reads were 
trimmed down to such regions. Trimmed reads were then aligned to the hg19 human 
genome assembly using Bowtie2 and the ‘very sensitive’ setting (Langmead & 
Salzberg, 2012). The resulting SAM file was converted into a BAM file, using a cut-off 
for the mapping quality score of 20, which reflects a minimum 99% confidence that the 
read was aligned correctly. The BAM files were analysed for peaks using GEM 
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(Genome wide Event finding and Motif discovery) with a quality score of 1. Here the 
quality score is q = -log10(FDR), which means one in 10 peaks might be false.  
Further, the BAM files were converted into BED files and fragment length was 
estimated using MaSC (mappability-sensitive cross-correlation) (Ramachandran et al., 
2013). The reads were then extended to the estimated fragment length and a BED file, 
scaled to reads per million, was generated. This was converted to a coverage file using 
the UCSC genomeCoverageBed tool and then to a BigWig file using UCSC 
bedGraphToBigWig, which was visualised using the UCSC genome browser 
(http://genome.ucsc.edu/) (Kent et al., 2002). Peaks were annotated using V19 of 
Gencode or the latest RefSeq annotation. 
All further analysis was carried out by myself. The peak data were used for a motif 
analysis with MEME ChIP (Machanick & Bailey, 2011). As the data were available only 
as genomic intervals, the sequences for the chromosomal peak regions had to be 
retrieved using the Galaxy function “Extract Genomic DNA” (Blankenberg et al., 2001; 
Giardine et al., 2005; Goecks et al., 2010). The resulting FASTA file was entered into 
MEME ChIP, compared versus the Jolma2013, JASPAR CORE and UniProbe Mouse 
motif databases and the top motifs detected by MEME and CentriMo were analysed 
further. 
The sequences in which CTCF motifs were detected were extracted, uploaded to 
Galaxy and converted into interval files. As CTCF motifs from 3 different sources 
(Jolma 2013, JASPAR CORE and MEME de novo motif) were used, three mostly 
overlapping, but partly distinct datasets were generated. Consequently, these datasets 
were fused using the “Join two Datasets” function, converted into a BED file and 
intersected with available ChIP-seq peak data for CTCF in GM12878 cells (UCSC 
accession wgEncodeEH000029). Further, all peak sequences were compared to 
publicly available H3K27ac and STAT3 ChIP-seq peaks from GM12878 cells (UCSC 
accessions wgEncodeEH000030 and wgEncodeEH001811). 
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Results 
4 PIM kinases in transcriptional regulation in B cell lymphoma 
Signalling kinases play an important role in transcriptional regulation by 
phosphorylating histone and non-histone proteins. PIM1 has been shown to associate 
with MYC, to phosphorylate histone H3S10 and to promote transcriptional elongation 
(Zippo et al., 2007; Zippo et al., 2009). Another H3S10 kinase, IKKα, associates with 
NFκB (Anest et al., 2003; Yamamoto et al., 2003), phosphorylates HP1γ and H3.3S31p 
and binds to the phosphorylated POL II CTD to travel with the elongating POL II 
(Thorne et al., 2012) (Figure 4.1). As kinases often have redundant functions at 
different genes or in response to different stimuli (Duncan et al., 2006) and as PIM1 
can also target HP1γ (Koike et al., 2000), we hypothesised that at MYC-dependent 
genes, PIM kinases might function like IKKα at NFκB target genes. It has been 
extensively shown that PIM2 can compensate for PIM1 knockout (Allen et al., 1997; 
van der Lugt et al., 1995) and that PIM1 and PIM2 share several substrates, so that we 
hypothesised that PIM2 might also be recruited to MYC and stimulate transcriptional 
elongation. 
 
Figure 4.1 IKKα travels with the elongating POL II and phosphorylates H3.3S31. 
IKKα binds to NFκB at the promoters of target genes, where it phosphorylates 
H3S10 and promotes transcriptional elongation. It also binds to the POL II CTD 
and travels with the elongating POL II. HP1γ, which is also bound to the CTD 
independent of IKKα, is phosphorylated by the latter and then loaded onto 
H3K9me3. It inhibits IKKα-mediated phosphorylation of H3S10, but stimulates 
H3.3S31 phosphorylation. Because PIM1 also stimulates elongation by 
phosphorylating H3S10 and also phosphorylates HP1γ, it might mimic the other 
functions of IKKα as well. 
 
PIM1 has been shown to be nuclear in DLBCL and BL and this is associated with 
progressive disease (Brault et al., 2012; Ionov et al., 2003). Further, high PIM1 and 
PIM2 mRNA expression are a distinguishing factor of ABC-DLBCL vs. GCB-DLBCL 
(Care et al., 2013; Wright et al., 2003). Therefore, MYC-dependent activation of 
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transcription by PIM kinases might play a role in survival of lymphoma cells and in 
disease progression. This part of the thesis aims to answer the following questions: 
1. Does PIM kinase inhibition reduce the viability of B cell lymphoma cell lines? 
2. Does PIM1 regulate MYC-dependent gene expression in BCL cell lines? And 
does it mimic the functions of IKKα at NFκB target genes? 
3. Is the effect of PIM kinase inhibition on viability due to a change in MYC-
dependent transcription? 
4. Do PIM kinases have other functions at the chromatin level? 
 
 Expression of PIM kinases in BCL cell lines 
First, expression of PIM kinases was assessed in the cytoplasm and nucleus of six 
different lymphoma cell lines (Figure 4.2). OCI-Ly3 and OCI-Ly10 are ABC-DLBCL cell 
lines, SUDHL6 and OCI-Ly19 are GCB-DLBCL cell lines and Raji and Ramos are BL 
cell lines. While Raji cells are EBV-transformed, Ramos cells are EBV-negative. 
Both the 34 and 44 kDa PIM1 isoforms can be detected by western blot. Further, in the 
nucleus, the antibody detected a 50 kDa protein of unknown identity, which might be a 
ubiquitinated or otherwise modified PIM1 variant. The PIM2 antibody also detects all 
three PIM2 isoforms of 34, 38 and 40 kDa. As expected, both ABC-DLBCL cell lines 
expressed high levels of PIM1 and PIM2 protein. Also consistent with the literature 
(Rainio et al., 2005), Raji BL cells showed high expression of PIM1, but lower PIM2 
levels, whereas non-EBV-transformed Ramos cells expressed lower levels of both 
PIM1 and PIM2. GCB-DLBCL cells had the lowest amounts of PIM1 and PIM2, the 
34 kDa PIM1 variant and PIM2 being completely undetectable in OCI-Ly19 cells 
(Figure 4.2 A). However, the kinases were detected mostly in the cytoplasmic 
compartment and nuclear PIM1 and PIM2 were only visible after longer exposure of the 
film (Figure 4.2 A). Comparable MYC expression was seen in all cell lines and its 
localisation was mainly nuclear (Figure 4.2 A). However, a substantial amount of MYC 
was also detected in the cytoplasm. This is in agreement with a previous study showing 
that MYC is present in both nucleus and cytoplasm of both BL and DLBCL cells 
(Ruzinova et al., 2010). 
Similarly, mRNA expression of PIM1 was higher in OCI-Ly3 and Raji than in Ramos 
and SUDHL6 cells. Of note, PIM1 levels were variable between experiments. Also 
consistent with the protein data, PIM2 mRNA expression was highest in OCI-Ly3, lower 
in the BL cell lines and lowest in SUDHL6 cells (Figure 4.2 B).  
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Figure 4.2 Expression of PIM kinases in B cell lymphoma cell lines.  
A Protein expression of PIM kinases was assessed in different BCL cell lines by 
western blot after nuclear-cytoplasmic fractionation (c = cytoplasm, n = nucleus). 
The data are representative of three independent experiments. PIM kinases were 
mainly cytoplasmic, while MYC predominantly localised to the nucleus in all cell 
lines tested. B mRNA expression of PIM1 and PIM2 was measured by RT-qPCR 
and is shown relative to TBP expression. Means and sd of three to five 
independent experiments are plotted for OCI-Ly3, Raji and SUDHL6 cells. For 
Ramos cells, the results of two independent experiments are shown. Expression 
levels were variable between experiments, but expression of both PIM1 and PIM2 
were on average highest in OCI-Ly3 and Raji cells. 
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 PIM1 expression under different conditions 
Because PIM1 expression was generally quite low, very variable between experiments 
and because PIM1 has been shown to be inducible by serum, certain stressors, like 
oxidative stress and exposure to cytotoxic agents (Katakami et al., 2004; Zemskova et 
al., 2008; Zippo et al., 2007), as well as by activation of STATs and NFκB (Asano et al., 
2011; Lilly et al., 1992; Matikainen et al., 1999; Morcinek et al., 2002; Nosaka et al., 
1999; Shirogane et al., 1999; Zhu et al., 2002), induction of PIM kinases in response to 
different stimuli was assessed in Raji cells. 
First, expression of PIM kinases and MYC was monitored after serum starvation and 
release into normal medium. PIM1 was inducible by serum starvation, with maximum 
protein levels being reached after 1 h. Protein levels then decreased to or below 
baseline at 4 h starvation. Release into normal medium resulted in PIM1 induction in 2 
out of 4 experiments, whereas PIM1 protein levels remained low in the other 2 
experiments. Surprisingly, MYC expression remained high after serum starvation and 
was reduced after release into normal medium in two out of three experiments (Figure 
4.3 A). At the mRNA level, PIM1 and PIM2 expression were also increased after 1 h 
starvation and reduced at later time points (Figure 4.3 B). However, PIM1 protein 
induction was a lot stronger, suggesting that PIM1 expression was also regulated at the 
posttranscriptional and/or -translational level. MYC mRNA expression was also induced 
after serum starvation (Figure 4.3 C). When PIM1 levels were monitored over 24 h after 
medium change, maximum protein levels were also reached at 1 h and remained high 
(Figure 4.3 D). 
Further, because PIM kinase expression is stimulated via STATs and NFκB, we 
reasoned that stimulation of the BCR might induce expression of PIM1. However, while 
MYC mRNA levels increased upon BCR stimulation in Raji cells, PIM1 and PIM2 levels 
decreased (Figure 4.4 A, B, C). This effect was not restricted to Raji cells, as BCR-
stimulated CLL cells also downregulated PIM1 (Figure 4.4 D). Similarly, phorbol-12-
myristate-13-acetate (PMA) treatment, which activates PKC and thus NFκB, did not 
induce PIM1 or PIM2 protein expression (Figure 4.4 E). 
This indicates that PIM1 and MYC expression are induced by certain stressors, like 
starvation. Interestingly, however, PIM1 expression was also responsive to addition of 
fresh medium but not to B cell receptor or PMA stimulation. Thus, PIM1 is acutely 
sensitive to serum-levels but not to the tested growth factors in Raji cells. 
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Figure 4.3 Regulation of PIM kinase expression by different serum levels.  
A Raji cells were serum starved in 0.5% FCS for 0 h to 4 h and then released into 
normal growth medium. The western blot shown is representative of four 
independent experiments for PIM1 and three independent experiments for MYC. 
PIM1 expression was induced in the first hour after serum starvation, but 
decreased afterwards. Release from starvation led to induction of PIM1 in two out 
of four experiments, but PIM1 levels remained low in the other two. MYC protein 
was not reduced by starvation, but by release into normal growth medium. B, C 
Raji cells were serum starved in 0.5% FCS and mRNA levels were assessed by 
RT-qPCR. One experiment was conducted. Like the protein, PIM1 and PIM2 
mRNAs were induced immediately after starvation and decreased at 4 to 24 h. 
MYC mRNA was also induced upon starvation and peaked at 4 h. D Culture 
medium of Raji cells was changed and PIM1 protein expression was evaluated 
before and after medium change. The western blot shown is representative of 
three independent experiments. PIM1 expression was induced 1 h after the 
medium change and remained elevated up to 24 h later. 
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Figure 4.4 Regulation of PIM kinase expression by different stimuli.  
A, B, C Raji cells were stimulated with 10 µg/ml anti-IgM/anti-IgG and expression 
of MYC, PIM1 and PIM2 mRNA was measured. One experiment conducted in 
duplicate wells of a 6-well plate is shown. Data are normalised to TBP expression 
and untreated cells. While MYC was induced after BCR cross-linking, both PIM1 
and PIM2 were downregulated. D CLL cells were stimulated with 10 µg/ml anti-
IgM and PIM1 mRNA expression was assessed. The results from two different 
patients are shown. Like in the Raji cell line, the PIM1 mRNA is decreased in 
patients 1 h after BCR cross-linking. E Raji cells were treated with 100 ng/ml 
PMA for indicated times. Protein was prepared and analysed by western blot. 
PMA did not induce the expression of PIM1, PIM2 or MYC but led to a 
downregulation of both PIM1 and PIM2 after 8 and 24 h. 
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 Treatment of BCL cell lines with PIM kinase inhibitors  
In order to test the potential role of PIM kinases in cell viability, two structurally similar 
kinase inhibitors, SMI4a, and PIM1/2 inhibitor VI (inh VI), and another structurally 
distinct inhibitor, Quercetagetin, were used as an initial strategy. First, Raji, Ramos, 
OCI-Ly3 and OCI-Ly10 cells were treated with the PIM kinase inhibitor SMI4a at a 
concentration of 40 μM (Figure 4.5). At least three experiments were carried out until 
day 3 in Raji cells or until day 4 in OCI-Ly3 and OCI-Ly10 cells. In Ramos cells, only 
two experiments were done. In each cell line, one experiment was done until day 9 or 
10, respectively, to assess whether the effect of SMI4a would persist over longer times. 
In all cell lines, SMI4a caused a reduction in cell viability. While DMSO-treated cells 
grew exponentially, SMI4a-treated cells showed hardly any increase in cell number, 
even after nine or ten days (Figure 4.5). 
Also, when relative cell numbers of different independent experiments were combined, 
cell numbers were significantly reduced in SMI4a-treated compared to DMSO-treated 
Raji cells on days 2 and 3 (Figure 4.5 A). Cell number was also greatly reduced in 
Ramos cells (Figure 4.5 B). No significant difference between SMI4a- and DMSO-
treated OCI-Ly10 cells on days 2 and 4 (n = 3) was observed, mainly because the drug 
effect was very variable between experiments (Figure 4.5 C). In SMI4a-treated OCI-
Ly3 cells, however, cell number was significantly decreased on day 4 (Figure 4.5 D). 
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Figure 4.5 Effects of SMI4a on cell number of B cell lymphoma cell lines.  
For each experiment Raji (A), Ramos (B), OCI-Ly10 (C) and OCI-Ly3 (D) cells 
were seeded into duplicate wells of 6-well plates on day -1, treated with DMSO or 
40 μM SMI4a from day 0 for up to 10 days. The medium was renewed every 
second day and cells were counted using the MTT assay or a haemocytometer. 
Left: For the growth curves, the means of technical duplicates of one 
representative experiment are shown for each cell line. SMI4a strongly reduced 
cell numbers in all four cell lines tested. Right: Cell numbers relative to DMSO are 
shown. For Ramos cells, the results of two independent experiments are plotted. 
For the other cell lines means and sd of at least three independent experiments 
are depicted. Student’s t-test was carried out: ns = not significant, * p < 0.05, 
** p < 0.01. SMI4a significantly reduced the cell number in Raji and OCI-Ly3 cells, 
whereas a trend towards reduction was observed in OCI-Ly10 cells, which did not 
reach significance. Similarly, cell number was reduced in Ramos cells in both 
experiments compared to DMSO-treated controls. 
- 138 - 
 
For each cell line, one experiment was conducted in duplicate wells using two other 
PIM kinase inhibitors: Quercetagetin and inh VI. At concentrations of 40 μM, both 
Quercetagetin and inh VI prevented an increase in cell number in the Raji and Ramos 
BL cell lines over a time course of three days (Figure 4.6 A). However, Quercetagetin 
was not effective in OCI-Ly3 and OCI-Ly10 cells and inh VI reduced cell number only 
on days three and four (Figure 4.6 B). 
As a control, PIM1/2-low SUDHL6 and OCI-Ly19 cells were also treated with all three 
inhibitors (one experiment in duplicate wells). The cell number was reduced in inhibitor-
treated SUDHL6 and OCI-Ly19 cells compared to DMSO-treated cells on days 3 and 4 
(Figure 4.6 C). Surprisingly, Quercetagetin was very toxic for OCI-Ly19 cells. As these 
cells do not express any detectable PIM1 or PIM2 (Figure 4.2 A), the effect was most 
likely not mediated via PIM kinase inhibition. Consistent with this, Quercetagetin has 
been shown to inhibit a plethora of other kinases that may promote cell proliferation 
and survival, like DYRK1A, DYRK2, DYRK3, AKT2, RSK2, TAK1, YES1 and Aurora B 
with similar efficiency to PIM kinases (http://www.kinase-screen.mrc.ac.uk, see 
appendix). 
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Figure 4.6 Effects of different PIM kinase inhibitors on cell number of B cell 
lymphoma cell lines. 
For each experiment Raji, Ramos (A), OCI-Ly3 and OCI-Ly10 (B) cells were 
seeded into duplicate wells of 6-well plates and treated with DMSO, 40 μM 
Quercetagetin or 40 μM inh VI for up to 4 days without refeeding. Cells were 
counted using Trypan blue staining and a haemocytometer. Means of technical 
duplicates of one experiment are shown. While inh VI effectively decreased cell 
numbers in all four cell lines, Quercetagetin treatment had no effect on the two 
ABC-DLBCL cell lines. C SUDHL6 and OCI-Ly19 cells were plated into duplicate 
wells of 6-well plates and treated with DMSO, 40 μM SMI4a, 40 μM 
Quercetagetin or 40 μM inh VI for up to 4 days without renewal of the medium. 
Cells were counted using Trypan blue staining and a haemocytometer. The 
means and sd of two independent experiments are plotted for DMSO-treated 
SUDHL6 cells. For all other conditions, the means of technical duplicates of one 
experiment are shown. All three inhibitors affected cell viability in SUDHL6 and 
OCI-Ly19 cells, with Quercetagetin being very toxic for OCI-Ly19 cells. 
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 Analysis of PIM1 and MYC occupancy at different promoter 
or enhancer regions in Raji and Ramos cells 
PIM1 has been shown to promote elongation at MYC-dependent genes and it is highly 
expressed in ABC-DLBCL and BL. As especially nuclear PIM1 is associated with a 
poor prognosis in DLBCL and mediates oncogenic effects in BL, we predicted that 
PIM1 might be involved in the regulation of transcriptional elongation in lymphoma. 
Further, we hypothesised that, at MYC-dependent genes, PIM1 might mimic the effects 
of IKKα at NFκB target genes (see Figure 4.1). 
To test these hypotheses, we sought to identify possible PIM1 target genes in 
lymphoma cell lines. The ABC-DLBCL metaprofile generated by Care et al. identified 
PIM1 and PIM2 among the top 20 genes associated with ABC-DLBCL (Care et al., 
2013). Therefore, it seemed plausible that other genes associated with the ABC profile 
in this study might be transcriptionally regulated by PIM kinases. For further analyses 
we picked the known oncogenes guanine nucleotide binding protein-like 3 (GNL3), AT-
rich interactive domain 3A (ARID3A), LYN and B cell CLL/lymphoma 2 (BCL2), as well 
as the cell surface marker CD44 and the methionine sulfoxide reductase B1 gene 
(MSRB1, SEPX1). Of those, GNL3 and SEPX1 have known E box elements in their 
promoters. Initially, ChIP was performed to identify directly PIM1-bound genes. 
 
 Optimising ChIP conditions 
For the ChIP experiments, chromatin sonication was optimised in Raji cells (Figure 4.7 
A). 2 x 15 minutes sonication was found to give a good spread of DNA fragment 
lengths (200 – 1000 bp), when chromatin was cross-linked with 1.5% formaldehyde for 
10 min. 
Then the PIM1 antibody used for ChIP (rabbit anti-PIM1, Bethyl Laboratories) was 
tested, as there were no publications available confirming its specificity in ChIP 
experiments. As shown in Figure 4.7 B and C, the antibody selectively precipitates the 
34 kDa, but not the 44 kDa PIM1 isoform from both Raji cell extract and formaldehyde 
cross-linked chromatin. However, under the conditions used, no co-precipitation of 
MYC was detected (Figure 4.7 B). Further, the antibody was specific for PIM1 and did 
not precipitate PIM2 (Figure 4.7 B). To further confirm specificity of the antibody, ChIP 
after PIM1 overexpression was performed. However, hardly any ChIP signal was 
detected in several experiments, which might be due to the mass of non-chromatin-
bound PIM1 blocking the antibody. Only PIM1 knockdown finally confirmed that the 
antibody specifically precipitates PIM1, because the ChIP signal was significantly 
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reduced in knockdown cells (Figure 5.16). In conclusion, the antibody can be used for 
ChIP and it precipitates PIM1 cross-linked to chromatin. 
 
 Identification of PIM1 and MYC target genes 
ChIP-qPCR was used to identify PIM1 and MYC binding sites in target genes. The 
presence of these proteins at the known E box elements in GNL3 (GNL3 +0.1, GNL3 
+0.4) and SEPX1 (SEPX1 -0.3) was analysed. Further, Zippo et al. described regions 
upstream of the ID2 (ID2 -1.4, ID2 -1.7) and within the FOSL1 gene (FOSL1 +1.15) to 
be occupied by PIM1 and MYC, which were also assessed in the present study (Zippo 
et al., 2007). The FOSL1 -37 region served as a negative control, NPM1 +1 was a 
positive control as it is a known MYC-bound site in BL cell lines (Seitz et al., 2011). 
ChIP-qPCR showed that both PIM1 and MYC bound to the GNL3 promoter and the 
NPM1 intronic enhancer in both Raji and Ramos cells (Figure 4.7 D). While no binding 
was observed at any of the other regions tested in Raji cells, some PIM1 binding could 
also be detected at the ID2 and FOSL1 regions in Ramos cells, but without a 
concomitant MYC signal. MYC and PIM1 were not detected at the SEPX1 E box, 
although POL II was bound there. A POL II signal was also seen at the PIM1- and 
MYC-bound regions of the GNL3 and NPM1 genes (Figure 4.7 D). 
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Figure 4.7 Identification of MYC and PIM1-bound chromatin regions.  
A Raji chromatin was sonicated for 2 x 15 min and analysed on a 1% agarose 
gel. The chromatin nicely spread between 200 and 1000 bp. B Raji lysate was 
immunoprecipitated with either rabbit IgG or a PIM1 antibody, showing that the 
antibody specifically precipitates PIM1. The results are representative of two 
independent experiments. C ChIP was done using chromatin from Raji cells and 
the eluate was subjected to western blotting. This confirms that the antibody 
precipitates PIM1 even when it is formaldehyde cross-linked to chromatin. D 
ChIP-qPCR was performed using the PIM1, MYC and POL II CTD antibodies. 
qPCR was done with primer pairs close to different E box elements or the FOSL1 
-37 kb control region. Results are normalised to input and the ID2 -1.4 kb region. 
For Raji cells, the means of technical duplicates are shown, whereas the result of 
one experiment is presented for Ramos cells. MYC and PIM1 were bound to the 
NPM1 enhancer and GNL3 promoter (NPM1 +1, GNL3 +0.1, GNL3 +0.4) in both 
cell lines, where POL II was also detected. 
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 Detailed analysis of the NPM1 and GNL3 genes by ChIP 
 GNL3 and NPM1 displayed an active gene signature 
As both PIM1 and MYC were bound to the GNL3 and NPM1 genes, we sought to 
analyse these further with respect to the distributions of PIM1, MYC and POL II, as well 
as histone modification patterns at these genes. Because PIM1 can, like IKKα, 
phosphorylate H3S10 and HP1γ and promote transcriptional elongation, it might also 
share other substrates and functions with IKKα. Consequently, the starting hypothesis 
was that PIM1 occupancy at the GNL3 gene might be similar to that of IKKα at the 
murine Tnf gene after LPS stimulation. IKKα binds to the elongating POL II and can be 
found enriched at the NFκB binding site, in the gene body and at the 3’ region of the 
Tnf gene after activation (Thorne et al., 2012; Witham et al., 2013). Further, IKKα 
phosphorylates H3.3S31 in the gene body (Thorne et al., 2012), so that we anticipated 
a similar function for PIM1 and hypothesised that H3.3S31 might be phosphorylated 
along the NPM1 and GNL3 genes. To test these assumptions, primers were designed 
over the whole lengths of both genes and ChIP was performed with different 
antibodies. 
For NPM1, ChIP was done using chromatin from both Raji and Ramos cells (Figure 
4.8). PIM1 was mainly bound to the +1 kb E-box-containing region of the gene in both 
cell types, but could also be found enriched in the gene body more than in upstream 
regions of the NPM1 gene, matching the POL II profile (Figure 4.8 A, C). Yet, no PIM1 
peak was seen at the 3’ end of the gene (NPM1 +24). Similarly, MYC was only bound 
to the +1 kb E-box-containing region of the NPM1 gene in both cell lines (Figure 4.8 B). 
Total POL II was also enriched around the +1 kb region and decreased over the length 
of the gene (Figure 4.8 C). 
A similar pattern was seen at the GNL3 gene in both Raji and OCI-Ly10 cells. PIM1 
peaked at the +0.1 kb E-box-containing site and its signal declined with distance from 
this region (Figure 4.9 A). Again, no peak was detected at the 3’ end of the gene 
(GNL3 +9). MYC was also only bound to the +0.1 kb region of the GNL3 gene in both 
cell lines (Figure 4.9 B). Any signal detected in other regions was most likely due to the 
close proximity of the -0.5 kb and +0.4 kb primer pairs to the binding site at +0.1 kb. 
Total POL II was enriched both in the upstream and downstream promoter regions 
(-0.5 kb to +0.1 kb) (Figure 4.9 C). 
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Figure 4.8 PIM1, MYC and POL II occupancy of the NPM1 gene.  
ChIP was performed in Raji and Ramos cells with antibodies against PIM1 (A), 
MYC (B) and POL II CTD (C). Primer pairs in different regions of the NPM1 gene 
were used for qPCR. A qPCR results are normalised to input and the 
NPM1 -36 kb region. For some regions in Raji cells, two independent 
experiments were performed, whereas only one experiment was done in Ramos 
cells. B qPCR results are shown normalised to input and the NPM1 -36 kb region. 
Results of one experiment are shown for each cell line. C Results are normalised 
to input and the +4 kb region of the NPM1 gene. One experiment was performed 
in each cell line. PIM1 and POL II show overlapping profiles for the NPM1 gene in 
both cell lines, while MYC binding is restricted to the NPM1 +1 kb site. 
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Figure 4.9 PIM1, MYC and POL II occupancy of the GNL3 gene.  
ChIP was carried out using chromatin from Raji and OCI-Ly10 cells and 
antibodies against PIM1 (A), MYC (B) or POL II CTD (C). Eluted gDNA was then 
subjected to qPCR using primer pairs in different regions of the GNL3 gene. 
A qPCR results were normalised to input and the GNL3 -3.5 kb region. For Raji 
cells, means and sd of six independent experiments are shown and one 
experiment was done in OCI-Ly10 cells. B Results are shown normalised to input 
and the GNL3 -3.5 kb region. Means and sd of five independent experiments are 
shown for Raji cells, whereas one experiment was carried out in OCI-Ly10 cells. 
C Results are normalised to input and the GNL3 -3.5 kb region. Two independent 
experiments are shown for Raji cells, one experiment was done in OCI-Ly10 
cells. PIM1, MYC and POL II show similar profiles along the GNL3 gene and 
peak in the GNL3 +0.1 kb region. 
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Next, to further analyse the transcriptional activity of the NPM1 and GNL3 genes, the 
distributions of different phosphorylated forms of POL II were analysed at these genes 
in Raji cells. ChIP was done for both the initiating (CTD S5p) and the elongating form of 
POL II (CTD S2p). As expected, POL II S5p peaked in the promoter region and around 
the PIM1/MYC-binding sites at both genes (Figure 4.10 A, C). In contrast, POL II S2p 
increased downstream of the promoter at NPM1 +4 kb and GNL3 +3.5 kb and 
remained high in the 3’ regions, which is expected for actively transcribing genes 
(Figure 4.10 B, D). 
The presence of different histone PTMs, which are indicative of actively transcribed 
genes, was also analysed at the NPM1 and GNL3 genes in Raji cells. ChIP for histone 
H3S10p was done because it is known to be targeted by PIM1 and to promote 
transcriptional elongation. H3.3S31p was analysed because it is targeted by IKKα and 
might be phosphorylated by PIM1 and histone H2BK120ub (H2Bub) was assessed as 
a mark for actively transcribed genes.  
As shown in Figure 4.11 A and Figure 4.12 A, H3 does not display any significant 
enrichments or depletions along the NPM1 or GNL3 genes. It was surprising at first 
that H3S10p was not detected around the PIM1 binding region in both genes, but only 
further downstream at NPM1 +4 kb and GNL3 +3.5 kb (Figure 4.11 B, Figure 4.12 B). 
Previous work on this mark in our group had, however, shown that the antibody is 
unable to recognise H3S10p when the adjacent K9 is also modified. Therefore, the 
ChIP was repeated with an antibody recognising the dual H3K9acS10p mark, which 
could be readily detected around the PIM1-binding site of the GNL3 gene (Figure 4.12 
C). Therefore, at the GNL3 gene, H3S10p was mainly present on histone tails that 
were also modified at the K9 residue. Interestingly, some enrichment for the H3.3S31p 
mark could also be detected around the PIM1 binding site at both the NPM1 and GNL3 
genes (Figure 4.11 C, Figure 4.12 D). As expected, H2Bub, a mark of actively 
transcribing genes, was also detected towards the 5’ end of both the NPM1 and GNL3 
genes (Figure 4.11 D, Figure 4.12 E). 
In conclusion, PIM1 and MYC show overlapping binding at both genes. Marks of 
actively transcribed genes were detected (POL II S2p, H2Bub) and H3 phosphorylation 
marks, which could be a result of PIM1 activity, were present around the PIM1-binding 
site, especially at the GNL3 gene. 
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Figure 4.10 POL II S5p and S2p occupancy of the NPM1 and GNL3 genes.  
Raji chromatin was used for ChIP with anti-POL II S5p (A, C) and S2p antibodies 
(B, D). Eluted gDNA was then subjected to qPCR with primer pairs spanning 
different regions of the NPM1 and GNL3 genes. A, B Results of one experiment 
are shown normalised to input and the NPM1 -36 kb region. C, D Means and sd 
of five independent experiments are shown normalised to input and the +0.1 kb 
(C) or +9 kb region (D). Both genes display the POL II signature of actively 
transcribed genes, with POL II S2p being detected in the gene body and at the 3’ 
end. 
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Figure 4.11 Analysis of different histone modifications at the NPM1 gene.  
ChIP was carried out using chromatin from Raji cells and antibodies against H3 
(A), H3S10p (B), H3.3S31p (C) and H2Bub (D). A The means and sd of three 
independent experiments are shown normalised to input and the +24 kb region. 
B-D Two independent experiments are plotted normalised to H3 and the +24 kb 
region. A trend towards increased H3S10p was detected downstream of the PIM1 
binding site, while H3.3S31p tended to be higher around the PIM1 binding site 
(NPM1 +1 kb). H2Bub was enriched downstream of the TSS in the gene body, as 
would be expected for an actively transcribed gene. 
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Figure 4.12 Analysis of different histone modifications at the GNL3 gene. 
Chromatin from Raji cells was used for ChIP with antibodies against H3 (A), 
H3S10p (B), H3K9acS10p (C), H3.3S31p (D) and H2Bub (E). A The means and 
sd of five independent experiments are shown normalised to input and the +9 kb 
region. B, C, D Results are presented as means and sd of three independent 
experiments and are normalised to H3 and the -3.5 kb region of GNL3. E Results, 
plotted as means and sd of three independent experiments, are normalised to H3 
and the -6.5 kb region. While H3S10p showed a moderate increase downstream 
of the PIM1 binding site, H3K9acS10p and H3.3S31p peaked around the 
promoter region. Both S10 and S31 might be targeted by PIM1 in this area. A 
trend towards increased H2Bub was detected downstream of the promoter, 
indicating that GNL3 is actively transcribed. 
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 Inhibition of transcription led to increased binding of PIM1 to 
the GNL3 promoter 
As described earlier, Thorne et al. discovered that IKKα binds to the POL II CTD 
preferentially when it is phosphorylated on S2. IKKα is then loaded onto the chromatin, 
which requires its binding to HP1γ. Because PIM1 can also bind HP1γ, we reasoned 
that PIM1 might also interact with the POL II CTD. Consistently, PIM1 occupancy was 
detected further into the 5’ regions of the NPM1 and GNL3 genes, whereas MYC was 
more restricted to its binding site (Figure 4.8 A, B, Figure 4.9 A, B). In the case of IKKα, 
treatment with the transcription elongation inhibitor 5,6-Dichloro-1-β-D-
ribofuranosylbenzimidazole (DRB) inhibited its enrichment at the Tnf gene after LPS 
treatment (Thorne et al., 2012). The question was therefore, whether a similar 
mechanism could be observed for PIM1 at the GNL3 gene.  
As shown in Figure 4.13 A, POL II was efficiently depleted from the gene body and at 
the 3’ end of GNL3 after 1 h of DRB treatment (compare w/o DRB to DRB), indicating 
an effective block of transcription elongation. At the same time, PIM1 occupancy 
increased in the promoter region, but did not change in the gene body or at the 3’end of 
the gene (Figure 4.13 B). Therefore, active elongation was not required for PIM1 
binding to the GNL3 gene. In contrast, active transcription might lead to a dynamic 
turnover of PIM1 at the GNL3 +0.1 region.  
This is very different to the observation made for IKKα at the Tnf gene, where DRB 
resulted in decreased recruitment to the chromatin. Hence, the role of PIM1 at the 
GNL3 gene is most likely different from the role of IKKα at the Tnf gene after LPS 
stimulation. This could be explained by the different transcriptional activities. Whereas 
the GNL3 gene is constitutively expressed, Tnf is normally silent but shows rapid 
induction kinetics. Therefore, the rates of transcription and the requirements for 
chromatin remodelling will be very different at both genes, so that distinct mechanisms 
of transcriptional regulation have to be in place. Additionally, the increased recruitment 
of PIM1 to its binding site upon transcriptional stalling and its induction by certain 
stressors (see section 4.2), might implicate this protein in the transcriptional stress 
response pathway. 
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Figure 4.13 Effects of DRB on PIM1 levels at the GNL3 gene.  
Raji cells were left untreated (w/o DRB) or were treated with DRB for 1 h (DRB), 
then washed extensively and released in fresh medium for 1 h (DRB + 1h). ChIP 
was performed with anti-POL II (A) or anti-PIM1 (B). Two independent 
experiments are shown. While POL II was depleted from the gene body, there 
was a trend towards increased binding of PIM1 in the promoter region of GNL3. 
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5 GNL3 as a transcriptional target of PIM1 and MYC 
 The GNL3 oncogene as a possible PIM1-regulated gene 
Several studies have described the GNL3 protein (also called nucleostemin) as an 
oncoprotein, which shows high expression in stem and tumour cells (Beekman et al., 
2006; Lin et al., 2010; Liu et al., 2004; Yaghoobi et al., 2005). It can promote cell 
proliferation and survival in both p53-dependent and -independent ways (Jafarnejad et 
al., 2008; Lo et al., 2014; Ma & Pederson, 2007; Meng et al., 2008; Nikpour et al., 
2009; Rahmati et al., 2014; Romanova et al., 2009). GNL3 had been shown to be a 
direct transcriptional target of MYC and Gnl3 haploinsufficiency is sufficient to inhibit 
MYC-dependent lymphomagenesis in mice (Zwolinska et al., 2011), making this gene 
an important contributor to MYC-dependent tumourigenesis. Strikingly, cardiomyocyte-
specific overexpression of PIM1 in mice leads to upregulation of GNL3 (Siddiqi et al., 
2008). As PIM1 binds to the GNL3 promoter (see sections 4.4, 4.5), this upregulation 
might be caused by a direct effect of PIM1 on GNL3 transcription.  
Additionally, GNL3 is a host gene for three intronic small nucleolar RNAs (snoRNAs): 
SNORD19, SNORD19B and SNORD69 (Figure 5.1). Depending on sequence 
conservation, snoRNAs are grouped into two classes: box C/D snoRNAs (like 
SNORD69, SNORD19 and SNORD19B) and box H/ACA snoRNAs (Balakin et al., 
1996). Their canonical function is to guide modification of rRNAs, tRNAs and small 
nuclear RNAs (snRNAs) (Bratkovič & Rogelj, 2011; Kiss, 2002). While C/D box 
snoRNAs guide 2’-O-ribose methylation, H/ACA box snoRNAs guide pseudouridylation 
(Kiss, 2002). However, many snoRNAs are complementary to mRNAs and especially 
box C/D snoRNAs can have miRNA-like functions or even regulate alternative splicing 
(Brameier et al., 2011; Kishore & Stamm, 2006; Kishore et al., 2010). These properties 
make snoRNAs potentially oncogenic, so that it could be important to study their 
regulation in the context of lymphoma. Processing of snoRNAs can occur via a 
splicing-dependent or a splicing-independent pathway (Hirose & Steitz, 2001; Hirose et 
al., 2003; Hirose et al., 2006). As PIM1 modulates the activity of HP1γ (Koike et al., 
2000), which has in turn been shown to regulate splicing (Saint-André et al., 2011), it is 
conceivable that PIM kinases might regulate processing of these snoRNAs. One can 
also imagine that PIM kinases could regulate the splicing-independent processing of 
these small RNAs. Accordingly, GNL3 seems to be an essential, possibly PIM-
regulated oncogene, so that, in the following, this study focussed on the regulation of 
the GNL3 gene and its intronic snoRNAs. 
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 Expression of GNL3, SNORD69, SNORD19 and 
SNORD19B in different BCL cell lines 
First, expression of GNL3, SNORD69, SNORD19 and SNORD19B was assessed 
by real time RT-PCR in OCI-Ly3, Raji, Ramos and SUDHL6 cells (Figure 5.3 A). 
snoRNA expression was normalised to hnRNA expression, as the primers will also 
amplify the GNL3 hnRNA and that way, a specific increase in snoRNAs over 
primary transcript can be detected (Figure 5.2). 
 
Figure 5.2 Amplification of GNL3 hnRNA and snoRNAs by the snoRNA 
primers.  
To specifically measure the increase in snoRNAs, their expression was 
normalised to that of an amplicon that is only present in the primary transcript. 
 
GNL3 mRNA levels were variable between experiments, but average expression of 
GNL3 was similar in all four cell lines and did therefore not correlate with the 
average PIM1 or PIM2 expression levels (compare Figure 5.3 A with Figure 4.2). 
Especially in OCI-Ly3 and SUDHL6 cells, SNORD69 expression levels also varied 
between experiments (Figure 5.3 A). However, there was again no correlation 
between average PIM1 or PIM2 and snoRNA expression levels in the different cell 
lines. 
Yet, when the expression of the GNL3 mRNA was compared to that of PIM1 in 
different experiments done in the same cell line, there was a significant correlation 
between their expression levels in both OCI-Ly3 and Raji, but not SUDHL6 cells 
(Figure 5.3 B). No significant correlations were observed for SNORD69, SNORD19 
or SNORD19B. However, a trend towards negative correlation between PIM1 and 
SNORD69 or SNORD19B and a trend towards positive correlation between PIM1 
and SNORD19 expression were seen (Figure 5.3 C - E). In conjunction with the 
observed binding of PIM1 to the GNL3 promoter, these data suggest a direct link 
between PIM1 and GNL3 expression, which might be due to a direct regulation of 
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GNL3 by PIM kinases. Further, both genes might be regulated by the same 
upstream factors and both mechanisms are not mutually exclusive. 
 
Figure 5.3 Expression of GNL3 and intronic snoRNAs in B cell lymphoma cell 
lines.  
A Expression of GNL3 and its intronic snoRNAs was assessed by RT-qPCR. 
Results were normalised to TBP or GNL3 hnRNA, respectively. The means 
and sd of n experiments are plotted, with n = 3 for OCI-Ly3, n = 4 for Raji and 
n = 5 for SUDHL6. Results of two independent experiments are plotted for 
Ramos cells. Expression levels of GNL3 and the snoRNAs were variable 
between experiments conducted in the same cell line, but were on average 
similar between different cell lines. B - E Normalised expression levels of 
GNL3, SNORD69, SNORD19 and SNORD19B were plotted against PIM1 
expression levels in OCI-Ly3, Raji and SUDHL6 cell lines. Linear regression 
was performed to analyse the correlation between GNL3 and PIM1 
expression. p values were calculated using a free software (Soper DS, 2014) 
and the trend line is only depicted for p < 0.05. A positive correlation between 
PIM1 and GNL3 expression levels was seen in OCI-Ly3 and Raji cells. There 
was a trend towards a positive correlation in SUDHL6 cells and between 
SNORD19 and PIM1 in all cell lines. Conversely, a trend towards negative 
correlation between PIM1 and SNORD69 or SNORD19B was seen. 
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 Effects of potential PIM kinase inhibitors on the 
expression of possible PIM1 target genes 
The data so far indicate that PIM kinases might directly regulate GNL3 expression. 
Thus, the influence of PIM kinase inhibition on GNL3 mRNA and hnRNA as well as 
SNORD69, SNORD19 and SNORD19B levels was determined. hnRNA expression 
was assessed as a more direct readout of transcription to avoid effects of mRNA 
stability that might mask changes in transcription. The mRNA levels of the other 
possible PIM target genes -– LYN, SEPX1, ARID3A, BCL2 and CD44 – were also 
measured, because on the basis of the ChIP-qPCR data, it was not possible to 
exclude binding of PIM1 and MYC to promoter or enhancer regions of these genes. 
Therefore, PIM kinases might still directly regulate their transcription.  
Raji, Ramos, OCI-Ly3, SUDHL6 and OCI-Ly19 cells were treated with SMI4a, 
inh VI, Quercetagetin or equivalent amounts of DMSO for 2 h to 24 h. Short periods 
of drug treatment were chosen, so that the outcome observed would be direct and 
not caused by secondary effects. Yet, no changes in GNL3 mRNA or hnRNA 
expression were observed, even after 11 h or 24 h of inhibitor treatment in Raji, 
Ramos, OCI-Ly3 or SUDHL6 cells using any of the three inhibitors (Figure 5.4). 
Similarly, expression of the intronic snoRNAs did not change significantly after 
SMI4a or inh VI treatment in any of the four cell lines (Figure 5.5). LYN, SEPX1, 
ARID3A and BCL2 expression was also mostly unchanged, but showed a trend 
towards increased expression in Raji cells (Figure 5.6, Figure 5.7 A, B). Ramos 
cells did not express detectable levels of BCL2. Similarly, CD44 was only 
expressed in OCI-Ly3 and OCI-Ly19 cells, but mRNA levels were unchanged after 
PIM inhibitor treatment (Figure 5.7 C). OCI-Ly19 was the only cell line, in which 
GNL3, LYN, SEPX1 and BCL2 were strongly downregulated 4 h and 6 h after 
treatment with Quercetagetin. This was, however, most likely not due to PIM 
inhibition, as these cells did not express detectable PIM1 or PIM2 levels (Figure 4.2 
A), but due to off-target effects and the strong toxic effect of Quercetagetin on OCI-
Ly19 cells. In conclusion, short-term inhibition of PIM kinases did not inhibit 
expression of possible PIM target genes in BCL cell lines. 
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Figure 5.4 Effects of PIM kinase inhibitors on GNL3 expression.  
The cells were plated in triplicate wells of 6-well plates and treated with 
DMSO, 40 μM SMI4a, 40 μM inh VI or 40 μM Quercetagetin for indicated 
times. Expression of GNL3 mRNA (A) and hnRNA (B) was analysed by RT-
qPCR. The data are shown as means of one experiment conducted in 
triplicate wells or means and sd of three independent experiments carried out 
in triplicate wells each (Raji and Ramos SMI4a, 4 h). GNL3 hnRNA 
expression was measured using the GNL3 +0.4 kb intronic primer. Expression 
was normalised to that of TBP and DMSO-treated cells. No effect of the 
inhibitors on GNL3 mRNA or hnRNA expression was detected in Raji, Ramos, 
OCI-LY3 or SUDHL6 cells, while the GNL3 mRNA was decreased in OCI-
Ly19 cells. 
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Figure 5.5 Effects of PIM kinase inhibitors on snoRNA expression.  
The cells were plated in triplicate wells of 6-well plates and treated with 
DMSO, 40 μM SMI4a or 40 μM inh VI for indicated times. Expression of 
SNORD69 (A), SNORD19 (B) and SNORD19B (C) was analysed by RT-
qPCR. The data are shown as means of one experiment conducted in 
triplicate wells or means and sd of three independent experiments carried out 
in triplicate wells each (Raji 4 h SMI4a). Results are normalised to GNL3 
hnRNA expression and to expression in DMSO-treated cells. Neither 
treatment of the cells with SMI4a nor inhibitor VI led to a change in snoRNA 
expression in any of the cell lines tested. 
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Figure 5.6 Effects of PIM kinase inhibitors on LYN and SEPX1 expression.  
The cells were plated in triplicate wells of 6-well plates and treated with 
DMSO, 40 μM SMI4a, 40 μM inh VI or 40 μM Quercetagetin for indicated 
times. LYN (A) and SEPX1 (B) mRNA levels were measured by RT-qPCR. 
The data are shown as means of one experiment conducted in triplicate wells. 
Expression was normalised to that of TBP and DMSO-treated cells. LYN 
showed a trend towards increase in inhibitor-treated Raji cells after 24 h, but 
its expression levels were unaltered at any other time point or in the other cell 
lines. In OCI-Ly19 cells, a decrease in LYN expression was observed. SEPX1 
expression also tended to increase in Raji cells after 6 and 24 h of inhibitor 
treatment, whereas it was unaltered in Ramos, OCI-Ly3 and SUDHL6 cells 
and was decreased in OCI-Ly19 cells. 
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Figure 5.7 Effects of PIM kinase inhibitors on ARID3A, BCL2 and CD44 
expression.  
The cells were plated in triplicate wells of 6-well plates and treated with 
DMSO, 40 μM SMI4a, 40 μM inh VI or 40 μM Quercetagetin for indicated 
times. ARID3A (A), BCL2 (B) and CD44 (C) expression levels were measured 
by RT-qPCR. The data are shown as means of one experiment conducted in 
triplicate wells. Results are normalised to TBP and to expression in DMSO-
treated cells. Expression of ARID3A and BCL2 showed a trend towards 
increase in Raji cells after 6 and 24 h of inhibitor treatment, whereas it 
remained unaltered in the other cell lines. BCL2 even decreased in OCI-Ly19 
cells. CD44 expression was unchanged in OCI-Ly3 and OCI-Ly19 cells after 
inhibitor treatment. 
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Because PIM kinase inhibition did not alter the expression of any of the possible 
target genes in BCL cells, the effect of the inhibitors on known PIM target genes 
was tested. PIM1 had been shown to be essential for the serum-induced stimulation 
of ID2 and FOSL1 expression in HEK293 cells (Zippo et al., 2007). Therefore, this 
experiment was reproduced and the effect of the three inhibitors on this response 
was analysed. After serum shock, only upregulation of FOSL1, but not ID2, was 
seen in our cells (Figure 5.8 A). Surprisingly, this induction was not inhibited when 
cells were treated with any of the three inhibitors over night before the serum shock 
(Figure 5.8 B). Therefore, the inhibitors might not be effective enough to prevent 
PIM-dependent gene expression and in the following, overexpression and 
knockdown of PIM kinases were used to evaluate their functions regarding the 
regulation of gene expression. 
 
Figure 5.8 Effect of PIM kinase inhibitors on serum-induced FOSL1 
expression in HEK293 cells. 
A HEK293 cells were serum shocked with 33% FCS and gene expression 
was analysed by RT-qPCR. Results were normalised to TBP and expression 
before serum shock (0 min). Two independent experiments conducted in 
triplicate wells of 6-well plates are shown. While FOSL1 was induced 90 and 
180 min after serum shock, ID2 was not. B HEK293 cells were treated with 
DMSO, SMI4a, inh VI or Quercetagetin overnight and then serum shocked 
with 33% FCS for 180 min. Gene expression was assessed by RT-qPCR and 
normalised to TBP and DMSO-treated cells. Two independent experiments 
conducted in triplicate wells of 6-well plates are shown. None of the inhibitors 
tested blocked the induction of FOSL1, although this induction had previously 
been described as PIM1-dependent (Zippo et al., 2007). Therefore, we 
questioned whether the inhibitors were targeting PIM1 at all. 
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 PIM1 overexpression did not alter GNL3 or snoRNA 
expression 
First, Raji and SUDHL6 cells were transfected with the pCMV6-XL4-PIM1 vector 
and PIM1 expression levels were analysed by western blot or qPCR. These two cell 
lines were chosen, because they express different levels of endogenous PIM1 and 
might therefore show different phenotypes upon PIM1 overexpression. As the 
transfected construct contains the full length PIM1 cDNA, including 5’ and 3’ UTRs, 
overexpression of both the 34 kDa and 44 kDa PIM1 isoforms was seen (Figure 5.9 
A). 48 h after transfection, cells were harvested in TRIzol, RNA was prepared and 
expression was measured by RT-qPCR. The experiment was repeated twice in Raji 
cells and four times in SUDHL6 cells with variable outcomes (Figure 5.9 C, E). 
Although, relative PIM1 expression levels, as measured by qPCR, were always 
higher than in untransfected cells, GNL3 and GNL3 hnRNA were either up- or 
downregulated (Figure 5.9 D, experiments 1 and 2, Figure 5.9 F). The amount of 
PIM1 overexpression did not correlate with the level of GNL3 expression, 
suggesting that overexpression of full-length PIM1 did not directly affect GNL3 
expression. 
Further, SNORD69, SNORD19 and SNORD19B expression levels were unaltered 
(Figure 5.9 C, E). The only highly significant change was a consistent 
downregulation of the PIM2 mRNA in SUDHL6 cells and a trend towards 
downregulation in Raji cells (Figure 5.9 C, E). As PIM1 and PIM2 have several 
shared substrates and PIM2 has been shown to compensate for PIM1 knockout 
during lymphomagenesis (van der Lugt et al., 1995), it can be anticipated that 
overexpression of PIM1 might lead to downregulation of PIM2. Therefore, PIM2 
downregulation served as a positive control for effective PIM1 overexpression 
(Figure 5.9 C, E). 
The PIM1 transcript is unstable due to AU-rich elements in the 3’ UTR (H.K. Kim et 
al., 2012), which might inhibit high level PIM1 protein expression. Therefore, a 
3xflag-tagged construct, containing the coding DNA sequence (CDS) only, was 
cloned into pCMV-SPORT6 and overexpressed in Raji cells. Furthermore, a kinase-
dead variant, carrying a D186A mutation, was cloned and overexpressed as a 
control. Western blot confirmed that both constructs were overexpressed and 
localised to the nucleus and cytoplasm (Figure 5.9 B). However, the kinase-dead 
variant seemed to be unstable. Although sufficient overexpression of PIM1 was 
-163- 
 
achieved compared to pGL2-transfected control cells, GNL3 and GNL3 hnRNA 
expression levels were unaltered (Figure 5.9 D, experiment 3). 
In conclusion, there was no evidence for a direct regulation of GNL3 by PIM1 from 
the overexpression experiments. However, PIM1 is recruited to the DNA by MYC, 
which might be a limiting factor. ChIP after PIM1 overexpression, using either the 
PIM1 or flag antibodies, did not pull down enough gDNA to be detected by qPCR, 
which might be due to the saturation of the antibody by non-chromatin bound, 
overexpressed PIM1. Alternatively, cell numbers might have been too low due to 
the observed toxicity of the transient transfection. Therefore, although 
overexpressed PIM1 was nuclear, it could not be established whether it was also 
binding to DNA. If it is not recruited to the GNL3 promoter, this might explain why 
no regulation of GNL3 or snoRNA expression was observed in PIM1 
overexpressing cells. For those reasons, we next attempted to knock down PIM 
kinases and MYC in Raji cells. 
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Figure 5.9 Effects of PIM1 overexpression on GNL3 and snoRNA expression. 
A Overexpression of full-length PIM1 in pCMV6-XL4 in Raji cells. The blot 
shown is representative of three independent experiments. B Overexpression 
of 3xflag-PIM1 and kinase-dead 3xflag-PIM1 in pCMV-SPORT in Raji cells. 
Western blot was done after nuclear-cytoplasmic fractionation. C RT-qPCR 
results of GNL3, SNORD69, SNORD19, SNORD19B and PIM2 expression in 
Raji cells. The means and sd of three experiments conducted in triplicate 
wells of 6-well plates are shown for GNL3, GNL3 hnRNA, SNORD69 and 
SNORD19. Two independent experiments conducted in triplicate wells of 6-
well plates are shown for SNORD19B and PIM2. Results were normalised to 
TBP or GNL3 hnRNA and control-transfected cells. D Relative amounts of 
PIM1 or GNL3 expression in Raji cells in different experiments. E Expression 
levels of GNL3, the snoRNAs and PIM2 in SUDHL6 after PIM1 
overexpression. The qPCR results are normalised to mock or control 
transfected cells and TBP or GNL3 hnRNA. The means and sd of at least 
three independent experiments conducted in triplicate wells of 6-well plates 
are plotted. ** p < 0.01 as determined by Student’s t test. F Relative amounts 
of PIM1 or GNL3 expression in different experiments in SUDHL6 cells. In 
conclusion, PIM1 overexpression did not influence GNL3 or snoRNA 
expression in Raji or SUDHL6 cells, while it induced a decrease in PIM2 
mRNA levels.  
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 Knockdown of MYC and PIM kinases 
Because the ChIP after PIM1 overexpression was not successful, we could not 
conclusively determine whether overexpressed PIM1 was recruited to the GNL3 
promoter and whether it regulates GNL3 transcription or not. Our hypothesis was 
that the amount of endogenous PIM1 might be sufficient to drive maximum 
expression of GNL3 and that an increase in the PIM1 levels, through 
overexpression, cannot further elevate GNL3 transcription. Therefore, an effect on 
GNL3 expression might only be observed after knockdown of PIM kinases. 
First, a transient transfection approach was chosen to knock down PIM1 or PIM2. 
Three shRNAs against PIM1 and three shRNAs against PIM2 were cloned into the 
pMSCV-miR30 vector and transiently transfected into Raji cells. However, 
transfection efficiency was too low to achieve a detectable knockdown. Further, 
transfection of these shRNAs into HEK293 cells did not result in knockdown of 
PIM1 or PIM2. Therefore, we decided to generate cells that were stably transfected 
with PIM1 or PIM2 shRNAs. Evidence from the literature suggested that knockdown 
of target proteins in Raji cells works best, when the shRNA is not expressed in a 
miR30 context, but as a classic shRNA from a U6 promoter (Lebbink et al., 2011). 
Further, an inducible system was preferred in this study, as knockdown of PIM 
kinases was expected to reduce cell viability, so that the generation of stable clones 
would be impossible when the shRNA is expressed constitutively. Hence, the 
pLKO_IPTG_3xLacO vector and validated shRNAs against PIM1 (shPIM1_1, 
shPIM1_2), PIM2 (shPIM2_1, shPIM2_2) and MYC (shMYC) were chosen and 
transfected into Raji cells. 
After a first attempt to generate stable knockdown cells from a mixed population 
failed, single cell clones were selected, expanded and tested for efficient 
knockdown. shRNA expression was induced with 5 mM IPTG. Only shPIM1_1 and 
shPIM2_1 clones showed knockdown of PIM1 or PIM2, respectively, whereas the 
other two PIM shRNAs were not effective. Also, PIM1/2 double knockdown clones 
were generated. Of note, these often lost the ability to knock down PIM1 after about 
two weeks in culture, but retained their ability to knock down PIM2. The clones used 
in this study were: shMYC clones 2 and 4, shPIM1_1 clones 1B, 2B and 4B, 
shPIM2_1 clones 1, 4 and 8 and the double knockdown clones shPIM1_1/2_1 
clones 6 and 8. 
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 Knockdowns of MYC, PIM1 or PIM2 differentially affected 
Raji cell viability 
First, the effect of PIM1, PIM2 or MYC knockdown on the viability of Raji cells was 
assessed over a time of ten days. Cell number and protein expression of IPTG-
treated cells were compared to untreated cells. Knockdown of PIM1 was seen in 
IPTG-treated cells from day 4 onwards (Figure 5.10 A), while expression of PIM2 
and MYC was unchanged. However, no effect on cell viability was detected when 
knockdown cells were compared to their untreated counterpart (Figure 5.10 B, 
Figure 5.11 A). The experiment was conducted twice with shPIM1_1 clone 2B and 
once with shPIM1_1 clone 4B and although the latter showed a more efficient 
knockdown, the outcome on viability was the same. Therefore, PIM1 is either 
dispensable for Raji cell viability or the residual low amount of PIM1 is sufficient to 
fulfil its essential cellular functions. 
Knockdown of PIM2 was more efficient than PIM1 knockdown and occurred from 
day 2 onwards (Figure 5.10 C). Interestingly, a moderate upregulation of MYC was 
seen after knockdown. Cell viability was significantly reduced on day 8 and day 10 
in these cells (Figure 5.10 D, Figure 5.11 B), suggesting that, in Raji cells, PIM2 
plays a more important role than PIM1. Results were comparable between different 
clones, the experiment was done once with each of the shPIM2_1 clones (1, 4 and 
8). MYC knockdown was very efficient (Figure 5.10 E) and resulted in a rapid loss 
of cell viability compared to untreated cells (Figure 5.10 F, Figure 5.11 C). This was 
expected, as BL cells are known to be obligatory dependent on MYC function. As 
Raji cells did, however, grow independent of the level of PIM1, the knockdown 
results favour a model, in which PIM1 is dispensable for MYC-dependent 
transcription in these cells under normal growth conditions. 
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Figure 5.10 Consequences of PIM1, PIM2 or MYC knockdown for the number 
of Raji cells. 
A, C, E Western blots showing knockdown of PIM1, PIM2 and MYC after 
treatment with 5 mM IPTG in one representative clone each. B, D, F Cell 
numbers, as determined by MTT assay, of untreated and IPTG-treated cells 
were normalised to untreated cells. The means and sd of three independent 
experiments conducted in duplicate wells of six-well plates are shown for 
shPIM1_1 days 0 to 6 and shPIM2_1 days 8 and 10. For all other time points 
the results of two independendent experiments are plotted individually. 
Knockdown of PIM1 did not reduce Raji cell number compared to control 
cells, whereas knockdown of PIM2 showed an effect on cell number on days 
8 and 10 and MYC knockdown cells showed a trend towards a reduction in 
cell number already on day 4. 
-168- 
 
 
Figure 5.11 Growth curves of different knockdown clones. 
Stably transfected Raji cell clones were seeded into duplicate wells of 6-well 
plates and treated with 5 mM IPTG or were left untreated. Cell numbers were 
determined every second day using an MTT assay. A Three experiments 
were done with different shPIM1 clones, but cell viability was unaffected by 
PIM1 knockdown in any of these experiments. B Two experiments were done 
with different shPIM2_1 clones and in both, cell number was strongly reduced 
in IPTG-treated compared to untreated cells on days 8 and 10. C Two 
experiments were done with the shMYC clone 4 and cell number was strongly 
reduced in IPTG-treated cells. 
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 Knockdowns of MYC, PIM1 or PIM2 did not alter GNL3 or 
snoRNA expression 
Next, the effects of PIM1, PIM2, PIM1/2 double and MYC knockdowns on the 
expression of GNL3 and its snoRNAs were analysed. PIM1 knockdown in three 
different clones (2B, 1B, 4B), which showed different levels of protein knockdown 
(Figure 5.12 A, B), did not result in any significant change in GNL3 or GNL3 hnRNA 
expression (Figure 5.12 E). Also, the PIM1 mRNA was only slightly reduced, 
probably due to a compensatory upregulation of PIM1 transcription (Figure 5.12 C), 
and PIM2 and MYC expression were unaffected (Figure 5.12 C, D). The shPIM2_1 
clones 1 and 4 both showed strong reduction in PIM2 expression on both protein 
and mRNA level (Figure 5.13 A, B). However, no consistent changes in expression 
of PIM1, MYC, GNL3 or GNL3 hnRNA were seen (Figure 5.13 B). Because PIM 
kinases have very similar functions and substrates, it is possible that knockdown of 
only PIM1 or PIM2 is not sufficient to see effects on the GNL3 expression levels. 
Therefore, PIM1/2 double knockdown was used to investigate this idea. But, 
although both PIM1 and PIM2 were knocked down efficiently (Figure 5.14 A), only a 
very mild effect on GNL3 mRNA and no effect on GNL3 hnRNA expression were 
observed (Figure 5.14 B).  
MYC might recruit other cofactors that allow for efficient transcription to occur. 
Thus, two shMYC clones with different knockdown efficiencies were analysed 
(Figure 5.15 A). As shown in Figure 5.10 and Figure 5.11, MYC knockdown was 
sufficient to inhibit cell growth. It was therefore very surprising not to see any effect 
on GNL3, GNL3 hnRNA, SNORD69, SNORD19 or SNORD19B expression (Figure 
5.15 B). Yet, MYC knockdown did have an effect: a compensatory upregulation of 
MYC, PIM1 and PIM2 mRNAs was detected (Figure 5.15 B). In conclusion, 
although PIM1 and MYC were bound to the GNL3 promoter, there was no evidence 
that they regulated GNL3 expression under normal growth conditions. 
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Figure 5.12 Effects of PIM1 knockdown on GNL3 expression.  
  A, B Western blots showing knockdown of PIM1 after treatment with 5 mM 
IPTG for indicated times in different clones. A and B are technical duplicates 
from different wells of 6-well plates. C, D Expression of PIM1, PIM2 and MYC 
in cells in A. Averages of technical duplicates are shown and qPCR results 
are normalised to TBP and non-IPTG-treated cells. E Expression of GNL3 
mRNA and hnRNA. Averages of technical duplicates, and for day 6 means 
and sd of the three different clones in A and B are shown. Results are 
normalised to TBP and untreated cells. Although PIM1 was knocked down, 
this did not result in any changes in GNL3 mRNA or hnRNA expression. 
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Figure 5.13 Influence of PIM2 knockdown on GNL3 expression.  
A Western blot showing PIM2 knockdown. The blot is representative of two 
different shPIM2_1 clones. B Expression of PIM2, PIM1, MYC, GNL3 and 
GNL3 hnRNA was measured by qPCR. Two independent experiments, 
conducted in duplicate wells of 6-well plates, are graphed. The results were 
normalised to TBP and non-IPTG-treated cells. Although PIM2 knockdown 
was very efficient on both the protein and mRNA level, no change in GNL3 
mRNA or hnRNA expression was seen. 
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Figure 5.14 Effect of PIM1/2 double knockdown on GNL3 expression.  
A Western blot confirming knockdown of both PIM1 and PIM2 in shPIM1/2 
double knockdown clones. A and B are technical duplicates from different 
wells of 6-well plates. B Expression of GNL3 and GNL3 hnRNA after double 
knockdown as determined by qPCR. Two independent experiments, carried 
out in duplicate wells of 6-well plates each, are depicted. The expression was 
normalised to that of TBP and non-IPTG-treated cells. Double knockdown 
was very efficient but only a small trend towards reduction of GNL3 
expression and no change in hnRNA levels could be observed. 
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Figure 5.15 Influence of MYC knockdown on GNL3 expression.  
A Western blots showing knockdown of MYC in two different single cell-
derived clones. A and B are cells from duplicate wells of 6-well plates. B RNA 
expression is plotted normalised to TBP or GNL3 hnRNA and non-IPTG-
treated cells. Results from the two independent clones in A are shown. 
Although MYC knockdown was efficient and strongly reduced cell viability, it 
did not affect GNL3 mRNA or hnRNA levels or the expression of the intronic 
snoRNAs. 
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 PIM1, PIM2, PIM1/2 double and MYC knockdown altered 
protein binding to the GNL3 promoter 
Because no change in GNL3 or snoRNA expression was detected, we asked 
whether the knockdowns were sufficient to reduce binding of PIM1 and MYC to the 
GNL3 promoter. ChIP confirmed that knockdown of PIM1 significantly reduced its 
binding to the GNL3 promoter compared to non-IPTG-treated cells (Figure 5.16 A). 
Interestingly, PIM2 knockdown led to an increase in PIM1 recruitment, suggesting 
an inhibitory function of PIM2 (Figure 5.16 A). As expected, PIM1/2 double 
knockdown also decreased PIM1 binding to the GNL3 promoter. But surprisingly, 
MYC knockdown had no effect on the presence of PIM1 at the GNL3 +0.1 site, 
although MYC was reduced in this region (Figure 5.16 A, B). This suggests that 
PIM1 can be recruited to the chromatin independent of MYC. In the reciprocal 
experiment, knockdown of the PIM kinases did not alter MYC occupancy at the 
GNL3 promoter (Figure 5.16 B).  
No significant change in H3K9acS10p was seen in any of the conditions tested, 
although there was a trend towards increase after PIM2 knockdown, consistent with 
the increased binding of PIM1, and a trend towards decrease in MYC knockdown 
cells (Figure 5.16 C). This suggests that another kinase distinct from PIM1 and 
PIM2 can replace PIM1 to phosphorylate H3S10 in PIM1 and PIM1/2 double 
knockdown cells. As a marker for active elongation, POL II S2p was also analysed 
(Figure 5.16 D). Its presence in the promoter region and at the 3’ end of GNL3 was 
largely unaltered; only knockdown of MYC led to a slight reduction in POL II S2p at  
Figure 5.16 Effects of PIM1, PIM2, PIM1/2 double and MYC knockdown on 
protein occupancy of the GNL3 promoter.  
 ChIP was performed in untreated or IPTG-treated pLKO-shRNA-transfected 
cells. Antibodies against PIM1 (A), MYC (B), H3K9acS10p (C) or POL II S2p 
(D) were used. The results are normalised to input and control regions (GNL3 
-3.5 and GNL3 +9 for PIM1 and MYC (A, B), CTCF1 for H3K9acS10p (C) and 
CTCF1 and GNL3 -3.5 for POL II S2p (D)) and plotted relative to untreated 
cells. Means and sd of three independent experiments are shown for 
shPIM1_1 and shPIM2_1, one experiment was done for shPIM1_1/2_1 and 
two independent experiments are plotted for shMYC. For n = 3 experiments, 
two-tailed Student’s t test was performed: * p < 0.05. PIM1 binding to the 
GNL3 promoter was reduced in PIM1 knockdown cells, but increased in PIM2 
and one of the MYC knockdowns. MYC binding to the promoter was largely 
unaffected by PIM kinase knockdown, but tended to be reduced by about 50% 
after MYC knockdown. However, H3K9acS10p was mostly unaltered in all the 
knockdown cells, a trend towards increased H3K9acS10p was only observed 
after PIM2 knockdown. Similarly, POL II S2p occupancy was unchanged in 
knockdown cells. A trend towards reduced POL II S2p occupancy was only 
observed in MYC knockdown cells at the GNL3 +9 kb region. 
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the 3’ end. This did, however, not result in any change in GNL3 expression (Figure 
5.15 B). 
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 The pan-PIM kinase inhibitor AZD1208 
The previous experiments suggested that PIM1 knockdown alone does not affect 
viability of Raji cells. It was, however, difficult to maintain double PIM1/2 knockdown 
cells over a prolonged period of time, so that I was unable to assess the effect of 
the double knockdown on cell viability. Further, the effect of specific PIM kinase 
inhibition on the ABC-DLBCL cell lines was still of interest, but the PIM kinase 
inhibitors used in section 4.3 and 5.3 were probably not specifically targeting PIM 
kinases and it was unclear, whether they exerted their effects on cell viability via 
PIM kinase inhibition. Consistently, SMI4a inhibited BAD phosphorylation only in 
OCI-Ly3, but not in Raji, Ramos or OCI-Ly10 cells (Figure 5.17). 
Therefore, a novel and more potent pan-PIM kinase inhibitor, AZD1208, was used 
to study the effect of pan-PIM kinase inhibition on cell viability, gene expression and 
chromatin structure at the GNL3 gene. Importantly, this inhibitor has been 
extensively tested against a panel of 442 kinases, and at a concentration of 1 μM 
only 13 other kinases were inhibited 50% or more, but the affinity of the inhibitor to 
PIM kinases was at least 43-fold greater than to any other kinase (Keeton et al., 
2014). 
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Figure 5.17 Effects of SMI4a on protein expression and BAD phosphorylation 
in B cell lymphoma cell lines. 
Raji (A), Ramos (B), OCI-Ly10 (C) and OCI-Ly3 (D) cells were cultured in T25 
flasks and treated with DMSO or 40 μM SMI4a. Protein samples were 
harvested at indicated times. SMI4a did not influence BAD-S112 
phosphorylation in Raji, Ramos or OCI-Ly10 cells. Only OCI-Ly3 cells showed 
reduced pBAD. 
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 AZD1208 had only minor effects on cell viability 
First, Raji, Ramos, OCI-Ly3 and OCI-Ly10 cells were treated with different 
concentrations of AZD1208 (1 μM to 10 μM) or DMSO, respectively, and cell 
number was assessed over a time of six days. Interestingly, Raji and Ramos cells 
were mostly resistant to the drug (Figure 5.18 A, B), an inhibition of cell growth was 
seen in Ramos cells at 10 μM AZD1208 in one experiment only. Similarly, OCI-Ly3 
cells showed a moderate reduction in cell number at 5 μM and 10 μM AZD1208 and 
only OCI-Ly10 cells displayed a reduced cell number already at 1 μM AZD1208 
(Figure 5.18 C, D).  
Surprisingly, PIM kinases were already strongly inhibited in all cell lines at 1 μM 
AZD1208, as assessed by BAD-S112 phosphorylation (p-BAD) (Figure 5.19 A, B). 
This observation does not match the hypothesis that PIM kinase activity is required 
for the proliferation or survival of lymphoma cells. In Raji, OCI-Ly3 and OCI-Ly10 
cells, an upregulation or stabilisation of BAD was also seen at higher AZD1208 
concentrations (Figure 5.19 A, B). Further, a compensatory upregulation or 
stabilisation of PIM1 and PIM2 could be observed in all four cell lines (Figure 5.19 
A, C). MYC levels were also higher in inhibitor-treated compared to DMSO-treated 
cells. 
These experiments show that both BL cell lines could grow independently of PIM 
kinase activity, although they had a strong requirement for MYC activity to survive. 
Therefore, PIM kinase activity does not seem to be essential for MYC-dependent 
transcription in general in these cells. Thus, although OCI-Ly3 and OCI-Ly10 cells 
were slightly more sensitive towards PIM kinase inhibition, this is most likely not 
due to its effects on transcription but on its other cellular targets. 
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Figure 5.18 Consequences of AZD1208 treatment for the proliferation of B cell 
lymhoma lines. 
A - D Cells were seeded into duplicate wells of 6-well plates and treated with 
DMSO, 1 μM, 5 μM or 10 μM AZD1208 for indicated times. The medium was 
replaced every second day and cell number was measured by MTT assay. 
For Raji (A) and Ramos (B), two independent experiments conducted in 
duplicate wells of 6-well plates are shown and for OCI-Ly3 (C) and OCI-Ly10 
(D) the means and sd of three independent experiments, conducted in 
duplicate wells of six-well plates, are plotted. While AZD1208 did not affect 
Raji cell viability, high concentrations of AZD1208 affected Ramos cells in one 
experiment but not the other. OCI-Ly3 cell number was reduced by 5 μM and 
10 μM AZD1208, and only OCI-Ly10 cells were sensitive to 1 μM AZD1208.  
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Figure 5.19 Consequences of AZD1208 treatment for protein expression and 
BAD phosphorylation in different BCL cell lines. 
A, B Cells were seeded into T25 flasks and treated with DMSO, 1 μM, 5 μM 
or 10 μM AZD1208 for indicated times. The medium was replaced every 
second day. Aliquots were harvested and analysed by western blot. C Cells 
were seeded into T25 flasks and treated with 1 μM, 2.5 μM, 5 μM, 7.5 μM or 
10 μM AZD1208 or a respective amount of DMSO for three days. Then, 
protein expression was evaluated by western blot. 1 μM AZD1208 inhibited 
BAD phosphorylation in all cell lines tested. Further, PIM1, PIM2 and MYC 
expression were elevated, which is indicative of efficient PIM kinase inhibition 
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 AZD1208 did not affect GNL3 expression in Raji cells 
Because PIM kinase inhibition did not affect viability of the Raji BL cell line, we 
predicted that gene expression would also be unaffected. Therefore, expression of 
the GNL3 gene was assessed in Raji cells after treatment with 1 μM, 5 μM or 10 μM 
AZD1208 for one, three or seven days. As expected, GNL3 and GNL3 hnRNA 
expression were unchanged, only DMSO-treated cells showed higher GNL3 mRNA 
levels on day seven, without a change in hnRNA (Figure 5.20 A, B). Therefore, PIM 
kinase inhibition did not affect transcription of the GNL3 gene. Similarly, SNORD69 
and SNORD19 expression levels were unaltered (Figure 5.20 C, D). 
 
 
 
Figure 5.20 Effects of AZD1208 on the expression of GNL3 and snoRNAs.  
Raji cells were plated in duplicate wells of 6-well plates and treated with 1 μM, 
5 μM or 10 μM AZD1208 for indicated times. The medium was changed every 
day. RNA expression was measured by RT-qPCR and normalised to TBP (A, 
B) or GNL3 hnRNA (C, D) and DMSO-treated cells on day 1. The results of 
one experiment are plotted. As expected, the expression of GNL3 mRNA and 
hnRNA, SNORD69 and SNORD19 were unaffected by AZD1208 treatment. 
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 AZD1208 affected PIM1, MYC and H3K9acS10p occupancy 
at the GNL3 gene 
Although PIM kinase activity was dispensable for survival of Raji BL cells and for 
the expression of GNL3, we were interested to see, whether chromatin structure at 
the GNL3 gene was affected regardless. Therefore, Raji cells were treated with 
5 μM AZD1208 for one, three or seven days. ChIP results showed that both PIM1 
and MYC were stabilised at the GNL3 promoter on day 1 of treatment (Figure 5.21 
A, B). This might indicate that PIM kinase activity is required for its turnover at the 
GNL3 promoter. AZD1208 might stabilize the PIM1 protein, which would correlate 
with the increased PIM1 and PIM2 protein levels in AZD-treated cells (Figure 5.19 
A). The increased presence of MYC might be a consequence of the increased PIM1 
binding at the promoter or might also be a result of MYC stabilisation or 
upregulation after AZD1208 treatment (Figure 5.19 A). However, no increased 
binding was seen on days 3 and 7 (Figure 5.21 A, B), although total PIM1 and MYC 
proteins were still elevated (Figure 5.19 A). 
In contrast to PIM1 knockdown cells (Figure 5.16 C), H3K9acS10p was reduced 
after AZD1208 treatment (Figure 5.21 C). This could be explained by the presence 
of inactive PIM1 at the promoter, which prevents the recruitment of an alternative 
H3S10 kinase. Unexpectedly, the reduced H3K9acS10p did not result in lower 
transcription (Figure 5.20). When POL II S2p occupancy at the promoter and the 3’ 
end of the GNL3 gene was investigated, no significant change could be seen 
(Figure 5.21 D). There was, however, a trend towards increase on day 7, which was 
not correlated with a change in expression of the gene (Figure 5.20). These data 
confirm that H3K9acS10p levels do not correlate closely with transcriptional activity 
of the GNL3 gene or POL II S2 phosphorylation. 
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Figure 5.21 Effects of AZD1208 on chromatin structure of the GNL3 gene.  
ChIP was performed in Raji cells after AZD1208 treatment. The cells were 
plated on day -1, treated with 5 μM AZD1208 or DMSO from day 0 for 1, 3 or 
7 days. ChIP was done with antibodies against PIM1 (A), MYC (B), 
H3K9acS10p (C) or POL II S2p (D). Results are normalised to input or H3 and 
control regions (CTCF1 and CTCF3 for PIM1, MYC and POL II S2p, CTCF3 
and GNL3 +9 for H3K9acS10p) and DMSO-treated cells. Two independent 
experiments are shown for days 1 and 7, the result of one experiment is 
plotted for day 3. Both PIM1 and MYC tended to be elevated at the GNL3 
promoter on the first day of AZD1208 treatment but were decreased again on 
days 3 and 7. We observed a trend towards decrease in H3K9acS10p at the 
promoter and variable changes in POL II S2p, with a trend towards increased 
POL II S2p at the GNL3 +9 kb region on day 7. 
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 MYC and PIM1 might be implicated in the regulation of 
DNA replication at the GNL3 promoter 
Although PIM1 and MYC were bound to the GNL3 promoter and influenced 
H3K9acS10p, they did not alter GNL3 expression. However, MYC is implicated in 
the regulation of DNA replication and regulates licensing of some replication origins 
independent of transcription. It mainly acts as an origin activating protein in G1 
phase (Dominguez-Sola et al., 2007; Swarnalatha et al., 2012). Further, 14-3-3 
proteins are required for initiation of DNA replication in S. cerevisiae (Yahyaoui & 
Zannis-Hadjopoulos, 2009). 14-3-3 proteins can be recruited to the chromatin by 
H3S10p and PIM1 might play a role here. Moreover, the MYST family 
acetyltransferase HBO1 is required for replication origin licensing (Iizuka et al., 
2006). Because PIM1 regulates the recruitment of another MYST family member – 
MOF – to stimulate transcriptional elongation, it might also regulate HBO1 
recruitment. Interestingly, origins of replication often overlap with active promoters, 
but it is important that transcription and replication are temporally separated 
(Meryet-Figuiere et al., 2014). Therefore, MYC and PIM1 might regulate DNA 
replication and the separation of DNA replication and transcripton at the GNL3 
promoter. 
To test this hypothesis, Raji cells were synchronised in M phase using a 
thymidine/nocodazole block and then released to progress through the cell cycle. 
PI-staining and flow cytometry were applied to determine the cell cycle stage. A 
high proportion of unsynchronised Raji cells were in S phase (Figure 5.22 A), 
whereas thymidine/nocodazole-synchronised cells were arrested in M phase 
(Figure 5.22 B). 4 h after release, cells had progressed into G1 phase (Figure 5.22 
C), 8 h after release they were mostly in G1 and early S phase (Figure 5.22 D) and 
after 12 h, the majority of cells had entered S phase (Figure 5.22 E). 
Then, ChIP was performed on synchronised cells to assess the recruitment of MYC 
and PIM1 to the GNL3 promoter region. Interestingly, in one experiment more than 
twice as much MYC as in G1 phase was bound to the promoter in G1/early S phase 
cells and the level was reduced again during S phase (Figure 5.23 A). In the same 
experiment, PIM1 binding to the promoter was increased in G1/early S phase cells 
and decreased during S phase (Figure 5.23 B). Intriguingly, no change in 
H3K9acS10p was seen (Figure 5.23 C) but POL II S2p decreased at the 3’ end of 
the GNL3 gene when cells progressed into S phase (Figure 5.23 D). Surprisingly, 
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however, no decrease in GNL3, SNORD69 or SNORD19 expression was observed 
while the cells progressed through the cell cycle (Figure 5.23 E). 
The increase in MYC and PIM1 binding to the GNL3 promoter in G1/S phase cells 
suggests a cell cycle-dependent function of these proteins, which might be the 
regulation of DNA replication or the coordination of DNA replication and 
transcription. 
 
 
  
-186- 
 
 
Figure 5.22 Analysis of cell cycle synchronisation by thymidine/nocodazole in 
Raji cells.  
 Raji cells were cultured in T125 flasks and synchronised in M phase of the cell 
cycle using a thymidine/nocodazole block. PI-staining and FACS were applied 
to monitor progression through the cell cycle. ModFit was used to make the 
graphs and calculate percentages of cells in different cell cycle phases. The 
results shown are representative of two independent experiments. A 
Exponentially growing, unsynchronised Raji cells were mainly in S phase B 
Raji cells after synchronisation with thymidine/nocodazole. The cell cycle was 
blocked in M phase C Raji cells 4 h after release from thymidine/nocodazole 
block. Cells rogressed into G1 phase. D Raji cells 8 h after release from 
thymidine/nocodazole block. The cell progressed into late G1/early S phase. 
E Raji cells 12 h after release from thymidine/nocodazole block were mainly in 
S phase. 
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Figure 5.23 Effects of the cell cycle phase on the chromatin structure of the 
GNL3 gene and its expression.  
Raji cells were synchronised using a thymidine/nocodazole block and then 
released into the cell cycle. After 4 h (G0/G1 phase), 8 h (G1/S phase) and 
12 h (S phase) chromatin was prepared and used for ChIP with anti-MYC (A), 
anti-PIM1 (B), anti-H3K9acS10p (C) or anti-POL II S2p (D) antibodies. 
Results are normalised to input (A, B, D) or total H3 (C), the CTCF1 control 
region and G0/G1 phase cells. Two independent experiments are shown in A, 
B and D, one experiment is plotted in C. MYC and PIM1 binding to the GNL3 
promoter was increased in G1/early S phase in one experiment. This did, 
however, not correlate with transcriptional activation, as POL II S2p was 
unchanged. E RNA expression was measured in synchronised cells using RT-
qPCR. Results of one experiment are shown. Expression of GNL3, SNORD69 
and SNORD19 did not change while cells progressed through G1 and S 
phase. 
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6 Gene expression in CLL cells and effects of Ibrutinib 
The irreversible BTK inhibitor Ibrutinib is a novel drug, which is currently being 
trialled for the treatment of CLL and other haematological malignancies and it has 
been shown to be effective in relapsed and refractory CLL (Advani et al., 2013; 
Byrd et al., 2013). Early studies have indicated that Ibrutinib has a reduced toxicity 
profile compared to standard CLL therapy with high response rates (Byrd et al., 
2013; O’Brien et al., 2014). However, its mechanism of action is unclear. 
As Ibrutinib targets BTK, it is expected to block BCR signalling and most 
downstream effects of the BCR signalling pathway, e.g. the activation of PLCγ, and 
thus Ca2+ signalling, PKCs, NFκB and ERK1/2. While knowledge about downstream 
signal transduction pathways is extensive, little is known about alterations at the 
chromatin level in response to BCR signalling in normal as well as CLL B cells. 
Therefore, we aim to study the chromatin structure at BCR target genes in CLL 
cells before and after BCR cross-linking and to elucidate possible effects of 
Ibrutinib. 
The focus of this study was laid on histone phosphorylation marks, because these 
are transient (half-life 20 to 30 min (Jackson et al., 1975)), rapidly changing, 
signalling-induced marks, which have been shown to result in transcriptional 
activation of target genes. In addition, several of the signalling kinases downstream 
of the BCR-signalling pathway, such as MSK1/2 or PKCβ, have been shown to 
directly target histones. Target genes are likely to be important survival and 
proliferation genes, as BCR signalling is vitally important for CLL. By identifying key 
pathways, which lead to histone phosphorylation, the understanding of Ibrutinib’s 
mechanism of action is improved and it might be possible to identify novel drug 
targets, inhibitors for which could be used in combination with Ibrutinib or in 
Ibrutinib-resistant patients. 
In addition, we wanted to analyse more stable histone PTMs, like methylation and 
acetylation marks, as these provide information about the long-term activation 
status of a gene. If Ibrutinib treatment leads to changes in these marks, they could 
later also be analysed in samples from patients, which are treated with Ibrutinib and 
serve as predictive markers for drug response and drug resistance. 
The aims of this part of the study were 
1. To test genes, which are activated upon BCR signalling in CLL cells and to 
assess the effect of Ibrutinib on expression of these genes. 
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2. To identify histone phosphorylation marks, which change at BCR target 
genes upon BCR signalling and to study the effect of Ibrutinib on these 
marks. 
3. To identify signalling pathways which are essential for histone 
phosphorylation. 
4. To study the effects of Ibrutinib on both activating and inhibitory histone 
methylation and acetylation marks at BCR target genes. 
 
 Gene expression of CLL cells co-cultured with CD40L or 
M210B4 cells 
CLL cell proliferation and survival are dependent on the microenvironment. This 
microenvironment can be partially reproduced in vitro by co-culturing PBMCs from 
CLL patients with CD40L or M210B4 cells. While M210B4 is a murine stromal cell 
line, CD40L cells are murine L cells expressing human CD40L. Therefore, it was 
expected that CD40L cells would stimulate pro-proliferative gene expression in CLL 
cells. To amplify cDNA from human PBMCs only, qPCR primers were designed to 
specifically bind to the human but not the murine sequence. Genes analysed were 
chosen on the basis of differentially expressed genes in anti-IgM-stimulated 
vs. -unstimulated CLL cells identified by Guarini et al., as our main aim was to study 
the effects of Ibrutinib on BCR signalling (Guarini et al., 2008). 
Expression of cyclin D2 (CCND2), MYC, dual-specificity phosphatase 4 (DUSP4), 
BCL2-related protein A1 (BCL2A1), chemokine (C-C motif) receptor 7 (CCR7), 
peroxiredoxin 1 (PRDX1) and nucleolin (NCL) was stimulated by CD40L but not 
M210B4 co-culture. In contrast, CDC25B was strongly downregulated in cells co-
cultured with CD40L cells. DUSP2 expression was enhanced in PBMCs co-cultured 
with either CD40L or M210B4. Early growth response 1 (EGR1) was unchanged in 
all but one patient, when PBMCs were cultured on M210B4 cells, while Toll-like 
receptor 10 (TLR10) expression was unaltered (Figure 6.1). 
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Figure 6.1 Influence of CD40L and M210B4 cells on gene expression in CLL 
cells.  
CD40L and M210B4 cells were seeded into 6-well plates. The day after, CLL 
cells were added and co-cultured for up to three days. RNA was prepared and 
gene expression was analysed by RT-qPCR using the indicated primers. The 
results are shown normalised to TBP and expression in unstimulated cells 
(day 0). Cells from the same patient are depicted using the same symbol, M = 
mutated CLL, UM = unmutated CLL. Stimulation via CD40 increased the 
expression of CCND2, MYC, DUSP4, BCL2A1, CCR7, PRDX1 and NCL, 
while expression of CDC25B was strongly decreased. DUSP2 expression was 
enhanced in PBMCs co-cultured with either CD40L or M210B4 and EGR1 
was upregulated in one patient when cells were co-cultured with M210B4. 
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 BCR stimulation and effects of Ibrutinib  
 Gene expression in CLL cells after BCR stimulation 
Because CLL cells are especially dependent on BCR signalling, we next assessed 
the effect of BCR stimulation on the gene expression in patient cells. Further, half 
the cells were treated with Ibrutinib to evaluate how Ibrutinib influences gene 
expression. It was anticipated that Ibrutinib would block activation of most 
downstream target genes, as it is believed to inhibit the key BCR signalling 
pathways. Although the initial plan was to keep CLL cells in co-culture with M210B4 
or CD40L cells, it was tested whether CLL cells would survive a few days in culture 
at high densities without feeder cells, as was described by Schulz et al. (Schulz et 
al., 2011). Indeed, CLL cells from most patients survived at cell densities of 5 x 106 
PBMCs/ml for a few days in culture. Therefore, BCR stimulation experiments were 
done with cells cultured without feeder cells, to prevent activation of BCR-
independent signalling pathways. 
After BCR stimulation, CLL cells rapidly upregulated expression of EGR1 and 
DUSP2 within 30 min. MYC mRNA levels increased after 1 to 4 h, whereas DUSP4 
and CCND2 were induced after 4 h. Expression of BCL2A1, PRDX1, NCL, 
CDC25B and TLR10 was largely unaltered, while PIM1 and CXCR4 expression 
decreased. Changes in CXCR5, CCR6 and CCR7 expression levels were variable 
and patient-dependent. Induction or repression of all the genes tested were blocked 
when cells were pre-treated with 1 µM Ibrutinib for 2 h (Figure 6.2). Interestingly, 
genes induced by BCR stimulation were different from those induced by CD40L. 
CCND2, MYC, DUSP4 and BCL2A1 were, for example, induced a lot stronger by 
CD40 activation, whereas CDC25B was not downregulated by BCR activation. Both 
pathways seem to complement each other, explaining why both stimulation via the 
BCR and CD40L are required for B cell proliferation in vivo. 
 
Figure 6.2 Effects of BCR stimulation and Ibrutinib on gene expression in CLL 
cells. 
 PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. RNA was prepared at 
indicated time points and gene expression was analysed by qPCR. Cells from 
the same patient are depicted using the same symbols. EGR1 and DUSP2 
expression were strongly increased 30 min after BCR cross-linking. MYC 
expression peaked 1 to 4 h after cross-linking and DUSP4 and CCND2 were 
upregulated after 4 h. PIM1 was transiently downregulated, while CXCR4 
expression was inhibited even 24 h after BCR activation. 
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 Effects of BCR stimulation and Ibrutinib treatment on global 
histone phosphorylation 
Histone phosphorylation downstream of the BCR was of particular interest, as these 
PTMs are especially found at a large number of inducible genes and mediate their 
expression. Phosphorylation of H3S10 and H3S28 has been associated with 
induction of gene expression downstream of diverse growth factors and cytokines in 
response to activation of the ERK1/2, p38 MAPK or NFκB pathways (Duncan et al., 
2006; Healy et al., 2012; Soloaga et al., 2003; Zippo et al., 2007). However, few 
studies so far concentrated on histone phosphorylation marks other than H3S10 
and histone phosphorylation downstream of the BCR has, to our knowledge, never 
been studied before. Therefore, it was initially assessed which histone 
phosphorylation marks increase globally in CLL cells after activation of the BCR. 
The phosphorylation of H3T3, T6, T11, S10 in conjunction with K9 acetylation, and 
H3.3S31 was analysed in anti-IgM-stimulated PBMCs from four different CLL 
patients. While H3T3p, H3T6p, H3T11p and H3.3S31p were variable and changes 
were not obviously associated with BCR stimulation, H3K9acS10p was induced in 
all four patients after 30 min of BCR activation when cells were pre-treated with 
DMSO and Ibrutinib clearly inhibited this induction (Figure 6.3). Different patients 
showed different levels of H3K9acS10p induction. These differences were most 
likely due to differences in the amount of pre-activation of the cells. CLL is a very 
heterogeneous disease and different patients show different percentages of 
activated, proliferating cells in their blood and also different strengths of chronic 
signalling. As a consequence, strongly activated or strongly chronically signalling 
cells express less surface IgM and can therefore hardly be activated further, which 
would result in weak induction of H3K9acS10p. Weakly chronically signalling cells 
are much more susceptible to IgM cross-linking, which would correlate with a 
stronger increase in H3K9acS10p. 
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Figure 6.3 Effects of BCR stimulation and Ibrutinib on histone 
phosphorylation in CLL cells.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO (D) or 
Ibrutinib (I) for 2 h and then stimulated with anti-IgM. The different histone H3 
phospho-modifications were analysed by western blot. H3K9acS10p was 
induced in all patients after 30 min anti-IgM stimulation. This was inhibited, 
when the cells were pre-treated with Ibrutinib. 
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 Effects of BCR stimulation and Ibrutinib treatment on gene-
specific histone phosphorylation 
Although most of the histone H3 phospho-modifications did not change at the global 
level, they might be induced or repressed locally at distinct promoter or enhancer 
regions. Therefore, the presence of these marks at BCR regulated genes was 
determined by ChIP. Initially, presence of the different marks was assessed both in 
the 5’ and the 3’ regions of the genes, because for most of these marks, their 
distribution along active genes was unknown and H3.3S31p has been shown to be 
enriched along the gene body of the active murine Tnf gene (Thorne et al., 2012). 
Therefore, some other phosphorylation marks might be found along the gene body 
or at the 3’ end. The genes analysed were EGR1, DUSP2, MYC, DUSP4 and 
CCND2, as these were induced after BCR stimulation. 
At the EGR1 gene, histone H3 occupancy was lower in DMSO-treated compared to 
Ibrutinib-treated cells 30 min to 1 h after anti-IgM stimulation at the promoter 
(EGR1 -0.1) and 30 min after anti-IgM stimulation also in the 3’ region (EGR1 +3.8). 
In the 3’ region, histone H3 occupancy increased in DMSO-treated cells after 4 h of 
stimulation, which might reflect a reinforcement of gene silencing and might inhibit 
aberrant transcription (Figure 6.4). An increase in H3K9acS10p was seen in 
DMSO-treated cells at 30 min anti-IgM-stimulation in the promoter region 
(EGR1 -0.85, EGR1 -0.1), which was inhibited in Ibrutinib-treated cells. However, 
after 1 h anti-IgM treatment, both Ibrutinib- and DMSO-treated cells showed 
comparable enrichment of H3K9acS10p in the EGR1 -0.1 region (Figure 6.5). 
Induction of both H3T6p and H3T11p mirrored the induction kinetics of the EGR1 
gene. They were elevated along the whole gene after 30 min of anti-IgM stimulation 
only in cells pre-treated with DMSO and after 1 h, both marks had decreased back 
to baseline (Figure 6.6, Figure 6.7). No induction of H3T6p and H3T11p was seen 
in Ibrutinib-treated cells. 
In the DUSP2 +2.4 region, H3 occupancy was lower in DMSO- than in Ibrutinib-
treated cells after 30 min of anti-IgM stimulation but no difference was seen in the 5’ 
region (DUSP2 -0.3) (Figure 6.8 A). H3K9acS10p was very variable between 
patients but mostly, no significant difference between DMSO- and Ibrutinib-treated 
cells was seen (Figure 6.8 B). Similar to the EGR1 gene, H3T6p and H3T11p 
matched the induction kinetics of the DUSP2 gene. They were increased in the 
DUSP2 +2.4 region after 30 min of anti-IgM stimulation in DMSO- but not Ibrutinib-
treated cells and decreased to baseline after 1 h of BCR activation (Figure 6.9). 
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At the other three genes tested, H3 occupancy was not decreased in DMSO-treated 
compared to Ibrutinib-treated cells (Figure 6.10 A, Figure 6.12 A, Figure 6.14 A). At 
the DUSP4 gene, there was even a tendency towards higher H3 occupancy in 
DMSO-treated cells after 4 h of BCR activation (Figure 6.12 A), which is the time 
point, when expression of the DUSP4 gene was seen (Figure 6.2 D). At the MYC 
gene, H3K9acS10p increased in the promoter region after 1 h of anti-IgM treatment 
in DMSO-treated cells (Figure 6.10 B), which matched the induction of MYC 
expression (Figure 6.2 C). At the DUSP4 and the CCND2 promoters, H3K9acS10p 
was not significantly increased at any time point. At the 3’ ends of both genes, the 
variation seen seemed to be background precipitation, as the precipitated DNA was 
amplified by qPCR with Ct values around the background level (Figure 6.12 B, 
Figure 6.14 B). Furthermore, no BCR signalling-induced increase in H3T6p or 
H3T11p was seen at the MYC, DUSP4 or CCND2 genes (Figure 6.11, Figure 6.13, 
Figure 6.15). No enrichment of H3T3p, H3.3S31p or IKKα was detected in any of 
the regions tested. 
 
In conclusion, H3 occupancy decreased upon activation at early genes (EGR1, 
DUSP2), but not at later activated genes. This possibly reflects the rate of 
transcription, which must be especially high at the EGR1 gene, as it is induced 
100 fold on average, and lower at later activated genes, like MYC, DUSP4 and 
CCND2. Higher transcription rates result in enhanced removal of nucleosomes to 
allow for the passage of POL II. Although H3K9acS10p increased globally after 
BCR crosslinking, this mark was generally very variable in the regions analysed and 
its induction was not completely blocked by Ibrutinib. Further, induction of this mark 
only partially matched the induction kinetics of the studied genes. However, other 
genes might be more dependent on H3K9acS10p for their expression and it will be 
interesting to identify such genes in future studies. The most interesting marks to 
study further were H3T6p and H3T11p. They were specifically induced at the early 
genes EGR1 and DUSP2 with kinetics mirroring the mRNA expression. Further, 
their induction was completely blocked when cells were pre-treated with Ibrutinib. 
Thus, H3T6p and H3T11p might be important for expression of EGR1 and DUSP2 
and possibly other genes. 
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Figure 6.8 Analysis of H3 and H3K9acS10p at the DUSP2 gene after BCR 
cross-linking without or with Ibrutinib.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3 (A) or 
H3K9acS10p (B) at different regions along the DUSP2 gene were analysed 
by ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to input (A) or H3 (B), the CTCF1 control region and DMSO-
treated cells at 0 h. The same symbols are used for cells from the same 
patients and the median is displayed as a line. H3 occupancy in the DUSP2 
+2.4 region was lower in DMSO-treated cells than in Ibrutinib-treated cells at 
30 min anti-IgM stimulation. H3K9acS10p was induced in this region and the 
induction was similar in Ibrutinib- and DMSO-treated cells. 
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Figure 6.9 Effects of BCR cross-linking and Ibrutinib on H3T6p and H3T11p at 
the DUSP2 gene.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3T6p (A) or 
H3T11p (B) at different regions along the DUSP2 gene were analysed by 
ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to H3, the CTCF1 control region and DMSO-treated cells at 0 h. 
The same symbols are used for cells from the same patients and the median 
is displayed as a line. Both H3T6p and H3T11p increased in the DUSP2 +2.4 
region after BCR cross-linking and this induction was blocked by Ibrutinib. 
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Figure 6.10 Influence of BCR cross-linking and Ibrutinib on H3 and 
H3K9acS10p occupancy of the MYC gene.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3 (A) or 
H3K9acS10p (B) at different regions along the MYC gene were analysed by 
ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to input (A) or H3 (B), the CTCF1 control region and DMSO-
treated cells at 0 h. The same symbols are used for cells from the same 
patients. No differences in H3 occupancy were seen at the 5’ or 3’ end of the 
MYC gene between Ibrutinib and DMSO-treated cells. In the one patient 
tested, H3K9acS10p was increased in the MYC promoter region 1 h after anti-
IgM stimulation and Ibrutinib partially inhibited this effect. 
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Figure 6.11 Effects of BCR cross-linking and Ibrutinib on H3T6p and H3T11p 
at the MYC gene.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3T6p (A) or 
H3T11p (B) at different regions along the MYC gene were analysed by ChIP 
at different time points after anti-IgM stimulation. ChIP results were 
normalised to H3, the CTCF1 control region and DMSO-treated cells at 0 h. 
The same symbols are used for cells from the same patients. No induction of 
H3T6p or H3T11p was seen after BCR cross-linking. 
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Figure 6.12 Analysis of H3 and H3K9acS10p occupancy at the DUSP4 gene 
after BCR cross-linking without and with Ibutinib.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3 (A) or 
H3K9acS10p (B) at different regions along the DUSP4 gene were analysed 
by ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to input (A) or H3 (B), the CTCF1 control region and DMSO-
treated cells at 0 h. The same symbols are used for cells from the same 
patients. H3 occupancy was not different between DMSO- or Ibrutinib-
pretreated cells and H3K9acS10p was not induced at the late activated 
DUSP4 gene.  
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Figure 6.13 Effects of BCR cross-linking and Ibrutinib on H3T6p and H3T11p 
at the DUSP4 gene.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3T6p (A) or 
H3T11p (B) at different regions along the DUSP4 gene were analysed by 
ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to H3, the CTCF1 control region and DMSO-treated cells at 0 h. 
The same symbols are used for cells from the same patients. No induction of 
H3T6p or H3T11p was observed at any of the time points. 
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Figure 6.14 Influence of BCR cross-linking and Ibrutinib-treatment on H3 and 
H3K9acS10p at the CCND2 gene.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3 (A) or 
H3K9acS10p (B) at different regions along the CCND2 gene were analysed 
by ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to input (A) or H3 (B), the CTCF1 control region and DMSO-
treated cells at 0 h. The same symbols are used for cells from the same 
patients. There was no difference in H3 occupancy at the CCND2 gene 
between Ibrutinib- and DMSO-pretreated cells up to 4 h after BCR cross-
linking. Further, H3K9acS10p was not induced. 
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Figure 6.15 Analysis of H3T6p and H3T11p at the CCND2 gene in response to 
BCR cross-linking and Ibrutinib treatment.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. Histone H3T6p (A) or 
H3T11p (B) at different regions along the CCND2 gene were analysed by 
ChIP at different time points after anti-IgM stimulation. ChIP results were 
normalised to H3, the CTCF1 control region and DMSO-treated cells at 0 h. 
The same symbols are used for cells from the same patients. No induction of 
H3T6p or H3T11p was detected after BCR cross-linking. 
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 Effects of BCR stimulation and Ibrutinib treatment on POL II 
Phosphorylation of histone H3T6 and H3T11 has been shown to induce 
transcription at AR-dependent genes and H3S10p stimulates POL II S2 
phosphorylation and transcriptional elongation. Therefore, the effects of BCR 
stimulation and Ibrutinib treatment on POL II and POL II S2p occupancy at the 
induced genes was analysed next. It was anticipated that BCR stimulation might 
increase recruitment of POL II, reduce pausing and increase elongating POL II, 
while Ibrutinib treatment would block these effects. 
Generally, the effects of BCR stimulation on POL II recruitment were variable 
between patients. One patient (Pat 15) showed a strong increase in POL II 
occupancy, another patient (Pat 34) showed a moderate increase and a third 
patient (Pat 25) displayed hardly any further POL II recruitment upon BCR 
stimulation (Figure 6.16 blue bars). This probably reflects the differing basal 
activation of BCR signalling and possibly also different levels of activation of gene 
expression. However, no matter by how much POL II increased along the EGR1, 
DUSP2, MYC or DUSP4 genes, Ibrutinib did not strongly affect POL II levels 
(Figure 6.16, compare blue bars (DMSO) to red bars (Ibrutinib)). 
Similarly, POL II S2p induction was inhibited in patient 34 at the EGR1 gene but 
was not completely blocked, as would have been expected because of the 
complete block in expression of EGR1. Further, POL II S2p was increased in 
patient 25 at the EGR1 and DUSP2 genes and the MYC promoter after 30 min of 
anti-IgM treatment, which might represent paused or stalled POL II. At the DUSP4 
gene, no increase in POL II S2p was seen compared to unstimulated, DMSO-
treated cells, which was expected, as the gene was only induced at later time points 
(Figure 6.17). 
Thus, although Ibrutinib blocks gene expression downstream of the BCR, it does 
not completely inhibit induction of transcription and elongation, but might instead 
inhibit processive elongation, release of stalled POL II, processing of the transcript 
or proper termination, so that some primary transcripts might be produced, which 
do, however, never develop into mature mRNAs and were therefore not detected by 
our RT-qPCR analysis. 
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Figure 6.16 Assessment of POL II occupancy at different genes after BCR 
cross-linking without and with Ibrutinib.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. POL II occupancy at 
different regions along the EGR1 (A), DUSP2 (B), MYC (C) and DUSP4 (D) 
genes was analysed by ChIP. Results were normalised to input, the CTCF1 
and CTCF3 control regions and DMSO-treated cells at 0 h. DMSO-treated 
cells are depicted in blue, Ibrutinib-treated cells in red. Samples from the 
same patient are shown next to each other. For patient 15, not all time points 
and regions were analysed. It could be shown that Ibrutinib treatment did not 
strongly affect POL II recruitment and occupancy at the EGR1, DUSP2, MYC 
and DUSP4 genes after BCR cross-linking. 
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Figure 6.17 Effects of BCR cross-linking and Ibrutinib on the presence of 
POL II S2p at different genes.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. POL II S2p occupancy at 
different regions along the EGR1 (A), DUSP2 (B), MYC (C) and DUSP4 (D) 
genes were analysed by ChIP. Results were normalised to input, the CTCF1 
and CTCF3 control regions and DMSO-treated cells at 0 h. DMSO-treated 
cells are depicted in blue, Ibrutinib-treated cells in red. Samples from the 
same patient are shown next to each other. Surprisingly, Ibrutinib only 
partially decreased POL II S2p along the EGR1 and DUSP2 genes after BCR 
cross-linking. 
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 Effects of BCR stimulation and Ibrutinib on H3 methylation 
and acetylation marks and the incorporation of H2A.Z 
It has so far been shown that Ibrutinib can inhibit the phosphorylation of certain 
histone H3 residues downstream of the BCR and that this correlates with gene 
expression. Because histone phosphorylation marks are mostly unstable and 
rapidly changing marks, it would be difficult to analyse them in patient samples or to 
use them as predictors of drug response or resistance in clinical trials. Therefore, 
we were also interested in the effect of Ibrutinib on more stable chromatin 
modifications, like histone methylation, acetylation or the use of histone variants. 
These alterations in the chromatin structure are also indicative of a gene’s 
activation status. H3K4me3 marks promoters of active genes or genes that had 
recently been activated, as well as genes that are poised for activation. H3K9ac is a 
mark for active genes. The H2A.Z histone variant is present at genes which can 
become activated and is decreased both in active and repressed genes. 
H3K27me3 marks genes, which are repressed or, when it is found together with 
H3K4me3, genes that are poised for activation. 
To analyse effects of Ibrutinib treatment on these chromatin modifications in vitro, 
CLL cells were first cultured overnight, then they were treated with DMSO or 
Ibrutinib and stimulated with anti-IgM for up to 24 h, before the medium was 
changed to fresh, DMSO- or inhibitor-containing medium. The cells were cultured 
under these conditions for up to 5 days and the medium with DMSO or Ibrutinib was 
renewed daily. 
On average, H3K4me3 levels were unchanged in DMSO-treated CLL cells after 
anti-IgM stimulation in all the regions analysed (Figure 6.18). However, there were 
some patient-to-patient variations; in some patients H3K4me3 was slightly 
increased, in others it was decreased upon BCR stimulation. This might be due to 
differences in basal BCR signalling levels. In contrast, H3K4me3 levels were 
elevated in Ibrutinib-treated cells before anti-IgM stimulation and H3K4me3 was 
further induced 30 min after BCR cross-linking in the EGR1, DUSP2 and DUSP4 
promoters, but not in the distal EGR1 -6.1 region or at the MYC promoter (Figure 
6.18). At later time points (1 h, 4 h, 24 h), H3K4me3 levels decreased to baseline in 
Ibrutinib-treated cells and after 3 to 5 days (72 – 120 h) of Ibrutinib treatment, 
H3K4me3 was reduced in all the regions tested. 
The puzzling observation that Ibrutinib increased H3K4me3 in the promoter regions 
before and after 30 min anti-IgM stimulation, could be explained through a reduction 
in histone turnover. In DMSO-treated CLL cells, which chronically signal via the 
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BCR, an equilibrium might exist between histone turnover, which would remove 
H3K4me3-carrying nucleosomes from the promoters, and H3K4 methylation. In 
agreement, nucleosomes are constantly turned over at inducible promoters in yeast 
(Cairns, 2009; Rufiange et al., 2007). Ibrutinib might selectively block histone 
turnover without influencing H3K4 methyltransferases, which would lead to the 
increased levels of H3K4me3 in the promoter regions. Further, although Ibrutinib is 
predicted to block BCR signalling, it does not seem to completely inhibit promoter 
activation at BCR target genes, as BCR stimulation was capable of enhancing 
H3K4me3 after 30 min. By some regulatory mechanism, possibly because inhibitory 
BCR signalling, e.g. via SHIP or SHP1, is not blocked by Ibrutinib, H3K4me3 levels 
were downregulated to equilibrium levels after BCR stimulation. Long-term Ibrutinib 
treatment decreased H3K4me3, most likely because chronic BCR signalling, and 
thus the maintenance of H3K4 methylation, were blocked. 
In contrast to H3K4me3, H3K9ac increased in DMSO-treated cells at the EGR1 and 
the DUSP2 promoters after BCR stimulation and this induction was only marginally 
inhibited by Ibrutinib treatment. These data suggest again that Ibrutinib does not 
completely block promoter activation downstream of the BCR. After 24 h, however, 
H3K9ac was reduced in Ibrutinib-treated cells at both the EGR1 and DUSP2 
promoters. At the MYC and DUSP4 promoters, H3K9ac levels were mostly 
unchanged in both DMSO- and Ibrutinib-treated CLL cells (Figure 6.19). 
H2A.Z occupancy of the promoter regions was largely unaltered after BCR 
stimulation in both DMSO- and Ibrutinib-treated CLL cells. Only in patient 18, H2A.Z 
was integrated into the EGR1, DUSP2 and MYC promoter chromatin upon BCR 
stimulation in both DMSO- and Ibrutinib-treated cells (Figure 6.20). As H2A.Z is 
present in promoters that are just being activated or that have been activated 
previously, the increase in H2A.Z might indicate that the cells had not been pre-
activated as much as the other patients’ cells and therefore incorporated more 
H2A.Z into the promoter in order to activate gene expression. When the gene is 
actually expressed, H2A.Z is removed again, explaining the drop in H2A.Z levels 
after 1 to 24 h of BCR activation. Interestingly, the same patient displayed a large 
increase in H2A.Z occupancy 3 days (72 h) after BCR stimulation in DMSO- but not 
Ibrutinib-treated cells, possibly reflecting the previous activation of gene expression 
and the establishment of an “expression memory”. Consistently, patient 29 also 
showed a slight increase in H2A.Z occupancy at the EGR1 and MYC promoters in 
DMSO-treated cells on day 3 (72 h). On day 5 (120 h), however, H2A.Z levels had 
dropped in both patients, probably due to the lack of stimulation (Figure 6.20). 
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Figure 6.18 Analysis of H3K4me3 at different time points after BCR cross-
linking without and with Ibrutinib.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. H3K4me3 levels at the 
promoters of EGR1 (A), DUSP2 (B), MYC (C) and DUSP4 (D) were analysed 
by ChIP. Results were normalised to input, the CTCF1 and CTCF3 control 
regions and unstimulated, DMSO-treated cells. Median H3K4me3 levels are 
displayed as a line. Cells pretreated with Ibrutinib showed an increase in 
H3K4me3 at the promoters of EGR1, DUSP2, MYC and DUSP4 before and 
30 min after BCR cross-linking. In contrast, long-term Ibrutinib treatment (72 h 
– 120 h) led to a decrease in H3K4me3 in the same regions. 
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Figure 6.19 Effects of Ibrutinib on H3K9ac at different genes after BCR 
stimulation.  
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. H3K9ac levels at the 
promoters of EGR1 (A), DUSP2 (B), MYC (C) and DUSP4 (D) were analysed 
by ChIP. Results were normalised to input, the CTCF1 and CTCF3 control 
regions and unstimulated, DMSO-treated cells. Median H3K9ac levels are 
displayed as a line. Ibrutinib did not block the BCR signalling-induced 
increase in H3K9ac at the EGR1 and DUSP2 genes, but led to a decrease in 
H3K9ac after 24 h compared to DMSO. 
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Figure 6.20 Influence of BCR cross-linking and Ibrutinib on H2A.Z occupancy 
at different genes. 
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. H2A.Z levels at the 
promoters of EGR1 (A), DUSP2 (B), MYC (C) and DUSP4 (D) were analysed 
by ChIP. Results were normalised to input, the CTCF1 and CTCF3 control 
regions and unstimulated, DMSO-treated cells. Median H2A.Z levels are 
displayed as a line. Ibrutinib did not inhibit H2A.Z incorporation 30 min after 
BCR cross-linking compared to DMSO-treated cells, but it blocked the later 
peak in H2A.Z incorporation 72 h after BCR cross-linking. 
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Next, the inhibitory H3K27me3 mark was analysed at the EGR1, DUSP2 and MYC 
promoters. H3K27me3 levels were generally very low in these regions and were 
only increased after 72 h and 120 h of treatment. In the EGR1 -0.85 region, Ibrutinib 
treatment led to an increase in H3K27me3 in cells of one patient, but not the other, 
while both DMSO- and Ibrutinib-treated cells showed an increase in H3K27me3 in 
the EGR1 -0.1 region. At the DUSP2 promoter, H3K27me3 was increased only in 
Ibrutinib-treated cells and no increase in H3K27me3 was seen at the MYC promoter 
(Figure 6.21). 
In summary, Ibrutinib does not seem to block BCR-induced promoter activation, 
including POL II recruitment, in general. However, because no induction of mRNA 
expression of any of the BCR target genes was seen, Ibrutinib treatment does most 
likely block a different step in the transcription process, for example pause release, 
processive transcriptional elongation and/or mRNA processing. It might, for 
example, inhibit full activation of gene expression by blocking histone turnover and 
H3T6 and H3T11 phosphorylation. 
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Figure 6.21 Analysis of H3K27me3 after BCR cross-linking with and without 
Ibrutinib at different genes. 
PBMCs were cultured in RPMI-1640 over night, treated with DMSO or 
Ibrutinib for 2 h and then stimulated with anti-IgM. H3K27me3 levels at the 
promoters of EGR1 (A), DUSP2 (B) and MYC (C) were analysed by ChIP. 
Results were normalised to input, the CTCF1 and CTCF3 control regions and 
unstimulated, DMSO-treated cells. Median H3K27me3 levels are displayed as 
a line. Ibrutinib treated cells showed a trend towards increased H3K27me3 
72 h and 120 h after anti-IgM stimulation, especially at the DUSP2 promoter. 
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7 Identification of signalling pathways leading to H3T6 and 
H3T11 phosphorylation 
We next wanted to identify signalling pathways or kinases that are required for the 
phosphorylation of H3T6p and H3T11p downstream of the BCR. The induction of 
both marks correlated well with the induction of gene expression, e.g. they were not 
induced in Ibrutinib-treated cells, and both marks were found along the whole EGR1 
and DUSP2 genes, so that they might be important mediators of transcriptional 
elongation. Consistently, Ibrutinib did not seem to block transcription initiation, 
including POL II recruitment, H3K9 acetylation and H2A.Z incorporation, at the 
studied genes, but did block generation of mature mRNAs, possibly by blocking 
processive elongation. Although we hypothesised that this might be mediated by 
H3T6 and H3T11 phosphorylation, we could not exclude effects of other histone 
marks. By specifically inhibiting H3T6 and/or H3T11 phosphorylation, for example 
by targeting the kinase directly phosphorylating these residues, the essential effects 
of these marks on transcription initiation and elongation could be elucidated. If 
H3T6p and H3T11p turn out to be important mediators of gene expression 
downstream of the BCR, essential downstream pathways might be targeted 
therapeutically together with BTK or in Ibrutinib-resistant patients.  
 
 PKCβ as a candidate kinase 
We first chose a candidate approach to identify the kinase or pathway responsible 
for H3T6 and H3T11 phosphorylation. As described earlier, PKCβ had been shown 
to phosphorylate H3T6 at androgen receptor-dependent genes and to stimulate 
transcription (Metzger et al., 2010). As PKCβ also plays an essential role 
downstream of the BCR, it seemed plausible that PKCβ might be the kinase 
targeting H3T6 and possibly H3T11 in CLL cells. 
To test this hypothesis, PBMCs of one patient were initially treated with 200 nM 
PKCβ inhibitor or with Ibrutinib and expression of EGR1, DUSP2, MYC and CXCR4 
were analysed. Further, H3T6p and H3T11p at the EGR1 gene were assessed by 
ChIP. No significant difference in expression of EGR1, MYC or CXCR4 mRNA 
levels were seen between DMSO- or PKCβ inhibitor-treated cells, while Ibrutinib 
reduced expression of EGR1 and MYC or inhibited repression of CXCR4 after anti-
IgM stimulation, respectively. Expression of DUSP2 was reduced to the same level 
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in Ibrutinib- and PKCβ inhibitor-treated cells only after 60 min anti-IgM stimulation. 
Further, H3T6p and H3T11p levels at the EGR1 gene were unaltered (Figure 7.1). 
 
Figure 7.1 Effects of PKCβ inhibition on gene expression as well as H3T6p 
and H3T11p at the EGR1 gene.  
PBMCs of one patient were cultured in RPMI-1640 over night, treated with 
DMSO, 1 μM Ibrutinib or 200 nM PKCβ inhibitor for 2 h and then stimulated 
with anti-IgM. A-D RNA was harvested and gene expression was analysed by 
RT-qPCR. Data are normalised to PPP6C expression and expression in 
unstimulated, DMSO-treated cells. Inhibition of PKCβ did not result in 
decreased expression of EGR1 or MYC, while DUSP2 expression was only 
reduced 60 min after BCR cross-linking compared to DMSO-treated cells. The 
inhibitor did also not affect the downregulation of CXCR4. E, F Chromatin was 
prepared before and after 30 min anti-IgM stimulation and the EGR1 gene 
was analysed for H3T6p and H3T11p by ChIP-qPCR. The data are 
normalised to H3, the CTCF1 control region and H3T6p or H3T11p in DMSO-
treated, unstimulated cells. H3T6p and H3T11p were unaltered in PKCβ 
inhibitor-treated compared to DMSO-treated cells 
-221- 
 
To ensure that PKCβ was sufficiently inhibited, higher concentrations of the inhibitor 
(1 μM,10 μM and 1 μM overnight) were applied to PBMCs of two other patients. 
Again, expression of both EGR1 and DUSP2 did not differ significantly between 
DMSO- and PKCβ inhibitor-treated cells, while Ibrutinib inhibited induction of both 
genes (Figure 7.2 A, B). Further, when H3T6p and H3T11p at the EGR1 gene were 
analysed, a trend towards increased phosphorylation was seen (Figure 7.2 C, D). 
From these experiments, it was concluded that PKCβ does not directly target H3T6 
and H3T11 in CLL cells. It might rather have an inhibitory function on BCR 
signalling by phosphorylating and inhibiting BTK, which would explain why H3T6p 
and H3T11p are slightly increased after PKCβ inhibitor treatment. 
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Figure 7.2 Consequences of high-dose PKCβ inhibitor treatment for the 
expression of EGR1 and DUSP2, as well as for H3T6p and H3T11p at the 
EGR1 gene.  
PBMCs of two patients were cultured in RPMI-1640 over night and treated 
with DMSO, 1 μM Ibrutinib, 1 μM or 10 μM PKCβ inhibitor for 2 h the next day 
or they were directly incubated with 1 μM PKCβ inhibitor overnight. Inhibitor-
treated cells were then stimulated with anti-IgM. A, B RNA was harvested and 
gene expression was analysed by RT-qPCR. Data are normalised to PPP6C 
expression and expression in unstimulated, DMSO-treated cells. The results 
from two different patients are shown. High doses of the PKCβ inhibitor were 
not sufficient to consistently inhibit the expression of EGR1 and DUSP2 after 
BCR stimulation. C, D From one of the patients, chromatin was prepared and 
the EGR1 gene was analysed for H3T6p and H3T11p by ChIP-qPCR. The 
data are normalised to H3, the CTCF1 control region and H3T6p or H3T11p in 
DMSO-treated, unstimulated cells. PKCβ inhibitor-treated cells tended to 
show higher levels of H3T6p and H3T11p than DMSO-treated cells, indicating 
that PKCβ does not directly target these residues downstream of the BCR. 
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 Identification of other candidate kinases for H3T6 and 
H3T11 
As PKCβ was most likely not the kinase targeting H3T6 and H3T11 downstream of 
the BCR signalling pathway and was also not involved in the pathway leading to 
H3T6 and H3T11 phosphorylation, I sought to identify other possible kinases 
targeting H3T6 and/or H3T11. To this end, a kinase prediction was performed using 
the freely available software GPS 2.1 (Xue et al., 2008) and the H3 N-terminal tail 
as input sequence. Among the kinases predicted to phosphorylate H3T6 and 
H3T11 were the kinases listed in Table 7.1. 
H3T6 H3T11 
Kinase Score Kinase Score 
MEK2 4 PKCa 2.873 
PKCa 5.284 PKCg 2.8 
PKCb 4.125 RSK1 3 
PKCg 2.2 RSK2 3.222 
PKCd 2.435 ZIPK 6.889 
PKCt 5.25   
PKCz 3.462   
RSK2 4.111   
ZIPK 4.056   
Table 7.1 Kinases predicted by GPS 2.1 (Xue et al., 2008) to phosphorylate 
H3T6 and H3T11. 
 
Among these kinases MEK2, RSK1/2 and PKCs are known downstream elements 
of the BCR signalling pathway. Consequently, inhibitors targeting these kinases 
were tested for their ability to inhibit expression of EGR1 and DUSP2 and 
phosphorylation of H3T6 and H3T11 along these genes. The inhibitors used were 
Gö6983, a pan-PKC inhibitor, RSK inhibitor II, a pan-RSK inhibitor, and U0126, a 
MEK1/2 inhibitor. All three inhibitors tested did not significantly inhibit the induction 
of EGR1 or DUSP2 expression after 30 and 90 min anti-IgM stimulation (Student’s t 
test p > 0.15) (Figure 7.3 A, Figure 7.4 A).  
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PBMCs from two of the patients were also analysed by ChIP (Figure 7.3, Figure 
7.4). The induction of H3T6p was reduced at the EGR1 gene when the cells were 
pre-treated with Gö6983 or RSK inh II, but not when MEK1/2 were inhibited (Figure 
7.3 D, E), whereas induction of H3T6p at the DUSP2 +2.4 region was only reduced 
by Gö6983 (Figure 7.4 D, E). In one patient, the increase in H3T11p was reduced 
by all inhibitors (Figure 7.3 F, Figure 7.4 F), but only Gö6983 pre-treatment led to 
inhibition of H3T11p induction in both patients (Figure 7.3 F, G, Figure 7.4 F, G). 
However, the induction of H3T11p in the second patient was on average very weak 
and it did not reach more than 2-fold induction at most EGR1 regions or at the 
DUSP2 gene, so that the observed inhibitor effects were also weak. From these 
experiments, it was concluded that PKCs and/or RSKs are likely involved in the 
upstream signalling to induce H3T6 or H3T11 phosphorylation, but are not directly 
targeting these residues in CLL cells. Further, other signalling pathways are 
expected to play a role, as the phosphorylation of H3T6 and H3T11 was not 
inhibited as strongly as after Ibrutinib treatment. 
 
 
 
 
 
Figure 7.3 Influence of different kinase inhibitors on the expression of EGR1 
and on H3T6p and H3T11p at the EGR1 gene.  
  PBMCs of CLL patients were cultured for 16 to 48 h and then treated with 
DMSO, 1 μM Ibrutinib, 1 μM Gö6983, 10 μM RSK inhibitor II or 10 μM U0126 
for 2 h, before the BCR was cross-linked. A Expression of EGR1 was 
assessed and the means and sd of at least three independent experiments 
from different patients are shown normalised to TBP and to the induction of 
EGR1 mRNA expression in DMSO-treated cells after 30 min. ** p < 0.01, ns = 
not significant in Student’s t test. None of the inhibitors, other than Ibrutinib, 
did significantly block induction of EGR1. B - G ChIP was performed before 
and after 30 min anti-IgM stimulation using primers along the EGR1 gene and 
antibodies against H3 (B, C), H3T6p (D, E) or H3T11p (F, G). ChIP results 
after 30 min anti-IgM stimulation are plotted. Results of two representative 
patient are shown normalised to input (B, C) or H3 (D-G), the CTCF1 and 
CTCF3 control regions and unstimulated, DMSO-treated cells. Ibrutinib was 
the most effective inhibitor leading to an increase in H3 occupancy and 
inhibition of H3T6p and H3T11p. Gö6983 also reduced H3T6 and H3T11 
phosphorylation in both patients, while RSK inhibitor II only affected H3T6p. 
U0126 did not alter H3T6p and H3T11p induction. 
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Figure 7.4 Effect of different kinase inhibitors on the expression of DUSP2 
and on H3T6p and H3T11p at the DUSP2 gene. 
PBMCs of CLL patients were cultured for 16 to 48 h and then treated with 
DMSO, 1 μM Ibrutinib, 1 μM Gö6983, 10 μM RSK inhibitor II or 10 μM U0126 
for 2 h. They were subsequently stimulated with anti-IgM. A Expression of 
DUSP2 was assessed and the means and sd of at least three independent 
experiments from different patients are shown normalised to TBP and to the 
induction of DUSP2 mRNA expression in DMSO-treated cells after 30 min. 
* p < 0.05, ns = not significant in Student’s t test. Only Ibrutinib did 
significantly block expression of DUSP2, while the other inhibitors did not 
inhibit its induction compared to DMSO-pretreated cells. B - F ChIP was 
performed before and after 30 min anti-IgM stimulation using primers along 
the DUSP2 gene and antibodies against H3 (B, C), H3T6p (D, E) or H3T11p 
(F, G). ChIP results after 30 min anti-IgM stimulation are plotted. Results from 
two different patients are shown normalised to input (B, C) or H3 (D-G), the 
CTCF1 and CTCF3 control regions and unstimulated, DMSO-treated cells. 
None of the inhibitors mimicked Ibrutinib’s effect on H3 occupancy after BCR 
cross-linking. Gö6983 did, however, inhibit H3T6p in one patient, but not the 
other and decreased H3T11p in both patients. RSK inh II and U0126 led to a 
decrease in H3T11p in the first patient only, but were not effective in the 
second patient. 
 
 
Surprisingly, however, treatment of CLL cells with high concentrations of the PKCβ 
inhibitor or with Gö6983 led to a global, BCR stimulation-independent reduction in 
H3T11p and an inhibition of H3K9acS10p induction upon BCR stimulation (Figure 
7.5). Therefore, a kinase inhibited by both drugs directly or indirectly mediated the 
global phosphorylation of H3T11, possibly at centromeric regions, but it was not 
directly responsible for BCR-induced H3T11 phosphorylation. The inhibition of 
H3K9acS10p upon BCR stimulation is probably due to inhibition of BCR 
downstream signal transduction pathways. 
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Figure 7.5 Effect of different kinase inhibitors on global histone 
phosphorylation in CLL cells. 
A PBMCs of two patients were cultured in RPMI-1640 over night and then 
treated with DMSO (D), 1 μM Ibrutinib (I), 1 μM or 10 μM PKCβ inhibitor (P) 
for 2 h or they were directly incubated with 1 μM PKCβ inhibitor overnight (P 
o/n). Inhibitor-treated cells were subsequently stimulated with anti-IgM. B 
PBMCs were cultured in RPMI-1640 overnight, treated with DMSO (D), 1 μM 
Gö6983 (G), 10 μM RSK inhibitor II (R) or 10 μM U0126 (U) for 2 h and were 
then stimulated with anti-IgM. Western blot was performed with antibodies 
against the different histone H3 phospho-modifications. High doses of the 
PKCβ inhibitor and Gö6983 led to a decrease in global H3T11p even before 
BCR cross-linking, indicating that a kinase targeted by both inhibitors is 
required to maintain H3T11 phosphorylation. Both inhibitors also blocked the 
BCR signalling-induced increase in H3K9acS10p. 
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 Zipper-interacting protein kinase (ZIPK) as a candidate 
kinase for H3T6 and H3T11 
All kinases tested so far did not directly target H3T6 or H3T11. However, among the 
kinases predicted by GPS 2.1, ZIPK (also known as death-associated protein 
kinase 3, DAPK3, or DAP-like kinase (DLK)) was the kinase with the highest score 
for H3T11 and was also predicted to phosphorylate H3T6 (see Table 7.1). ZIPK 
belongs to the death-associated protein kinase family together with DAPK1, DAPK2 
(DRP1), death-associated protein kinase related protein 1 (DRAK1) and DRAK2. 
Interestingly, a splice variant of DRP1 has been detected, which resembles ZIPK 
(Shoval et al., 2011). ZIPK is activated by phosphorylation and 
autophosphorylation. The active ZIPK is an oligomeric protein and it oligomerises 
via its leucine zipper and kinase domains (Graves et al., 2005).  
However, ZIPK has mostly been associated with cell death signalling and tumour 
suppression (Bi et al., 2009; Brognard et al., 2011; Kawai et al., 2003; Kocher et al., 
2014 p. 2003; Kögel et al., 2003; Wu et al., 2010). It is believed to mediate its 
effects on cell death primarily through autophagy by phosphorylating myosin light 
chain and thus linking autophagy proteins to cytoskeletal reorganisation (Murata-
Hori et al., 1999; Murata-Hori et al., 2001; Tang et al., 2011). Consistently, no 
cleavage of caspase 3 or poly-(ADP-ribose) polymerase (PARP) are seen in ZIPK 
overexpressing cells (Shani et al., 2004). 
When overexpressed in HeLa cells, human ZIPK shows a predominantly 
cytoplasmic localisation (Murata-Hori et al., 2001) and phosphorylation of T299 
triggers its nuclear export (Graves et al., 2005). Conversely, deletion of the leucine 
zipper leads to nuclear retention of the kinase (Graves et al., 2005). Interestingly, a 
splice variant lacking the leucine zipper has been described (Takamoto et al., 
2006). One kinase that can phosphorylate T299 is DAPK1 and both DAPK1 and 
ZIPK synergistically induce apoptosis upon overexpression (Shani et al., 2004). In 
contrast, murine ZIPK lacks the T299 residue and is consequently localised 
predominantly in the nucleus, is associated with chromatin and has been shown to 
phosphorylate histones (Kögel et al., 1998; Weitzel et al., 2011), specifically histone 
H3T11 at centromeres during mitosis (Preuss et al., 2003).  
In mice and rats, diffuse nuclear localisation of ZIPK is associated with cell survival, 
while localisation to the cytoplasm through interaction with prostate apoptosis 
response 4 (PAR4) or within nuclear bodies is required for ZIPK-mediated 
apoptosis (Kawai et al., 2003; Kögel et al., 1999; G. Page et al., 1999). As PAR4 
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interacts with the actin cytoskeleton and leads to stress fibre formation, it was 
proposed that PAR4 recruits ZIPK to actin bundles, where it can activate myosin 
and induce apoptosis (Vetterkind et al., 2005). However, human ZIPK fails to 
interact with PAR4 (Shoval et al., 2007). 
Nevertheless, nuclear localisation of ZIPK might also inhibit its proapoptotic effects 
in humans, as mutations in the leucine zipper domain lead to nuclear localisation of 
the enzyme and reduce induction of apoptosis while increasing kinase activity 
(Graves et al., 2005). Moreover, the stimulation of apoptosis seems to be cell type-
specific, as ZIPK also stimulates contraction of smooth and cardiac muscle cells by 
inhibiting myosin light chain phosphatase and by phosphorylating the myosin light 
chain (Chang et al., 2010; Haystead, 2005; Komatsu & Ikebe, 2014; MacDonald et 
al., 2001; Moffat et al., 2011; Niiro & Ikebe, 2001). Further, ZIPK also induces 
proliferation of smooth muscle cells (Usui et al., 2014) and is required for migration 
of fibroblasts (Komatsu & Ikebe, 2004). 
ZIPK is activated in cells stimulated with IL-6 and the IL-6 family cytokine leukaemia 
inhibitory factor (LIF) (Sato et al., 2006). It can interact with RHOD-GTP, which 
inhibits stress fibre and focal adhesion formation (Nehru et al., 2013), but it is also 
activated by Rho kinase 1 (ROCK1) (Hagerty et al., 2007). It stabilises the cell cycle 
regulator p21 and activates MDM2 (Burch et al., 2004; Zhou et al., 2001). Further, 
ZIPK has been shown to bind and phosphorylate STAT3 (Sato et al., 2005) and to 
bind the AR to stimulate its ubiquitination by MDM2, which enhances transactivation 
and degradation (Felten et al., 2013; Leister et al., 2008). Both murine and human 
ZIPK bind the activating transcription factor 4 (ATF4) (Kawai et al., 1998; Shoval et 
al., 2011) and murine ZIPK has been shown to bind apoptosis antagonising 
transcription factor (AATF) (G Page et al., 1999), as well as the rat homolog of the 
S.pombe splicing factor CDC5 (CDC5L) (Engemann et al., 2002). 
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 Effects of ZIPK inhibition on gene expression, H3T6 and 
H3T11 phosphorylation 
Although ZIPK has, to our knowledge, never been described as a kinase 
downstream of the BCR signalling pathway, it had already been shown to associate 
with chromatin, to phosphorylate H3T11 and to be capable of binding to several 
transcription factors. Further, ZIPK is overexpressed in CLL compared to normal B 
cells (Marina et al., 2010), but it might not function as a cell death-inducing kinase, 
because DAPK1 is downregulated in CLL cells through epigenetic silencing (Raval 
et al., 2007), so that the synergy between both kinases is abrogated. Therefore, we 
assessed the effects of ZIPK inhibition on the expression of EGR1 and DUSP2 and 
on histone phosphorylation at these genes. 
Treatment of CLL cells with DAPK inhibitor, which targets both ZIPK and DAPK1, 
resulted in reduced induction of both EGR1 and DUSP2 upon BCR activation, 
which was comparable to the effect of Ibrutinib (Figure 7.6 A, Figure 7.7 A). 
Similarly, the induction of H3T6 and H3T11 phosphorylation at the EGR1 and 
DUSP2 genes was inhibited to the same extent as in Ibrutinib-treated cells, 
indicating that ZIPK might be the kinase directly targeting H3T6 and H3T11 in 
response to BCR stimulation in CLL cells (Figure 7.6 D - G, Figure 7.7 D - F). One 
representative ChIP is shown (Figure 7.6 B, D, F, Figure 7.7 B, D, F) and then the 
means and standard deviations of the fold occupancy or induction relative to 
DMSO-treated cells of three patients are displayed (Figure 7.6 C, E, G, Figure 7.7 
C, E). Only data points showing at least a twofold induction over unstimulated, 
DMSO-treated cells were used for this analysis. For H3T11p at the DUSP2 gene, 
only one patient fulfilled these criteria, so that no average induction was calculated. 
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Figure 7.6 ZIPK inhibition affects the expression of EGR1 and H3T6p and 
T11p. 
PBMCs of CLL patients were cultured for 16 to 48 h and then treated with 
DMSO, 1 μM Ibrutinib or 20 μM DAPK inhibitor for 2 h. They were 
subsequently stimulated with anti-IgM. A Expression of EGR1 was assessed 
and the means and sd of at least three independent experiments from 
different patients are shown normalised to TBP and to the induction of EGR1 
mRNA expression in DMSO-treated cells after 30 min. * p < 0.05, ** p < 0.01, 
ns = not significant in Student’s t test. Ibrutinib and DAPK inhibitor showed a 
similar efficiency in inhibiting expression of EGR1 30 min after activation of 
BCR signalling. B - G ChIP was performed before and after 30 min anti-IgM 
stimulation using primers along the EGR1 gene and antibodies against H3 (B, 
C), H3T6p (D, E) or H3T11p (F, G). ChIP results after 30 min anti-IgM 
stimulation are plotted. B, D, F Results of one representative patient are 
shown normalised to input (B) or H3 (D, F), the CTCF1 and CTCF3 control 
regions and unstimulated, DMSO-treated cells. C, E, G The occupancy of H3 
or the induction of H3T6p or H3T11p are shown normalised to DMSO-treated 
cells after 30 min anti-IgM stimulation. The means and sd of three 
independent experiments from different patients are plotted. Only data points 
that showed more than two fold induction over unstimulated cells were used 
for the analysis. Inhibition of ZIPK was as effective as Ibrutinib in blocking 
H3T6p and H3T11p at the EGR1 gene. 
 
 
 
 
 
Figure 7.7 Effects of ZIPK inhibition on DUSP2 expression and H3T6p and 
H3T11p at the DUSP2 gene. 
 PBMCs of CLL patients were cultured for 16 to 48 h and then treated with 
DMSO, 1 μM Ibrutinib or 20 μM DAPK inhibitor for 2 h. They were 
subsequently stimulated with anti-IgM. A Expression of DUSP2 was assessed 
and the means and sd of at least three independent experiments from 
different patients are shown normalised to TBP and to the induction of DUSP2 
mRNA expression in DMSO-treated cells after 30 min. ** p < 0.01, ns = not 
significant in Student’s t test. DAPK inhibitor and Ibrutnib both showed similar 
efficiencies for the inhibition of DUSP2 expression. B - F ChIP was performed 
before and after 30 min anti-IgM stimulation using primers along the DUSP2 
gene and antibodies against H3 (B, C), H3T6p (D, E) or H3T11p (F). ChIP 
results after 30 min anti-IgM stimulation are plotted. B, D, F Results of one 
representative patient are shown normalised to input (B) or H3 (D, F), the 
CTCF1 and CTCF3 control regions and unstimulated, DMSO-treated cells. C, 
E The occupancy of H3 or the induction of H3T6p are shown normalised to 
DMSO-treated cells after 30 min anti-IgM stimulation. The means and sd of 
three independent experiments from different patients are plotted. Only data 
points that showed more than two fold induction over unstimulated cells were 
used for the analysis. DAPK inhibitor reduced the induction of H3T6p and 
H3T11p at the DUSP2 gene to a similar level to Ibrutinib. 
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 Expression of ZIPK and subcellular localisation in CLL cells 
Because ZIPK is a promising candidate kinase for phosphorylation of H3T6 and 
H3T11, it was next investigated whether BCR signalling could induce expression or 
nuclear translocation of ZIPK. To this end, CLL cells of two different patients were 
treated with different inhibitors and stimulated with anti-IgM. However, protein levels 
of ZIPK did not change upon inhibitor treatment or BCR stimulation (Figure 7.8 A, 
B). PBMCs from another two patients were stimulated with anti-IgM and subjected 
to nuclear-cytoplasmic fractionation. ZIPK was localised to both the cytoplasm and 
the nucleus in cells from both patients and nuclear translocation was not induced 
after activation of BCR signalling (Figure 7.8 C). However, these experiments do 
not exclude that ZIPK might become activated by phosphorylation, which was not 
assessed in this study. 
 
 
Figure 7.8 Expression of ZIPK in CLL cells in response to BCR signalling and 
treatment with different inhibitors. 
A, B PBMCs were treated with DMSO (D), 1 μM Ibrutinib (I), 20 μM DAPK 
inhibitor (Z), 1 μM Gö6983 (G), 10 μM RSK inhibitor II (R) or 10 μM U0126 (U) 
for 2 h and then harvested or stimulated with anti-IgM. Protein lysates were 
prepared and used for western blot. Inhibitor treatment did not affect total 
levels of ZIPK. However, activating phosphorylation of ZIPK might be altered. 
C PBMCs were left unstimulated or were stimulated with anti-IgM and 
subjected to nuclear-cytoplasmic fractionation. The western blot shown is 
representative of two independent experiments. ZIPK was present in both the 
cytoplasm and the nucleus of CLL cells from both patients before and after 
stimulation with anti-IgM. 
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 Analysis of global H3T11 phosphorylation by ChIP-seq 
Inhibition of ZIPK led to both the loss of H3T6p and H3T11p and to inhibition of 
expression of EGR1 and DUSP2. Therefore, H3T11p and H3T6p seemed to be 
closely associated with activation of gene expression downstream of the BCR. 
Induction of H3T6p and H3T11p had so far only been detected at the EGR1 and 
DUSP2 genes, but other regions, which were not analysed by ChIP-qPCR, might 
also be marked by these PTMs. Further, global H3T11 phosphorylation was also 
detected independent of BCR-stimulation and treatment of CLL cells with PKC 
inhibitors globally decreased this mark without influencing BCR-induced H3T11 
phosphorylation. 
Therefore, we wanted to establish, whether H3T6p and H3T11p were globally 
associated with active genes before BCR cross-linking and/or with genes that 
became activated downstream of the BCR. Consistently, it was hypothesised that 
Ibrutinib would inhibit BCR-induced H3T6 and H3T11 phosphorylation. As a first 
approach, we focussed on H3T11p, because this mark seemed to be more closely 
associated with gene expression. In one patient, Gö6983, RSK inhibitor II and 
U0126 all reduced the induction of EGR1 and DUSP2 and also H3T11 
phosphorylation at these genes, while U0126 did not inhibit H3T6 phosphorylation. 
Samples of two patients were used for ChIP-seq and they were treated as 
displayed in Table 7.2. 
Unfortunately, although the induction of H3T11 phosphorylation at the EGR1 and 
DUSP2 genes was confirmed by ChIP-qPCR before using the DNA for library 
preparation, only the input samples and CLL_1 H3T11p_DMSO_0 gave good 
sequencing results. 3853 peaks were called in the CLL_1 H3T11p_DMSO_0 
sample, while only 198 peaks were detected in the CLL_1 H3T11p_DMSO_30 
sample and no peaks could be called in any of the other samples, which was most 
likely due to low amounts of DNA used for library preparation. Therefore, the 
analysis was mostly restricted to the CLL_1 H3T11p_DMSO_0 sample. 
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Sample Drug 
Time of anti-IgM 
stimulation 
CLL_1 Input_DMSO_0 DMSO 0 h 
CLL_1 Input_DMSO_30 DMSO 30 min 
CLL_1 Input_Ibrutinib_30 Ibrutinib 30 min 
CLL_1 H3T11p_DMSO_0 DMSO 0 h 
CLL_1 H3T11p_DMSO_30 DMSO 30 min 
CLL_1 H3T11p _Ibrutinib_30 Ibrutinib 30 min 
CLL_2 Input_DMSO_0 DMSO 0 h 
CLL_2 Input_DMSO_30 DMSO 30 min 
CLL_2 Input_Ibrutinib_30 Ibrutinib 30 min 
CLL_2 H3T11p_DMSO_0 DMSO 0 h 
CLL_2 H3T11p_DMSO_30 DMSO 30 min 
CLL_2 H3T11p _Ibrutinib_30 Ibrutinib 30 min 
Table 7.2 Samples used for ChIP-seq.  
Only the samples printed in bold gave good sequencing results and were 
used for further analysis. 
 
43 or 51.5% of the peaks before or after anti-IgM treatment, respectively, were 
detected in intragenic regions, about 40% were found in intergenic regions and 15% 
or 10% were detected in promoters. The distribution of peaks between the different 
genomic regions was largely unaltered before and after anti-IgM stimulation (Figure 
7.9). However, due to the poor quality of the 30 min sample, the analysis will need 
to be repeated to confirm the results. 
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Figure 7.9 Distribution of ChIP-seq peaks annotated using the latest Ref-Seq 
annotation in the CLL_1 H3T11p_DMSO_0 and CLL_1 H3T11p_DMSO_30 
samples. 
 
Then, both the CLL_1 H3T11p_DMSO_0 and CLL_1 H3T11p_DMSO_30 peak 
sequences were used for a motif analysis with MEME-ChIP, comparing them 
against the JASPAR CORE and the Jolma vertebrate databases (Machanick & 
Bailey, 2011). 31% of the peaks in the CLL_1 H3T11p_DMSO_0 overlapped with 
CTCF motifs with very high confidence, while no CTCF motif was found in the 
CLL_1 H3T11p_DMSO_30 peaks. The CTCF consensus motif from the Jolma 
database and the detected motif are shown in Figure 7.10 A. Further, CentriMo 
analysis showed that the CTCF motif is very strongly centrally enriched in the peak 
sequences (Figure 7.10 B). As H3, and thus the H3T11p mark, is part of the 
nucleosome, it was hypothesised that the H3T11p-carrying nucleosome actually 
blocks binding of CTCF to these sites. Therefore, the sequences for all the peaks 
containing a CTCF motif were extracted and compared to CTCF ChIP-seq data 
from GM12878, which is an EBV-transformed lymphoblastoid cell line. In this cell 
line, 80% of our CTCF motif-containing peaks would overlap with actual CTCF 
binding sites. Consequently, if CTCF binding sites are conserved in CLL cells, 24% 
of the H3T11p peaks overlap with CTCF and the nucleosome would not block 
CTCF binding to the chromatin. 
The second motif discovered with high confidence in 66% of the CLL_1 
H3T11p_DMSO_0 peaks and in over 80% of the CLL_1 H3T11p_DMSO_30 peaks 
is an ETS factor motif (SPI1, SPIC, SPIB). The consensus and detected motifs are 
shown in Figure 7.10 C. ETS factor motifs were not as strongly centrally enriched in 
the CLL_1 H3T11p_DMSO_0 peaks as CTCF motifs (Figure 7.10 D). Further, 50% 
of the CLL_1 H3T11p_DMSO_0 peaks overlap with E boxes (Figure 7.10 E) and 
25% of the peak sequences have a ZIC consensus binding site 
(CCCCCCGGGGGGG) (Figure 7.10 F), both of which are also centrally enriched. 
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In conclusion, H3T11p seemed to generally overlap with regulatory regions in CLL 
cells. Indeed, when CLL_1 H3T11p_DMSO_0 peaks were compared to the 
H3K27ac track of GM12878 cells, over 50% overlapped with this mark and only 
10% of the peaks overlapped with both H3K27ac and CTCF, indicating that there 
might be two different groups of H3T11 phosphorylated regions, those that overlap 
with active regulatory elements, and those that overlap with structural sites. 
Because ZIPK has been shown to bind to STAT3, which is constitutively active in 
CLL cells and is also activated downstream of the BCR (Hazan-Halevy et al., 2010; 
Rozovski et al., 2014), CLL_1 H3T11p_DMSO_0 peak data were also compared to 
STAT3 ChIP-seq peaks from GM12878 cells and it was found that 30% of the CLL 
H3T11p peaks overlap with STAT3 sites. 
A few example ChIP-seq peaks are shown in Figure 7.11, Figure 7.12 and Figure 
7.13. Although only a few strong peaks could be called in the CLL_1 
H3T11p_DMSO_30 data set, some interesting results could be obtained. For 
example, a new H3T11p peak occurred in the CDK14 intragenic alternative 
promoter 30 min after BCR stimulation, which might indicate activation of CDK14 
expression (Figure 7.11). CDK14 is a cyclin-dependent kinase, which associates 
with CCND3 and promotes cell cycle progression at the G1/M border (Shu et al., 
2007). Another H3T11p peak was only seen in unstimulated cells and overlapped 
with a PU.1 binding site in GM12878 cells. Both peaks were found in H3K27 
acetylated, regulatory regions (Figure 7.11). 
In Figure 7.12, a constitutive H3T11p peak is shown within the TNFRSF17 gene, 
which encodes for a BAFF-R that is constitutively expressed on CLL cells (Endo et 
al., 2007). This peak also overlaps with H3K27ac and a PU.1 site. Upstream of the 
SYK gene, a H3T11p peak that overlaps with a CTCF-site but not with H3K27ac in 
GM12878 cells, was detected in unstimulated CLL cells. Furthermore, two more 
peaks were seen in the SYK intragenic promoter, overlapping with H3K27ac (Figure 
7.13). 
More H3T11p peaks were detected around other genes associated with normal B 
and CLL cells. Peaks in the TLR4 and the BLNK promoter and enhancer were 
present in both CLL_1 H3T11p_DMSO_0 and _30, peaks near the CD5, LYN and 
CXCR4 genes were called in CLL_1 H3T11p_DMSO_0 only. 
In summary, H3T11p was generally associated with active promoters and 
enhancers, as well as structural chromatin regions in CLL cells, both before and 
after BCR stimulation. 
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Figure 7.10 Motifs predicted by MEME-ChIP to be enriched in the peak data 
from CLL_1 H3T11p_DMSO_0.  
A The consensus CTCF motif aligned with the motif detected in the peak 
sequences. B CentriMo plot showing central enrichment of the CTCF motif in 
the peak sequences. The CTCF motif was the motif detected with the lowest 
p-value, which is the probability to randomly find this motif enriched in any set 
of sequences. C The consensus SPI1, SPIC and SPIB motifs aligned with the 
motif detected in the peak sequences. D, E, F CentriMo plots showing central 
enrichment of the ETS, E box and ZIC motifs in the peak sequences. 
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8 Discussion 
 PIM kinases in DLBCL and BL 
 Summary of main results 
Consistent with the literature (Brault et al., 2012; Gómez-Abad et al., 2011), PIM 
kinase inhibition was found to only marginally affect the viability of ABC-DLBCL cell 
lines. Further, the MYC-dependent Burkitt lymphoma cell lines were capable of 
growing independent of PIM kinase activity. Only knockdown of PIM2 decreased 
proliferation of Raji cells.  
PIM1 and MYC were bound to the GNL3 promoter and the H3K9acS10p mark was 
present in this region as assessed by ChIP. However, inhibition of PIM kinases, 
overexpression of PIM1 or knockdown of PIM1 and/or PIM2 did not alter expression 
of GNL3, although changes in PIM1 and H3K9acS10p occupancy at the promoter 
could be observed. 
However, PIM kinases might be implicated in stress response pathways, as PIM1 
was upregulated after both serum shock and serum starvation and was elevated at 
the GNL3 promoter after DRB treatment. Consistently, both PIM1 and PIM2 have 
been shown previously, to be involved in different stress response pathways (Jian 
Chen et al., 2009; Zemskova et al., 2008; Zirkin et al., 2013). 
 
 PIM kinase inhibition alone did not efficiently reduce the 
viability of DLBCL and BL cell lines in vitro 
The small molecule inhibitors SMI4a and inh VI efficiently inhibited viability of the 
two Burkitt lymphoma, the two ABC-DLBCL and the two GCB-DLBCL cell lines in 
vitro. Quercetagetin additionally reduced the viability of the Raji, Ramos, OCI-Ly19 
and SUDHL6 cell lines. However, the reduced viability is possibly due to inhibition 
of several kinases and might be independent of PIM kinase inhibition. First, OCI-
Ly19 cells did not express detectable levels of PIM1 and PIM2, but viability was as 
strongly or even more strongly inhibited as in the other cell lines. Second, all three 
inhibitors have been described to target several kinases other than PIM1/2/3, which 
might also be important for lymphoma cell survival. Quercetagetin does, for 
example, inhibit JNK and PI3K (Baek et al., 2013), as well as Aurora A, B and C, 
which leads to mitotic arrest and to induction of apoptosis (Jung et al., 2014). Other 
kinases, which might play a role in lymphoma cell survival and are inhibited by 
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Quercetagetin, include DYRK1A, DYRK2, DYRK3, AKT2, RSK2, TAK1 and YES1 
(http://www.kinase-screen.mrc.ac.uk, see appendix). SMI4a and inh VI (also called 
SMI16a) are structurally similar inhibitors and both are also active against DYRK1A 
(Xia et al., 2009), which does for example phosphorylate and inhibit GSK3β (W.-J. 
Song et al., 2014), so that it might have oncogenic potential. Further, both inhibitors 
are structurally very similar to potent PI3K inhibitors (Pinson et al., 2011), making it 
plausible that PI3K is also inhibited by SMI4a and inh VI. Because BL cells are 
dependent on PI3K activity (Schmitz et al., 2012), inhibition of PI3K might be the 
reason for the strong inhibition of BL cell viability by SMI4a and inh VI. Inhibition of 
other kinases is very likely, because all inhibitors were used at very high 
concentrations of 40 µM, while SMI4a and inh VI have IC50 values of less than 
150 nM for both PIM1 and PIM2. In keeping with such an off-target effect, BAD-
S112 phosphorylation, which is a major target of PIM kinases, was inhibited in OCI-
Ly3, but not in Raji, Ramos and OCI-Ly10 cells until day 6 of treatment. Further, 
none of the inhibitors blocked the induction of the FOSL1 gene in HEK293 cells 
after serum shock, which had been described by Zippo et al. to be a PIM1-
dependent effect. The main target of these inhibitors might therefore not be PIM1. 
In support of this, a potent and seemingly more selective inhibitor of PIM kinases, 
AZD1208, did not significantly reduce the viability of BL or ABC-DLBLC cell lines. 
AZD1208 has been extensively tested against a panel of 442 kinases and inhibited 
only 13 kinases other than PIM1/2/3 by 50% or more, but was still at least 43-fold 
selective for PIM kinases (Keeton et al., 2014). In the study by Keeton et al., 
AZD1208-sensitive cell lines showed increased apoptosis already at 1 µM 
AZD1208 (Keeton et al., 2014). At this concentration none of the cell lines tested in 
our study displayed reduced viability, while AZD1208 efficiently inhibited BAD-S112 
phosphorylation in the two BL and the two ABC-DLBCL cell lines. In agreement with 
a previous study, in which pan-PIM kinase inhibition led to stabilisation of PIM3 (Z. 
Guo et al., 2014), efficient inhibition of PIM kinases also led to a stabilisation of 
PIM1 and PIM2 in our study. Of note, SMI4a treatment did not stabilise PIM1 or 
PIM2. In conclusion, inhibition of PIM kinases alone does not seem to inhibit the 
viability of BL and DLBCL cell lines. 
However, the effect of PIM kinase inhibition on BL and DLBCL cells has so far, in 
this and other studies (Brault et al., 2012; Gómez-Abad et al., 2011), only been 
assessed in vitro. PIM kinases might be more important for cell growth and survival 
under in vivo conditions, when suboptimal and changing levels of growth and 
survival factors are present, when cells encounter oxidative stress or nutrient 
deprivation. I could show that PIM1 is induced in the Raji BL cell line both by serum 
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starvation and by serum shock and its levels were also altered after simply 
changing the culture medium. However, this seems to be more a stress response 
than a response to growth factors, as stimulation of pro-survival pathways by BCR 
cross-linking or PMA treatment did not lead to upregulation of PIM kinases. 
Therefore, PIM kinase levels seemed to be very sensitive to any environmental 
change. This is in keeping with previous studies showing that PIM kinases are 
induced by several stressors, like DNA damage in U2OS osteosarcoma and in 
neuronal cells (Yi Zhang et al., 2010; Zirkin et al., 2013), oxidative stress in 
cardiomyocytes (Borillo et al., 2010) and hypoxia in pancreatic cancer (J. Chen et 
al., 2009; Reiser-Erkan et al., 2008). Inhibition or knockdown of PIM kinases 
renders cells more sensitive to these stress conditions, so that PIM kinase inhibition 
might enhance apoptotsis of BL or DLBCL cells in vivo (Jian Chen et al., 2009; 
Zirkin et al., 2013; Hsu et al., 2012). Further, PIM kinases induce resistance of cells 
to chemotherapy and knockdown or inhibition of these proteins sensitises cells to 
apoptosis induced by chemotherapeutic agents, like Docetaxel (Zemskova et al., 
2008), Paclitaxel (Hsu et al., 2012) or Cytarabine (Kelly et al., 2012). Therefore, 
PIM kinase inhibition might still be a valid therapeutic strategy in combination with 
other chemotherapeutic drugs in vivo. Combined inhibition of PIM kinases and the 
AKT pathway has been suggested as a promising therapeutic strategy for the 
treatment of AML (Meja et al., 2014) and might also be effective against prostate 
cancer (Toren & Zoubeidi, 2013). These findings are reinforced by a study showing 
that targeting cap-dependent translation, which is activated by both the AKT and 
PIM pathways is a valid therapeutic approach in B cell lymphoma (Schatz et al., 
2011). Therefore, combination therapy with an AKT and a PIM kinase inhibitor 
should also be evaluated in BL and DLBCL. 
Apart from PIM kinase inhibition, knockdown of PIM1 did not inhibit Raji cell 
viability, while PIM2 knockdown reduced cell numbers after several days. One 
could argue that PIM2 might be the more important kinase for Burkitt lymphoma cell 
proliferation and survival. PIM2 is more frequently overexpressed in different 
haematological malignancies than PIM1 and is more significantly associated with 
the activation of oncogenic pathways (Gómez-Abad et al., 2011). However, only 
inhibition of all PIM kinases effectively induced apoptosis of BCL cell lines in the 
study by Gómez-Abad et al. In my study, the knockdown of PIM2 was more efficient 
than that of PIM1, so that a dose-effect might play a role. If a certain amount of PIM 
kinases is present in the cell, no phenotypic effect can be observed. However, if the 
levels fall beneath a certain threshold, cell viability would be affected. Because pan-
PIM kinase inhibition did not significantly reduce cell viability, although it clearly 
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abrogated PIM activity as assessed by BAD phosphorylation, it can be 
hypothesised that PIM kinases might have kinase-independent functions in DLBCL 
and BL. This is in agreement with findings by Hogan et al. and Wood et al., showing 
that overexpression of kinase-dead PIM1 can mimic some functions of active PIM1 
(Hogan et al., 2008; Wood et al., 2009). Further, PIM1 is recurrently targeted by 
aberrant somatic hypermutation in DLBCL, but out of 5 mutant proteins analysed, 
only one showed increased kinase activity, while three mutants were significantly 
less active than the wildtype protein (Kumar et al., 2005), which also indicates that 
PIM kinases might have kinase-independent functions in lymphomagenesis. 
Alternatively, their expression could be maintained as a result of increased NFκB 
activity in ABC-DLBCL, although the protein itself is redundant. Thus, PIM kinases 
might just be “messengers” of the level of NFκB or STAT activity in these cells, 
without having any vital function in tumour cell proliferation or survival. This is in 
agreement with the findings by Brault et al. that PIM kinase expression correlates 
with active STAT3 and STAT5 and their hypothesis that PIM kinases are 
progression markers, but not bona fide therapeutic targets in DLBCL (Brault et al., 
2012). 
The efficient inhibition of cell viability by PIM2 knockdown but not by pan-PIM 
inhibition could also be interpreted as PIM2-mediated inhibition of PIM1. PIM1 
binding to the GNL3 promoter and H3K9acS10p in this region were increased in 
PIM2 knockdown cells, which might be a consequence of direct competition, or it 
might indicate other antagonistic functions of PIM1 and PIM2. PIM2 could, for 
example, inhibit nuclear translocation of PIM1 or inhibit association of PIM1 with the 
chromatin. This would mean that PIM1 has anti-tumour effects in BL, which would 
be counteracted by PIM2, because knockdown of PIM2 decreased cell viability, 
while knockdown of PIM1 alone or inhibition of both kinases with AZD1208 did not. 
This theory would also be in agreement with the reduced kinase activity of 
somatically hypermutated PIM1 in DLBCL. Furthermore, activation of the BCR led 
to an unexpected reduction in PIM1 mRNA expression in the Raji cell line as well as 
in primary B cells from CLL patients. Similarly, PMA treatment led to a reduction in 
PIM protein expression. Signalling via the BCR is supposed to enhance proliferation 
and survival of B cells, indicating that PIM1 might indeed inhibit B cell proliferation 
and survival, at least in response to certain stimuli or under certain environmental 
conditions. These findings are in apparent disagreement with PIM kinases being 
potent oncogenes in murine B and T cell lymphomas. However, expression of PIM 
kinases is associated with a good prognosis in prostate and pancreatic 
adenocarcinomas (Dhanasekaran et al., 2001; Reiser-Erkan et al., 2008) and 
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overexpression of PIM kinases has been associated with the induction of apoptosis 
in rat fibroblasts (Mochizuki et al., 1999) and with increased p53 levels (Hogan et 
al., 2008; Zemskova et al., 2010). A recent study implicates PIM1 in the induction of 
cellular senescence through the formation of heterochromatin, which suppress pro-
proliferative genes (Jin et al., 2014). Therefore, its functions, like those of most 
oncogenes, might depend on the status of a cell, the cell type and the presence, 
absence or activation of other proteins. 
In conclusion, PIM kinases do not seem to be useful exclusive targets for the 
treatment of DLBCL or BL. Pan-PIM kinase inhibitors might, however, be effective 
in vivo and in combination with DNA-damaging chemotherapeutics or AKT pathway 
inhibitors, but this remains to be evaluated. 
 
 PIM kinases might be dispensable for MYC-dependent gene 
expression in unstressed Raji cells 
I have shown that MYC and PIM1 bind to the GNL3 promoter and the NPM1 
enhancer in Raji, Ramos and OCI-LY10 cells. Both genes also displayed an active 
gene signature in Raji cells. They showed increased occupancy of POL II S2p 
towards the 3’ end and they were marked by H2Bub. Further, high levels of total 
and S5 phosphorylated POL II, possibly representing paused POL II, were found in 
the 5’ regions of the gene, overlapping with the MYC and PIM1 binding sites, 
matching the finding that MYC and PIM1 are important for pause release and 
elongation but not initiation of transcription (Eberhardy & Farnham, 2002; Zippo et 
al., 2009; Zippo et al., 2007). At the GNL3 promoter, the dual H3K9acS10p mark 
was also detected, while the single H3S10p mark was mostly absent at both genes. 
GNL3 had been described before as a MYC-regulated gene in murine B cells and 
has been shown to be essential for MYC-induced tumourigenesis in vitro in rat 
fibroblasts and human colon cancer cells and in vivo in MYC transgenic mice 
(Zwolinska et al., 2011). I could, however, not confirm a direct regulation of GNL3 
expression or expression of its three intronic snoRNAs by MYC in the Raji cell line. 
Knockdown of MYC decreased its binding to the GNL3 promoter, but did not affect 
expression of the GNL3 gene or the snoRNAs. The discrepancies between the two 
studies might arise from the different cell types and the different approaches used. 
Zwolinska et al. overexpressd MYC and saw an increase in GNL3 expression, 
which might be due to MYC occupying novel binding sites in GNL3 enhancers. 
Alternatively, the effect on GNL3 expression might be indirect, through MYC 
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upregulating other transcription factors that then influence GNL3 expression. 
Knockdown of MYC, however, might not influence GNL3 expression, because only 
a low level of MYC might be required to facilitate GNL3 expression or because 
other transcription factors present at the GNL3 promoter maintain its expression 
independent of MYC. A study on 59 different transcription factors conducted by 
Cusanovich et al. also showed that genes that are bound by a transcription factor 
do mostly not change their expression upon knockdown of this factor (Cusanovich 
et al., 2014). These sites were called non-functional sites. However, transcription 
factor binding sites around 10 kb of the TSS were assigned to each gene, without 
actual knowledge about the real target gene. Consistently, MYC and PIM1 might be 
bound to the GNL3 promoter but might influence the expression of another gene, 
for example the PBRM1 gene, which has a promoter overlapping with the GNL3 
promoter. Alternatively, the GNL3 promoter region might be a long-distance 
enhancer for another gene, which could be regulated by MYC. In support of this 
hypothesis, promoters have been shown to interact with each other, even over long 
distances, and to influence each other’s expression (Li et al., 2012). Another 
possibility is that changes in GNL3 expression were not detected, because all 
expressed genes might have been downregulated in Raji cells, in agreement with 
recent findings that MYC amplifies expression of all genes (Lin et al., 2012; Nie et 
al., 2012; Rahl et al., 2010). Normalisation of GNL3 expression to that of another 
gene would therefore mask the reduction in its expression. Further, the reduction in 
MYC binding to the promoter did not affect recruitment of PIM1 or H3K9acS10p in 
this region, making it possible that PIM1 might be recruited in a MYC-independent 
fashion to maintain expression. For example, one of the other MYC family proteins, 
MYCN or MYCL, might occupy the E box element in absence of MYC and recruit 
PIM1. Alternatively, since PIM1 recruitment to the promoter was very low as 
assessed by ChIP-qPCR, even low MYC levels may suffice. Therefore, PIM1 but 
not MYC might be the limiting factor for complex formation between the two 
proteins.  
Overexpression of PIM1, knockdown of PIM1, PIM2 or PIM1 and PIM2 or inhibition 
of PIM kinases using SMI4a, inh VI, Quercetagetin or AZD1208 did also not show 
any effect on GNL3 and intronic snoRNA expression. Consistently, PIM1 
expression in the different lymphoma cell lines did not correlate with GNL3 
expression. While PIM1 and PIM2 mRNA levels were variable, the levels of GNL3 
and the snoRNAs were similar between the different BL and DLBCL cell lines. 
However, levels of nuclear PIM1 were very low in all the cell lines, which might be 
the reason for the similar GNL3 expression levels. Overexpressed PIM1 
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translocates to the nucleus, but I could not determine, whether it is bound to the 
GNL3 promoter, because all attempts to perform ChIP in PIM1-overexpressing cells 
failed. Nevertheless, overexpression of PIM1 led to a downregulation of PIM2 
expression, indicating that the overexpressed protein is functional. This suggests 
that GNL3 might not be a PIM1-regulated gene in non-stimulated and -stressed Raji 
and SUDHL6 cells. 
Binding of PIM1 to the promoter decreased after knockdown, but H3K9acS10p was 
unaffected, which might indicate that PIM1 is not responsible for H3S10 
phosphorylation at the GNL3 promoter. However, treatment of Raji cells with 
AZD1208 increased total PIM1 and chromatin-associated PIM1 at the GNL3 
promoter but reduced H3K9acS10p in this region. Furthermore knockdown of PIM2 
led to an increased recruitment of PIM1 and a concomitant increase in 
H3K9acS10p, which was not seen in PIM1/2 double knockdown cells. Together 
these observations support the argument that PIM1 is indeed one of the kinases 
phosphorylating H3S10 at the GNL3 promoter. The lack of effect of PIM1 and the 
PIM1/2 double knockdown on H3K9acS10p levels could be explained by MYC or 
another transcription factor recruiting a different H3S10 kinase in the absence of 
PIM1. Following AZD1208 treatment, the presence of inactive PIM1 at the promoter 
would block the recruitment of the alternative kinase. Because the PIM1/2 double 
knockdown did not reduce phosphorylation of H3S10, PIM2 is most likely not the 
alternative H3S10 kinase. Alternatively, the remaining PIM1 at the GNL3 promoter 
might be sufficient to mediate H3S10 phosphorylation or feedback regulation might 
reduce the activity of phosphatases for H3S10 and thus maintain H3S10p levels, 
although kinase activity is reduced. Consistent with such a model, the H3S10 
phosphatase MKP1 has been shown to preferentially bind histone H3 that is 
phosphoacetylated (Gadewal et al., 2013). 
The experiments after PIM2 knockdown and AZD1208 treatment showed that the 
H3K9acS10p levels at the GNL3 promoter did not correlate well with GNL3 
expression. S10 phosphorylation might be important for the induction of gene 
expression, but once a gene is active, this chromatin mark might be dispensable. 
H3S10 phosphorylation is usually a very transient mark (Barth & Imhof, 2010; 
Jackson et al., 1975), which only appears in the promoters of inducible genes after 
stimulation of cells with growth factors, cytokines or after exposure to stress (Li et 
al., 2001; Mahadevan et al., 1991; Soloaga et al., 2003; Yamamoto et al., 2003; 
Zippo et al., 2007). This mark might lead to the establishment of other chromatin 
marks, the recruitment of transcription factors and other chromatin-bound proteins, 
which could form a stable complex at promoter or enhancer regions without the 
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need for prolonged maintenance of the H3S10p mark. The gene would then 
continue to be in an active state, independent of the presence of PIM kinases and 
the H3S10p mark. Several histone marks are only established upon transcription of 
a gene because the modifying enzymes are recruited to the transcribing POL II or 
require the presence of other transcription-associated histone marks for their 
efficient establishment. Examples of such marks include H2Bub, which requires 
ongoing transcription to be deposited (Kim et al., 2009), H3K4me3, which is 
stimulated by H2Bub (Kim et al., 2009; Milne et al., 2010; Muntean et al., 2010), 
H3K36me3, because SETD2 most likely interacts with the elongating POL II (Kizer 
et al., 2005) and H3K79me3, because the enzyme DOT1L also interacts with the 
elongating POL II and is stimulated by H2Bub (S.-K. Kim et al., 2012; McGinty et 
al., 2008; McGinty et al., 2009). These methylation marks are then capable of 
recruiting transcription factors or chromatin modifiers to activate transcription 
independent of H3 phosphorylation. Indeed, recruitment of BRD4 and thus P-TEFb, 
which has so far been shown to be the main function of PIM1-mediated H3S10p, 
can be generally mediated by acetylated histones (Dey et al., 2003) and 
transcription factors, like NFκB (Huang et al., 2009), indicating that H3S10p is not 
obligatory for this function. 
 
PIM1 also seems to be dispensable for global regulation of MYC-dependent genes 
in unstressed cells. MYC knockdown efficiently and rapidly reduced Raji cell 
viability, confirming that these cells are dependent on MYC. However, knockdown 
of PIM1 or inhibition of PIM kinases had no such effect, although PIM1 had been 
shown to be required for the expression of 20% of the MYC-regulated genes in 
HEK293 cells 120 min after serum shock (Zippo et al., 2007). The results from our 
study show that PIM kinase activity seems to be dispensable for the maintenance of 
expression of MYC-dependent genes under stable environmental conditions. 
However, because PIM1 is generally induced under cellular stress conditions, it 
might be possible that “switching on” new genes requires its activity, which would 
match the findings of Zippo et al., as well as our findings that expression of the 
GNL3 gene was maintained at a constant level in unstressed Raji cells, 
independent of the presence of MYC, PIM1 or the level of H3K9acS10p at the 
promoter. This is in agreement with the very low nuclear levels of both PIM1 and 
PIM2 in all six B cell lymphoma cell lines used in this study. After stimulation of cells 
with growth factors, or when cells are exposed to stress conditions, nuclear 
translocation of PIM kinases might be induced to facilitate the induction of gene 
expression. Consistent with this, it has been shown that irradiation or stimulation 
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with EGF induced nuclear translocation of PIM1 in squamocellular cancer cells 
(Peltola et al., 2009). 
Therefore, the small effect of AZD1208 on the viability of ABC-DLBCL cell lines is 
most likely also independent of the inhibition of MYC-mediated transcription, but 
dependent on other cellular activities of PIM kinases. Indeed, PIM kinases have 
been shown to target a plethora of substrates, including cell cycle and apoptosis 
regulators, other transcription factors and the cap-dependent translation machinery. 
Moreover, several studies have shown already that expression of PIM kinases does 
not correlate with MYC in DLBCL (Brault et al., 2012) or lymphoid and myeloid 
leukaemias (Amson et al., 1989). 
In summary, it seems that PIM kinases are not required for MYC-dependent 
transcription under steady-state conditions. Consistently, H3K9acS10p might not be 
required to maintain transcription at already active genes, like GNL3, but might be 
essential to activate the expression of repressed genes. Therefore, PIM kinases 
could play a role in lymphoma development and maintenance under conditions, 
where changes in gene expression are required. 
 
 PIM1 and MYC might have transcription-independent 
functions at the GNL3 gene 
Although PIM1 and MYC do not regulate GNL3 expression under our experimental 
conditions, they are bound to the GNL3 promoter and it is therefore likely that they 
fulfil some function in this region. It was first hypothesised that PIM1 might, like 
IKKα bind to the POL II CTD and travel with the elongating POL II along the gene. 
IKKα had been shown to phosphorylate HP1γ and to be loaded from the POL II 
CTD onto the chromatin in an HP1γ-dependent fashion. HP1γ would then inhibit 
IKKα-dependent H3S10 phosphorylation but stimulate its activity towards H3.3S31 
(Thorne et al., 2012). However, several lines of evidence indicate that PIM1 does 
not travel with the elongating POL II. First, in contrast to IKKα, PIM1 was mainly 
associated with the promoter and not the 3’ region of the GNL3 and NPM1 genes. 
This could, however, also be a result of the relatively low transcription rate of the 
GNL3 gene as compared to the murine Tnf gene, so that sufficient amounts of 
PIM1 could just not be detected in the gene body. Second, both H3K9acS10p and 
the possible PIM1 target H3.3S31p were only associated with the GNL3 and NPM1 
promoter regions and not the 3’ end. And third, association of PIM1 with the GNL3 
gene was independent of transcriptional elongation, as assessed after DRB 
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treatment. Quite the contrary, PIM1 association with the promoter region increased 
when elongation was inhibited. PIM1 might therefore be recruited to the chromatin 
upon stalling of the polymerase and function in the transcriptional stress response. 
PIM1 might, in contrast to IKKα, associate with the S5-phosphorylated POL II, but it 
could also be recruited completely independent of the polymerase. As mentioned 
before, GNL3 and Tnf are kinetically very different genes. While the former is a 
housekeeping gene, which is constitutively active, the latter is rapidly and strongly 
induced upon stimulation of macrophages with LPS. Thus, the requirement for 
nucleosome remodelling and histone turnover are likely to be very different at both 
genes and IKKα-mediated H3.3S31 phosphorylation might play a role in these 
processes. It has, for example been shown that ZMYND11 binds H3.3K36me3 and 
critically recognises the S31 residue (Qin & Min, 2014; Wen et al., 2014). 
ZMYND11 represses elongation (Wen et al., 2014) and regulates splicing, 
stimulating intron inclusion (R. Guo et al., 2014). One can imagine that 
phosphorylation of the H3.3S31 site would change the binding of ZMYND11 to 
H3.3K36me3, possibly inhibiting its recruitment and allowing for the high elongation 
rate necessary for LPS-induced Tnf expression, which is not necessary at the 
GNL3 gene. 
Further, MYC has been shown to regulate the induction of DNA replication 
independent of its effects on transcription (Dominguez-Sola et al., 2007). MYC does 
not participate in the recruitment of the origin recognition complex, but mediates 
origin licensing (Swarnalatha et al., 2012). Of note, origins of replication often 
overlap with TSS of coding and non-coding genes (Dellino et al., 2013). After 
synchronisation of Raji cells using a thymidine-nocodazole block, MYC was 
recruited to the GNL3 promoter in a cell cycle-dependent fashion. Its recruitment 
peaked in late G1/early S phase, when origin-licensing takes place (Machida et al., 
2005), and association of PIM1 with the chromatin was also high in late G1 and 
throughout S phase. It might therefore be possible that MYC and PIM1 regulate 
DNA replication from the GNL3 promoter. They could coordinate the expression of 
GNL3 and DNA replication throughout the cell cycle by inhibiting replication from 
the GNL3 promoter, which would be in agreement with the observed constant 
expression of GNL3 during S phase. Transcription and DNA replication are 
temporally separate in S phase, with early replicating genes being transcribed late 
in S phase and late replicating genes being transcribed early (Meryet-Figuiere et 
al., 2014). This separation needs to be tightly regulated, as head-on collisions 
between POL II and the DNA polymerase lead to recombination events (Prado & 
Aguilera, 2005). In this context, it had been shown that a stress-activated kinase in 
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yeast inhibits DNA replication upon osmotic stress, when transcription is required 
(Duch et al., 2013). PIM1 might have a similar role at the GNL3 gene. Alternatively, 
MYC and PIM1 might activate replication from the GNL3 promoter. This is 
consistent with a known function of yeast 14-3-3 proteins in replication (Yahyaoui & 
Zannis-Hadjopoulos, 2009). PIM1 might phosphorylate H3S10 or other target 
proteins and facilitate the recruitment of 14-3-3 proteins and thus DNA replication. 
However, the activation of too many origins, for example after MYC overexpression, 
results in DNA damage and the occurrence of γ-H2A.X (Dominguez-Sola et al., 
2007). Interestingly, PIM1 and PIM2 have been implicated in DNA repair and the 
removal of γ-H2A.X foci (Hsu et al., 2012; Zirkin et al., 2013). They might therefore 
contribute to MYC-induced transformation by resolving MYC-induced replication 
stress. 
 
 Limitations of the study and future directions 
One limitation was that the study was conducted in vitro in cell lines. As mentioned 
earlier, effects of PIM kinase inhibition under physiological, non-optimal conditions 
might have a different effect on survival and proliferation of lymphoma cells. 
Further, stable knockdown cells were generated only from EBV-transformed Raji 
cells and it is possible that knockdown of PIM kinases might have a different effect 
on the viability of other, non-EBV transformed Burkitt lymphoma or ABC-DLBCL cell 
lines. In the future, it would be interesting to see, whether PIM kinase inhibition is 
useful as a combination therapy together with other kinase inhibitors, for example 
PI3K inhibitors, or together with DNA-damaging agents. However, it seems that 
most PIM kinase inhibitors, which have been used so far, target multiple kinases 
and the results of our study indicate that PIM kinases are not the main targets. It is 
therefore difficult to determine, which effects on cell viability are actually mediated 
by PIM kinases and which are due to the inhibition of other targets. 
Effects of PIM kinases on MYC-dependent transcription should in the future be 
studied in an inducible system, because H3S10 phosphorylation does not seem to 
be important for the regulation of constitutively expressed genes, but mainly for the 
activation of immediate gene expression in response to external stimuli (Li et al., 
2001; Mahadevan et al., 1991; Soloaga et al., 2003; Yamamoto et al., 2003; Zippo 
et al., 2007). Therefore, it is not surprising that PIM kinases did not affect MYC-
dependent transcription in general in exponentially growing, unstimulated cells. I 
tried to induce PIM kinase expression in Raji cells by a defined stimulus, but neither 
BCR cross-linking, nor PMA treatment led to an induction of PIM1. 
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Another difficulty encountered during this study was that three of the four PIM1 
antibodies tested, were not specific for PIM1 and did not even detect the 
endogenous protein in western blot. Further, validation of the antibody used for 
ChIP was very tedious, because it bound to multiple proteins as assessed by 
western blot and it was not clear, whether PIM1 was one of those. The antibody did, 
however, precipitate PIM1 in both conventional IP and ChIP experiments, but 
because any manipulation of PIM kinases did not alter expression of GNL3, we 
were concerned about its specificity. It was unclear, whether the protein associated 
with the GNL3 promoter was actually PIM1 or another, unknown protein. There was 
no known positive control region available to compare the signal to, because the 
only known PIM1 target regions upstream of the FOSL1 and ID2 genes were not 
bound by PIM1 in non-induced cells, consistent with the absence of FOSL1 and ID2 
expression in Raji cells. Moreover, none of the other antibodies, especially not the 
antibody that very specifically detected PIM1 in western blots, precipitated PIM1 
from this region. Further, because ChIP after PIM1 overexpression did not work, 
only generation of the stable knockdown cell lines finally confirmed that PIM1 was 
specifically bound to the GNL3 promoter, because knockdown of PIM1 led to a 
decrease in the ChIP signal in that region.  
Overall, due to its sensitivity to environmental changes, the limited availability of 
specific antibodies and the unspecific targeting of most PIM inhibitors, PIM1 turned 
out to be quite difficult to study. Further, the use B cell lymphoma cell lines made 
the application of overexpression and knockdown systems very challenging, as 
these cells could not be efficiently transiently transfected using the methods 
available to us. Therefore, stable cell lines had to be generated to facilitate the 
analysis of PIM kinase function in these cells. 
In the future, it would be interesting to study other effects and functions of PIM 
kinases. I could, for example, show that PIM1 was acutely and strongly induced by 
serum starvation in Raji cells, which might be required to regulate a metabolic 
switch and to minimise ROS production in starved cells. This is important for tumour 
cells, which are frequently exposed to altering environmental conditions and to 
nutrient deprivation. In agreement with this hypothesis, it has recently been shown 
that PIM kinases stimulate glucose uptake and the expression of glycolytic 
enzymes in hepatocellular carcinoma and in mouse embryonic fibroblasts (MEFs) 
(Leung et al., 2015; J.H. Song et al., 2014). Further, PIM triple ko (TKO) MEFs 
showed an increased ROS production and a decrease in metabolites of the 
pentose-phosphate pathway (PPP), as well as in mitochondrial oxidative 
phosphorylation, indicating that PIM kinases are intricately linked to metabolic 
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regulation in cells (J.H. Song et al., 2014). PIM kinases might regulate an 
analogous pathway to MAPK14/p38α or be involved in this pathway. MAPK14 is 
activated in starved HeLa cells, where it stimulates glucose uptake and the PPP to 
facilitate the generation of NADPH and thus inhbit ROS accumulation, autophagy 
and cell death (Desideri et al., 2014). Therefore, it could be very interesting to study 
PIM kinase functions in starvation. 
Moreover, I could show that PIM1 mRNA expression decreases after cross-linking 
of the BCR. It would be very interesting to study the exact mechanism of regulation 
of PIM1 in this context, the effects on PIM protein levels and the involvement of PIM 
kinases in BCR signalling. In contrast to BCR signalling, knockdown of MYC or 
inhibition of PIM kinases increased PIM1 and PIM2 expression. Further, knockdown 
or inhibition of PIM kinases led to an increase in MYC protein expression, while 
PIM1 overexpression decreased the expression of PIM2. This indicates, that MYC, 
PIM1 and PIM2 expression levels are regulated by each other through negative 
feedback loops and it might be important to understand such regulatory pathways. 
Therefore, future studies could focus on the regulation of PIM kinase and MYC 
expression and their interdependence under different conditions. 
And last, I could show that binding of PIM1 to the GNL3 promoter increases after 
inhibition of transcriptional elongation with DRB, after treatment of cells with 
AZD1208 and after knockdown of PIM2. This indicates that active transcription and 
PIM kinase activity might be required to mediate a dynamic turnover of PIM1 at its 
binding sites. Future studies should investigate the mechanisms of PIM1 
recruitment and binding to the cromatin and its chromatin-associated functions, as 
well as its possible regulation by PIM2. 
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 Effects of Ibrutinib and inhibitors of the BCR pathway on 
the chromatin structure in CLL cells 
 Summary of the main results 
Cross-linking of the BCR on CLL cells led to the induction or repression of several 
different genes with different kinetics and all changes were inhibited in Ibrutinib-pre-
treated cells. Globally, H3K9acS10p was induced in DMSO- but not Ibrutinib-
treated cells 30 min after BCR cross-linking. Locally, at the genes studied in this 
work, it was difficult to detect H3K9acS10p and when it was present, its induction 
was not consistently inhibited by Ibrutinib. However, especially H3T6 and H3T11 
phosphorylation correlated well with the induction kinetics of the early genes EGR1 
and DUSP2 and the induction of these two histone marks was completely inhibited 
in Ibrutinib-treated cells. A promising candidate kinase for the phosphorylation of 
the two threonine residues downstream of the BCR is ZIPK. Another kinase, which 
was inhibited by high levels of the PKCβ inhibitor and by Gö6983, mediated 
constitutive, but not inducible, H3T11 phosphorylation. Indeed, H3T11p was 
globally associated with active regulatory and structural chromatin elements already 
before cross-linking of the BCR. 
In contrast to histone phosphorylation, POL II recruitment, POL II S2p occupancy, 
H3K4 methylation, H3K9 acetylation and H2A.Z incorporation were largely 
unaltered in Ibrutinib-treated cells upon BCR stimulation at the genes analysed. 
This indicates that activation of the promoter and transcription initiation are 
mediated through a BCR-downstream pathway that is not blocked by Ibrutinib. In 
contrast, Ibrutinib seems to inhibit processive transcriptional elongation, it might 
influence nucleosome turnover and probably the release of stalled POL II. 
H3K4me3, H3K9ac and H2A.Z levels at the studied promoters were reduced after 
longer Ibrutinib treatment, probably because the genes were chronically inactivated. 
Further, H3K27me3 was increased in Ibrutinib-treated cells after 3 to 5 days at 
some of the promoters analysed. 
 
 Ibrutinib inhibited expression of BCR-induced genes, 
without preventing all the BCR-induced chromatin changes 
Induction of all tested genes, which were increased in CLL cells upon BCR cross-
linking, was inhibited, when the cells were pre-treated with Ibrutinib. In parallel with 
this, expression of downregulated genes was maintained after Ibrutinib-treatment. 
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These results were expected, because Ibrutinib is predicted to inhibit most of the 
BCR downstream signal transduction pathways through the covalent inhibition of 
BTK. However, we found that many of the BCR-induced changes to the chromatin 
were not affected by Ibrutinib treatment, indicating that BCR signalling is actually 
only partially inhibited. 
Ibrutinib inhibited the BCR-induced decrease in H3 occupancy at both the EGR1 
and DUSP2 genes. This might be a consequence of its inhibition of transcription or 
might be causal for its effect on transcription. In agreement with a direct role for 
transcription in nucleosome exchange, inhibition of POL II elongation in Drosophila 
decreases nucleosome turnover (Teves & Henikoff, 2011). On the other hand, 
nucleosome remodelling complexes, like the SWI/SNF complex, can specifically 
activate the transcription of some genes by remodelling nucleosomes (Armstrong et 
al., 1998; Bakshi et al., 2010; Sun et al., 2009). Thus, by mediating the inhibition of 
nucleosome remodelling enzymes, Ibrutinib might inhibit nucleosome removal and 
affect transcription. Both hypotheses would also be in agreement with BCR 
stimulation not having a detectable effect on nucleosome removal from the MYC, 
DUSP4 and CCND2 genes. The transcription rates at all three genes are most 
likely lower than those at the EGR1 and DUSP2 genes, which would lead to lower 
nucleosome turnover. Alternatively, only the two early genes might depend on 
nucleosome remodelling complexes for their activation, while MYC, DUSP4 and 
CCND2 might not. 
Globally, Ibrutinib inhibited the BCR-induced increase in H3K9acS10p. However, 
locally, at the promoters analysed, H3K9acS10p was not strongly induced. This 
might be due to the regions analysed not being targeted by H3S10 phosphorylation 
or because signalling-induced H3S10 phosphorylation is a very transient mark 
(Barth & Imhof, 2010; Jackson et al., 1975) and occurred mainly outside the time 
window analysed in this study. ChIP-sequencing at different time points after BCR 
stimulation might give insight into the local dynamics of H3K9acS10p in different 
regions. Furthermore, even when induction of H3K9acS10p was seen, Ibrutinib did 
not completely inhibit this induction. H3S10 phosphorylation at some promoters 
might be regulated by a pathway, which is not inhibited by Ibrutinib. Consistent with 
this, RSKs, which are putative H3S10 kinases (Sassone-Corsi et al., 1999), can be 
activated downstream of the BCR in a SYK-dependent but LYN- and MAPK-
independent manner (Li et al., 1997). However, the global H3S10 phosphorylation 
was inhibited by Ibrutinib, indicating that it blocks the main S10-targeting pathways. 
Such discrepancies between global and local changes of histone modifications 
have also been observed after HDAC inhibitor treatment. Although global histone 
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acetylation is strongly increased, levels in promoters of differentially expressed 
genes hardly change (Boudadi et al., 2013; Halsall et al., 2012). 
H3T6p and H3T11p were not consistently altered at the global level after BCR 
cross-linking in either DMSO- or Ibrutinib-pre-treated CLL cells. However, locally, at 
the EGR1 and DUSP2 genes, both marks were strongly induced 30 min after BCR 
cross-linking and this induction was completely blocked by Ibrutinib. Only these two 
early genes, but not MYC, DUSP4 or CCND2 showed an increase in H3T6 and 
H3T11 phosphorylation. Therefore, only a small number of genes might be targeted 
by H3T6 and H3T11 phosphorylation, explaining why no global increase in the two 
marks was detected. A difference between the global and local change in histone 
phosphorylation marks is not uncommon. An even more extreme difference 
between global and local changes can be seen in Drosophila cells after heat shock. 
While global histone phosphorylation decreases, the heat shock loci display 
increased phosphorylation (Nowak & Corces, 2000). Interestingly, both H3T6 and 
H3T11 phosphorylation were not restricted to the promoter regions. They were 
found along the whole length of the EGR1 and mostly at the 3’ end of the DUSP2 
gene. This is typical for chromatin marks, which are associated with elongation, like 
H3K36me3 (Bannister et al., 2005). Therefore, we hypothesised that these 
phosphorylation marks somehow contribute to proper transcription elongation at 
highly expressed immediate early genes, but are dispensable at later activated 
genes. It is, however, unclear whether H3T6 and H3T11 phosphorylation precede 
elongation, whether on-going elongation leads to the establishment of the marks, or 
whether a combination of both occurs. Presence of H3T11p might inhibit gene body 
acetylation and thus aberrant transcription initiation, as acetylation of H3K14 by 
yeast Gcn5 is inhibited, when H3T11 is phosphorylated (Liokatis et al., 2012). 
These proposed functions for H3T6p and H3T11p are in contrast to the functions 
described for H3T6 and H3T11 phosphorylation at androgen receptor target genes. 
Here, they contribute to transcription initiation by enhancing H3K9 demethylation 
and H3K4 methylation (Kim et al., 2014; Metzger et al., 2010; Metzger et al., 2008). 
Consistent with a different role of these two phosphorylation marks at the EGR1 
and DUSP2 genes, no increase in H3K4me3 was seen in their promoter regions. 
Intriguingly, Ibrutinib treatment did not inhibit POL II recruitment to the EGR1 and 
DUSP2 genes, indicating that transcription initiation is not inhibited by Ibrutinib. It 
was surprising, however, that total POL II in the gene body and at the 3’ end was 
also unaltered and that elongation, as assessed by the presence of POL II S2p at 
the 3’ end of the genes, was not completely blocked, because generation of the 
mature mRNAs was completely inhibited. Therefore, the polymerase is either 
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unproductive because it fails to associate with RNA processing enzymes or its 
processivity is very low. When assessed by ChIP, many highly processive 
transcription complexes can result in the same signal as few low processive 
enzymes. To assess the actual transcription rate, individual POL II complexes 
would need to be analysed, for example by fluorescence microscopy. We did not 
assess other posttranslational modifications of the POL II CTD, so that other 
modifications, which are required for proper transcription, like T4, S5 or S7 
phosphorylation (Chapman et al., 2007; Heidemann et al., 2013; Hintermair et al., 
2012; Hsin et al., 2011), might be altered after Ibrutinib treatment, leading to the 
observed phenotype. 
Consistent with an alteration of transcriptional elongation but not initiation by 
Ibrutinib, H3K4me3, H3K9ac and H2A.Z incorporation into the promoter were not 
inhibited in Ibrutinib-treated CLL cells after cross-linking of the BCR. H3K4me3 was 
on average unaltered in the promoter regions of EGR1, DUSP2, and DUSP4 in 
DMSO-treated cells upon BCR-stimulation, while it increased in Ibrutinib-treated 
cells. The levels of H3K4me3 in promoters were increased in Ibrutinib-treated cells 
even before anti-IgM addition. At least in yeast, inducible promoters display high 
nucleosome turnover (Cairns, 2009; Rufiange et al., 2007) and we hypothesised 
that the same happens in B cells. Ibrutinib might block this dynamic nucleosome 
exchange and thus lead to an apparent increase in H3K4me3. Further, H3K4 
methylation upon BCR stimulation seems to be mediated by a BCR-downstream 
pathway, which is not inhibited in Ibrutinib-treated cells, because H3K4me3 further 
increased in promoter regions 30 min after BCR stimulation. Due to the enhanced 
histone turnover after BCR cross-linking, as measured by a decrease in total H3, no 
increase in H3K4me3 would be seen in DMSO-pre-treated cells, even if H3K4 
trimethylation was induced. Interestingly, this Ibrutinib-mediated increase in 
H3K4me3 also happened at the DUSP4 promoter, although the gene is only 
activated 4 h after BCR cross-linking, indicating that the promoter might be poised 
for later activation already at early time points. 
Also surprisingly, H3K9ac was generally increased at the EGR1 and the DUSP2 
promoters independent of the presence or absence of Ibrutinib. Again, Ibrutinib did 
not seem to influence the pathway activating the H3K9 acetyltransferase. Unlike 
H3K4me3, no increase in H3K9ac was seen at the DUSP4 promoter, indicating that 
this mark correlates with direct transcriptional activation. Further, H2A.Z, which 
marks promoters that can be rapidly activated as well as promoters that had been 
recently active (Gévry et al., 2009; Hardy et al., 2009), was incorporated into the 
EGR1 and DUSP2 promoters after 30 min of BCR activation in one patient and this 
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was not inhibited by Ibrutinib. This incorporation occurred in one patient only, 
possibly because the cells from this patient had not been strongly activated before, 
so that the promoters were devoid of H2A.Z, while cells of the other patients had 
possibly been recently stimulated and had established a H2A.Z-dependent 
“expression memory” at these promoters. The same patient showed a huge 
increase in H2A.Z in the EGR1, DUSP2 and MYC promoter regions 3 days after 
BCR stimulation, indicating the establishment of an expression memory. This 
memory function of H2A.Z had before also been described in yeast, where recently 
inactivated genes incorporate H2A.Z, which allows for their rapid reactivation 
(Brickner et al., 2007). However, the formation of an expression memory is inhibited 
by Ibrutinib, consistent with its inhibition of gene expression after BCR stimulation. 
The other patient analysed on days 3 and 5 showed a lower increase in H2A.Z, 
which was also inhibited by Ibrutinib, consistent with an already established 
memory before anti-IgM stimulation. 
Long-term Ibrutinib treatment led to a decrease in H3K4me3 and H3K9ac in the 
promoter regions of all the genes analysed. On-going transcription, which is 
possibly maintained at a low level due to chronic BCR signalling, is required to 
deposit both marks (Kim et al., 2009; Rybtsova et al., 2007). Chronic signalling and 
low-level transcription are, however, thought to be inhibited by Ibrutinib, so that the 
renewal of H3K4me3 and H3K9ac would be blocked. Transcriptional inactivity of 
the loci also explains the increase in H3K27me3, especially at the DUSP2 
promoter. It was recently proposed that PRCs are generally recruited to inactive 
CpG islands (Riising et al., 2014) and a CpG island has been described 5’ of the 
DUSP2 gene, explaining the strong increase in H3K27me3 upon inactivation of the 
gene (Gasco et al., 2008). 
In conclusion, Ibrutinib mainly blocked processive elongation of the genes studied, 
but did not inhibit transcription initiation. This defect in elongation might be 
mediated by the loss of H3T6 and H3T11 phosphorylation, two marks which were 
found in the gene body of the EGR1 and DUSP2 genes. How promoter activation 
after BCR cross-linking was maintained in Ibrutinib-treated cells is unclear, because 
the main kinase targeted by Ibrutinib, BTK, is supposedly required for full activation 
of most downstream signalling pathways. However, although BTK mutant mice only 
develop low numbers of peripheral B cells, these show impaired, but not absent, 
PI3K and Ca2+ signalling (Rigley et al., 1989). Consistently, kinase-inactive BTK can 
function as an adapter molecule and is capable of partially inducing NFκB and B 
cell survival in mice (Middendorp et al., 2003). Therefore, it is possible that some 
pathways can be activated in Ibrutinib-treated cells, but that only activation of both 
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BTK activity-dependent and -independent pathways is sufficient to trigger the full 
activation of transcription as well as B cell proliferation and survival. 
 
 Inhibition of most BTK downstream pathways was not 
sufficient to block transcriptional activation of the EGR1 
and DUSP2 genes 
Because H3T6p and H3T11p seemed to be the main histone modifications 
mediating Ibrutinib-dependent inhibition of gene expression downstream of the 
BCR, we sought to identify signalling kinases that facilitate the establishment of 
these marks. Although PKCβ had been shown to phosphorylate H3T6 at androgen-
dependent genes (Metzger et al., 2010), it did not mediate phosphorylation of this 
residue in response to BCR cross-linking. In contrast, CLL cells showed a trend 
towards higher H3T6 and H3T11 phosphorylation after BCR cross-linking when 
PKCβ was inhibited. Consistently, PKCβ negatively regulates BTK and inhibition of 
PKCβ has been shown to lead to enhanced calcium signalling in murine B cells 
(Kang et al., 2001). PKCβ not being the kinase targeting H3T6 in B cells also 
argues for a different function of these marks at BCR-dependent compared to AR-
dependent genes. 
Similarly, pan-PKC, RSK and MEK1/2 inhibitors did not inhibit expression of EGR1 
and DUSP2, although they partially inhibited H3T6 and/or H3T11 phosphorylation. 
Patient-to-patient variations were observed, and on average, inhibition of MEK1/2 
had no effect on either phosphorylation mark, indicating that the kinase responsible 
for H3T6 and/or H3T11 phosphorylation might be downstream of PKCs or RSKs. 
However, these kinases were not the kinases directly responsible for H3T6 and 
H3T11 phosphorylation upon induction of BCR signalling, because phosphorylation 
was only partially inhibited. Therefore, there must also be a different pathway 
activating H3T6 and H3T11 phosphorylation. These marks might be deposited in a 
PI3K/AKT-dependent way or through an as yet unidentified pathway. Further, a 
kinase inhibited by high concentrations of the PKCβ inhibitor and by the pan-PKC 
inhibitor was responsible for the mass of H3T11 phosphorylation in unstimulated 
cells. This kinase might be a PKC or another unknown kinase targeted by those 
inhibitors. H3T11 phosphorylation in unstimulated cells might be associated with 
constitutively active genes, which would be in agreement with our ChIP-seq data, 
which show that H3T11p is constitutively associated with active regulatory elements 
and genes that would be expected to be active in B cells. Alternatively, PKC 
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inhibitor-targeted H3T11p might be associated with heterochromatin, as H3T11p 
has been shown to be deposited at centromeric heterochromatin (Preuss et al., 
2003). Signalling cascades other than the BCR pathways might signal through 
PKCs to mediate H3T11p. In this context, H3S10 phosphorylation can, for example, 
be mediated by different kinases in response to different stimuli (Duncan et al., 
2006). 
In conclusion, none of the inhibitors tested is sufficient to repress immediate early 
gene expression downstream of the BCR and none of the pathways influenced is 
the sole pathway activating H3T6 and T11 phosphorylation. However, in resting 
cells, and possibly in response to different stimuli, H3T11 phosphorylation was 
mediated by a kinase targeted by the PKC inhibitor. Therefore, two distinct and 
independent pools of H3T11p seem to exist in B cells, one constitutive and one 
inducible, which are regulated by different pathways. 
 
 ZIPK might be the kinase directly targeting H3T6 and H3T11 
downstream of the BCR 
ZIPK was the top kinase predicted by GPS2.1 to be targeting H3T11 and treating 
CLL cells with an inhibitor against DAPK1 and ZIPK inhibited BCR-induced 
expression of EGR1 and DUSP2 and H3T6 and H3T11 phosphorylation as strongly 
as Ibrutinib. Because DAPK1 is usually repressed in CLL cells through methylation 
of the promoter (Raval et al., 2007), the effects of the inhibitor are most likely 
mediated through inhibition of ZIPK. Although ZIPK had been described mainly as 
an apoptosis-inducing kinase so far, its expression in CLL cells is higher than in 
normal B cells (Bojarska-Junak et al., 2011), arguing for a tumour promoting 
function. Consistently, it stimulates proliferation of smooth muscle cells (Usui et al., 
2014) and is required for migration of fibroblasts (Komatsu & Ikebe, 2004). Further, 
its pro-apoptotic effects seem to depend on cytoplasmic localisation and 
overexpression. In CLL cells, however, ZIPK can be found both in the cytoplasm 
and the nucleus and this might be sufficient to stimulate its pro-proliferative activity. 
ZIPK synergistically induces apoptosis together with DAPK1 (Shani et al., 2004), 
but because the latter is repressed in CLL cells, ZIPK-mediated apoptosis might be 
suppressed. Further, ZIPK had been described before to interact with a number of 
transcription factors, and had been shown to activate AR-dependent transcription 
(Felten et al., 2013; Leister et al., 2008; Sato et al., 2005; Shoval et al., 2011), 
making it plausible that it activates transcription downstream of the BCR. Moreover, 
ZIPK had been shown to interact with STAT3, which is constitutively active in CLL 
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cells as well as activated downstream of the BCR (Hazan-Halevy et al., 2010; Sato 
et al., 2005). Importantly, ZIPK had been described as a H3T11 kinase before, it 
phosphorylates this residue in centromeric regions during mitosis (Preuss et al., 
2003). It is therefore likely that ZIPK phosphorylates H3T11 downstream of the 
BCR. At the time of writing, it was, however, unclear whether ZIPK mediates H3T11 
phosphorylation only at a few loci, or whether it globally phosphorylates H3T11. In 
the future, ChIP using a ZIPK antibody, as well as ChIP-seq after ZIPK inhibition 
and knockdown will clarify this question. 
In summary, ZIPK is a good candidate kinase for the induced phosphorylation of 
H3T6 and H3T11 downstream of the BCR. It might be recruited by different 
transcription factors or might be constitutively associated with the chromatin, as has 
been shown for murine ZIPK (Kögel et al., 1998), and become activated in a gene-
specific manner after BCR cross-linking. 
 
 H3T11p was globally associated with active regulatory 
elements  
ChIP-seq showed that H3T11p was globally associated with active regulatory 
elements before BCR cross-linking. Unfortunately, we cannot draw any conclusions 
from the ChIP-seq data 30 min after BCR activation, because the quality of the data 
was poor and only a very small number of peaks could be called.  
H3T11p was found associated with either CTCF sites or active regulatory regions. 
H3T11p seems to be a mark positively associated with transcription, because it was 
found in the vicinity of genes, which are actively transcribed in CLL cells, like CD5, 
SYK, LYN, BLNK and CXCR4. Consistent with a role for ZIPK in mediating H3T11 
phosphorylation at CTCF sites, it has been shown to associate with the cohesin 
subunit RAD21 (Panigrahi et al., 2012), which in turn associates with CTCF 
(Parelho et al., 2008). Further, ZIPK binds to several transcription factors, and one 
of those, STAT3, is constitutively active in CLL cells. Interestingly, about 30% of the 
detected constitutive H3T11p peaks overlap with STAT3 peaks from GM12878 
cells. However, most of the H3T11p might be mediated by another kinase, because 
treatment of CLL cells with a PKC inhibitor reduced global H3T11 phosphorylation. 
Nevertheless, this kinase might be upstream of ZIPK in resting CLL cells and 
another pathway might stimulate ZIPK upon BCR cross-linking, explaining why 
treatment of the cells with Gö6983 did not block BCR-induced H3T11 
phosphorylation.  
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 Limitations of the study and future directions 
The main limitation of this study was the use of an in vitro system to culture CLL 
cells. While multiple signal transduction pathways and signalling molecules 
contribute to the activation of the cell in vivo, we restricted our analysis to cross-
linking of the BCR only. In vivo, this cross-linking is usually accompanied by 
activation of several co-receptors, for example CD19 by complement (Carroll & 
Isenman, 2012). Further, IgD and IgM are normally both activated, while we 
restricted our system to IgM cross-linking, mainly because IgD cross-linking has 
been shown to trigger different outcomes to IgM cross-linking and to enhance 
apoptosis of CLL cells (Kim & Reth, 1995; Tavolaro et al., 2013). Therefore, effects 
of Ibrutinib and ZIPK inhibition on transcription could be different in vivo. 
A complication of this study was the heterogeneity of CLL as a disease. Patients 
responded very differently to anti-IgM cross-linking and the response was not 
correlated with any obvious clinical feature, for example the mutation status of the 
BCR, although other studies show that UM-CLL cells respond better to IgM cross-
linking in vitro than M-CLL cells (Guarini et al., 2008). To make consistent 
conclusions, more samples will need to be analysed in the future. Due to time 
constraints, only 3 to 5 patients were analysed per experiment so far.  
Another limitation was that protein functions were mainly analysed using inhibitors. 
These are, however, rarely specific, so that is not absolutely certain whether the 
enzyme intended to be targeted is really the enzyme mediating the observed 
effects. In the future, other, structurally different inhibitors should be used as a 
control. Knockdown experiments could serve as good controls as well. Primary B 
cells are, however, very hard to transfect and viral transduction will possibly need to 
be used. Optimisation of viral transduction could therefore be an important tool for 
future studies. Moreover, ChIP-seq experiments, looking at H3T6p, H3T11p and 
ZIPK will provide helpful information about chromatin association of the kinase and 
the degree of co-localisation of ZIPK and these histone phospho-modifications. 
Motif analyses might also be useful to identify transcription factors likely recruiting 
ZIPK. Further, effects of ZIPK inhibition on the viability of CLL cells will be analysed 
in vitro, to assess whether ZIPK might be a useful therapeutic target in CLL. 
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10 Appendix  
 
 Quercetagetin kinase screen 
This kinase screen was performed by the MRC Protein Phosphorylation and 
Ubiquiylation Unit (Dundee, UK). The data are available at http://www.kinase-
screen.mrc.ac.uk/screening-compounds/348817.  
Screening Concentration: 10µM Screening Concentration: 1µM 
Kinase 
% Activity 
Remaining 
Standard 
Deviation Kinase 
% Activity 
Remaining 
Standard 
Deviation 
PIM3 0 0  PKB beta 21 7 
PKB beta 1 0  RSK2 22 0 
PRAK 1 0  VEGFR1 27 4 
DYRK2 1 0  FGF-R1 27 1 
PHK 2 0  NUAK1 33 7 
DYRK3 2 0  PIM3 34 1 
DYRK1A 3 0  MARK4 34 1 
SRPK1 3 0  PIM1 37 6 
CHK2 5 1  Src 38 0 
TAK1 5 2  MARK1 40 0 
MARK3 6 1  YES1 42 1 
BRSK1 7 0  DYRK2 45 2 
CK2 7 0  CK2 46 3 
PIM1 7 0  CHK2 48 12 
RIPK2 7 0  CAMK1 49 1 
VEGFR1 7 0  PAK4 50 3 
Aurora B 8 1  RSK1 51 0 
AMPK 9 3  MARK3 51 1 
MELK 9 1  MELK 53 3 
MST2 9 0  TBK1 54 4 
YES1 9 0  SRPK1 55 10 
MINK1 10 0  MINK1 56 4 
MARK1 11 0  PAK6 58 2 
PIM2 11 0  MST2 58 2 
HIPK1 11 1  CLK2 58 9 
RSK2 12 1  DYRK3 59 3 
MNK1 12 4  MNK1 61 2 
NUAK1 12 0  BTK 61 2 
BRSK2 13 1  PKC zeta 62 0 
NEK2a 13 1  MLK3 62 1 
JAK2 13 7  HIPK2 62 7 
S6K1 14 0  Aurora B 62 4 
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MAPKAP-K3 14 0  MNK2 63 7 
FGF-R1 14 0  PAK5 67 0 
RSK1 15 0  MEKK1 67 4 
PKD1 15 6  PKD1 69 3 
IKK beta 16 5  IKK epsilon 69 4 
MLK3 16 0  EPH-B2 69 4 
CAMK1 19 3  DYRK1A 71 11 
GSK3 beta 19 1  BRSK2 71 10 
HIPK2 19 0  CAMKK beta 72 0 
PKC zeta 20 0  AMPK 73 6 
MARK4 20 0  PIM2 74 1 
NEK6 21 1  TTK 75 0 
IKK epsilon 21 1  IRR 76 4 
IRR 21 1  IRAK4 80 3 
SmMLCK 23 0  BRSK1 82 1 
PLK1 23 4  RIPK2 83 10 
GCK 23 1  MKK1 84 0 
MKK1 24 4  EPH-B1 85 8 
SGK1 24 2  NEK2a 86 3 
MLK1 24 0  MARK2 86 2 
Src 25 2  IR 86 0 
MNK2 26 5  SmMLCK 87 0 
MARK2 26 3  SGK1 87 3 
Aurora A 28 2  PRAK 87 1 
CK1 delta 29 1  MST4 87 2 
TrkA 29 2  MSK1 88 1 
CHK1 32 1  HIPK3 88 10 
CDK2-Cyclin 
A 32 0  SYK 89 6 
BTK 32 2  ERK8 89 0 
TTK 36 6  
CDK2-Cyclin 
A 89 12 
MSK1 38 0  EPH-B4 90 13 
PAK4 38 6  CK1 delta 90 0 
IGF-1R 43 2  JAK2 91 5 
HER4 44 2  TrkA 92 9 
IRAK4 46 0  MAPKAP-K3 92 3 
MAPKAP-K2 53 14  CHK1 92 12 
ERK1 54 4  JNK1 93 1 
LKB1 55 6  HIPK1 93 5 
HIPK3 55 0  GCK 93 1 
PAK5 55 6  EPH-B3 93 5 
ROCK 2 56 3  TAO1 94 11 
EPH-B4 56 11  TAK1 94 10 
MST4 58 5  MKK2 94 1 
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PAK6 60 12  MAPKAP-K2 94 1 
CAMKK beta 61 5  GSK3 beta 94 5 
EPH-B3 61 6  EPH-A2 94 14 
IR 62 3  ROCK 2 95 4 
TBK1 64 10  LKB1 95 12 
ERK8 65 1  DAPK1 95 11 
EPH-A2 73 6  Aurora A 95 11 
MEKK1 74 6  PAK2 96 7 
CSK 74 0  
p38 delta 
MAPK 96 7 
EPH-A4 74 6  IGF-1R 96 3 
PKA 79 2  PHK 98 2 
PKC alpha 80 13  PKC alpha 99 7 
PDK1 83 13  NEK6 99 8 
p38 gamma 
MAPK 88 6  
p38 alpha 
MAPK 100 4 
JNK3 89 1  MLK1 100 5 
p38 beta 
MAPK 90 0  IKK beta 100 6 
JNK1 93 3  
p38 beta 
MAPK 101 7 
SYK 93 8  ERK1 101 2 
Lck 95 9  MKK6 102 7 
p38 delta 
MAPK 97 8  Lck 102 15 
PAK2 98 2  S6K1 104 3 
PKB alpha 99 10  PDK1 104 0 
JNK2 100 9  PRK2 106 7 
PRK2 102 1  PKB alpha 106 9 
ERK2 105 1  JNK2 106 7 
EF2K 109 1  PLK1 107 11 
p38 alpha 
MAPK 119 6  
p38 gamma 
MAPK 107 2 
    JNK3 107 2 
    ERK2 107 8 
    PKA 109 7 
    HER4 109 4 
    EF2K 110 8 
    EPH-A4 117 3 
    ASK1 118 0 
    CSK 125 12 
 
 
